Abken, H., Allison, J.P., Brentjens, R., June, C.H., Lotze, M.T., Mackall, C., Majzner, R.G., Rosenberg, S.A., Sadelain, M., Smith, E., & Maus, M.V. (2025). Zelig Eshhar (1941-2025): a tribute for a life for immunotherapy. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 13(8).BMJ. doi: 10.1136/jitc-2025-013161.
Anderko, R.R., Bowman, A.E., Murthy, P., Murthy, P., Chopra, A., Tirukkovalur, N.V., Ceuppens, S., Paniccia, A., Lee, K.K., Mailliard, R.B., Lotze, M.T., Singhi, A.D., & Zureikat, A.H. (2025). Pancreatic cancer organoids recapitulate chemotherapy response and identify a potent cytotoxic T cell population. Clin Cancer Res.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-25-1110.
Buchbinder, E., Lotze, M.T., Margolin, K.A., Amaria, R., Sarnaik, A., Seery, V., Eroglu, Z., Khaddour, K., Betof Warner, A., Kluger, H.M., Sznol, M., Atkins, M.B., Mcdermott, D.F., & Silk, A.W. (2025). Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. J Immunother Cancer, 13(5).BMJ. doi: 10.1136/jitc-2024-011119.
Carleton, N., & Lotze, M.T. (2025). Reciprocal immune-epithelial interaction during breast cancer induction. J Immunother Cancer, 13(6).BMJ. doi: 10.1136/jitc-2024-011453.
Carleton, N., Rosen, A.B.I., Das, J., & Lotze, M.T. (2025). Immuno-oncology recapitulates ontogeny: Modern cell and gene therapy for cancer. Mol Ther, 33(5), 2229-2237.Elsevier. doi: 10.1016/j.ymthe.2025.03.042.
Cottrell, T.R., Lotze, M.T., Ali, A., Bifulco, C.B., Capitini, C.M., Chow, L.Q.M., Cillo, A.R., Collyar, D., Cope, L., Deutsch, J.S., Dubrovsky, G., Gnjatic, S., Goh, D., Halabi, S., Kohanbash, G., Maecker, H.T., Maleki Vareki, S., Mullin, S., Seliger, B., Taube, J., Vos, W., Yeong, J., Anderson, K.G., Bruno, T.C., Chiuzan, C., Diaz-Padilla, I., Garrett-Mayer, E., Glitza Oliva, I.C., Grandi, P., Hill, E.G., Hobbs, B.P., Najjar, Y.G., Pettit Nassi, P., Simons, V.H., Subudhi, S.K., Sullivan, R.J., & Takimoto, C.H. (2025). Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer, 13(3).BMJ. doi: 10.1136/jitc-2024-010928.
Coukos, G., Donia, M., Gastman, B.R., Goff, S.L., Gros, A., Harari, A., Hernandez, S., Ito, F., Maker, A.V., Mullinax, J.E., Murthy, P., Pai, S.I., Prabhakaran, S., Restifo, N.P., Silver, N.L., Marincola Smith, P., Turcotte, S., Wagner, P.L., Yang, J.C., & Lotze, M.T. (2025). The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. J Immunother Cancer, 13(11), e013420.BMJ. doi: 10.1136/jitc-2025-013420.
Ellsworth, S.G., Abdelhakiem, M., Elgohari, B., Mohammed, M., Shogan, J., Vera, A., Burton, S.A., Olson, A.C., Lee, K.K.W., Paniccia, A., Zhang, J.Y., Lotze, M.T., & Zureikat, A.H. (2025). Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRT. J Natl Compr Canc Netw, 23(7).Harborside Press. doi: 10.6004/jnccn.2025.7013.
Kang, R., Chen, R., Xie, M., Cao, L., Lotze, M.T., Tang, D., & Zeh, H.J. (2025). Correction to: The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. J Immunol, 214(10), 2806.Oxford University Press (OUP). doi: 10.1093/jimmun/vkaf261.
Kang, R., Tang, D., Schapiro, N.E., Livesey, K.M., Farkas, A., Loughran, P., Bierhaus, A., Lotze, M.T., & Zeh, H.J. (2025). Correction to: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ, 32(12), 2427.Springer Nature. doi: 10.1038/s41418-025-01539-y.
Li, C., Zhang, Y., Cheng, X., Yuan, H., Zhu, S., Liu, J., Wen, Q., Xie, Y., Liu, J., Kroemer, G., Klionsky, D.J., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2025). PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Dev Cell, 60(16), 2209-2210.Elsevier. doi: 10.1016/j.devcel.2025.07.018.
Murthy, P., Zenati, M., Preston, W., Chopra, A., Nasar, N., Aldakkak, M., AlMasri, S., Singhi, A., Ellsworth, S., Paniccia, A., Lee, K., Lotze, M., Tsai, S., Wei, A., & Zureikat, A. (2025). The SII predicts neoadjuvant therapy response and survival in pancreatic cancer CA19-9 non-secretors. Hepato Pancreato Biliary, 27, s83-s84.Elsevier. doi: 10.1016/j.hpb.2025.03.156.
Olejniczak, S.H., Lotze, M.T., & Skokos, D. (2025). Second signals for cancer immunotherapy. J Immunother Cancer, 13(9).BMJ. doi: 10.1136/jitc-2024-010530.
Ramírez-Fernández, Á., Dimitri, A.J., Chen, F., Bartoszek, R., Chen, G.M., Córdoba-Espejo, L., Zhou, Y., Tang, Y.H., Lin, C.T., Acosta, R., Scholler, J., Ghilardi, G., Porazzi, P., Pellicer, M., Profitós-Pelejà, N., Barta, S.K., Chew, A., Jadlowsky, J.K., Gonzalez, V.E., Siegel, D.L., Levine, B.L., Roué, G., Ruella, M., Lotze, M.T., June, C.H., Riley, J.L., & Fraietta, J.A. (2025). CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy. Nat Biomed Eng.Springer Nature. doi: 10.1038/s41551-025-01527-0.
Schumacher, C., Hoffman, H., Syaj, S., Hodges, J.C., Lotze, M.T., Lee, K.K., Zureikat, A.H., Paniccia, A., Gorantla, V.C., Rhee, J.C., Malhotra, M.K., Hsu, D., Sahin, I.H., Saeed, A., Singhi, A.D., & Zhang, J.Y. (2025). Prognostic and predictive impact of next-generation sequencing in metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology, 43(16_suppl), 4170.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2025.43.16_suppl.4170.
Tang, D., Kang, R., Cheh, C.W., Livesey, K.M., Liang, X., Schapiro, N.E., Benschop, R., Sparvero, L.J., Amoscato, A.A., Tracey, K.J., Zeh, H.J., & Lotze, M.T. (2025). Correction: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene, 44(32), 2927-2928.Springer Nature. doi: 10.1038/s41388-025-03510-0.
Turcotte, S., Donia, M., Gastman, B., Besser, M., Brown, R., Coukos, G., Creelan, B., Mullinax, J., Sondak, V.K., Yang, J.C., Rohaan, M.W., Marie Svane, I., Lotze, M.T., Haanen, J.B.A.G., & Goff, S.L. (2025). Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. J Immunother Cancer, 13(1).BMJ. doi: 10.1136/jitc-2024-010207.
Anderko, R., Murthy, P., Murthy, P., Chopra, A., Singhi, A., Paniccia, A., Lee, K., Mailliard, R., Lotze, M., & Zureikat, A. (2024). Pancreatic cancer organoids recapitulate chemotherapy response and identify potent T cell subsets. Hepato Pancreato Biliary, 26, s91-s92.Elsevier. doi: 10.1016/j.hpb.2024.03.156.
Anderko, R.R., Murthy, P., Murthy, P., Chopra, A., Singhi, A.D., Paniccia, A., Lee, K.K., Mailliard, R.B., Lotze, M.T., & Zureikat, A.H. (2024). Pancreatic cancer organoids recapitulate chemotherapy response and identify potent T cell subsets. Hepato Pancreato Biliary, 26, s609-s610.Elsevier. doi: 10.1016/j.hpb.2024.04.033.
Carleton, N., Lee, S., Li, R., Zou, J., Brown, D.D., Hooda, J., Chang, A., Kumar, R., Klei, L.R., Rigatti, L.H., Newsome, J., John Mary, D.J.S., Atkinson, J.M., West, R.E., Nolin, T.D., Oberly, P.J., Huang, Z., Poirier, D., Diego, E.J., Lucas, P.C., Tseng, G., Lotze, M.T., McAuliffe, P.F., Zervantonakis, I.K., Oesterreich, S., & Lee, A.V. (2024). Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women. bioRxiv, 2024.10.18.616978.Cold Spring Harbor Laboratory. doi: 10.1101/2024.10.18.616978.
Dai, E., Chen, X., Linkermann, A., Jiang, X., Kang, R., Kagan, V.E., Bayir, H., Yang, W.S., Garcia-Saez, A.J., Ioannou, M.S., Janowitz, T., Ran, Q., Gu, W., Gan, B., Krysko, D.V., Zhu, X., Wang, J., Krautwald, S., Toyokuni, S., Xie, Y., Greten, F.R., Yi, Q., Schick, J., Liu, J., Gabrilovich, D.I., Liu, J., Zeh, H.J., Zhang, D.D., Yang, M., Iovanna, J., Kopf, M., Adolph, T.E., Chi, J.T., Li, C., Ichijo, H., Karin, M., Sankaran, V.G., Zou, W., Galluzzi, L., Bush, A.I., Li, B., Melino, G., Baehrecke, E.H., Lotze, M.T., Klionsky, D.J., Stockwell, B.R., Kroemer, G., & Tang, D. (2024). A guideline on the molecular ecosystem regulating ferroptosis. Nat Cell Biol, 26(9), 1447-1457.Springer Nature. doi: 10.1038/s41556-024-01360-8.
Dubrovsky, G., Ross, A., Jalali, P., & Lotze, M. (2024). Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications. Int J Mol Sci, 25(20).MDPI. doi: 10.3390/ijms252011013.
Ellsworth, S.G., Ross, A., Shiue, K.R.Y., Murthy, P., Byrne-Steel, M.L., Patel, R., Zellars, R.C., Kong, F.M.S., Miller, A., Russ, K.A., & Lotze, M.T. (2024). Survey of Changes in Absolute Lymphocyte Counts and Peripheral Immune Repertoire Diversity after External Beam Radiotherapy. Radiat Res, 202(6), 837-846.Radiation Research Society. doi: 10.1667/RADE-24-00010.1.
Lotze, M.T., Cottrell, T., Bifulco, C., Chow, L., Cope, L., Gnjatic, S., Maecker, H.T., & Yeong Poh Shen, J. (2024). SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials. J Immunother Cancer, 12(3).BMJ. doi: 10.1136/jitc-2023-008655.
Lotze, M.T., Maeurer, M., Quezada, S.A., & Coukos, G. (2024). Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage. Cancer Discov, 14(8), 1366-1368.American Association for Cancer Research (AACR). doi: 10.1158/2159-8290.CD-24-0645.
Lotze, M.T., Olejniczak, S.H., & Skokos, D. (2024). CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol, 24(12), 878-895.Springer Nature. doi: 10.1038/s41577-024-01061-1.
Luke, J.J., Hamid, O., Fox, B.A., Ascierto, P.A., Osman, I., Mule, J.J., Romero, P.J., & Lotze, M.T. (2024). Jeffrey S Weber, MD, PhD (1952-2024): in memoriam to discovery, friendship and family. J Immunother Cancer, 12(9).BMJ. doi: 10.1136/jitc-2024-010464.
van der Burg, S.H., & Lotze, M.T. (2024). Perspectives from the leadership of Journal for ImmunoTherapy of Cancer. J Immunother Cancer, 12(6).BMJ. doi: 10.1136/jitc-2024-009661.
Yurube, T., Buchser, W.J., Zhang, Z., Silwal, P., Lotze, M.T., Kang, J.D., Sowa, G.A., & Vo, N.V. (2024). Rapamycin mitigates inflammation-mediated disc matrix homeostatic imbalance by inhibiting mTORC1 and inducing autophagy through Akt activation. JOR Spine, 7(1), e1303.Wiley. doi: 10.1002/jsp2.1303.
Ivey, A.D., Matthew Fagan, B., Murthy, P., Lotze, M.T., Zeh, H.J., Hazlehurst, L.A., Geldenhuys, W.J., & Boone, B.A. (2023). Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4). Clin Exp Immunol, 211(3), 239-247.Oxford University Press (OUP). doi: 10.1093/cei/uxad005.
Murthy, P., Zenati, M.S., AlMasri, S.S., DeSilva, A., Singhi, A.D., Paniccia, A., Lee, K.K., Simmons, R.L., Bahary, N., Lotze, M.T., & Zureikat, A.H. (2023). Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. J Natl Compr Canc Netw, 22(1D), e237070.Harborside Press. doi: 10.6004/jnccn.2023.7070.
Perales-Linares, R., Leli, N.M., Mohei, H., Beghi, S., Rivera, O.D., Kostopoulos, N., Giglio, A., George, S.S., Uribe-Herranz, M., Costabile, F., Pierini, S., Pustylnikov, S., Skoufos, G., Barash, Y., Hatzigeorgiou, A.G., Koumenis, C., Maity, A., Lotze, M.T., & Facciabene, A. (2023). Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance. Cancer Res, 83(21), 3562-3576.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-22-2499.
Tang, D., Kang, R., Zeh, H.J., & Lotze, M.T. (2023). The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol, 23(12), 824-841.Springer Nature. doi: 10.1038/s41577-023-00894-6.
Bergmann, C., Poli, A., Agache, I., Bianchini, R., Bax, H.J., Castells, M., Crescioli, S., Dombrowicz, D., Ferastraoaru, D., Fiebiger, E., Gould, H.J., Hartmann, K., Izquierdo, E., Jordakieva, G., Josephs, D.H., Jutel, M., Levi-Schaffer, F., de Las Vecillas, L., Lotze, M.T., Osborn, G., Pascal, M., Redegeld, F., Rosenstreich, D., Roth-Walter, F., Schmidt-Weber, C., Shamji, M., Steveling, E.H., Turner, M.C., Untersmayr, E., Jensen-Jarolim, E., & Karagiannis, S.N. (2022). AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy, 77(9), 2594-2617.Wiley. doi: 10.1111/all.15255.
Biradar, S., Agarwal, Y., Lotze, M.T., Bility, M.T., & Mailliard, R.B. (2022). The BLT Humanized Mouse Model as a Tool for Studying Human Gamma Delta T Cell-HIV Interactions In Vivo. Front Immunol, 13, 881607.Frontiers. doi: 10.3389/fimmu.2022.881607.
Carleton, N., Nasrazadani, A., Gade, K., Beriwal, S., Barry, P.N., Brufsky, A.M., Bhargava, R., Berg, W.A., Zuley, M.L., van Londen, G.J., Marroquin, O.C., Thull, D.L., Mai, P.L., Diego, E.J., Lotze, M.T., Oesterreich, S., McAuliffe, P.F., & Lee, A.V. (2022). Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. Lancet Healthy Longev, 3(1), e54-e66.Elsevier. doi: 10.1016/s2666-7568(21)00280-4.
Cuyler, J., Murthy, P., Spada, N.G., McGuire, T.F., Lotze, M.T., & Xie, X.Q. (2022). Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discov Today, 27(1), 362-370.Elsevier. doi: 10.1016/j.drudis.2021.09.011.
Dhupar, R., Jones, K.E., Powers, A.A., Eisenberg, S.H., Ding, K., Chen, F., Nasarre, C., Cen, Z., Gong, Y.N., LaRue, A.C., Yeh, E.S., Luketich, J.D., Lee, A.V., Oesterreich, S., Lotze, M.T., Gemmill, R.M., & Soloff, A.C. (2022). Isoforms of Neuropilin-2 Denote Unique Tumor-Associated Macrophages in Breast Cancer. Front Immunol, 13, 830169.Frontiers. doi: 10.3389/fimmu.2022.830169.
Ekeke, C.N., Russell, K.L., Murthy, P., Guo, Z.S., Soloff, A.C., Weber, D., Pan, W., Lotze, M.T., & Dhupar, R. (2022). Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. J Thorac Cardiovasc Surg, 163(4), e313-e328.Elsevier. doi: 10.1016/j.jtcvs.2020.11.160.
Murthy, P., Li, K., Anderko, R.R., Singhi, A.D., DeSilva, A., Chopra, A., Hammad, A.Y., Paniccia, A., Morris, A., Lee, K.K., Mailliard, R.B., Lotze, M.T., Methe, B., & Zureikat, A.H. (2022). Gut microbiota composition and outcomes following neoadjuvant therapy in patients with localized pancreatic cancer: A prospective biomarker study. Journal of Clinical Oncology, 40(16_suppl), 4143.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2022.40.16_suppl.4143.
Powers, A.A., Eisenberg, S.H., Jones, K.E., Stabile, L.P., Lotze, M.T., Dhupar, R., & Soloff, A.C. (2022). 6.27 Cellular Indoctrination: How the Tumor Microenvironment Reeducates Macrophages Towards Nefarious Ends. In Comprehensive Pharmacology. (pp. 552-579).Elsevier. doi: 10.1016/b978-0-12-820472-6.00084-0.
AlMasri, S.S., Zenati, M.S., Desilva, A., Nassour, I., Boone, B.A., Singhi, A.D., Bartlett, D.L., Liotta, L.A., Espina, V., Loughran, P., Lotze, M.T., Paniccia, A., Zeh, H.J., Zureikat, A.H., & Bahary, N. (2021). Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. Cancer Med, 10(20), 7233-7241.Wiley. doi: 10.1002/cam4.4211.
Biradar, S., Agarwal, Y., Lotze, M.T., Rinaldo, C.R., Bility, M.T., & Mailliard, R.B. (2021). Adoptive transfer of allogeneic gamma delta T cells promotes HIV replication in a humanized mouse model. In bioRxiv. doi: 10.1101/2021.02.08.430263.
Chopra, A., Hodges, J.C., Olson, A., Burton, S., Ellsworth, S.G., Bahary, N., Singhi, A.D., Boone, B.A., Beane, J.D., Bartlett, D., Lee, K.K., Hogg, M.E., Lotze, M.T., Paniccia, A., Zeh, H., & Zureikat, A.H. (2021). Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Ann Surg Oncol, 28(7), 3779-3788.Springer Nature. doi: 10.1245/s10434-020-09391-9.
Chopra, A., Zamora, R., Vodovotz, Y., Hodges, J.C., Barclay, D., Brand, R., Simmons, R.L., Lee, K.K., Paniccia, A., Murthy, P., Lotze, M.T., Boone, B.A., & Zureikat, A.H. (2021). Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. J Immunother, 44(5), 185-192.Wolters Kluwer. doi: 10.1097/CJI.0000000000000370.
Ekeke, C.N., Russell, K.L., Joubert, K., Bartlett, D.L., Luketich, J.D., Soloff, A.C., Guo, Z.S., Lotze, M.T., & Dhupar, R. (2021). Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. Ann Surg Oncol, 28(5), 2715-2727.Springer Nature. doi: 10.1245/s10434-020-09477-4.
Feist, M., Zhu, Z., Dai, E., Ma, C., Liu, Z., Giehl, E., Ravindranathan, R., Kowalsky, S.J., Obermajer, N., Kammula, U.S., Lee, A.J.H., Lotze, M.T., Guo, Z.S., & Bartlett, D.L. (2021). Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther, 28(1-2), 98-111.Springer Nature. doi: 10.1038/s41417-020-0189-4.
Giehl, E., Kosaka, H., Liu, Z., Feist, M., Kammula, U.S., Lotze, M.T., Ma, C., Guo, Z.S., & Bartlett, D.L. (2021). In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. Front Immunol, 12, 610042.Frontiers. doi: 10.3389/fimmu.2021.610042.
Huang, J., Chen, P., Liu, K., Liu, J., Zhou, B., Wu, R., Peng, Q., Liu, Z.X., Li, C., Kroemer, G., Lotze, M., Zeh, H., Kang, R., & Tang, D. (2021). CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut, 70(5), 890-899.BMJ. doi: 10.1136/gutjnl-2019-320441.
Lotze, M.T., & Dhupar, R. (2021). ASO Author Reflection: Viruses, the Lung, and Thoracic Neoplasms: Breaking Bad. Ann Surg Oncol, 28(5), 2728-2729.Springer Nature. doi: 10.1245/s10434-020-09484-5.
Mendonça Gorgulho, C., Krishnamurthy, A., Lanzi, A., Galon, J., Housseau, F., Kaneno, R., & Lotze, M.T. (2021). Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. J Immunother, 44(2), 49-62.Wolters Kluwer. doi: 10.1097/CJI.0000000000000357.
Mohindroo, C., Hasanov, M., Rogers, J.E., Dong, W., Prakash, L.R., Baydogan, S., Mizrahi, J.D., Overman, M.J., Varadhachary, G.R., Wolff, R.A., Javle, M.M., Fogelman, D.R., Lotze, M.T., Kim, M.P., Katz, M.H.G., Pant, S., Tzeng, C.W.D., & McAllister, F. (2021). Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med, 10(15), 5041-5050.Wiley. doi: 10.1002/cam4.3870.
Murthy, P., Zenati, M., AlMasri, S., DeSilva, A., Bahary, N., Singhi, A., Ellsworth, S., Paniccia, A., Lee, K., Lotze, M., & Zureikat, A. (2021). The systemic immune-inflammation index (SII) predicts neoadjuvant therapy response and survival in patients with pancreatic cancer who are CA 19-9 non-secretors. Hepato Pancreato Biliary, 23, s457-s458.Elsevier. doi: 10.1016/j.hpb.2021.06.025.
Powers, A.A., Jones, K.E., Eisenberg, S.H., Rigatti, L.H., Ryan, J.P., Luketich, J.D., Lotze, M.T., LaRue, A.C., Dhupar, R., & Soloff, A.C. (2021). Experimental respiratory exposure to putative Gulf War toxins promotes persistent alveolar macrophage recruitment and pulmonary inflammation. Life Sci, 282, 119839.Elsevier. doi: 10.1016/j.lfs.2021.119839.
Telmer, C.A., Sayed, K., Butchy, A.A., Bocan, K., Kaltenmeier, C., Lotze, M., & Miskov-Zivanov, N. (2021). Computational modeling of cell signaling and mutations in pancreatic cancer. 2021.06.08.447557.Cold Spring Harbor Laboratory. doi: 10.1101/2021.06.08.447557.
Yuan, J.M., Wang, Y., Wang, R., Luu, H.N., Adams-Haduch, J., Koh, W.P., Gao, Y.T., Behari, J., & Lotze, M.T. (2021). Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Case-Control Studies. Cancer Epidemiol Biomarkers Prev, 30(2), 388-395.American Association for Cancer Research (AACR). doi: 10.1158/1055-9965.EPI-20-1081.
Zhang, X., Deibert, C.P., Kim, W.J., Jaman, E., Rao, A.V., Lotze, M.T., & Amankulor, N.M. (2021). Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. Cancer Gene Ther, 28(9), 971-983.Springer Nature. doi: 10.1038/s41417-020-0205-8.
Allen, A., Gau, D., Francoeur, P., Sturm, J., Wang, Y., Martin, R., Maranchie, J., Duensing, A., Kaczorowski, A., Duensing, S., Wu, L., Lotze, M.T., Koes, D., Storkus, W.J., & Roy, P. (2020). Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. J Biol Chem, 295(46), 15636-15649.Elsevier. doi: 10.1074/jbc.RA120.013963.
Ascierto, P.A., Fox, B.A., Urba, W.J., Anderson, A.C., Atkins, M.B., Borden, E.C., Brahmer, J.R., Butterfield, L.H., Cesano, A., Chen, D.C., de Gruijl, T.D., Dillman, R.O., Drake, C.G., Emens, L.A., Gajewski, T.F., Gulley, J.L., Stephen Hodi, F.J., Hwu, P., Kaufman, D., Kaufman, H.L., Lotze, M.T., McNeel, D.G., Margolin, K.M., Marincola, F.M., Mastrangelo, M.J., Maus, M.V., Parkinson, D.R., Romero, P.J., Sondel, P.M., Spranger, S., Sznol, M., Weiner, G.J., Wigginton, J.M., & Weber, J.S. (2020). Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer, 8(1).BMJ. doi: 10.1136/jitc-2020-000878.
Ascierto, P.A., Fox, B.A., Urba, W.J., Anderson, A.C., Atkins, M.B., Borden, E.C., Brahmer, J.R., Butterfield, L.H., Cesano, A., Chen, D.S., de Gruijl, T.D., Dillman, R.O., Drake, C.G., Emens, L.A., Gajewski, T.F., Gulley, J.L., Hodi, F.S.J., Hwu, P., Kaufman, D., Kaufman, H.L., Lotze, M.T., McNeel, D.G., Margolin, K.A., Marincola, F.M., Mastrangelo, M.J., Maus, M.V., Parkinson, D.R., Romero, P.J., Sondel, P.M., Spranger, S., Sznol, M., Weiner, G.J., Wigginton, J.M., & Weber, J.S. (2020). Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'. J Immunother Cancer, 8(2).BMJ. doi: 10.1136/jitc-2020-000878corr1Amendment.
Ascierto, P.A., Fox, B.A., Urba, W.J., Anderson, A.C., Atkins, M.B., Borden, E.C., Brahmer, J.R., Butterfield, L.H., Cesano, A., Chen, D.S., de Gruijl, T.D., Dillman, R.O., Drake, C.G., Emens, L.A., Gajewski, T.F., Gulley, J.L., Jr, H.F.S., Hwu, P., Kaufman, D., Kaufman, H.L., Lotze, M.T., McNeel, D.G., Margolin, K.A., Marincola, F.M., Mastrangelo, M.J., Maus, M.V., Parkinson, D.R., Romero, P.J., Sondel, P.M., Spranger, S., Sznol, M., Weiner, G.J., Wigginton, J.M., & Weber, J.S. (2020). Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer, 8(1).BMJ. doi: 10.1136/jitc-2020-000878corr1.
Biradar, S., Lotze, M., & Mailliard, R.B. (2020). Immunologic outcomes of bidirectional cross talk between gamma delta T cells and dendritic cells is context dependent. The Journal of Immunology, 204(1_Supplement), 74.1.Oxford University Press (OUP). doi: 10.4049/jimmunol.204.supp.74.1.
Biradar, S., Lotze, M.T., & Mailliard, R.B. (2020). The Unknown Unknowns: Recovering Gamma-Delta T Cells for Control of Human Immunodeficiency Virus (HIV). Viruses, 12(12).MDPI. doi: 10.3390/v12121455.
Borhani, A.A., Dewan, R., Furlan, A., Seiser, N., Zureikat, A.H., Singhi, A.D., Boone, B., Bahary, N., Hogg, M.E., Lotze, M., Zeh, H.J., & Tublin, M.E. (2020). Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol, 214(2), 362-369.American Roentgen Ray Society. doi: 10.2214/AJR.19.21152.
Brufsky, A., & Lotze, M.T. (2020). DC/L-SIGNs of hope in the COVID-19 pandemic. J Med Virol, 92(9), 1396-1398.Wiley. doi: 10.1002/jmv.25980.
Brufsky, A., & Lotze, M.T. (2020). Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic. J Med Virol, 92(11), 2379-2380.Wiley. doi: 10.1002/jmv.26067.
Brufsky, A., Marti, J.L.G., Nasrazadani, A., & Lotze, M.T. (2020). Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med, 18(1), 261.Springer Nature. doi: 10.1186/s12967-020-02433-6.
Chen, R., Huang, Y., Quan, J., Liu, J., Wang, H., Billiar, T.R., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2020). HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon, 6(12), e05672.Elsevier. doi: 10.1016/j.heliyon.2020.e05672.
Chopra, A., Hodges, J.C., Olson, A., Burton, S.A., Lee, K.K., Bahary, N., Singhi, A.D., Boone, B.A., Lotze, M.T., Hogg, M.E., Zeh, H., & Zureikat, A.H. (2020). Outcomes and efficacy of neoadjuvant chemoradiation versus chemotherapy in localized pancreatic cancer. Journal of Clinical Oncology, 38(4_suppl), 727.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2020.38.4_suppl.727.
Dhupar, R., Okusanya, O.T., Eisenberg, S.H., Monaco, S.E., Ruffin, A.T., Liu, D., Luketich, J.D., Kammula, U.S., Bruno, T.C., Lotze, M.T., & Soloff, A.C. (2020). Characteristics of Malignant Pleural Effusion Resident CD8+ T Cells from a Heterogeneous Collection of Tumors. Int J Mol Sci, 21(17).MDPI. doi: 10.3390/ijms21176178.
Fei, N., Wen, S., Ramanathan, R., Hogg, M.E., Zureikat, A., Lotze, M.T., Bahary, N., Singhi, A.D., Zeh, H.J., & Boone, B.A. (2020). SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma. In Research Square. doi: 10.21203/rs.3.rs-125334/v1.
Fei, N., Wen, S., Rao, P., Ramanathan, R., Hogg, M.E., Zureikat, A.H., Lotze, M.T., Bahary, N., Singhi, A.D., Zeh, H., & Boone, B.A. (2020). Association of SMAD4 loss with response to neoadjuvant chemotherapy with the autophagy inhibitor hydroxychloroquine in patients with pancreatic adenocarcinoma. Journal of Clinical Oncology, 38(4_suppl), 761.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2020.38.4_suppl.761.
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A.B., Chan, T.A., Coukos, G., Demaria, S., Deutsch, E., Draganov, D., Edelson, R.L., Formenti, S.C., Fucikova, J., Gabriele, L., Gaipl, U.S., Gameiro, S.R., Garg, A.D., Golden, E., Han, J., Harrington, K.J., Hemminki, A., Hodge, J.W., Hossain, D.M.S., Illidge, T., Karin, M., Kaufman, H.L., Kepp, O., Kroemer, G., Lasarte, J.J., Loi, S., Lotze, M.T., Manic, G., Merghoub, T., Melcher, A.A., Mossman, K.L., Prosper, F., Rekdal, O., Rescigno, M., Riganti, C., Sistigu, A., Smyth, M.J., Spisek, R., Stagg, J., Strauss, B.E., Tang, D., Tatsuno, K., van Gool, S.W., Vandenabeele, P., Yamazaki, T., Zamarin, D., Zitvogel, L., Cesano, A., & Marincola, F.M. (2020). Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer, 8(1).BMJ. doi: 10.1136/jitc-2019-000337corr1.
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A.B., Chan, T.A., Coukos, G., Demaria, S., Deutsch, E., Draganov, D., Edelson, R.L., Formenti, S.C., Fucikova, J., Gabriele, L., Gaipl, U.S., Gameiro, S.R., Garg, A.D., Golden, E., Han, J., Harrington, K.J., Hemminki, A., Hodge, J.W., Hossain, D.M.S., Illidge, T., Karin, M., Kaufman, H.L., Kepp, O., Kroemer, G., Lasarte, J.J., Loi, S., Lotze, M.T., Manic, G., Merghoub, T., Melcher, A.A., Mossman, K.L., Prosper, F., Rekdal, Ø., Rescigno, M., Riganti, C., Sistigu, A., Smyth, M.J., Spisek, R., Stagg, J., Strauss, B.E., Tang, D., Tatsuno, K., van Gool, S.W., Vandenabeele, P., Yamazaki, T., Zamarin, D., Zitvogel, L., Cesano, A., & Marincola, F.M. (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer, 8(1).BMJ. doi: 10.1136/jitc-2019-000337.
Gastman, B., Agarwal, P.K., Berger, A., Boland, G., Broderick, S., Butterfield, L.H., Byrd, D., Fecci, P.E., Ferris, R.L., Fong, Y., Goff, S.L., Grabowski, M.M., Ito, F., Lim, M., Lotze, M.T., Mahdi, H., Malafa, M., Morris, C.D., Murthy, P., Neves, R.I., Odunsi, A., Pai, S.I., Prabhakaran, S., Rosenberg, S.A., Saoud, R., Sethuraman, J., Skitzki, J., Slingluff, C.L., Sondak, V.K., Sunwoo, J.B., Turcotte, S., Yeung, C.C., & Kaufman, H.L. (2020). Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer, 8(2).BMJ. doi: 10.1136/jitc-2020-001583.
Guo, Z.S., Lotze, M.T., Zhu, Z., Storkus, W.J., & Song, X.T. (2020). Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines, 8(7).MDPI. doi: 10.3390/biomedicines8070204.
Han, J., & Lotze, M.T. (2020). The Adaptome as Biomarker for Assessing Cancer Immunity and Immunotherapy. Methods Mol Biol, 2055, 369-397.Springer Nature. doi: 10.1007/978-1-4939-9773-2_17.
Kammula, U.S., & Lotze, M.T. (2020). Cellular Therapy for Melanoma. In Cutaneous Melanoma. (pp. 1267-1299).Springer Nature. doi: 10.1007/978-3-030-05070-2_36.
Kang, R., Zeh, H., Lotze, M., & Tang, D. (2020). The Multifaceted Effects of Autophagy on the Tumor Microenvironment. Adv Exp Med Biol, 1225, 99-114.Springer Nature. doi: 10.1007/978-3-030-35727-6_7.
Ludwig, N., & Lotze, M.T. (2020). A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside. HNO, 68(2), 71-79.Springer Nature. doi: 10.1007/s00106-019-00803-1.
Murthy, P., Zenati, M.S., Al Abbas, A.I., Rieser, C.J., Bahary, N., Lotze, M.T., Zeh, H.J., Zureikat, A.H., & Boone, B.A. (2020). Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Ann Surg Oncol, 27(3), 898-906.Springer Nature. doi: 10.1245/s10434-019-08094-0.
Niu, X., Li, S., Li, P., Pan, W., Wang, Q., Feng, Y., Mo, X., Yan, Q., Ye, X., Luo, J., Qu, L., Weber, D., Byrne-Steele, M.L., Wang, Z., Yu, F., Li, F., Myers, R.M., Lotze, M.T., Zhong, N., Han, J., & Chen, L. (2020). Corrigendum: Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients. Front Immunol, 11, 633815.Frontiers. doi: 10.3389/fimmu.2020.633815.
Niu, X., Li, S., Li, P., Pan, W., Wang, Q., Feng, Y., Mo, X., Yan, Q., Ye, X., Luo, J., Qu, L., Weber, D., Byrne-Steele, M.L., Wang, Z., Yu, F., Li, F., Myers, R.M., Lotze, M.T., Zhong, N., Han, J., & Chen, L. (2020). Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients. Front Immunol, 11, 582010.Frontiers. doi: 10.3389/fimmu.2020.582010.
Soloff, A.C., Jones, K.E., Powers, A.A., Murthy, P., Wang, Y., Russell, K.L., Byrne-Steele, M., Lund, A.W., Yuan, J.M., Monaco, S.E., Han, J., Dhupar, R., & Lotze, M.T. (2020). HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions. Front Immunol, 11, 2027.Frontiers. doi: 10.3389/fimmu.2020.02027.
Zamame Ramirez, J.A., Romagnoli, G.G., Falasco, B.F., Gorgulho, C.M., Sanzochi Fogolin, C., Dos Santos, D.C., Junior, J.P.A., Lotze, M.T., Ureshino, R.P., & Kaneno, R. (2020). Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate. Int Immunopharmacol, 84, 106495.Elsevier. doi: 10.1016/j.intimp.2020.106495.
Zeh, H.J., Bahary, N., Boone, B.A., Singhi, A.D., Miller-Ocuin, J.L., Normolle, D.P., Zureikat, A.H., Hogg, M.E., Bartlett, D.L., Lee, K.K., Tsung, A., Marsh, J.W., Murthy, P., Tang, D., Seiser, N., Amaravadi, R.K., Espina, V., Liotta, L., & Lotze, M.T. (2020). A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res, 26(13), 3126-3134.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-19-4042.
Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K.K., Ziv, E., Chowell, D., Coussens, L.M., De Carvalho, D.D., DeNardo, D.G., Galon, J., Kaufman, H.L., Kirchhoff, T., Lotze, M.T., Luke, J.J., Minn, A.J., Politi, K., Shultz, L.D., Simon, R., Thórsson, V., Weidhaas, J.B., Ascierto, M.L., Ascierto, P.A., Barnes, J.M., Barsan, V., Bommareddy, P.K., Bot, A., Church, S.E., Ciliberto, G., De Maria, A., Draganov, D., Ho, W.S., McGee, H.M., Monette, A., Murphy, J.F., Nisticò, P., Park, W., Patel, M., Quigley, M., Radvanyi, L., Raftopoulos, H., Rudqvist, N.P., Snyder, A., Sweis, R.F., Valpione, S., Zappasodi, R., Butterfield, L.H., Disis, M.L., Fox, B.A., Cesano, A., Marincola, F.M., & Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. (2019). Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer, 7(1), 131.BMJ. doi: 10.1186/s40425-019-0602-4.
Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K.K., Ziv, E., Chowell, D., Coussens, L.M., De Carvalho, D.D., DeNardo, D.G., Galon, J., Kaufman, H.L., Kirchhoff, T., Lotze, M.T., Luke, J.J., Minn, A.J., Politi, K., Shultz, L.D., Simon, R., Thórsson, V., Weidhaas, J.B., Ascierto, M.L., Ascierto, P.A., Barnes, J.M., Barsan, V., Bommareddy, P.K., Bot, A., Church, S.E., Ciliberto, G., De Maria, A., Draganov, D., Ho, W.S., McGee, H.M., Monette, A., Murphy, J.F., Nisticò, P., Park, W., Patel, M., Quigley, M., Radvanyi, L., Raftopoulos, H., Rudqvist, N.P., Snyder, A., Sweis, R.F., Valpione, S., Zappasodi, R., Butterfield, L.H., Disis, M.L., Fox, B.A., Cesano, A., Marincola, F.M., & Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. (2019). Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer, 7(1), 167.BMJ. doi: 10.1186/s40425-019-0640-y.
Boone, B.A., Murthy, P., Miller-Ocuin, J.L., Liang, X., Russell, K.L., Loughran, P., Gawaz, M., Lotze, M.T., Zeh, H.J., & Vogel, S. (2019). The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Ann Hematol, 98(7), 1603-1610.Springer Nature. doi: 10.1007/s00277-019-03692-0.
Dafni, U., Michielin, O., Lluesma, S.M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M.J., Haanen, J., Svane, I.M., Ohashi, P.S., Kammula, U.S., Orcurto, A., Zimmermann, S., Trueb, L., Klebanoff, C.A., Lotze, M.T., Kandalaft, L.E., & Coukos, G. (2019). Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol, 30(12), 1902-1913.Elsevier. doi: 10.1093/annonc/mdz398.
Dafni, U., Michielin, O., Lluesma, S.M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M.J., Haanen, J., Svane, I.M., Ohashi, P.S., Kammula, U.S., Orcurto, A., Zimmermann, S., Trueb, L., Klebanoff, C.A., Lotze, M.T., Kandalaft, L.E., & Coukos, G. (2019). Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol, 30(12), 1902-1913. doi: 10.1093/annonc/mdz398.
Gorgulho, C.M., Romagnoli, G.G., Bharthi, R., & Lotze, M.T. (2019). Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1. Front Immunol, 10(JULY), 1561.Frontiers. doi: 10.3389/fimmu.2019.01561.
Kammula, U.S., & Lotze, M.T. (2019). Cellular Therapy for Melanoma. In Cutaneous Melanoma. (pp. 1-33).Springer Nature. doi: 10.1007/978-3-319-46029-1_36-1.
Li, G., Sachdev, U., Peters, K., Liang, X., & Lotze, M.T. (2019). The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration. J Immunother, 42(7), 237-243.Wolters Kluwer. doi: 10.1097/CJI.0000000000000290.
Mendonça Gorgulho, C., Murthy, P., Liotta, L., Espina, V., & Lotze, M.T. (2019). Different measures of HMGB1 location in cancer immunology. In TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - MOLECULAR METHODS. 629, (pp. 195-217).Elsevier. doi: 10.1016/bs.mie.2019.10.011.
Miller-Ocuin, J.L., Liang, X., Boone, B.A., Doerfler, W.R., Singhi, A.D., Tang, D., Kang, R., Lotze, M.T., & Zeh, H.J. (2019). DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth. Oncoimmunology, 8(9), e1605822.Taylor & Francis. doi: 10.1080/2162402X.2019.1605822.
Murthy, P., Ekeke, C.N., Russell, K.L., Butler, S.C., Wang, Y., Luketich, J.D., Soloff, A.C., Dhupar, R., & Lotze, M.T. (2019). Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology, 8(4), e1554969.Taylor & Francis. doi: 10.1080/2162402X.2018.1554969.
Murthy, P., Singhi, A.D., Ross, M.A., Loughran, P., Paragomi, P., Papachristou, G.I., Whitcomb, D.C., Zureikat, A.H., Lotze, M.T., Zeh Iii, H.J., & Boone, B.A. (2019). Enhanced Neutrophil Extracellular Trap Formation in Acute Pancreatitis Contributes to Disease Severity and Is Reduced by Chloroquine. Front Immunol, 10(JAN), 28.Frontiers. doi: 10.3389/fimmu.2019.00028.
Russell, K.L., Gorgulho, C.M., Allen, A., Vakaki, M., Wang, Y., Facciabene, A., Lee, D., Roy, P., Buchser, W.J., Appleman, L.J., Maranchie, J., Storkus, W.J., & Lotze, M.T. (2019). Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer J, 25(3), 165-177.Wolters Kluwer. doi: 10.1097/PPO.0000000000000374.
Soloff, A.C., & Lotze, M.T. (2019). A peaceful death orchestrates immune balance in a chaotic environment. Proc Natl Acad Sci U S A, 116(46), 22901-22903.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.1916211116.
Soloff, A.C., Stanton, R.A., Radio, N.M., Freilino-Glunt, M., Nasarre, C., Dimou, A., Nasarre, P., Denlinger, C.E., Oesterreich, S., Lee, A.V., Lotze, M.T., Dhupar, R., & Gemmill, R. (2019). Neuropilin-2 Isoforms Regulate Distinct Functions of Tumor-associated Macrophages in Breast Cancer. The Journal of Immunology, 202(1_Supplement), 187.23.Oxford University Press (OUP). doi: 10.4049/jimmunol.202.supp.187.23.
Tandon, M., Coudriet, G.M., Criscimanna, A., Socorro, M., Eliliwi, M., Singhi, A.D., Cruz-Monserrate, Z., Bailey, P., Lotze, M.T., Zeh, H., Hu, J., Goffin, V., Gittes, G.K., Biankin, A.V., & Esni, F. (2019). Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Cancer Res, 79(20), 5316-5327.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-18-3064.
Vogel, S., Murthy, P., Cui, X., Lotze, M.T., Zeh, H.J., & Sachdev, U. (2019). TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia. Biochem Biophys Res Commun, 508(2), 614-619.Elsevier. doi: 10.1016/j.bbrc.2018.11.125.
Yang, M., Chen, P., Liu, J., Zhu, S., Kroemer, G., Klionsky, D.J., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2019). Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv, 5(7), eaaw2238.American Association for the Advancement of Science (AAAS). doi: 10.1126/sciadv.aaw2238.
Yurube, T., Buchser, W.J., Moon, H.J., Hartman, R.A., Takayama, K., Kawakami, Y., Nishida, K., Kurosaka, M., Vo, N.V., Kang, J.D., Lotze, M.T., & Sowa, G.A. (2019). Serum and nutrient deprivation increase autophagic flux in intervertebral disc annulus fibrosus cells: an in vitro experimental study. Eur Spine J, 28(5), 993-1004.Springer Nature. doi: 10.1007/s00586-019-05910-9.
Anunobi, R., Boone, B.A., Cheh, N., Tang, D., Kang, R., Loux, T., Lotze, M.T., & Zeh, H.J. (2018). Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy. J Surg Res, 226, 181-191.Elsevier. doi: 10.1016/j.jss.2018.02.042.
Boone, B.A., Murthy, P., Miller-Ocuin, J., Doerfler, W.R., Ellis, J.T., Liang, X., Ross, M.A., Wallace, C.T., Sperry, J.L., Lotze, M.T., Neal, M.D., & Zeh, H.J. (2018). Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer, 18(1), 678.Springer Nature. doi: 10.1186/s12885-018-4584-2.
Chang, P.L. (2018). Somatic Gene Therapy. In Somatic Gene Therapy, Chang, P.L. (Ed.). (pp. 263-286).CRC Press. doi: 10.1201/9781351076760.
Chen, R., Zhu, S., Fan, X.G., Wang, H., Lotze, M.T., Zeh, H.J., Billiar, T.R., Kang, R., & Tang, D. (2018). High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology, 67(5), 1823-1841.Wolters Kluwer. doi: 10.1002/hep.29663.
Kim, H.Y., Wang, X., Kang, R., Tang, D., Boone, B.A., Zeh, H.J., Lotze, M.T., & Edwards, W.B. (2018). RAGE-specific single chain Fv for PET imaging of pancreatic cancer. In Hudson, B.I. (Ed.). PLoS One, 13(3), e0192821.Public Library of Science (PLoS). doi: 10.1371/journal.pone.0192821.
Li, C., Zhang, Y., Cheng, X., Yuan, H., Zhu, S., Liu, J., Wen, Q., Xie, Y., Liu, J., Kroemer, G., Klionsky, D.J., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2018). PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Dev Cell, 46(4), 441-455.e8.Elsevier. doi: 10.1016/j.devcel.2018.07.012.
Song, X., Zhu, S., Chen, P., Hou, W., Wen, Q., Liu, J., Xie, Y., Liu, J., Klionsky, D.J., Kroemer, G., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2018). AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol, 28(15), 2388-2399.e5.Elsevier. doi: 10.1016/j.cub.2018.05.094.
Song, X., Zhu, S., Xie, Y., Liu, J., Sun, L., Zeng, D., Wang, P., Ma, X., Kroemer, G., Bartlett, D.L., Billiar, T.R., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2018). JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology, 154(5), 1480-1493.Elsevier. doi: 10.1053/j.gastro.2017.12.004.
Appleman, L.J., Logan, T.F., Normolle, D.P., Ernstoff, M.S., Parikh, R.A., McDermott, D.F., Monk, P., Olencki, T., Friedland, D., Maranchie, J.K., & Lotze, M.T. (2017). Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study. Journal of Clinical Oncology, 35(6_suppl), 440.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2017.35.6_suppl.440.
Dhupar, R., Van Der Kraak, L., Pennathur, A., Schuchert, M.J., Nason, K.S., Luketich, J.D., & Lotze, M.T. (2017). Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. Ann Thorac Surg, 103(4), 1340-1349.Elsevier. doi: 10.1016/j.athoracsur.2016.12.011.
Goding, S.R., Yu, S., Bailey, L.M., Lotze, M.T., & Basse, P.H. (2017). Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells. Clin Immunol, 177, 76-86.Elsevier. doi: 10.1016/j.clim.2016.06.013.
Kaltenmeier, C.T., Vollmer, L.L., Vernetti, L.A., Caprio, L., Davis, K., Korotchenko, V.N., Day, B.W., Tsang, M., Hulkower, K.I., Lotze, M.T., & Vogt, A. (2017). A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther, 361(1), 39-50.Elsevier. doi: 10.1124/jpet.116.239756.
Kang, R., Xie, Y., Zhang, Q., Hou, W., Jiang, Q., Zhu, S., Liu, J., Zeng, D., Wang, H., Bartlett, D.L., Billiar, T.R., Zeh, H.J., Lotze, M.T., & Tang, D. (2017). Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res, 27(7), 916-932.Springer Nature. doi: 10.1038/cr.2017.51.
Marincola, F.M., & Lotze, M.T. (2017). Introduction to Basic Sciences—Cracking the Code of Cancer Immune Responsiveness and the Evolution of Cancer Biology. In Cancer Immunotherapy Principles and Practice. Springer Publishing Company. doi: 10.1891/9781617052736.0002.
Murthy, P., Durco, F., Miller-Ocuin, J.L., Takedai, T., Shankar, S., Liang, X., Liu, X., Cui, X., Sachdev, U., Rath, D., Lotze, M.T., Zeh, H.J., Gawaz, M., Weber, A.N., & Vogel, S. (2017). The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. Biochem Biophys Res Commun, 483(1), 230-236.Elsevier. doi: 10.1016/j.bbrc.2016.12.161.
Sachdev, U., & Lotze, M.T. (2017). Perpetual change: autophagy, the endothelium, and response to vascular injury. J Leukoc Biol, 102(2), 221-235.Oxford University Press (OUP). doi: 10.1189/jlb.3RU1116-484RR.
Snyder, H.M., Ahles, T., Calderwood, S., Carrillo, M.C., Chen, H., Chang, C.C.H., Craft, S., De Jager, P., Driver, J.A., Fillit, H., Knopman, D., Lotze, M., Tierney, M.C., Petanceska, S., Saykin, A., Seshadri, S., Shineman, D., & Ganguli, M. (2017). Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. Alzheimers Dement, 13(3), 267-273.Wiley. doi: 10.1016/j.jalz.2016.11.002.
Snyder, H.M., Ahles, T., Calderwood, S., Carrillo, M.C., Chen, H., Chang, C.C.H., Craft, S., De Jager, P., Driver, J.A., Fillit, H., Knopmann, D., Lotze, M., Tierney, M.C., Petanceska, S., Saykin, A., Seshadri, S., Shineman, D., & Ganguli, M. (2017). Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association. & Alzheimer's Drug Discovery Foundation. ALZHEIMERS & DEMENTIA, 13(3), 267-273. doi: 10.1016/j.jalz.2016.11.002.
Xie, Y., Zhu, S., Song, X., Sun, X., Fan, Y., Liu, J., Zhong, M., Yuan, H., Zhang, L., Billiar, T.R., Lotze, M.T., Zeh, H.J., Kang, R., Kroemer, G., & Tang, D. (2017). The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Rep, 20(7), 1692-1704.Elsevier. doi: 10.1016/j.celrep.2017.07.055.
Xie, Y., Zhu, S., Zhong, M., Yang, M., Sun, X., Liu, J., Kroemer, G., Lotze, M., Zeh, H.J., Kang, R., & Tang, D. (2017). Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Gastroenterology, 153(5), 1429-1443.e5.Elsevier. doi: 10.1053/j.gastro.2017.07.036.
Zhu, S., Zhang, Q., Sun, X., Zeh, H.J., Lotze, M.T., Kang, R., & Tang, D. (2017). HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Res, 77(8), 2064-2077.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-16-1979.
Chen, R., Xie, Y., Zhong, X., Fu, Y., Huang, Y., Zhen, Y., Pan, P., Wang, H., Bartlett, D.L., Billiar, T.R., Lotze, M.T., Zeh, H.J., Fan, X.G., Tang, D., & Kang, R. (2016). Novel chemokine-like activities of histones in tumor metastasis. Oncotarget, 7(38), 61728-61740.Impact Journals. doi: 10.18632/oncotarget.11226.
Goel, G., Ramanan, K., Kaltenmeier, C., Zhang, L., Freeman, G.J., Normolle, D.P., Tang, D., & Lotze, M.T. (2016). Effect of 5-fluorouracil on membranous PD-L1 expression in colon cancer cells. JOURNAL OF CLINICAL ONCOLOGY, 34(4).American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2016.34.4_suppl.592.
Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2016). Autophagy promotes ferroptosis by degradation of ferritin. Autophagy, 12(8), 1425-1428.Taylor & Francis. doi: 10.1080/15548627.2016.1187366.
Kang, R., Chen, R., Xie, M., Cao, L., Lotze, M.T., Tang, D., & Zeh, H.J. (2016). The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. J Immunol, 196(10), 4331-4337.Oxford University Press (OUP). doi: 10.4049/jimmunol.1502340.
Klionsky, D.J., Abdelmohsen, K., Abe, A., Abedin, M.J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C.M., Adams, P.D., Adeli, K., Adhihetty, P.J., Adler, S.G., Agam, G., Agarwal, R., Aghi, M.K., Agnello, M., Agostinis, P., Aguilar, P.V., Aguirre-Ghiso, J., Airoldi, E.M., Ait-Si-Ali, S., Akematsu, T., Akporiaye, E.T., Al-Rubeai, M., Albaiceta, G.M., Albanese, C., Albani, D., Albert, M.L., Aldudo, J., Algül, H., Alirezaei, M., Alloza, I., Almasan, A., Almonte-Beceril, M., Alnemri, E.S., Alonso, C., Altan-Bonnet, N., Altieri, D.C., Alvarez, S., Alvarez-Erviti, L., Alves, S., Amadoro, G., Amano, A., Amantini, C., Ambrosio, S., Amelio, I., Amer, A.O., Amessou, M., Amon, A., An, Z., Anania, F.A., Andersen, S.U., Andley, U.P., Andreadi, C.K., Andrieu-Abadie, N., Anel, A., Ann, D.K., Anoopkumar-Dukie, S., Antonioli, M., Aoki, H., Apostolova, N., Aquila, S., Aquilano, K., Araki, K., Arama, E., Aranda, A., Araya, J., Arcaro, A., Arias, E., Arimoto, H., Ariosa, A.R., Armstrong, J.L., Arnould, T., Arsov, I., Asanuma, K., Askanas, V., Asselin, E., Atarashi, R., Atherton, S.S., Atkin, J.D., Attardi, L.D., Auberger, P., Auburger, G., Aurelian, L., Autelli, R., Avagliano, L., Avantaggiati, M.L., Avrahami, L., Awale, S., Azad, N., Bachetti, T., Backer, J.M., Bae, D.H., Bae, J.S., Bae, O.N., Bae, S.H., Baehrecke, E.H., Baek, S.H., Baghdiguian, S., Bagniewska-Zadworna, A., Bai, H., Bai, J., Bai, X.Y., Bailly, Y., Balaji, K.N., Balduini, W., Ballabio, A., Balzan, R., Banerjee, R., Bánhegyi, G., Bao, H., Barbeau, B., Barrachina, M.D., Barreiro, E., Bartel, B., Bartolomé, A., Bassham, D.C., Bassi, M.T., Bast, R.C., Basu, A., Batista, M.T., Batoko, H., Battino, M., Bauckman, K., Baumgarner, B.L., Bayer, K.U., Beale, R., Beaulieu, J.F., Beck, G.R., Becker, C., Beckham, J.D., Bédard, P.A., Bednarski, P.J., Begley, T.J., Behl, C., Behrends, C., Behrens, G.M., Behrns, K.E., Bejarano, E., Belaid, A., Belleudi, F., Bénard, G., Berchem, G., Bergamaschi, D., Bergami, M., Berkhout, B., Berliocchi, L., Bernard, A., Bernard, M., Bernassola, F., Bertolotti, A., Bess, A.S., Besteiro, S., Bettuzzi, S., Bhalla, S., Bhattacharyya, S., Bhutia, S.K., Biagosch, C., Bianchi, M.W., Biard-Piechaczyk, M., Billes, V., Bincoletto, C., Bingol, B., Bird, S.W., Bitoun, M., Bjedov, I., Blackstone, C., Blanc, L., Blanco, G.A., Blomhoff, H.K., Boada-Romero, E., Böckler, S., Boes, M., Boesze-Battaglia, K., Boise, L.H., Bolino, A., Boman, A., Bonaldo, P., Bordi, M., Bosch, J., Botana, L.M., Botti, J., Bou, G., Bouché, M., Bouchecareilh, M., Boucher, M.J., Boulton, M.E., Bouret, S.G., Boya, P., Boyer-Guittaut, M., Bozhkov, P.V., Brady, N., Braga, V.M., Brancolini, C., Braus, G.H., Bravo-San Pedro, J.M., Brennan, L.A., Bresnick, E.H., Brest, P., Bridges, D., Bringer, M.A., Brini, M., Brito, G.C., Brodin, B., Brookes, P.S., Brown, E.J., Brown, K., Broxmeyer, H.E., Bruhat, A., Brum, P.C., Brumell, J.H., Brunetti-Pierri, N., Bryson-Richardson, R.J., Buch, S., Buchan, A.M., Budak, H., Bulavin, D.V., Bultman, S.J., Bultynck, G., Bumbasirevic, V., Burelle, Y., Burke, R.E., Burmeister, M., Bütikofer, P., Caberlotto, L., Cadwell, K., Cahova, M., Cai, D., Cai, J., Cai, Q., Calatayud, S., Camougrand, N., Campanella, M., Campbell, G.R., Campbell, M., Campello, S., Candau, R., Caniggia, I., Cantoni, L., Cao, L., Caplan, A.B., Caraglia, M., Cardinali, C., Cardoso, S.M., Carew, J.S., Carleton, L.A., Carlin, C.R., Carloni, S., Carlsson, S.R., Carmona-Gutierrez, D., Carneiro, L.A., Carnevali, O., Carra, S., Carrier, A., Carroll, B., Casas, C., Casas, J., Cassinelli, G., Castets, P., Castro-Obregon, S., Cavallini, G., Ceccherini, I., Cecconi, F., Cederbaum, A.I., Ceña, V., Cenci, S., Cerella, C., Cervia, D., Cetrullo, S., Chaachouay, H., Chae, H.J., Chagin, A.S., Chai, C.Y., Chakrabarti, G., Chamilos, G., Chan, E.Y., Chan, M.T., Chandra, D., Chandra, P., Chang, C.P., Chang, R.C.C., Chang, T.Y., Chatham, J.C., Chatterjee, S., Chauhan, S., Che, Y., Cheetham, M.E., Cheluvappa, R., Chen, C.J., Chen, G., Chen, G.C., Chen, G., Chen, H., Chen, J.W., Chen, J.K., Chen, M., Chen, M., Chen, P., Chen, Q., Chen, Q., Chen, S.D., Chen, S., Chen, S.S.L., Chen, W., Chen, W.J., Chen, W.Q., Chen, W., Chen, X., Chen, Y.H., Chen, Y.G., Chen, Y., Chen, Y., Chen, Y., Chen, Y.J., Chen, Y.Q., Chen, Y., Chen, Z., Chen, Z., Cheng, A., Cheng, C.H., Cheng, H., Cheong, H., Cherry, S., Chesney, J., Cheung, C.H.A., Chevet, E., Chi, H.C., Chi, S.G., Chiacchiera, F., Chiang, H.L., Chiarelli, R., Chiariello, M., Chieppa, M., Chin, L.S., Chiong, M., Chiu, G.N., Cho, D.H., Cho, S.G., Cho, W.C., Cho, Y.Y., Cho, Y.S., Choi, A.M., Choi, E.J., Choi, E.K., Choi, J., Choi, M.E., Choi, S.I., Chou, T.F., Chouaib, S., Choubey, D., Choubey, V., Chow, K.C., Chowdhury, K., Chu, C.T., Chuang, T.H., Chun, T., Chung, H., Chung, T., Chung, Y.L., Chwae, Y.J., Cianfanelli, V., Ciarcia, R., Ciechomska, I.A., Ciriolo, M.R., Cirone, M., Claerhout, S., Clague, M.J., Clària, J., Clarke, P.G., Clarke, R., Clementi, E., Cleyrat, C., Cnop, M., Coccia, E.M., Cocco, T., Codogno, P., Coers, J., Cohen, E.E., Colecchia, D., Coletto, L., Coll, N.S., Colucci-Guyon, E., Comincini, S., Condello, M., Cook, K.L., Coombs, G.H., Cooper, C.D., Cooper, J.M., Coppens, I., Corasaniti, M.T., Corazzari, M., Corbalan, R., Corcelle-Termeau, E., Cordero, M.D., Corral-Ramos, C., Corti, O., Cossarizza, A., Costelli, P., Costes, S., Cotman, S.L., Coto-Montes, A., Cottet, S., Couve, E., Covey, L.R., Cowart, L.A., Cox, J.S., Coxon, F.P., Coyne, C.B., Cragg, M.S., Craven, R.J., Crepaldi, T., Crespo, J.L., Criollo, A., Crippa, V., Cruz, M.T., Cuervo, A.M., Cuezva, J.M., Cui, T., Cutillas, P.R., Czaja, M.J., Czyzyk-Krzeska, M.F., Dagda, R.K., Dahmen, U., Dai, C., Dai, W., Dai, Y., Dalby, K.N., Dalla Valle, L., Dalmasso, G., D'Amelio, M., Damme, M., Darfeuille-Michaud, A., Dargemont, C., Darley-Usmar, V.M., Dasarathy, S., Dasgupta, B., Dash, S., Dass, C.R., Davey, H.M., Davids, L.M., Dávila, D., Davis, R.J., Dawson, T.M., Dawson, V.L., Daza, P., de Belleroche, J., de Figueiredo, P., de Figueiredo, R.C.B.Q., de la Fuente, J., De Martino, L., De Matteis, A., De Meyer, G.R., De Milito, A., De Santi, M., de Souza, W., De Tata, V., De Zio, D., Debnath, J., Dechant, R., Decuypere, J.P., Deegan, S., Dehay, B., Del Bello, B., Del Re, D.P., Delage-Mourroux, R., Delbridge, L.M., Deldicque, L., Delorme-Axford, E., Deng, Y., Dengjel, J., Denizot, M., Dent, P., Der, C.J., Deretic, V., Derrien, B., Deutsch, E., Devarenne, T.P., Devenish, R.J., Di Bartolomeo, S., Di Daniele, N., Di Domenico, F., Di Nardo, A., Di Paola, S., Di Pietro, A., Di Renzo, L., DiAntonio, A., Díaz-Araya, G., Díaz-Laviada, I., Diaz-Meco, M.T., Diaz-Nido, J., Dickey, C.A., Dickson, R.C., Diederich, M., Digard, P., Dikic, I., Dinesh-Kumar, S.P., Ding, C., Ding, W.X., Ding, Z., Dini, L., Distler, J.H., Diwan, A., Djavaheri-Mergny, M., Dmytruk, K., Dobson, R.C., Doetsch, V., Dokladny, K., Dokudovskaya, S., Donadelli, M., Dong, X.C., Dong, X., Dong, Z., Donohue, T.M., Doran, K.S., D'Orazi, G., Dorn, G.W., Dosenko, V., Dridi, S., Drucker, L., Du, J., Du, L.L., Du, L., du Toit, A., Dua, P., Duan, L., Duann, P., Dubey, V.K., Duchen, M.R., Duchosal, M.A., Duez, H., Dugail, I., Dumit, V.I., Duncan, M.C., Dunlop, E.A., Dunn, W.A., Dupont, N., Dupuis, L., Durán, R.V., Durcan, T.M., Duvezin-Caubet, S., Duvvuri, U., Eapen, V., Ebrahimi-Fakhari, D., Echard, A., Eckhart, L., Edelstein, C.L., Edinger, A.L., Eichinger, L., Eisenberg, T., Eisenberg-Lerner, A., Eissa, N.T., El-Deiry, W.S., El-Khoury, V., Elazar, Z., Eldar-Finkelman, H., Elliott, C.J., Emanuele, E., Emmenegger, U., Engedal, N., Engelbrecht, A.M., Engelender, S., Enserink, J.M., Erdmann, R., Erenpreisa, J., Eri, R., Eriksen, J.L., Erman, A., Escalante, R., Eskelinen, E.L., Espert, L., Esteban-Martínez, L., Evans, T.J., Fabri, M., Fabrias, G., Fabrizi, C., Facchiano, A., Færgeman, N.J., Faggioni, A., Fairlie, W.D., Fan, C., Fan, D., Fan, J., Fang, S., Fanto, M., Fanzani, A., Farkas, T., Faure, M., Favier, F.B., Fearnhead, H., Federici, M., Fei, E., Felizardo, T.C., Feng, H., Feng, Y., Feng, Y., Ferguson, T.A., Fernández, Á.F., Fernandez-Barrena, M.G., Fernandez-Checa, J.C., Fernández-López, A., Fernandez-Zapico, M.E., Feron, O., Ferraro, E., Ferreira-Halder, C.V., Fesus, L., Feuer, R., Fiesel, F.C., Filippi-Chiela, E.C., Filomeni, G., Fimia, G.M., Fingert, J.H., Finkbeiner, S., Finkel, T., Fiorito, F., Fisher, P.B., Flajolet, M., Flamigni, F., Florey, O., Florio, S., Floto, R.A., Folini, M., Follo, C., Fon, E.A., Fornai, F., Fortunato, F., Fraldi, A., Franco, R., Francois, A., François, A., Frankel, L.B., Fraser, I.D., Frey, N., Freyssenet, D.G., Frezza, C., Friedman, S.L., Frigo, D.E., Fu, D., Fuentes, J.M., Fueyo, J., Fujitani, Y., Fujiwara, Y., Fujiya, M., Fukuda, M., Fulda, S., Fusco, C., Gabryel, B., Gaestel, M., Gailly, P., Gajewska, M., Galadari, S., Galili, G., Galindo, I., Galindo, M.F., Galliciotti, G., Galluzzi, L., Galluzzi, L., Galy, V., Gammoh, N., Gandy, S., Ganesan, A.K., Ganesan, S., Ganley, I.G., Gannagé, M., Gao, F.B., Gao, F., Gao, J.X., García Nannig, L., García Véscovi, E., Garcia-Macía, M., Garcia-Ruiz, C., Garg, A.D., Garg, P.K., Gargini, R., Gassen, N.C., Gatica, D., Gatti, E., Gavard, J., Gavathiotis, E., Ge, L., Ge, P., Ge, S., Gean, P.W., Gelmetti, V., Genazzani, A.A., Geng, J., Genschik, P., Gerner, L., Gestwicki, J.E., Gewirtz, D.A., Ghavami, S., Ghigo, E., Ghosh, D., Giammarioli, A.M., Giampieri, F., Giampietri, C., Giatromanolaki, A., Gibbings, D.J., Gibellini, L., Gibson, S.B., Ginet, V., Giordano, A., Giorgini, F., Giovannetti, E., Girardin, S.E., Gispert, S., Giuliano, S., Gladson, C.L., Glavic, A., Gleave, M., Godefroy, N., Gogal, R.M., Gokulan, K., Goldman, G.H., Goletti, D., Goligorsky, M.S., Gomes, A.V., Gomes, L.C., Gomez, H., Gomez-Manzano, C., Gómez-Sánchez, R., Gonçalves, D.A., Goncu, E., Gong, Q., Gongora, C., Gonzalez, C.B., Gonzalez-Alegre, P., Gonzalez-Cabo, P., González-Polo, R.A., Goping, I.S., Gorbea, C., Gorbunov, N.V., Goring, D.R., Gorman, A.M., Gorski, S.M., Goruppi, S., Goto-Yamada, S., Gotor, C., Gottlieb, R.A., Gozes, I., Gozuacik, D., Graba, Y., Graef, M., Granato, G.E., Grant, G.D., Grant, S., Gravina, G.L., Green, D.R., Greenhough, A., Greenwood, M.T., Grimaldi, B., Gros, F., Grose, C., Groulx, J.F., Gruber, F., Grumati, P., Grune, T., Guan, J.L., Guan, K.L., Guerra, B., Guillen, C., Gulshan, K., Gunst, J., Guo, C., Guo, L., Guo, M., Guo, W., Guo, X.G., Gust, A.A., Gustafsson, Å.B., Gutierrez, E., Gutierrez, M.G., Gwak, H.S., Haas, A., Haber, J.E., Hadano, S., Hagedorn, M., Hahn, D.R., Halayko, A.J., Hamacher-Brady, A., Hamada, K., Hamai, A., Hamann, A., Hamasaki, M., Hamer, I., Hamid, Q., Hammond, E.M., Han, F., Han, W., Handa, J.T., Hanover, J.A., Hansen, M., Harada, M., Harhaji-Trajkovic, L., Harper, J.W., Harrath, A.H., Harris, A.L., Harris, J., Hasler, U., Hasselblatt, P., Hasui, K., Hawley, R.G., Hawley, T.S., He, C., He, C.Y., He, F., He, G., He, R.R., He, X.H., He, Y.W., He, Y.Y., Heath, J.K., Hébert, M.J., Heinzen, R.A., Helgason, G.V., Hensel, M., Henske, E.P., Her, C., Herman, P.K., Hernández, A., Hernandez, C., Hernández-Tiedra, S., Hetz, C., Hiesinger, P.R., Higaki, K., Hilfiker, S., Hill, B.G., Hill, J.A., Hill, W.D., Hino, K., Hofius, D., Hofman, P., Höglinger, G.U., Höhfeld, J., Holz, M.K., Hong, Y., Hood, D.A., Hoozemans, J.J., Hoppe, T., Hsu, C., Hsu, C.Y., Hsu, L.C., Hu, D., Hu, G., Hu, H.M., Hu, H., Hu, M.C., Hu, Y.C., Hu, Z.W., Hua, F., Hua, Y., Huang, C., Huang, H.L., Huang, K.H., Huang, K.Y., Huang, S., Huang, S., Huang, W.P., Huang, Y.R., Huang, Y., Huang, Y., Huber, T.B., Huebbe, P., Huh, W.K., Hulmi, J.J., Hur, G.M., Hurley, J.H., Husak, Z., Hussain, S.N., Hussain, S., Hwang, J.J., Hwang, S., Hwang, T.I., Ichihara, A., Imai, Y., Imbriano, C., Inomata, M., Into, T., Iovane, V., Iovanna, J.L., Iozzo, R.V., Ip, N.Y., Irazoqui, J.E., Iribarren, P., Isaka, Y., Isakovic, A.J., Ischiropoulos, H., Isenberg, J.S., Ishaq, M., Ishida, H., Ishii, I., Ishmael, J.E., Isidoro, C., Isobe, K.I., Isono, E., Issazadeh-Navikas, S., Itahana, K., Itakura, E., Ivanov, A.I., Iyer, A.K.V., Izquierdo, J.M., Izumi, Y., Izzo, V., Jäättelä, M., Jaber, N., Jackson, D.J., Jackson, W.T., Jacob, T.G., Jacques, T.S., Jagannath, C., Jain, A., Jana, N.R., Jang, B.K., Jani, A., Janji, B., Jannig, P.R., Jansson, P.J., Jean, S., Jendrach, M., Jeon, J.H., Jessen, N., Jeung, E.B., Jia, K., Jia, L., Jiang, H., Jiang, H., Jiang, L., Jiang, T., Jiang, X., Jiang, X., Jiang, X., Jiang, Y., Jiang, Y., Jiménez, A., Jin, C., Jin, H., Jin, L., Jin, M., Jin, S., Jinwal, U.K., Jo, E.K., Johansen, T., Johnson, D.E., Johnson, G.V., Johnson, J.D., Jonasch, E., Jones, C., Joosten, L.A., Jordan, J., Joseph, A.M., Joseph, B., Joubert, A.M., Ju, D., Ju, J., Juan, H.F., Juenemann, K., Juhász, G., Jung, H.S., Jung, J.U., Jung, Y.K., Jungbluth, H., Justice, M.J., Jutten, B., Kaakoush, N.O., Kaarniranta, K., Kaasik, A., Kabuta, T., Kaeffer, B., Kågedal, K., Kahana, A., Kajimura, S., Kakhlon, O., Kalia, M., Kalvakolanu, D.V., Kamada, Y., Kambas, K., Kaminskyy, V.O., Kampinga, H.H., Kandouz, M., Kang, C., Kang, R., Kang, T.C., Kanki, T., Kanneganti, T.D., Kanno, H., Kanthasamy, A.G., Kantorow, M., Kaparakis-Liaskos, M., Kapuy, O., Karantza, V., Karim, M.R., Karmakar, P., Kaser, A., Kaushik, S., Kawula, T., Kaynar, A.M., Ke, P.Y., Ke, Z.J., Kehrl, J.H., Keller, K.E., Kemper, J.K., Kenworthy, A.K., Kepp, O., Kern, A., Kesari, S., Kessel, D., Ketteler, R., Kettelhut, I.D.C., Khambu, B., Khan, M.M., Khandelwal, V.K., Khare, S., Kiang, J.G., Kiger, A.A., Kihara, A., Kim, A.L., Kim, C.H., Kim, D.R., Kim, D.H., Kim, E.K., Kim, H.Y., Kim, H.R., Kim, J.S., Kim, J.H., Kim, J.C., Kim, J.H., Kim, K.W., Kim, M.D., Kim, M.M., Kim, P.K., Kim, S.W., Kim, S.Y., Kim, Y.S., Kim, Y., Kimchi, A., Kimmelman, A.C., Kimura, T., King, J.S., Kirkegaard, K., Kirkin, V., Kirshenbaum, L.A., Kishi, S., Kitajima, Y., Kitamoto, K., Kitaoka, Y., Kitazato, K., Kley, R.A., Klimecki, W.T., Klinkenberg, M., Klucken, J., Knævelsrud, H., Knecht, E., Knuppertz, L., Ko, J.L., Kobayashi, S., Koch, J.C., Koechlin-Ramonatxo, C., Koenig, U., Koh, Y.H., Köhler, K., Kohlwein, S.D., Koike, M., Komatsu, M., Kominami, E., Kong, D., Kong, H.J., Konstantakou, E.G., Kopp, B.T., Korcsmaros, T., Korhonen, L., Korolchuk, V.I., Koshkina, N.V., Kou, Y., Koukourakis, M.I., Koumenis, C., Kovács, A.L., Kovács, T., Kovacs, W.J., Koya, D., Kraft, C., Krainc, D., Kramer, H., Kravic-Stevovic, T., Krek, W., Kretz-Remy, C., Krick, R., Krishnamurthy, M., Kriston-Vizi, J., Kroemer, G., Kruer, M.C., Kruger, R., Ktistakis, N.T., Kuchitsu, K., Kuhn, C., Kumar, A.P., Kumar, A., Kumar, A., Kumar, D., Kumar, D., Kumar, R., Kumar, S., Kundu, M., Kung, H.J., Kuno, A., Kuo, S.H., Kuret, J., Kurz, T., Kwok, T., Kwon, T.K., Kwon, Y.T., Kyrmizi, I., La Spada, A.R., Lafont, F., Lahm, T., Lakkaraju, A., Lam, T., Lamark, T., Lancel, S., Landowski, T.H., Lane, D.J.R., Lane, J.D., Lanzi, C., Lapaquette, P., Lapierre, L.R., Laporte, J., Laukkarinen, J., Laurie, G.W., Lavandero, S., Lavie, L., LaVoie, M.J., Law, B.Y.K., Law, H.K.W., Law, K.B., Layfield, R., Lazo, P.A., Le Cam, L., Le Roch, K.G., Le Stunff, H., Leardkamolkarn, V., Lecuit, M., Lee, B.H., Lee, C.H., Lee, E.F., Lee, G.M., Lee, H.J., Lee, H., Lee, J.K., Lee, J., Lee, J.H., Lee, J.H., Lee, M., Lee, M.S., Lee, P.J., Lee, S.W., Lee, S.J., Lee, S.J., Lee, S.Y., Lee, S.H., Lee, S.S., Lee, S.J., Lee, S., Lee, Y.R., Lee, Y.J., Lee, Y.H., Leeuwenburgh, C., Lefort, S., Legouis, R., Lei, J., Lei, Q.Y., Leib, D.A., Leibowitz, G., Lekli, I., Lemaire, S.D., Lemasters, J.J., Lemberg, M.K., Lemoine, A., Leng, S., Lenz, G., Lenzi, P., Lerman, L.O., Lettieri Barbato, D., Leu, J.I.J., Leung, H.Y., Levine, B., Lewis, P.A., Lezoualc'h, F., Li, C., Li, F., Li, F.J., Li, J., Li, K., Li, L., Li, M., Li, M., Li, Q., Li, R., Li, S., Li, W., Li, W., Li, X., Li, Y., Lian, J., Liang, C., Liang, Q., Liao, Y., Liberal, J., Liberski, P.P., Lie, P., Lieberman, A.P., Lim, H.J., Lim, K.L., Lim, K., Lima, R.T., Lin, C.S., Lin, C.F., Lin, F., Lin, F., Lin, F.C., Lin, K., Lin, K.H., Lin, P.H., Lin, T., Lin, W.W., Lin, Y.S., Lin, Y., Linden, R., Lindholm, D., Lindqvist, L.M., Lingor, P., Linkermann, A., Liotta, L.A., Lipinski, M.M., Lira, V.A., Lisanti, M.P., Liton, P.B., Liu, B., Liu, C., Liu, C.F., Liu, F., Liu, H.J., Liu, J., Liu, J.J., Liu, J.L., Liu, K., Liu, L., Liu, L., Liu, Q., Liu, R.Y., Liu, S., Liu, S., Liu, W., Liu, X.D., Liu, X., Liu, X.H., Liu, X., Liu, X., Liu, X., Liu, Y., Liu, Y., Liu, Z., Liu, Z., Liuzzi, J.P., Lizard, G., Ljujic, M., Lodhi, I.J., Logue, S.E., Lokeshwar, B.L., Long, Y.C., Lonial, S., Loos, B., López-Otín, C., López-Vicario, C., Lorente, M., Lorenzi, P.L., Lõrincz, P., Los, M., Lotze, M.T., Lovat, P.E., Lu, B., Lu, B., Lu, J., Lu, Q., Lu, S.M., Lu, S., Lu, Y., Luciano, F., Luckhart, S., Lucocq, J.M., Ludovico, P., Lugea, A., Lukacs, N.W., Lum, J.J., Lund, A.H., Luo, H., Luo, J., Luo, S., Luparello, C., Lyons, T., Ma, J., Ma, Y., Ma, Y., Ma, Z., Machado, J., Machado-Santelli, G.M., Macian, F., MacIntosh, G.C., MacKeigan, J.P., Macleod, K.F., MacMicking, J.D., MacMillan-Crow, L.A., Madeo, F., Madesh, M., Madrigal-Matute, J., Maeda, A., Maeda, T., Maegawa, G., Maellaro, E., Maes, H., Magariños, M., Maiese, K., Maiti, T.K., Maiuri, L., Maiuri, M.C., Maki, C.G., Malli, R., Malorni, W., Maloyan, A., Mami-Chouaib, F., Man, N., Mancias, J.D., Mandelkow, E.M., Mandell, M.A., Manfredi, A.A., Manié, S.N., Manzoni, C., Mao, K., Mao, Z., Mao, Z.W., Marambaud, P., Marconi, A.M., Marelja, Z., Marfe, G., Margeta, M., Margittai, E., Mari, M., Mariani, F.V., Marin, C., Marinelli, S., Mariño, G., Markovic, I., Marquez, R., Martelli, A.M., Martens, S., Martin, K.R., Martin, S.J., Martin, S., Martin-Acebes, M.A., Martín-Sanz, P., Martinand-Mari, C., Martinet, W., Martinez, J., Martinez-Lopez, N., Martinez-Outschoorn, U., Martínez-Velázquez, M., Martinez-Vicente, M., Martins, W.K., Mashima, H., Mastrianni, J.A., Matarese, G., Matarrese, P., Mateo, R., Matoba, S., Matsumoto, N., Matsushita, T., Matsuura, A., Matsuzawa, T., Mattson, M.P., Matus, S., Maugeri, N., Mauvezin, C., Mayer, A., Maysinger, D., Mazzolini, G.D., McBrayer, M.K., McCall, K., McCormick, C., McInerney, G.M., McIver, S.C., McKenna, S., McMahon, J.J., McNeish, I.A., Mechta-Grigoriou, F., Medema, J.P., Medina, D.L., Megyeri, K., Mehrpour, M., Mehta, J.L., Mei, Y., Meier, U.C., Meijer, A.J., Meléndez, A., Melino, G., Melino, S., de Melo, E.J.T., Mena, M.A., Meneghini, M.D., Menendez, J.A., Menezes, R., Meng, L., Meng, L.H., Meng, S., Menghini, R., Menko, A.S., Menna-Barreto, R.F., Menon, M.B., Meraz-Ríos, M.A., Merla, G., Merlini, L., Merlot, A.M., Meryk, A., Meschini, S., Meyer, J.N., Mi, M.T., Miao, C.Y., Micale, L., Michaeli, S., Michiels, C., Migliaccio, A.R., Mihailidou, A.S., Mijaljica, D., Mikoshiba, K., Milan, E., Miller-Fleming, L., Mills, G.B., Mills, I.G., Minakaki, G., Minassian, B.A., Ming, X.F., Minibayeva, F., Minina, E.A., Mintern, J.D., Minucci, S., Miranda-Vizuete, A., Mitchell, C.H., Miyamoto, S., Miyazawa, K., Mizushima, N., Mnich, K., Mograbi, B., Mohseni, S., Moita, L.F., Molinari, M., Molinari, M., Møller, A.B., Mollereau, B., Mollinedo, F., Mongillo, M., Monick, M.M., Montagnaro, S., Montell, C., Moore, D.J., Moore, M.N., Mora-Rodriguez, R., Moreira, P.I., Morel, E., Morelli, M.B., Moreno, S., Morgan, M.J., Moris, A., Moriyasu, Y., Morrison, J.L., Morrison, L.A., Morselli, E., Moscat, J., Moseley, P.L., Mostowy, S., Motori, E., Mottet, D., Mottram, J.C., Moussa, C.E.H., Mpakou, V.E., Mukhtar, H., Mulcahy Levy, J.M., Muller, S., Muñoz-Moreno, R., Muñoz-Pinedo, C., Münz, C., Murphy, M.E., Murray, J.T., Murthy, A., Mysorekar, I.U., Nabi, I.R., Nabissi, M., Nader, G.A., Nagahara, Y., Nagai, Y., Nagata, K., Nagelkerke, A., Nagy, P., Naidu, S.R., Nair, S., Nakano, H., Nakatogawa, H., Nanjundan, M., Napolitano, G., Naqvi, N.I., Nardacci, R., Narendra, D.P., Narita, M., Nascimbeni, A.C., Natarajan, R., Navegantes, L.C., Nawrocki, S.T., Nazarko, T.Y., Nazarko, V.Y., Neill, T., Neri, L.M., Netea, M.G., Netea-Maier, R.T., Neves, B.M., Ney, P.A., Nezis, I.P., Nguyen, H.T., Nguyen, H.P., Nicot, A.S., Nilsen, H., Nilsson, P., Nishimura, M., Nishino, I., Niso-Santano, M., Niu, H., Nixon, R.A., Njar, V.C., Noda, T., Noegel, A.A., Nolte, E.M., Norberg, E., Norga, K.K., Noureini, S.K., Notomi, S., Notterpek, L., Nowikovsky, K., Nukina, N., Nürnberger, T., O'Donnell, V.B., O'Donovan, T., O'Dwyer, P.J., Oehme, I., Oeste, C.L., Ogawa, M., Ogretmen, B., Ogura, Y., Oh, Y.J., Ohmuraya, M., Ohshima, T., Ojha, R., Okamoto, K., Okazaki, T., Oliver, F.J., Ollinger, K., Olsson, S., Orban, D.P., Ordonez, P., Orhon, I., Orosz, L., O'Rourke, E.J., Orozco, H., Ortega, A.L., Ortona, E., Osellame, L.D., Oshima, J., Oshima, S., Osiewacz, H.D., Otomo, T., Otsu, K., Ou, J.H.J., Outeiro, T.F., Ouyang, D.Y., Ouyang, H., Overholtzer, M., Ozbun, M.A., Ozdinler, P.H., Ozpolat, B., Pacelli, C., Paganetti, P., Page, G., Pages, G., Pagnini, U., Pajak, B., Pak, S.C., Pakos-Zebrucka, K., Pakpour, N., Palková, Z., Palladino, F., Pallauf, K., Pallet, N., Palmieri, M., Paludan, S.R., Palumbo, C., Palumbo, S., Pampliega, O., Pan, H., Pan, W., Panaretakis, T., Pandey, A., Pantazopoulou, A., Papackova, Z., Papademetrio, D.L., Papassideri, I., Papini, A., Parajuli, N., Pardo, J., Parekh, V.V., Parenti, G., Park, J.I., Park, J., Park, O.K., Parker, R., Parlato, R., Parys, J.B., Parzych, K.R., Pasquet, J.M., Pasquier, B., Pasumarthi, K.B., Patschan, D., Patterson, C., Pattingre, S., Pattison, S., Pause, A., Pavenstädt, H., Pavone, F., Pedrozo, Z., Peña, F.J., Peñalva, M.A., Pende, M., Peng, J., Penna, F., Penninger, J.M., Pensalfini, A., Pepe, S., Pereira, G.J., Pereira, P.C., Pérez-de la Cruz, V., Pérez-Pérez, M.E., Pérez-Rodríguez, D., Pérez-Sala, D., Perier, C., Perl, A., Perlmutter, D.H., Perrotta, I., Pervaiz, S., Pesonen, M., Pessin, J.E., Peters, G.J., Petersen, M., Petrache, I., Petrof, B.J., Petrovski, G., Phang, J.M., Piacentini, M., Pierdominici, M., Pierre, P., Pierrefite-Carle, V., Pietrocola, F., Pimentel-Muiños, F.X., Pinar, M., Pineda, B., Pinkas-Kramarski, R., Pinti, M., Pinton, P., Piperdi, B., Piret, J.M., Platanias, L.C., Platta, H.W., Plowey, E.D., Pöggeler, S., Poirot, M., Polčic, P., Poletti, A., Poon, A.H., Popelka, H., Popova, B., Poprawa, I., Poulose, S.M., Poulton, J., Powers, S.K., Powers, T., Pozuelo-Rubio, M., Prak, K., Prange, R., Prescott, M., Priault, M., Prince, S., Proia, R.L., Proikas-Cezanne, T., Prokisch, H., Promponas, V.J., Przyklenk, K., Puertollano, R., Pugazhenthi, S., Puglielli, L., Pujol, A., Puyal, J., Pyeon, D., Qi, X., Qian, W.B., Qin, Z.H., Qiu, Y., Qu, Z., Quadrilatero, J., Quinn, F., Raben, N., Rabinowich, H., Radogna, F., Ragusa, M.J., Rahmani, M., Raina, K., Ramanadham, S., Ramesh, R., Rami, A., Randall-Demllo, S., Randow, F., Rao, H., Rao, V.A., Rasmussen, B.B., Rasse, T.M., Ratovitski, E.A., Rautou, P.E., Ray, S.K., Razani, B., Reed, B.H., Reggiori, F., Rehm, M., Reichert, A.S., Rein, T., Reiner, D.J., Reits, E., Ren, J., Ren, X., Renna, M., Reusch, J.E., Revuelta, J.L., Reyes, L., Rezaie, A.R., Richards, R.I., Richardson, D.R., Richetta, C., Riehle, M.A., Rihn, B.H., Rikihisa, Y., Riley, B.E., Rimbach, G., Rippo, M.R., Ritis, K., Rizzi, F., Rizzo, E., Roach, P.J., Robbins, J., Roberge, M., Roca, G., Roccheri, M.C., Rocha, S., Rodrigues, C.M.P., Rodríguez, C.I., de Cordoba, S.R., Rodriguez-Muela, N., Roelofs, J., Rogov, V.V., Rohn, T.T., Rohrer, B., Romanelli, D., Romani, L., Romano, P.S., Roncero, M.I.G., Rosa, J.L., Rosello, A., Rosen, K.V., Rosenstiel, P., Rost-Roszkowska, M., Roth, K.A., Roué, G., Rouis, M., Rouschop, K.M., Ruan, D.T., Ruano, D., Rubinsztein, D.C., Rucker, E.B., Rudich, A., Rudolf, E., Rudolf, R., Ruegg, M.A., Ruiz-Roldan, C., Ruparelia, A.A., Rusmini, P., Russ, D.W., Russo, G.L., Russo, G., Russo, R., Rusten, T.E., Ryabovol, V., Ryan, K.M., Ryter, S.W., Sabatini, D.M., Sacher, M., Sachse, C., Sack, M.N., Sadoshima, J., Saftig, P., Sagi-Eisenberg, R., Sahni, S., Saikumar, P., Saito, T., Saitoh, T., Sakakura, K., Sakoh-Nakatogawa, M., Sakuraba, Y., Salazar-Roa, M., Salomoni, P., Saluja, A.K., Salvaterra, P.M., Salvioli, R., Samali, A., Sanchez, A.M., Sánchez-Alcázar, J.A., Sanchez-Prieto, R., Sandri, M., Sanjuan, M.A., Santaguida, S., Santambrogio, L., Santoni, G., Dos Santos, C.N., Saran, S., Sardiello, M., Sargent, G., Sarkar, P., Sarkar, S., Sarrias, M.R., Sarwal, M.M., Sasakawa, C., Sasaki, M., Sass, M., Sato, K., Sato, M., Satriano, J., Savaraj, N., Saveljeva, S., Schaefer, L., Schaible, U.E., Scharl, M., Schatzl, H.M., Schekman, R., Scheper, W., Schiavi, A., Schipper, H.M., Schmeisser, H., Schmidt, J., Schmitz, I., Schneider, B.E., Schneider, E.M., Schneider, J.L., Schon, E.A., Schönenberger, M.J., Schönthal, A.H., Schorderet, D.F., Schröder, B., Schuck, S., Schulze, R.J., Schwarten, M., Schwarz, T.L., Sciarretta, S., Scotto, K., Scovassi, A.I., Screaton, R.A., Screen, M., Seca, H., Sedej, S., Segatori, L., Segev, N., Seglen, P.O., Seguí-Simarro, J.M., Segura-Aguilar, J., Seki, E., Sell, C., Seiliez, I., Semenkovich, C.F., Semenza, G.L., Sen, U., Serra, A.L., Serrano-Puebla, A., Sesaki, H., Setoguchi, T., Settembre, C., Shacka, J.J., Shajahan-Haq, A.N., Shapiro, I.M., Sharma, S., She, H., Shen, C.K.J., Shen, C.C., Shen, H.M., Shen, S., Shen, W., Sheng, R., Sheng, X., Sheng, Z.H., Shepherd, T.G., Shi, J., Shi, Q., Shi, Q., Shi, Y., Shibutani, S., Shibuya, K., Shidoji, Y., Shieh, J.J., Shih, C.M., Shimada, Y., Shimizu, S., Shin, D.W., Shinohara, M.L., Shintani, M., Shintani, T., Shioi, T., Shirabe, K., Shiri-Sverdlov, R., Shirihai, O., Shore, G.C., Shu, C.W., Shukla, D., Sibirny, A.A., Sica, V., Sigurdson, C.J., Sigurdsson, E.M., Sijwali, P.S., Sikorska, B., Silveira, W.A., Silvente-Poirot, S., Silverman, G.A., Simak, J., Simmet, T., Simon, A.K., Simon, H.U., Simone, C., Simons, M., Simonsen, A., Singh, R., Singh, S.V., Singh, S.K., Sinha, D., Sinha, S., Sinicrope, F.A., Sirko, A., Sirohi, K., Sishi, B.J., Sittler, A., Siu, P.M., Sivridis, E., Skwarska, A., Slack, R., Slaninová, I., Slavov, N., Smaili, S.S., Smalley, K.S., Smith, D.R., Soenen, S.J., Soleimanpour, S.A., Solhaug, A., Somasundaram, K., Son, J.H., Sonawane, A., Song, C., Song, F., Song, H.K., Song, J.X., Song, W., Soo, K.Y., Sood, A.K., Soong, T.W., Soontornniyomkij, V., Sorice, M., Sotgia, F., Soto-Pantoja, D.R., Sotthibundhu, A., Sousa, M.J., Spaink, H.P., Span, P.N., Spang, A., Sparks, J.D., Speck, P.G., Spector, S.A., Spies, C.D., Springer, W., Clair, D.S., Stacchiotti, A., Staels, B., Stang, M.T., Starczynowski, D.T., Starokadomskyy, P., Steegborn, C., Steele, J.W., Stefanis, L., Steffan, J., Stellrecht, C.M., Stenmark, H., Stepkowski, T.M., Stern, S.T., Stevens, C., Stockwell, B.R., Stoka, V., Storchova, Z., Stork, B., Stratoulias, V., Stravopodis, D.J., Strnad, P., Strohecker, A.M., Ström, A.L., Stromhaug, P., Stulik, J., Su, Y.X., Su, Z., Subauste, C.S., Subramaniam, S., Sue, C.M., Suh, S.W., Sui, X., Sukseree, S., Sulzer, D., Sun, F.L., Sun, J., Sun, J., Sun, S.Y., Sun, Y., Sun, Y., Sun, Y., Sundaramoorthy, V., Sung, J., Suzuki, H., Suzuki, K., Suzuki, N., Suzuki, T., Suzuki, Y.J., Swanson, M.S., Swanton, C., Swärd, K., Swarup, G., Sweeney, S.T., Sylvester, P.W., Szatmari, Z., Szegezdi, E., Szlosarek, P.W., Taegtmeyer, H., Tafani, M., Taillebourg, E., Tait, S.W., Takacs-Vellai, K., Takahashi, Y., Takáts, S., Takemura, G., Takigawa, N., Talbot, N.J., Tamagno, E., Tamburini, J., Tan, C.P., Tan, L., Tan, M.L., Tan, M., Tan, Y.J., Tanaka, K., Tanaka, M., Tang, D., Tang, D., Tang, G., Tanida, I., Tanji, K., Tannous, B.A., Tapia, J.A., Tasset-Cuevas, I., Tatar, M., Tavassoly, I., Tavernarakis, N., Taylor, A., Taylor, G.S., Taylor, G.A., Taylor, J.P., Taylor, M.J., Tchetina, E.V., Tee, A.R., Teixeira-Clerc, F., Telang, S., Tencomnao, T., Teng, B.B., Teng, R.J., Terro, F., Tettamanti, G., Theiss, A.L., Theron, A.E., Thomas, K.J., Thomé, M.P., Thomes, P.G., Thorburn, A., Thorner, J., Thum, T., Thumm, M., Thurston, T.L., Tian, L., Till, A., Ting, J.P.Y., Titorenko, V.I., Toker, L., Toldo, S., Tooze, S.A., Topisirovic, I., Torgersen, M.L., Torosantucci, L., Torriglia, A., Torrisi, M.R., Tournier, C., Towns, R., Trajkovic, V., Travassos, L.H., Triola, G., Tripathi, D.N., Trisciuoglio, D., Troncoso, R., Trougakos, I.P., Truttmann, A.C., Tsai, K.J., Tschan, M.P., Tseng, Y.H., Tsukuba, T., Tsung, A., Tsvetkov, A.S., Tu, S., Tuan, H.Y., Tucci, M., Tumbarello, D.A., Turk, B., Turk, V., Turner, R.F., Tveita, A.A., Tyagi, S.C., Ubukata, M., Uchiyama, Y., Udelnow, A., Ueno, T., Umekawa, M., Umemiya-Shirafuji, R., Underwood, B.R., Ungermann, C., Ureshino, R.P., Ushioda, R., Uversky, V.N., Uzcátegui, N.L., Vaccari, T., Vaccaro, M.I., Váchová, L., Vakifahmetoglu-Norberg, H., Valdor, R., Valente, E.M., Vallette, F., Valverde, A.M., Van den Berghe, G., Van Den Bosch, L., van den Brink, G.R., van der Goot, F.G., van der Klei, I.J., van der Laan, L.J., van Doorn, W.G., van Egmond, M., van Golen, K.L., Van Kaer, L., van Lookeren Campagne, M., Vandenabeele, P., Vandenberghe, W., Vanhorebeek, I., Varela-Nieto, I., Vasconcelos, M.H., Vasko, R., Vavvas, D.G., Vega-Naredo, I., Velasco, G., Velentzas, A.D., Velentzas, P.D., Vellai, T., Vellenga, E., Vendelbo, M.H., Venkatachalam, K., Ventura, N., Ventura, S., Veras, P.S., Verdier, M., Vertessy, B.G., Viale, A., Vidal, M., Vieira, H.L.A., Vierstra, R.D., Vigneswaran, N., Vij, N., Vila, M., Villar, M., Villar, V.H., Villarroya, J., Vindis, C., Viola, G., Viscomi, M.T., Vitale, G., Vogl, D.T., Voitsekhovskaja, O.V., von Haefen, C., von Schwarzenberg, K., Voth, D.E., Vouret-Craviari, V., Vuori, K., Vyas, J.M., Waeber, C., Walker, C.L., Walker, M.J., Walter, J., Wan, L., Wan, X., Wang, B., Wang, C., Wang, C.Y., Wang, C., Wang, C., Wang, C., Wang, D., Wang, F., Wang, F., Wang, G., Wang, H.J., Wang, H., Wang, H.G., Wang, H., Wang, H.D., Wang, J., Wang, J., Wang, M., Wang, M.Q., Wang, P.Y., Wang, P., Wang, R.C., Wang, S., Wang, T.F., Wang, X., Wang, X.J., Wang, X.W., Wang, X., Wang, X., Wang, Y., Wang, Y., Wang, Y., Wang, Y.J., Wang, Y., Wang, Y., Wang, Y.T., Wang, Y., Wang, Z.N., Wappner, P., Ward, C., Ward, D.M., Warnes, G., Watada, H., Watanabe, Y., Watase, K., Weaver, T.E., Weekes, C.D., Wei, J., Weide, T., Weihl, C.C., Weindl, G., Weis, S.N., Wen, L., Wen, X., Wen, Y., Westermann, B., Weyand, C.M., White, A.R., White, E., Whitton, J.L., Whitworth, A.J., Wiels, J., Wild, F., Wildenberg, M.E., Wileman, T., Wilkinson, D.S., Wilkinson, S., Willbold, D., Williams, C., Williams, K., Williamson, P.R., Winklhofer, K.F., Witkin, S.S., Wohlgemuth, S.E., Wollert, T., Wolvetang, E.J., Wong, E., Wong, G.W., Wong, R.W., Wong, V.K.W., Woodcock, E.A., Wright, K.L., Wu, C., Wu, D., Wu, G.S., Wu, J., Wu, J., Wu, M., Wu, M., Wu, S., Wu, W.K., Wu, Y., Wu, Z., Xavier, C.P., Xavier, R.J., Xia, G.X., Xia, T., Xia, W., Xia, Y., Xiao, H., Xiao, J., Xiao, S., Xiao, W., Xie, C.M., Xie, Z., Xie, Z., Xilouri, M., Xiong, Y., Xu, C., Xu, C., Xu, F., Xu, H., Xu, H., Xu, J., Xu, J., Xu, J., Xu, L., Xu, X., Xu, Y., Xu, Y., Xu, Z.X., Xu, Z., Xue, Y., Yamada, T., Yamamoto, A., Yamanaka, K., Yamashina, S., Yamashiro, S., Yan, B., Yan, B., Yan, X., Yan, Z., Yanagi, Y., Yang, D.S., Yang, J.M., Yang, L., Yang, M., Yang, P.M., Yang, P., Yang, Q., Yang, W., Yang, W.Y., Yang, X., Yang, Y., Yang, Y., Yang, Z., Yang, Z., Yao, M.C., Yao, P.J., Yao, X., Yao, Z., Yao, Z., Yasui, L.S., Ye, M., Yedvobnick, B., Yeganeh, B., Yeh, E.S., Yeyati, P.L., Yi, F., Yi, L., Yin, X.M., Yip, C.K., Yoo, Y.M., Yoo, Y.H., Yoon, S.Y., Yoshida, K.I., Yoshimori, T., Young, K.H., Yu, H., Yu, J.J., Yu, J.T., Yu, J., Yu, L., Yu, W.H., Yu, X.F., Yu, Z., Yuan, J., Yuan, Z.M., Yue, B.Y., Yue, J., Yue, Z., Zacks, D.N., Zacksenhaus, E., Zaffaroni, N., Zaglia, T., Zakeri, Z., Zecchini, V., Zeng, J., Zeng, M., Zeng, Q., Zervos, A.S., Zhang, D.D., Zhang, F., Zhang, G., Zhang, G.C., Zhang, H., Zhang, H., Zhang, H., Zhang, H., Zhang, J., Zhang, J., Zhang, J., Zhang, J., Zhang, J.P., Zhang, L., Zhang, L., Zhang, L., Zhang, L., Zhang, M.Y., Zhang, X., Zhang, X.D., Zhang, Y., Zhang, Y., Zhang, Y., Zhang, Y., Zhang, Y., Zhao, M., Zhao, W.L., Zhao, X., Zhao, Y.G., Zhao, Y., Zhao, Y., Zhao, Y.X., Zhao, Z., Zhao, Z.J., Zheng, D., Zheng, X.L., Zheng, X., Zhivotovsky, B., Zhong, Q., Zhou, G.Z., Zhou, G., Zhou, H., Zhou, S.F., Zhou, X.J., Zhu, H., Zhu, H., Zhu, W.G., Zhu, W., Zhu, X.F., Zhu, Y., Zhuang, S.M., Zhuang, X., Ziparo, E., Zois, C.E., Zoladek, T., Zong, W.X., Zorzano, A., & Zughaier, S.M. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 12(1), 1-222.Taylor & Francis. doi: 10.1080/15548627.2015.1100356.
Klionsky, D.J., Abdelmohsen, K., Abe, A., Abedin, M.J., Abeliovich, H., Arozena, A.A., Adachi, H., Adams, C.M., Adams, P.D., Adeli, K., Adhihetty, P.J., Adler, S.G., Agam, G., Agarwal, R., Aghi, M.K., Agnello, M., Agostinis, P., Aguilar, P.V., Aguirre-Ghiso, J., Airoldi, E.M., Ait-Si-Ali, S., Akematsu, T., Akporiaye, E.T., Al-Rubeai, M., Albaiceta, G.M., Albanese, C., Albani, D., Albert, M.L., Aldudo, J., Algül, H., Alirezaei, M., Alloza, I., Almasan, A., Almonte-Beceril, M., Alnemri, E.S., Alonso, C., Altan-Bonnet, N., Altieri, D.C., Alvarez, S., Alvarez-Erviti, L., Alves, S., Amadoro, G., Amano, A., Amantini, C., Ambrosio, S., Amelio, I., Amer, A.O., Amessou, M., Amon, A., An, Z., Anania, F.A., Andersen, S.U., Andley, U.P., Andreadi, C.K., Andrieu-Abadie, N., Anel, A., Ann, D.K., Anoopkumar-Dukie, S., Antonioli, M., Aoki, H., Apostolova, N., Aquila, S., Aquilano, K., Araki, K., Arama, E., Aranda, A., Araya, J., Arcaro, A., Arias, E., Arimoto, H., Ariosa, A.R., Armstrong, J.L., Arnould, T., Arsov, I., Asanuma, K., Askanas, V., Asselin, E., Atarashi, R., Atherton, S.S., Atkin, J.D., Attardi, L.D., Auberger, P., Auburger, G., Aurelian, L., Autelli, R., Avagliano, L., Avantaggiati, M.L., Avrahami, L., Azad, N., Awale, S., Bachetti, T., Backer, J.M., Bae, D.H., Bae, J.S., Bae, O.N., Bae, S.H., Baehrecke, E.H., Baek, S.H., Baghdiguian, S., & Bagniewska-Zadworna, A. (2016). Erratum. Autophagy, 12(2), 443.Taylor & Francis. doi: 10.1080/15548627.2016.1147886.
Lotfi, R., Kaltenmeier, C., Lotze, M.T., & Bergmann, C. (2016). Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfus Med Hemother, 43(2), 120-132.Karger Publishers. doi: 10.1159/000444941.
Patnaik, A., Appleman, L.J., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Weiss, G.J., Sachdev, J.C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J.M., Lotze, M.T., Toledo, F.G.S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., & Ramanathan, R.K. (2016). First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol, 27(10), 1928-1940.Elsevier. doi: 10.1093/annonc/mdw282.
Van Der Kraak, L., Goel, G., Ramanan, K., Kaltenmeier, C., Zhang, L., Normolle, D.P., Freeman, G.J., Tang, D., Nason, K.S., Davison, J.M., Luketich, J.D., Dhupar, R., & Lotze, M.T. (2016). 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer, 4(1), 65.BMJ. doi: 10.1186/s40425-016-0163-8.
Vogel, S., Rath, D., Borst, O., Mack, A., Loughran, P., Lotze, M.T., Neal, M.D., Billiar, T.R., & Gawaz, M. (2016). Platelet-derived high-mobility group box 1 promotes recruitment and suppresses apoptosis of monocytes. Biochem Biophys Res Commun, 478(1), 143-148.Elsevier. doi: 10.1016/j.bbrc.2016.07.078.
Wang, Q., Miskov-Zivanov, N., Liu, B., Faeder, J.R., Lotze, M., & Clarke, E.M. (2016). Formal Modeling and Analysis of Pancreatic Cancer Microenvironment. In arXiv. doi: 10.48550/arxiv.1606.03138.
Xie, Y., Song, X., Sun, X., Huang, J., Zhong, M., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2016). Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem Biophys Res Commun, 473(4), 775-780.Elsevier. doi: 10.1016/j.bbrc.2016.03.052.
Yoo, J.Y., Jaime-Ramirez, A.C., Bolyard, C., Dai, H., Nallanagulagari, T., Wojton, J., Hurwitz, B.S., Relation, T., Lee, T.J., Lotze, M.T., Yu, J.G., Zhang, J., Croce, C.M., Yu, J., Caligiuri, M.A., Old, M., & Kaur, B. (2016). Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy. Clin Cancer Res, 22(21), 5265-5276.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-16-1003.
Zhang, X., Rao, A., Sette, P., Deibert, C., Pomerantz, A., Kim, W.J., Kohanbash, G., Chang, Y., Park, Y., Engh, J., Choi, J., Chan, T., Okada, H., Lotze, M., Grandi, P., & Amankulor, N. (2016). IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol, 18(10), 1402-1412.Oxford University Press (OUP). doi: 10.1093/neuonc/now061.
Zhang, X., Rao, A., Sette, P., Deibert, C., Pomerantz, A., Kim, W.J., Kohanbash, G., Chang, Y., Park, Y., Engh, J., Choi, J., Chan, T., Okada, H., Lotze, M., Grandi, P., & Amankulor, N. (2016). IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. NEURO-ONCOLOGY, 18(10), 1402-1412. doi: 10.1093/neuonc/now061.
Apetoh, L., Smyth, M.J., Drake, C.G., Abastado, J.P., Apte, R.N., Ayyoub, M., Blay, J.Y., Bonneville, M., Butterfield, L.H., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Chen, L., Colombo, M.P., Comin-Anduix, B., Coukos, G., Dhodapkar, M.V., Dranoff, G., Frazer, I.H., Fridman, W.H., Gabrilovich, D.I., Gilboa, E., Gnjatic, S., Jäger, D., Kalinski, P., Kaufman, H.L., Kiessling, R., Kirkwood, J., Knuth, A., Liblau, R., Lotze, M.T., Lugli, E., Marincola, F., Melero, I., Melief, C.J., Mempel, T.R., Mittendorf, E.A., Odun, K., Overwijk, W.W., Palucka, A.K., Parmiani, G., Ribas, A., Romero, P., Schreiber, R.D., Schuler, G., Srivastava, P.K., Tartour, E., Valmori, D., van der Burg, S.H., van der Bruggen, P., van den Eynde, B.J., Wang, E., Zou, W., Whiteside, T.L., Speiser, D.E., Pardoll, D.M., Restifo, N.P., & Anderson, A.C. (2015). Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology, 4(4), e998538.Taylor & Francis. doi: 10.1080/2162402X.2014.998538.
Boone, B.A., Bahary, N., Zureikat, A.H., Moser, A.J., Normolle, D.P., Wu, W.C., Singhi, A.D., Bao, P., Bartlett, D.L., Liotta, L.A., Espina, V., Loughran, P., Lotze, M.T., & Zeh, H.J. (2015). Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol, 22(13), 4402-4410.Springer Nature. doi: 10.1245/s10434-015-4566-4.
Boone, B.A., Orlichenko, L., Schapiro, N.E., Loughran, P., Gianfrate, G.C., Ellis, J.T., Singhi, A.D., Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2015). The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther, 22(6), 326-334.Springer Nature. doi: 10.1038/cgt.2015.21.
Chen, M., Liu, Y., Varley, P., Chang, Y., He, X.X., Huang, H., Tang, D., Lotze, M.T., Lin, J., & Tsung, A. (2015). High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res, 75(8), 1645-1656.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-14-2147.
Chen, R., Fu, S., Fan, X.G., Lotze, M.T., Zeh, H.J., Tang, D., & Kang, R. (2015). Nuclear DAMP complex-mediated RAGE-dependent macrophage cell death. Biochem Biophys Res Commun, 458(3), 650-655.Elsevier. doi: 10.1016/j.bbrc.2015.01.159.
Diniz, B.S., Sibille, E., Ding, Y., Tseng, G., Aizenstein, H.J., Lotrich, F., Becker, J.T., Lopez, O.L., Lotze, M.T., Klunk, W.E., Reynolds, C.F., & Butters, M.A. (2015). Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry, 20(5), 594-601.Springer Nature. doi: 10.1038/mp.2014.76.
Ganguli, M., & Lotze, M.T. (2015). Parkinson Disease and Malignant Disease: Minding Cancer's Own Business. JAMA Oncol, 1(5), 641-642.American Medical Association (AMA). doi: 10.1001/jamaoncol.2015.1810.
Huang, J., Xie, Y., Sun, X., Zeh, H.J., Kang, R., Lotze, M.T., & Tang, D. (2015). DAMPs, ageing, and cancer: The 'DAMP Hypothesis'. Ageing Res Rev, 24(Pt A), 3-16.Elsevier. doi: 10.1016/j.arr.2014.10.004.
Ito, N., Zeh, H.J., & Lotze, M.T. (2015). Activated Natural Killer Cells. In Encyclopedia of Cancer. (pp. 26-30).Springer Nature. doi: 10.1007/978-3-662-46875-3_48.
Ito, N., Zeh, H.J., & Lotze, M.T. (2015). Activated Natural Killer Cells. In Encyclopedia of Cancer. (pp. 1-5).Springer Nature. doi: 10.1007/978-3-642-27841-9_48-2.
Liang, X., Wang, W., Li, G., Zhang, X., Jankovic, V., Herzberg, U., Hofgartner, W., & Lotze, M.T. (2015). Efficacy of adoptive transfer of expanded fetal liver-derived precursor syngeneic and allogeneic murine NK cells against solid tumors. Journal for ImmunoTherapy of Cancer, 3(Suppl 2), p30.BMJ. doi: 10.1186/2051-1426-3-s2-p30.
Liu, Y., Yan, W., Tohme, S., Chen, M., Fu, Y., Tian, D., Lotze, M., Tang, D., & Tsung, A. (2015). Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol, 63(1), 114-121.Elsevier. doi: 10.1016/j.jhep.2015.02.009.
Sehgal, A.R., Konig, H., Johnson, D.E., Tang, D., Amaravadi, R.K., Boyiadzis, M., & Lotze, M.T. (2015). You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia, 29(3), 517-525.Springer Nature. doi: 10.1038/leu.2014.349.
Shakir, M., Tang, D., Zeh, H.J., Tang, S.W., Anderson, C.J., Bahary, N., & Lotze, M.T. (2015). The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow. Pancreas, 44(4), 528-534.Wolters Kluwer. doi: 10.1097/MPA.0000000000000298.
Vogel, S., Bodenstein, R., Chen, Q., Feil, S., Feil, R., Rheinlaender, J., Schäffer, T.E., Bohn, E., Frick, J.S., Borst, O., Münzer, P., Walker, B., Markel, J., Csanyi, G., Pagano, P.J., Loughran, P., Jessup, M.E., Watkins, S.C., Bullock, G.C., Sperry, J.L., Zuckerbraun, B.S., Billiar, T.R., Lotze, M.T., Gawaz, M., & Neal, M.D. (2015). Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest, 125(12), 4638-4654.American Society for Clinical Investigation. doi: 10.1172/JCI81660.
Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M.T., Zeh, H.J., Kang, R., & Tang, D. (2015). The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol, 2(4), e1054549.Taylor & Francis. doi: 10.1080/23723556.2015.1054549.
Zhang, X., Rao, A., Deibert, C., Sette, P., Kim, J., Lotze, M., Grandi, P., & Amankulor, N. (2015). IMPS-45IDH MUTANT GLIOMAS ESCAPE NATURAL KILLER CELL IMMUNE SURVEILLANCE THROUGH DOWNREGULATION OF NKG2D LIGANDS. Neuro-Oncology, 17(suppl_5), v123.Oxford University Press (OUP). doi: 10.1093/neuonc/nov217.44.
Zhu, X., Messer, J.S., Wang, Y., Lin, F., Cham, C.M., Chang, J., Billiar, T.R., Lotze, M.T., Boone, D.L., & Chang, E.B. (2015). Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest, 125(3), 1098-1110.American Society for Clinical Investigation. doi: 10.1172/JCI76344.
Bauer, E.M., Zheng, H., Lotze, M.T., & Bauer, P.M. (2014). Recombinant human interferon alpha 2b prevents and reverses experimental pulmonary hypertension. In Zhao, Y.Y. (Ed.). PLoS One, 9(5), e96720.Public Library of Science (PLoS). doi: 10.1371/journal.pone.0096720.
Boone, B.A., & Lotze, M.T. (2014). Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma. Methods Mol Biol, 1102, 537-552.Springer Nature. doi: 10.1007/978-1-62703-727-3_29.
Boone, B.A., Schapiro, N.E., Neal, M.D., Ellis, J.T., Lotze, M.T., & Zeh, H.J. (2014). Neutrophil Extracellular Traps (NETs) are Upregulated in Pancreatic Cancer as a Result of Autophagy and Promote Hypercoagulability. Journal of Surgical Research, 186(2), 638.Elsevier. doi: 10.1016/j.jss.2013.11.657.
Dutta-Moscato, J., Gopalakrishnan, V., Lotze, M.T., & Becich, M.J. (2014). Creating a pipeline of talent for informatics: STEM initiative for high school students in computer science, biology, and biomedical informatics. J Pathol Inform, 5(1), 12.Elsevier. doi: 10.4103/2153-3539.129448.
Eisenbacher, J.L., Schrezenmeier, H., Jahrsdörfer, B., Kaltenmeier, C., Rojewski, M.T., Yildiz, T., Beyer, T., Erle, A., Wiegmann, D.S., Grassl, S., Hang, R., Körper, S., Wiesneth, M., Lotze, M.T., & Lotfi, R. (2014). S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. J Immunol, 192(12), 6102-6110.Oxford University Press (OUP). doi: 10.4049/jimmunol.1303144.
Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.M., Buqué, A., Senovilla, L., Baracco, E.E., Bloy, N., Castoldi, F., Abastado, J.P., Agostinis, P., Apte, R.N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J.Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M.P., Coussens, L., Dhodapkar, M.V., Eggermont, A.M., Fearon, D.T., Fridman, W.H., Fučíková, J., Gabrilovich, D.I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jäger, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J.M., Klein, E., Knuth, A., Lewis, C.E., Liblau, R., Lotze, M.T., Lugli, E., Mach, J.P., Mattei, F., Mavilio, D., Melero, I., Melief, C.J., Mittendorf, E.A., Moretta, L., Odunsi, A., Okada, H., Palucka, A.K., Peter, M.E., Pienta, K.J., Porgador, A., Prendergast, G.C., Rabinovich, G.A., Restifo, N.P., Rizvi, N., Sautès-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M.J., Speiser, D.E., Spisek, R., Srivastava, P.K., Talmadge, J.E., Tartour, E., Van Der Burg, S.H., Van Den Eynde, B.J., Vile, R., Wagner, H., Weber, J.S., Whiteside, T.L., Wolchok, J.D., Zitvogel, L., Zou, W., & Kroemer, G. (2014). Classification of current anticancer immunotherapies. Oncotarget, 5(24), 12472-12508.Impact Journals. doi: 10.18632/oncotarget.2998.
Galluzzi, L., Vacchelli, E., Pedro, J.M.B.S., Buqué, A., Senovilla, L., Baracco, E.E., Bloy, N., Castoldi, F., Abastado, J.P., Agostinis, P., Apte, R.N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J.Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M.P., Coussens, L., Dhodapkar, M.V., Eggermont, A.M., Fearon, D.T., Fridman, W.H., Fučíková, J., Gabrilovich, D.I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jäger, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J.M., Klein, E., Knuth, A., Lewis, C.E., Liblau, R., Lotze, M.T., Lugli, E., Mach, J.P., Mattei, F., Mavilio, D., Melero, I., Melief, C.J., Mittendorf, E.A., Moretta, L., Odunsi, A., Okada, H., Palucka, A.K., Peter, M.E., Pienta, K.J., Porgador, A., Prendergast, G.C., Rabinovich, G.A., Restifo, N.P., Rizvi, N., Sautès-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M.J., Speiser, D.E., Spisek, R., Srivastava, P.K., Talmadge, J.E., Tartour, E., Van Der Burg, S.H., Van Den Eynde, B.J., Vile, R., Wagner, H., Weber, J.S., Whiteside, T.L., Wolchok, J.D., Zitvogel, L., Zou, W., & Kroemer, G. (2014). Classification of current anticancer immunotherapies. Oncotarget, 5(24), 12472-12508.Impact Journals, LLC. doi: 10.18632/oncotarget.v5i24.
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.G., Yan, Z., Sun, X., Wang, H., Wang, Q., Tsung, A., Billiar, T.R., Zeh, H.J., Lotze, M.T., & Tang, D. (2014). HMGB1 in health and disease. Mol Aspects Med, 40, 1-116.Elsevier. doi: 10.1016/j.mam.2014.05.001.
Kang, R., Hou, W., Zhang, Q., Chen, R., Lee, Y.J., Bartlett, D.L., Lotze, M.T., Tang, D., & Zeh, H.J. (2014). RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis, 5(10), e1480.Springer Nature. doi: 10.1038/cddis.2014.445.
Kang, R., Lotze, M.T., Zeh, H.J., Billiar, T.R., & Tang, D. (2014). Cell death and DAMPs in acute pancreatitis. Mol Med, 20(1), 466-477.Springer Nature. doi: 10.2119/molmed.2014.00117.
Kang, R., Tang, D., Schapiro, N.E., Loux, T., Livesey, K.M., Billiar, T.R., Wang, H., Van Houten, B., Lotze, M.T., & Zeh, H.J. (2014). The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene, 33(5), 567-577.Springer Nature. doi: 10.1038/onc.2012.631.
Kang, R., Zhang, Q., Hou, W., Yan, Z., Chen, R., Bonaroti, J., Bansal, P., Billiar, T.R., Tsung, A., Wang, Q., Bartlett, D.L., Whitcomb, D.C., Chang, E.B., Zhu, X., Wang, H., Lu, B., Tracey, K.J., Cao, L., Fan, X.G., Lotze, M.T., Zeh, H.J., & Tang, D. (2014). Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology, 146(4), 1097-1107.Elsevier. doi: 10.1053/j.gastro.2013.12.015.
Kaufmann, S.H.E., Lange, C., Rao, M., Balaji, K.N., Lotze, M., Schito, M., Zumla, A.I., & Maeurer, M. (2014). Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. Lancet Respir Med, 2(4), 301-320.Elsevier. doi: 10.1016/S2213-2600(14)70033-5.
Kaus, J., Guanqiao, L., & Lotze, M. (2014). NK cell produced HMGB1 regulates DC maturation and Tim-3 expression (INC6P.339). The Journal of Immunology, 192(Supplement_1), 121.6.Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.121.6.
Milutinovic, P.S., Englert, J.M., Crum, L.T., Mason, N.S., Ramsgaard, L., Enghild, J.J., Sparvero, L.J., Lotze, M.T., & Oury, T.D. (2014). Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products. In Abrams, W.R. (Ed.). PLoS One, 9(3), e88259.Public Library of Science (PLoS). doi: 10.1371/journal.pone.0088259.
Tang, D., Kang, R., Van Houten, B., Zeh, H.J., Billiar, T.R., & Lotze, M.T. (2014). High mobility group box 1 (HMGB1) phenotypic role revealed with stress. Mol Med, 20(1), 359-362.Springer Nature. doi: 10.2119/molmed.2014.00063.
Wang, W., & Lotze, M.T. (2014). Good things come in small packages: exosomes, immunity and cancer. Cancer Gene Ther, 21(4), 139-141.Springer Nature. doi: 10.1038/cgt.2014.14.
Wang, W., Vernon, P., Li, G., Sampath, P., Stephen, T., Liang, X., & Lotze, M. (2014). Depletion of high mobility group box 1(HMGB1) in dendritic cells (DCs) suppresses tumorigenesis and promotes viral clearance. Journal for ImmunoTherapy of Cancer, 2(Suppl 3), p64.BMJ. doi: 10.1186/2051-1426-2-s3-p64.
Yang, L., Xie, M., Yang, M., Yu, Y., Zhu, S., Hou, W., Kang, R., Lotze, M.T., Billiar, T.R., Wang, H., Cao, L., & Tang, D. (2014). PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun, 5(1), 4436.Springer Nature. doi: 10.1038/ncomms5436.
Zhu, X., Messer, J.S., Wang, Y., Lin, F., Cham, C.M., Chang, J., Billiar, T., Lotze, M.T., Boone, D.L., & Chang, E.B. (2014). Sa1731 HMGB1 Controls the Intestinal Epithelial Autophagy/Apoptosis Checkpoint During Mucosal Inflammation and IBD. Gastroenterology, 146(5), s-283.Elsevier. doi: 10.1016/s0016-5085(14)61002-7.
Boone, B.A., Zureikat, A., Bahary, N., Bartlett, D.L., Amaravadi, R., Lotze, M.T., & Zeh, H.J. (2013). Phase I/II Trial of Autophagy Inhibition in Combination with Neoadjuvant Gemcitabine in High Risk Pancreatic Adenocarcinoma: Safety and Response to Treatment. Journal of Surgical Research, 179(2), 243.Elsevier. doi: 10.1016/j.jss.2012.10.454.
Criscimanna, A., Duan, L.J., Rhodes, J.A., Fendrich, V., Wickline, E., Hartman, D.J., Monga, S.P.S., Lotze, M.T., Gittes, G.K., Fong, G.H., & Esni, F. (2013). PanIN-specific regulation of Wnt signaling by HIF2α during early pancreatic tumorigenesis. Cancer Res, 73(15), 4781-4790.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-13-0566.
Gelfand, E.W., Simon, D., Simon, H.U., Thomas, A., Busse, W.W., Nair, P., Gauvreau, G.M., Denburg, J.A., Bivins-Smith, E.R., Jacoby, D.B., Davis, B.P., Rothenberg, M.E., Khoury, P., Klion, A.D., Lotfi, R., Spada, N., Lotze, M.T., Schleimer, R.P., Kato, A., Kern, R., Lavigne, M.C., Eppihimer, M.J., Roufosse, F., Massart, A., Benghiat, F.S., Lemaitre, P., Le Moine, A., Krahn, M., Bartoli, M., & Levy, N. (2013). Eosinophils in Human Disease. In Eosinophils in Health and Disease. (pp. 431-536).Elsevier. doi: 10.1016/b978-0-12-394385-9.00013-4.
Gelfand, E.W., Simon, D., Simon, H.U., Thomas, A., Busse, W.W., Nair, P., Gauvreau, G.M., Denburg, J.A., Bivins-Smith, E.R., Jacoby, D.B., Davis, B.P., Rothenberg, M.E., Khoury, P., Klion, A.D., Lotfi, R., Spada, N., Lotze, M.T., Schleimer, R.P., Kato, A., Kern, R., Lavigne, M.C., Eppihimer, M.J., Roufosse, F., Massart, A., Benghiat, F.S., Lemaitre, P., Le Moine, A., Krahn, M., Bartoli, M., & Levy, N. (2013). Chapter 13 Eosinophils in Human Disease. In Eosinophils in Health and Disease. (pp. 431-536).Elsevier. doi: 10.1016/b978-0-12-394385-9.00013-4.
Guo, Z.S., Liu, Z., Bartlett, D.L., Tang, D., & Lotze, M.T. (2013). Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res, 3(1), 1-20.
Hou, W., Zhang, Q., Yan, Z., Chen, R., Zeh Iii, H.J., Kang, R., Lotze, M.T., & Tang, D. (2013). Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis, 4(12), e966.Springer Nature. doi: 10.1038/cddis.2013.493.
Kang, R., Tang, D., Lotze, M.T., & Zeh Iii, H.J. (2013). Autophagy is required for IL-2-mediated fibroblast growth. Exp Cell Res, 319(4), 556-565.Elsevier. doi: 10.1016/j.yexcr.2012.11.012.
Kang, R., Zhang, Q., Zeh, H.J., Lotze, M.T., & Tang, D. (2013). HMGB1 in cancer: good, bad, or both?. Clin Cancer Res, 19(15), 4046-4057.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-13-0495.
Kaufman, H.L., Kirkwood, J.M., Hodi, F.S., Agarwala, S., Amatruda, T., Bines, S.D., Clark, J.I., Curti, B., Ernstoff, M.S., Gajewski, T., Gonzalez, R., Hyde, L.J., Lawson, D., Lotze, M., Lutzky, J., Margolin, K., McDermott, D.F., Morton, D., Pavlick, A., Richards, J.M., Sharfman, W., Sondak, V.K., Sosman, J., Steel, S., Tarhini, A., Thompson, J.A., Titze, J., Urba, W., White, R., & Atkins, M.B. (2013). The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol, 10(10), 588-598.Springer Nature. doi: 10.1038/nrclinonc.2013.153.
Kim, S., Kim, S.Y., Pribis, J.P., Lotze, M., Mollen, K.P., Shapiro, R., Loughran, P., Scott, M.J., & Billiar, T.R. (2013). Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med, 19(1), 88-98.Springer Nature. doi: 10.2119/molmed.2012.00306.
Li, A., Zenati, M.S., Krasinskas, A.M., Steve, J., Lotze, M.T., & Zeh, H.J. (2013). Autophagy Activity and SMAD4 Status in Patients With Primary Resectable Pancreatic Adenocarcinoma. Journal of Surgical Research, 179(2), 193.Elsevier. doi: 10.1016/j.jss.2012.10.211.
Li, G., Liang, X., & Lotze, M.T. (2013). HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol, 4(MAR), 68.Frontiers. doi: 10.3389/fimmu.2013.00068.
Li, G., Tang, D., & Lotze, M.T. (2013). Ménage à Trois in stress: DAMPs, redox and autophagy. Semin Cancer Biol, 23(5), 380-390.Elsevier. doi: 10.1016/j.semcancer.2013.08.002.
Lotze, M.T., Maranchie, J., & Appleman, L. (2013). Inhibiting autophagy: a novel approach for the treatment of renal cell carcinoma. Cancer J, 19(4), 341-347.Wolters Kluwer. doi: 10.1097/PPO.0b013e31829da0d6.
Lotze, M.T., Robinson, B.W.S., June, C.H., & Whiteside, T.L. (2013). Tumor immunotherapy. In Clinical Immunology. (pp. 935-945).Elsevier. doi: 10.1016/b978-0-7234-3691-1.00091-x.
Lotze, M.T., Robinson, B.W.S., June, C.H., & Whiteside, T.L. (2013). 77 Tumor immunotherapy. In Clinical Immunology. (pp. 935-945).Elsevier. doi: 10.1016/b978-0-7234-3691-1.00091-x.
Lu, Y., Zhang, Z., Yan, Z., Chen, L., Deng, W., Lotze, M., Wang, Z., Lin, X., & Li, L.Y. (2013). Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo. Apoptosis, 18(10), 1214-1223.Springer Nature. doi: 10.1007/s10495-013-0863-1.
Rubartelli, A., Lotze, M.T., Latz, E., & Manfredi, A. (2013). Mechanisms of sterile inflammation. Front Immunol, 4(NOV), 398.Frontiers. doi: 10.3389/fimmu.2013.00398.
Tang, D., & Lotze, M.T. (2013). Autophagy and the Tumor Microenvironment. In Autophagy and Cancer. (pp. 167-189).Springer Nature. doi: 10.1007/978-1-4614-6561-4_9.
Tang, S., Bonaroti, J., Unlu, S., Liang, X., Tang, D., Zeh, H.J., & Lotze, M.T. (2013). Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas, 42(5), 740-759.Wolters Kluwer. doi: 10.1097/MPA.0b013e3182854ab0.
Vernon, P.J., Loux, T.J., Schapiro, N.E., Kang, R., Muthuswamy, R., Kalinski, P., Tang, D., Lotze, M.T., & Zeh, H.J. (2013). The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol, 190(3), 1372-1379.Oxford University Press (OUP). doi: 10.4049/jimmunol.1201151.
Vernon, P.J., Zeh Iii, H.J., & Lotze, M.T. (2013). The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products. Oncoimmunology, 2(5), e24184.Taylor & Francis. doi: 10.4161/onci.24184.
Whiteside, T.L., Robinson, B.W.S., June, C.H., & Lotze, M.T. (2013). Principles of tumor immunology. In Clinical Immunology. (pp. 925-934).Elsevier. doi: 10.1016/b978-0-7234-3691-1.00090-8.
Whiteside, T.L., Robinson, B.W.S., June, C.H., & Lotze, M.T. (2013). 76 Principles of tumor immunology. In Clinical Immunology. (pp. 925-934).Elsevier. doi: 10.1016/b978-0-7234-3691-1.00090-8.
Zhang, Q., Kang, R., Zeh, H.J., Lotze, M.T., & Tang, D. (2013). DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy, 9(4), 451-458.Taylor & Francis. doi: 10.4161/auto.23691.
Buchser, W.J., Laskow, T.C., Pavlik, P.J., Lin, H.M., & Lotze, M.T. (2012). Cell-mediated autophagy promotes cancer cell survival. Cancer Res, 72(12), 2970-2979.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-11-3396.
Ferris, R.L., Lotze, M.T., Leong, S.P.L., Hoon, D.S.B., & Morton, D.L. (2012). Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. Clin Exp Metastasis, 29(7), 729-736.Springer Nature. doi: 10.1007/s10585-012-9520-2.
Kang, R., Loux, T., Tang, D., Schapiro, N.E., Vernon, P., Livesey, K.M., Krasinskas, A., Lotze, M.T., & Zeh, H.J. (2012). The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A, 109(18), 7031-7036.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.1113865109.
Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2012). AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy, 8(6), 989-991.Taylor & Francis. doi: 10.4161/auto.20258.
Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J.A., Ahn, H.J., Ait-Mohamed, O., Ait-Si-Ali, S., Akematsu, T., Akira, S., Al-Younes, H.M., Al-Zeer, M.A., Albert, M.L., Albin, R.L., Alegre-Abarrategui, J., Aleo, M.F., Alirezaei, M., Almasan, A., Almonte-Becerril, M., Amano, A., Amaravadi, R., Amarnath, S., Amer, A.O., Andrieu-Abadie, N., Anantharam, V., Ann, D.K., Anoopkumar-Dukie, S., Aoki, H., Apostolova, N., Arancia, G., Aris, J.P., Asanuma, K., Asare, N.Y.O., Ashida, H., Askanas, V., Askew, D.S., Auberger, P., Baba, M., Backues, S.K., Baehrecke, E.H., Bahr, B.A., Bai, X.Y., Bailly, Y., Baiocchi, R., Baldini, G., Balduini, W., Ballabio, A., Bamber, B.A., Bampton, E.T.W., Bánhegyi, G., Bartholomew, C.R., Bassham, D.C., Bast, R.C., Batoko, H., Bay, B.H., Beau, I., Béchet, D.M., Begley, T.J., Behl, C., Behrends, C., Bekri, S., Bellaire, B., Bendall, L.J., Benetti, L., Berliocchi, L., Bernardi, H., Bernassola, F., Besteiro, S., Bhatia-Kissova, I., Bi, X., Biard-Piechaczyk, M., Blum, J.S., Boise, L.H., Bonaldo, P., Boone, D.L., Bornhauser, B.C., Bortoluci, K.R., Bossis, I., Bost, F., Bourquin, J.P., Boya, P., Boyer-Guittaut, M., Bozhkov, P.V., Brady, N.R., Brancolini, C., Brech, A., Brenman, J.E., Brennand, A., Bresnick, E.H., Brest, P., Bridges, D., Bristol, M.L., Brookes, P.S., Brown, E.J., Brumell, J.H., Brunetti-Pierri, N., Brunk, U.T., Bulman, D.E., Bultman, S.J., Bultynck, G., Burbulla, L.F., Bursch, W., Butchar, J.P., Buzgariu, W., Bydlowski, S.P., Cadwell, K., Cahová, M., Cai, D., Cai, J., Cai, Q., Calabretta, B., Calvo-Garrido, J., Camougrand, N., Campanella, M., Campos-Salinas, J., Candi, E., Cao, L., Caplan, A.B., Carding, S.R., Cardoso, S.M., Carew, J.S., Carlin, C.R., Carmignac, V., Carneiro, L.A.M., Carra, S., Caruso, R.A., Casari, G., Casas, C., Castino, R., Cebollero, E., Cecconi, F., Celli, J., Chaachouay, H., Chae, H.J., Chai, C.Y., Chan, D.C., Chan, E.Y., Chang, R.C.C., Che, C.M., Chen, C.C., Chen, G.C., Chen, G.Q., Chen, M., Chen, Q., Chen, S.S.L., Chen, W., Chen, X., Chen, X., Chen, X., Chen, Y.G., Chen, Y., Chen, Y., Chen, Y.J., Chen, Z., Cheng, A., Cheng, C.H.K., Cheng, Y., Cheong, H., Cheong, J.H., Cherry, S., Chess-Williams, R., Cheung, Z.H., Chevet, E., Chiang, H.L., Chiarelli, R., Chiba, T., Chin, L.S., Chiou, S.H., Chisari, F.V., Cho, C.H., Cho, D.H., Choi, A.M.K., Choi, D., Choi, K.S., Choi, M.E., Chouaib, S., Choubey, D., Choubey, V., Chu, C.T., Chuang, T.H., Chueh, S.H., Chun, T., Chwae, Y.J., Chye, M.L., Ciarcia, R., Ciriolo, M.R., Clague, M.J., Clark, R.S.B., Clarke, P.G.H., Clarke, R., Codogno, P., Coller, H.A., Colombo, M.I., Comincini, S., Condello, M., Condorelli, F., Cookson, M.R., Coombs, G.H., Coppens, I., Corbalan, R., Cossart, P., Costelli, P., Costes, S., Coto-Montes, A., Couve, E., Coxon, F.P., Cregg, J.M., Crespo, J.L., Cronjé, M.J., Cuervo, A.M., Cullen, J.J., Czaja, M.J., D'Amelio, M., Darfeuille-Michaud, A., Davids, L.M., Davies, F.E., De Felici, M., de Groot, J.F., de Haan, C.A.M., De Martino, L., De Milito, A., De Tata, V., Debnath, J., Degterev, A., Dehay, B., Delbridge, L.M.D., Demarchi, F., Deng, Y.Z., Dengjel, J., Dent, P., Denton, D., Deretic, V., Desai, S.D., Devenish, R.J., Di Gioacchino, M., Di Paolo, G., Di Pietro, C., Díaz-Araya, G., Díaz-Laviada, I., Diaz-Meco, M.T., Diaz-Nido, J., Dikic, I., Dinesh-Kumar, S.P., Ding, W.X., Distelhorst, C.W., Diwan, A., Djavaheri-Mergny, M., Dokudovskaya, S., Dong, Z., Dorsey, F.C., Dosenko, V., Dowling, J.J., Doxsey, S., Dreux, M., Drew, M.E., Duan, Q., Duchosal, M.A., Duff, K., Dugail, I., Durbeej, M., Duszenko, M., Edelstein, C.L., Edinger, A.L., Egea, G., Eichinger, L., Eissa, N.T., Ekmekcioglu, S., El-Deiry, W.S., Elazar, Z., Elgendy, M., Ellerby, L.M., Eng, K.E., Engelbrecht, A.M., Engelender, S., Erenpreisa, J., Escalante, R., Esclatine, A., Eskelinen, E.L., Espert, L., Espina, V., Fan, H., Fan, J., Fan, Q.W., Fan, Z., Fang, S., Fang, Y., Fanto, M., Fanzani, A., Farkas, T., Farré, J.C., Faure, M., Fechheimer, M., Feng, C.G., Feng, J., Feng, Q., Feng, Y., Fésüs, L., Feuer, R., Figueiredo-Pereira, M.E., Fimia, G.M., Fingar, D.C., Finkbeiner, S., Finkel, T., Finley, K.D., Fiorito, F., Fisher, E.A., Fisher, P.B., Flajolet, M., Florez-McClure, M.L., Florio, S., Fon, E.A., Fornai, F., Fortunato, F., Fotedar, R., Fowler, D.H., Fox, H.S., Franco, R., Frankel, L.B., Fransen, M., Fuentes, J.M., Fueyo, J., Fujii, J., Fujisaki, K., Fujita, E., Fukuda, M., Furukawa, R.H., Gaestel, M., Gailly, P., Gajewska, M., Galliot, B., Galy, V., Ganesh, S., Ganetzky, B., Ganley, I.G., Gao, F.B., Gao, G.F., Gao, J., Garcia, L., Garcia-Manero, G., Garcia-Marcos, M., Garmyn, M., Gartel, A.L., Gatti, E., Gautel, M., Gawriluk, T.R., Gegg, M.E., Geng, J., Germain, M., Gestwicki, J.E., Gewirtz, D.A., Ghavami, S., Ghosh, P., Giammarioli, A.M., Giatromanolaki, A.N., Gibson, S.B., Gilkerson, R.W., Ginger, M.L., Ginsberg, H.N., Golab, J., Goligorsky, M.S., Golstein, P., Gomez-Manzano, C., Goncu, E., Gongora, C., Gonzalez, C.D., Gonzalez, R., González-Estévez, C., González-Polo, R.A., Gonzalez-Rey, E., Gorbunov, N.V., Gorski, S., Goruppi, S., Gottlieb, R.A., Gozuacik, D., Granato, G.E., Grant, G.D., Green, K.N., Gregorc, A., Gros, F., Grose, C., Grunt, T.W., Gual, P., Guan, J.L., Guan, K.L., Guichard, S.M., Gukovskaya, A.S., Gukovsky, I., Gunst, J., Gustafsson, A.B., Halayko, A.J., Hale, A.N., Halonen, S.K., Hamasaki, M., Han, F., Han, T., Hancock, M.K., Hansen, M., Harada, H., Harada, M., Hardt, S.E., Harper, J.W., Harris, A.L., Harris, J., Harris, S.D., Hashimoto, M., Haspel, J.A., Hayashi, S.I., Hazelhurst, L.A., He, C., He, Y.W., Hébert, M.J., Heidenreich, K.A., Helfrich, M.H., Helgason, G.V., Henske, E.P., Herman, B., Herman, P.K., Hetz, C., Hilfiker, S., Hill, J.A., Hocking, L.J., Hofman, P., Hofmann, T.G., Höhfeld, J., Holyoake, T.L., Hong, M.H., Hood, D.A., Hotamisligil, G.S., Houwerzijl, E.J., Høyer-Hansen, M., Hu, B., Hu, C.A.A., Hu, H.M., Hua, Y., Huang, C., Huang, J., Huang, S., Huang, W.P., Huber, T.B., Huh, W.K., Hung, T.H., Hupp, T.R., Hur, G.M., Hurley, J.B., Hussain, S.N.A., Hussey, P.J., Hwang, J.J., Hwang, S., Ichihara, A., Ilkhanizadeh, S., Inoki, K., Into, T., Iovane, V., Iovanna, J.L., Ip, N.Y., Isaka, Y., Ishida, H., Isidoro, C., Isobe, K.I., Iwasaki, A., Izquierdo, M., Izumi, Y., Jaakkola, P.M., Jäättelä, M., Jackson, G.R., Jackson, W.T., Janji, B., Jendrach, M., Jeon, J.H., Jeung, E.B., Jiang, H., Jiang, H., Jiang, J.X., Jiang, M., Jiang, Q., Jiang, X., Jiang, X., Jiménez, A., Jin, M., Jin, S., Joe, C.O., Johansen, T., Johnson, D.E., Johnson, G.V.W., Jones, N.L., Joseph, B., Joseph, S.K., Joubert, A.M., Juhász, G., Juillerat-Jeanneret, L., Jung, C.H., Jung, Y.K., Kaarniranta, K., Kaasik, A., Kabuta, T., Kadowaki, M., Kagedal, K., Kamada, Y., Kaminskyy, V.O., Kampinga, H.H., Kanamori, H., Kang, C., Kang, K.B., Kang, K.I., Kang, R., Kang, Y.A., Kanki, T., Kanneganti, T.D., Kanno, H., Kanthasamy, A.G., Kanthasamy, A., Karantza, V., Kaushal, G.P., Kaushik, S., Kawazoe, Y., Ke, P.Y., Kehrl, J.H., Kelekar, A., Kerkhoff, C., Kessel, D.H., Khalil, H., Kiel, J.A.K.W., Kiger, A.A., Kihara, A., Kim, D.R., Kim, D.H., Kim, D.H., Kim, E.K., Kim, H.R., Kim, J.S., Kim, J.H., Kim, J.C., Kim, J.K., Kim, P.K., Kim, S.W., Kim, Y.S., Kim, Y., Kimchi, A., Kimmelman, A.C., King, J.S., Kinsella, T.J., Kirkin, V., Kirshenbaum, L.A., Kitamoto, K., Kitazato, K., Klein, L., Klimecki, W.T., Klucken, J., Knecht, E., Ko, B.C.B., Koch, J.C., Koga, H., Koh, J.Y., Koh, Y.H., Koike, M., Komatsu, M., Kominami, E., Kong, H.J., Kong, W.J., Korolchuk, V.I., Kotake, Y., Koukourakis, M.I., Kouri Flores, J.B., Kovács, A.L., Kraft, C., Krainc, D., Krämer, H., Kretz-Remy, C., Krichevsky, A.M., Kroemer, G., Krüger, R., Krut, O., Ktistakis, N.T., Kuan, C.Y., Kucharczyk, R., Kumar, A., Kumar, R., Kumar, S., Kundu, M., Kung, H.J., Kurz, T., Kwon, H.J., La Spada, A.R., Lafont, F., Lamark, T., Landry, J., Lane, J.D., Lapaquette, P., Laporte, J.F., László, L., Lavandero, S., Lavoie, J.N., Layfield, R., Lazo, P.A., Le, W., Le Cam, L., Ledbetter, D.J., Lee, A.J.X., Lee, B.W., Lee, G.M., Lee, J., Lee, J.H., Lee, M., Lee, M.S., Lee, S.H., Leeuwenburgh, C., Legembre, P., Legouis, R., Lehmann, M., Lei, H.Y., Lei, Q.Y., Leib, D.A., Leiro, J., Lemasters, J.J., Lemoine, A., Lesniak, M.S., Lev, D., Levenson, V.V., Levine, B., Levy, E., Li, F., Li, J.L., Li, L., Li, S., Li, W., Li, X.J., Li, Y.B., Li, Y.P., Liang, C., Liang, Q., Liao, Y.F., Liberski, P.P., Lieberman, A., Lim, H.J., Lim, K.L., Lim, K., Lin, C.F., Lin, F.C., Lin, J., Lin, J.D., Lin, K., Lin, W.W., Lin, W.C., Lin, Y.L., Linden, R., Lingor, P., Lippincott-Schwartz, J., Lisanti, M.P., Liton, P.B., Liu, B., Liu, C.F., Liu, K., Liu, L., Liu, Q.A., Liu, W., Liu, Y.C., Liu, Y., Lockshin, R.A., Lok, C.N., Lonial, S., Loos, B., Lopez-Berestein, G., López-Otín, C., Lossi, L., Lotze, M.T., Lőw, P., Lu, B., Lu, B., Lu, B., Lu, Z., Luciano, F., Lukacs, N.W., Lund, A.H., Lynch-Day, M.A., Ma, Y., Macian, F., MacKeigan, J.P., Macleod, K.F., Madeo, F., Maiuri, L., Maiuri, M.C., Malagoli, D., Malicdan, M.C.V., Malorni, W., Man, N., Mandelkow, E.M., Manon, S., Manov, I., Mao, K., Mao, X., Mao, Z., Marambaud, P., Marazziti, D., Marcel, Y.L., Marchbank, K., Marchetti, P., Marciniak, S.J., Marcondes, M., Mardi, M., Marfe, G., Mariño, G., Markaki, M., Marten, M.R., Martin, S.J., Martinand-Mari, C., Martinet, W., Martinez-Vicente, M., Masini, M., Matarrese, P., Matsuo, S., Matteoni, R., Mayer, A., Mazure, N.M., McConkey, D.J., McConnell, M.J., McDermott, C., McDonald, C., McInerney, G.M., McKenna, S.L., McLaughlin, B., McLean, P.J., McMaster, C.R., McQuibban, G.A., Meijer, A.J., Meisler, M.H., Meléndez, A., Melia, T.J., Melino, G., Mena, M.A., Menendez, J.A., Menna-Barreto, R.F.S., Menon, M.B., Menzies, F.M., Mercer, C.A., Merighi, A., Merry, D.E., Meschini, S., Meyer, C.G., Meyer, T.F., Miao, C.Y., Miao, J.Y., Michels, P.A.M., Michiels, C., Mijaljica, D., Milojkovic, A., Minucci, S., Miracco, C., Miranti, C.K., Mitroulis, I., Miyazawa, K., Mizushima, N., Mograbi, B., Mohseni, S., Molero, X., Mollereau, B., Mollinedo, F., Momoi, T., Monastyrska, I., Monick, M.M., Monteiro, M.J., Moore, M.N., Mora, R., Moreau, K., Moreira, P.I., Moriyasu, Y., Moscat, J., Mostowy, S., Mottram, J.C., Motyl, T., Moussa, C.E.H., Müller, S., Muller, S., Münger, K., Münz, C., Murphy, L.O., Murphy, M.E., Musarò, A., Mysorekar, I., Nagata, E., Nagata, K., Nahimana, A., Nair, U., Nakagawa, T., Nakahira, K., Nakano, H., Nakatogawa, H., Nanjundan, M., Naqvi, N.I., Narendra, D.P., Narita, M., Navarro, M., Nawrocki, S.T., Nazarko, T.Y., Nemchenko, A., Netea, M.G., Neufeld, T.P., Ney, P.A., Nezis, I.P., Nguyen, H.P., Nie, D., Nishino, I., Nislow, C., Nixon, R.A., Noda, T., Noegel, A.A., Nogalska, A., Noguchi, S., Notterpek, L., Novak, I., Nozaki, T., Nukina, N., Nürnberger, T., Nyfeler, B., Obara, K., Oberley, T.D., Oddo, S., Ogawa, M., Ohashi, T., Okamoto, K., Oleinick, N.L., Oliver, F.J., Olsen, L.J., Olsson, S., Opota, O., Osborne, T.F., Ostrander, G.K., Otsu, K., Ou, J.H.J., Ouimet, M., Overholtzer, M., Ozpolat, B., Paganetti, P., Pagnini, U., Pallet, N., Palmer, G.E., Palumbo, C., Pan, T., Panaretakis, T., Pandey, U.B., Papackova, Z., Papassideri, I., Paris, I., Park, J., Park, O.K., Parys, J.B., Parzych, K.R., Patschan, S., Patterson, C., Pattingre, S., Pawelek, J.M., Peng, J., Perlmutter, D.H., Perrotta, I., Perry, G., Pervaiz, S., Peter, M., Peters, G.J., Petersen, M., Petrovski, G., Phang, J.M., Piacentini, M., Pierre, P., Pierrefite-Carle, V., Pierron, G., Pinkas-Kramarski, R., Piras, A., Piri, N., Platanias, L.C., Pöggeler, S., Poirot, M., Poletti, A., Poüs, C., Pozuelo-Rubio, M., Prætorius-Ibba, M., Prasad, A., Prescott, M., Priault, M., Produit-Zengaffinen, N., Progulske-Fox, A., Proikas-Cezanne, T., Przedborski, S., Przyklenk, K., Puertollano, R., Puyal, J., Qian, S.B., Qin, L., Qin, Z.H., Quaggin, S.E., Raben, N., Rabinowich, H., Rabkin, S.W., Rahman, I., Rami, A., Ramm, G., Randall, G., Randow, F., Rao, V.A., Rathmell, J.C., Ravikumar, B., Ray, S.K., Reed, B.H., Reed, J.C., Reggiori, F., Régnier-Vigouroux, A., Reichert, A.S., Reiners, J.J., Reiter, R.J., Ren, J., Revuelta, J.L., Rhodes, C.J., Ritis, K., Rizzo, E., Robbins, J., Roberge, M., Roca, H., Roccheri, M.C., Rocchi, S., Rodemann, H.P., Rodríguez de Córdoba, S., Rohrer, B., Roninson, I.B., Rosen, K., Rost-Roszkowska, M.M., Rouis, M., Rouschop, K.M.A., Rovetta, F., Rubin, B.P., Rubinsztein, D.C., Ruckdeschel, K., Rucker, E.B., Rudich, A., Rudolf, E., Ruiz-Opazo, N., Russo, R., Rusten, T.E., Ryan, K.M., Ryter, S.W., Sabatini, D.M., Sadoshima, J., Saha, T., Saitoh, T., Sakagami, H., Sakai, Y., Salekdeh, G.H., Salomoni, P., Salvaterra, P.M., Salvesen, G., Salvioli, R., Sanchez, A.M.J., Sánchez-Alcázar, J.A., Sánchez-Prieto, R., Sandri, M., Sankar, U., Sansanwal, P., Santambrogio, L., Saran, S., Sarkar, S., Sarwal, M., Sasakawa, C., Sasnauskiene, A., Sass, M., Sato, K., Sato, M., Schapira, A.H.V., Scharl, M., Schätzl, H.M., Scheper, W., Schiaffino, S., Schneider, C., Schneider, M.E., Schneider-Stock, R., Schoenlein, P.V., Schorderet, D.F., Schüller, C., Schwartz, G.K., Scorrano, L., Sealy, L., Seglen, P.O., Segura-Aguilar, J., Seiliez, I., Seleverstov, O., Sell, C., Seo, J.B., Separovic, D., Setaluri, V., Setoguchi, T., Settembre, C., Shacka, J.J., Shanmugam, M., Shapiro, I.M., Shaulian, E., Shaw, R.J., Shelhamer, J.H., Shen, H.M., Shen, W.C., Sheng, Z.H., Shi, Y., Shibuya, K., Shidoji, Y., Shieh, J.J., Shih, C.M., Shimada, Y., Shimizu, S., Shintani, T., Shirihai, O.S., Shore, G.C., Sibirny, A.A., Sidhu, S.B., Sikorska, B., Silva-Zacarin, E.C.M., Simmons, A., Simon, A.K., Simon, H.U., Simone, C., Simonsen, A., Sinclair, D.A., Singh, R., Sinha, D., Sinicrope, F.A., Sirko, A., Siu, P.M., Sivridis, E., Skop, V., Skulachev, V.P., Slack, R.S., Smaili, S.S., Smith, D.R., Soengas, M.S., Soldati, T., Song, X., Sood, A.K., Soong, T.W., Sotgia, F., Spector, S.A., Spies, C.D., Springer, W., Srinivasula, S.M., Stefanis, L., Steffan, J.S., Stendel, R., Stenmark, H., Stephanou, A., Stern, S.T., Sternberg, C., Stork, B., Strålfors, P., Subauste, C.S., Sui, X., Sulzer, D., Sun, J., Sun, S.Y., Sun, Z.J., Sung, J.J.Y., Suzuki, K., Suzuki, T., Swanson, M.S., Swanton, C., Sweeney, S.T., Sy, L.K., Szabadkai, G., Tabas, I., Taegtmeyer, H., Tafani, M., Takács-Vellai, K., Takano, Y., Takegawa, K., Takemura, G., Takeshita, F., Talbot, N.J., Tan, K.S.W., Tanaka, K., Tanaka, K., Tang, D., Tang, D., Tanida, I., Tannous, B.A., Tavernarakis, N., Taylor, G.S., Taylor, G.A., Taylor, J.P., Terada, L.S., Terman, A., Tettamanti, G., Thevissen, K., Thompson, C.B., Thorburn, A., Thumm, M., Tian, F., Tian, Y., Tocchini-Valentini, G., Tolkovsky, A.M., Tomino, Y., Tönges, L., Tooze, S.A., Tournier, C., Tower, J., Towns, R., Trajkovic, V., Travassos, L.H., Tsai, T.F., Tschan, M.P., Tsubata, T., Tsung, A., Turk, B., Turner, L.S., Tyagi, S.C., Uchiyama, Y., Ueno, T., Umekawa, M., Umemiya-Shirafuji, R., Unni, V.K., Vaccaro, M.I., Valente, E.M., Van den Berghe, G., van der Klei, I.J., van Doorn, W., van Dyk, L.F., van Egmond, M., van Grunsven, L.A., Vandenabeele, P., Vandenberghe, W.P., Vanhorebeek, I., Vaquero, E.C., Velasco, G., Vellai, T., Vicencio, J.M., Vierstra, R.D., Vila, M., Vindis, C., Viola, G., Viscomi, M.T., Voitsekhovskaja, O.V., von Haefen, C., Votruba, M., Wada, K., Wade-Martins, R., Walker, C.L., Walsh, C.M., Walter, J., Wan, X.B., Wang, A., Wang, C., Wang, D., Wang, F., Wang, F., Wang, G., Wang, H., Wang, H.G., Wang, H.D., Wang, J., Wang, K., Wang, M., Wang, R.C., Wang, X., Wang, X., Wang, Y.J., Wang, Y., Wang, Z., Wang, Z.C., Wang, Z., Wansink, D.G., Ward, D.M., Watada, H., Waters, S.L., Webster, P., Wei, L., Weihl, C.C., Weiss, W.A., Welford, S.M., Wen, L.P., Whitehouse, C.A., Whitton, J.L., Whitworth, A.J., Wileman, T., Wiley, J.W., Wilkinson, S., Willbold, D., Williams, R.L., Williamson, P.R., Wouters, B.G., Wu, C., Wu, D.C., Wu, W.K.K., Wyttenbach, A., Xavier, R.J., Xi, Z., Xia, P., Xiao, G., Xie, Z., Xie, Z., Xu, D.Z., Xu, J., Xu, L., Xu, X., Yamamoto, A., Yamamoto, A., Yamashina, S., Yamashita, M., Yan, X., Yanagida, M., Yang, D.S., Yang, E., Yang, J.M., Yang, S.Y., Yang, W., Yang, W.Y., Yang, Z., Yao, M.C., Yao, T.P., Yeganeh, B., Yen, W.L., Yin, J.J., Yin, X.M., Yoo, O.J., Yoon, G., Yoon, S.Y., Yorimitsu, T., Yoshikawa, Y., Yoshimori, T., Yoshimoto, K., You, H.J., Youle, R.J., Younes, A., Yu, L., Yu, L., Yu, S.W., Yu, W.H., Yuan, Z.M., Yue, Z., Yun, C.H., Yuzaki, M., Zabirnyk, O., Silva-Zacarin, E., Zacks, D., Zacksenhaus, E., Zaffaroni, N., Zakeri, Z., Zeh, H.J., Zeitlin, S.O., Zhang, H., Zhang, H.L., Zhang, J., Zhang, J.P., Zhang, L., Zhang, L., Zhang, M.Y., Zhang, X.D., Zhao, M., Zhao, Y.F., Zhao, Y., Zhao, Z.J., Zheng, X., Zhivotovsky, B., Zhong, Q., Zhou, C.Z., Zhu, C., Zhu, W.G., Zhu, X.F., Zhu, X., Zhu, Y., Zoladek, T., Zong, W.X., Zorzano, A., Zschocke, J., & Zuckerbraun, B. (2012). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 8(4), 445-544.Taylor & Francis. doi: 10.4161/auto.19496.
Liang, X., De Vera, M.E., Buchser, W.J., Romo de Vivar Chavez, A., Loughran, P., Beer Stolz, D., Basse, P., Wang, T., Van Houten, B., Zeh, H.J., & Lotze, M.T. (2012). Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res, 72(11), 2791-2801.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-12-0320.
Livesey, K.M., Kang, R., Vernon, P., Buchser, W., Loughran, P., Watkins, S.C., Zhang, L., Manfredi, J.J., Zeh, H.J., Li, L., Lotze, M.T., & Tang, D. (2012). p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res, 72(8), 1996-2005.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-11-2291.
Livesey, K.M., Kang, R., Zeh, H.J., Lotze, M.T., & Tang, D. (2012). Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy, 8(5), 846-848.Taylor & Francis. doi: 10.4161/auto.19891.
Lotze, M.T. (2012). Pancreatic cancer is not noble. J Innate Immun, 4(1), 4-5.Karger Publishers. doi: 10.1159/000334593.
Lotze, M.T., Appleman, L.J., Ramanathan, R.K., Tolcher, A.W., Beeram, M., Papadopoulos, K.P., Rasco, D.W., Weiss, G.J., Mountz, J.M., Toledo, F.G.S., Alvarez, R.J., Oborski, M.J., Rajagopalan, P., Jeffers, M., Roth, D., Dubowy, R.L., & Patnaik, A. (2012). Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. Journal of Clinical Oncology, 30(15_suppl), 3019.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2012.30.15_suppl.3019.
Lotze, M.T., Buchser, W.J., & Liang, X. (2012). Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy, 8(8), 1264-1266.Taylor & Francis. doi: 10.4161/auto.20752.
Tang, D., & Lotze, M.T. (2012). Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol, 13(9), 808-810.Springer Nature. doi: 10.1038/ni.2396.
Tang, D., Billiar, T.R., & Lotze, M.T. (2012). A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med, 18(1), 1360-1362.Springer Nature. doi: 10.2119/molmed.2012.00314.
Tang, D., Kang, R., Coyne, C.B., Zeh, H.J., & Lotze, M.T. (2012). PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev, 249(1), 158-175.Wiley. doi: 10.1111/j.1600-065X.2012.01146.x.
Tang, S., & Lotze, M.T. (2012). The power of negative thinking: which cells limit tumor immunity?. Clin Cancer Res, 18(19), 5157-5159.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-12-2418.
Unlu, S., Tang, S., Wang, E., Martinez, I., Tang, D., Bianchi, M.E., Zeh, H.J., & Lotze, M.T. (2012). Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. In Wachsmann, D. (Ed.). PLoS One, 7(6), e38899.Public Library of Science (PLoS). doi: 10.1371/journal.pone.0038899.
Weiner, L.M., & Lotze, M.T. (2012). Tumor-cell death, autophagy, and immunity. N Engl J Med, 366(12), 1156-1158.Massachusetts Medical Society. doi: 10.1056/NEJMcibr1114526.
Yan, W., Chang, Y., Liang, X., Cardinal, J.S., Huang, H., Thorne, S.H., Monga, S.P.S., Geller, D.A., Lotze, M.T., & Tsung, A. (2012). High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology, 55(6), 1863-1875.Wolters Kluwer. doi: 10.1002/hep.25572.
Yu, Y., Cao, L., Yang, L., Kang, R., Lotze, M., & Tang, D. (2012). microRNA 30A promotes autophagy in response to cancer therapy. Autophagy, 8(5), 853-855.Taylor & Francis. doi: 10.4161/auto.20053.
Amaravadi, R.K., Lippincott-Schwartz, J., Yin, X.M., Weiss, W.A., Takebe, N., Timmer, W., DiPaola, R.S., Lotze, M.T., & White, E. (2011). Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res, 17(4), 654-666.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-10-2634.
Fox, B.A., Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Håkansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufman, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Maccalli, C., Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Melief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van Der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., & Disis, M.L. (2011). Defining the critical hurdles in cancer immunotherapy. J Transl Med, 9(1), 214.Springer Nature. doi: 10.1186/1479-5876-9-214.
Ito, N., Lotze, M.T., & Zeh, H.J. (2011). Activated Natural Killer Cells. In Encyclopedia of Cancer. (pp. 19-23).Springer Nature. doi: 10.1007/978-3-642-16483-5_48.
Kang, R., Livesey, K.M., Zeh, H.J., Lotze, M.T., & Tang, D. (2011). Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy, 7(10), 1256-1258.Taylor & Francis. doi: 10.4161/auto.7.10.16753.
Kang, R., Livesey, K.M., Zeh, H.J., Lotze, M.T., & Tang, D. (2011). HMGB1 as an autophagy sensor in oxidative stress. Autophagy, 7(8), 904-906.Taylor & Francis. doi: 10.4161/auto.7.8.15704.
Kang, R., Tang, D., Livesey, K.M., Schapiro, N.E., Lotze, M.T., & Zeh, H.J. (2011). The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal, 15(8), 2175-2184.Mary Ann Liebert. doi: 10.1089/ars.2010.3378.
Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2011). RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy, 7(4), 442-444.Taylor & Francis. doi: 10.4161/auto.7.4.14681.
Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2011). Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). AUTOPHAGY, 7(1), 91-93.Taylor & Francis. doi: 10.4161/auto.7.1.13852.
Kang, R., Zeh, H.J., Lotze, M.T., & Tang, D. (2011). The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ, 18(4), 571-580.Springer Nature. doi: 10.1038/cdd.2010.191.
Liu, L., Yang, M., Kang, R., Wang, Z., Zhao, Y., Yu, Y., Xie, M., Yin, X., Livesey, K.M., Lotze, M.T., Tang, D., & Cao, L. (2011). HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia, 25(1), 23-31.Springer Nature. doi: 10.1038/leu.2010.225.
Liu, L., Yang, M., Kang, R., Wang, Z., Zhao, Y., Yu, Y., Xie, M., Yin, X., Livesey, K.M., Loze, M.T., Tang, D., & Cao, L. (2011). DAMP-mediated autophagy contributes to drug resistance. Autophagy, 7(1), 112-114.Taylor & Francis. doi: 10.4161/auto.7.1.14005.
Loux, T.J., Schapiro, N.E., Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2011). Pancreatic Cancer Induces Systemic Autophagy. Journal of Surgical Research, 165(2), 336.Elsevier. doi: 10.1016/j.jss.2010.11.207.
Patnaik, A., Appleman, L.J., Mountz, J.M., Ramanathan, R.K., Beeram, M., Tolcher, A.W., Papadopoulos, K.P., Lotze, M.T., Petro, D.P., Laymon, C., Paige, L., Rajagopalan, P., Jeffers, M., Roth, D., & Dubowy, R.L. (2011). A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. Journal of Clinical Oncology, 29(15_suppl), 3035.American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2011.29.15_suppl.3035.
Tang, D., Kang, R., Livesey, K.M., Kroemer, G., Billiar, T.R., Van Houten, B., Zeh, H.J., & Lotze, M.T. (2011). High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab, 13(6), 701-711.Elsevier. doi: 10.1016/j.cmet.2011.04.008.
Tang, D., Kang, R., Livesey, K.M., Zeh, H.J., & Lotze, M.T. (2011). High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal, 15(8), 2185-2195.Mary Ann Liebert. doi: 10.1089/ars.2010.3666.
Tang, D., Kang, R., Zeh, H.J., & Lotze, M.T. (2011). High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal, 14(7), 1315-1335.Mary Ann Liebert. doi: 10.1089/ars.2010.3356.
Tang, D., Lotze, M.T., Kang, R., & Zeh, H.J. (2011). Apoptosis promotes early tumorigenesis. Oncogene, 30(16), 1851-1854.Springer Nature. doi: 10.1038/onc.2010.573.
Wong, J.L., Mailliard, R.B., Moschos, S.J., Edington, H., Lotze, M.T., Kirkwood, J.M., & Kalinski, P. (2011). Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother, 34(3), 270-278.Wolters Kluwer. doi: 10.1097/CJI.0b013e31820b370b.
Wong, J.L., Mailliard, R.B., Moschos, S.J., Edington, H., Lotze, M.T., Kirkwood, J.M., & Kalinski, P. (2011). Helper Activity of Natural Killer Cells During The Dendritic Cell-Mediated Induction of Melanoma-Specific Cytotoxic T Cells. JOURNAL OF IMMUNOTHERAPY, 34(2), 226.
de Vivar Chavez, A.R., Liang, X., Lotze, M.T., & De Vera, M.E. (2010). Expression and Effects of IL-33 and Its Receptor in a Murine Pancreatic Cell Line. Journal of Surgical Research, 158(2), 197-198.Elsevier. doi: 10.1016/j.jss.2009.11.084.
Demaria, S., Pikarsky, E., Karin, M., Coussens, L.M., Chen, Y.C., El-Omar, E.M., Trinchieri, G., Dubinett, S.M., Mao, J.T., Szabo, E., Krieg, A., Weiner, G.J., Fox, B.A., Coukos, G., Wang, E., Abraham, R.T., Carbone, M., & Lotze, M.T. (2010). Cancer and inflammation: promise for biologic therapy. J Immunother, 33(4), 335-351.Wolters Kluwer. doi: 10.1097/CJI.0b013e3181d32e74.
John, E., Laskow, T.C., Buchser, W.J., Pitt, B.R., Basse, P.H., Butterfield, L.H., Kalinski, P., & Lotze, M.T. (2010). Zinc in innate and adaptive tumor immunity. J Transl Med, 8(1), 118.Springer Nature. doi: 10.1186/1479-5876-8-118.
Kang, R., Livesey, K.M., Zeh, H.J., Loze, M.T., & Tang, D. (2010). HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy, 6(8), 1209-1211.Informa UK Limited. doi: 10.4161/auto.6.8.13651.
Kang, R., Tang, D., Schapiro, N.E., Livesey, K.M., Farkas, A., Loughran, P., Bierhaus, A., Lotze, M.T., & Zeh, H.J. (2010). The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ, 17(4), 666-676.Springer Nature. doi: 10.1038/cdd.2009.149.
Lesinski, G.B., Carson, W.E., Repasky, E.A., Wei, W.Z., Kalinski, P., Lotze, M.T., June, C.H., Petros, W., Muthusamy, N., & Olencki, T. (2010). Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. J Immunother, 33(7), 659-662.Wolters Kluwer. doi: 10.1097/CJI.0b013e3181eccbf7.
Liang, X., de Vivar, A.R., Lotze, M.T., & de Vera, M.E. (2010). Ethyl Pyruvate Alters Tumor Cell Metabolism and Inhibits Hepatic Tumor Growth. Journal of Surgical Research, 158(2), 197.Elsevier. doi: 10.1016/j.jss.2009.11.082.
Lotze, M.T., & Thomson, A.W. (2010). Natural Killer Cells. Elsevier. doi: 10.1016/c2009-0-00213-x.
Lotze, M.T., Tang, D., Buchser, W.J., Liang, X., DeVera, M., Plevy, S.E., John, E., Pitt, B., Basse, P.H., Butterfield, L., Kalinski, P., Zeh, H.J., Lotfi, R., & Rubartelli, A. (2010). E14 Damage associated molecular pattern molecules (DAMPs) redox and autophagy. Journal of Crohn's and Colitis, 4(1), 11-12.Oxford University Press (OUP). doi: 10.1016/s1873-9954(10)70018-5.
Loux, T.J., Lotze, M.T., & Zeh, H.J. (2010). NK cells as recipients of cytokine signals. In Natural Killer Cells. (pp. 189-201).Elsevier. doi: 10.1016/b978-0-12-370454-2.00014-4.
Loux, T.J., Lotze, M.T., & Zeh, H.J. (2010). Chapter Fourteen NK cells as recipients of cytokine signals. In Natural Killer Cells. (pp. 189-201).Elsevier. doi: 10.1016/b978-0-12-370454-2.00014-4.
Loux, T.J., Schapiro, N.E., Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2010). Inhibition of Autophagy by Chloroquine Enhances Chemotherapy in an Orthotopic Murine Model of Pancreatic Cancer. Journal of Surgical Research, 158(2), 393-394.Elsevier. doi: 10.1016/j.jss.2009.11.617.
Maecker, H.T., McCoy, J.P., FOCIS Human Immunophenotyping Consortium, Amos, M., Elliott, J., Gaigalas, A., Wang, L., Aranda, R., Banchereau, J., Boshoff, C., Braun, J., Korin, Y., Reed, E., Cho, J., Hafler, D., Davis, M., Fathman, C.G., Robinson, W., Denny, T., Weinhold, K., Desai, B., Diamond, B., Gregersen, P., Di Meglio, P., Nestle, F.O., Peakman, M., Villanova, F., Ferbas, J., Field, E., Kantor, A., Kawabata, T., Komocsar, W., Lotze, M., Nepom, J., Ochs, H., O'Lone, R., Phippard, D., Plevy, S., Rich, S., Roederer, M., Rotrosen, D., & Yeh, J.H. (2010). A model for harmonizing flow cytometry in clinical trials. Nat Immunol, 11(11), 975-978.Springer Nature. doi: 10.1038/ni1110-975.
Okada, H., Kohanbash, G., & Lotze, M.T. (2010). MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol, 42(8), 1256-1261.Elsevier. doi: 10.1016/j.biocel.2010.02.002.
Sasaki, K., Kohanbash, G., Hoji, A., Ueda, R., McDonald, H.A., Reinhart, T.A., Martinson, J., Lotze, M.T., Marincola, F.M., Wang, E., Fujita, M., & Okada, H. (2010). miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med, 8(1), 17.Springer Nature. doi: 10.1186/1479-5876-8-17.
Sun, L.T., Bencherif, S.A., Gilbert, T.W., Farkas, A.M., Lotze, M.T., & Washburn, N.R. (2010). Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. Wound Repair Regen, 18(3), 302-310.Wiley. doi: 10.1111/j.1524-475X.2010.00591.x.
Sun, L.T., Bencherif, S.A., Gilbert, T.W., Lotze, M.T., & Washburn, N.R. (2010). Design principles for cytokine-neutralizing gels: Cross-linking effects. Acta Biomater, 6(12), 4708-4715.Elsevier. doi: 10.1016/j.actbio.2010.06.029.
Sun, L.T., Buchholz, K.S., Lotze, M.T., & Washburn, N.R. (2010). Cytokine binding by polysaccharide-antibody conjugates. Mol Pharm, 7(5), 1769-1777.American Chemical Society (ACS). doi: 10.1021/mp100150z.
Tang, D., Kang, R., Cheh, C.W., Livesey, K.M., Liang, X., Schapiro, N.E., Benschop, R., Sparvero, L.J., Amoscato, A.A., Tracey, K.J., Zeh, H.J., & Lotze, M.T. (2010). HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene, 29(38), 5299-5310.Springer Nature. doi: 10.1038/onc.2010.261.
Tang, D., Kang, R., Livesey, K.M., Cheh, C.W., Farkas, A., Loughran, P., Hoppe, G., Bianchi, M.E., Tracey, K.J., Zeh, H.J., & Lotze, M.T. (2010). Endogenous HMGB1 regulates autophagy. J Cell Biol, 190(5), 881-892.Taylor & Francis. doi: 10.1083/jcb.200911078.
Tang, D., Kang, R., Livesey, K.M., Cheh, C.W., Farkas, A., Loughran, P., Hoppe, G., Bianchi, M.E., Tracey, K.J., Zeh, H.J., & Lotze, M.T. (2010). Endogenous HMGB1 regulates autophagy. Journal of Experimental Medicine, 207(10), i27.Rockefeller University Press. doi: 10.1084/jem20710oia27.
Tang, D., Kang, R., Zeh, H.J., & Lotze, M.T. (2010). High-mobility group box 1 and cancer. Biochim Biophys Acta, 1799(1-2), 131-140.Elsevier. doi: 10.1016/j.bbagrm.2009.11.014.
Tang, D., Loze, M.T., Zeh, H.J., & Kang, R. (2010). The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy, 6(8), 1181-1183.Taylor & Francis. doi: 10.4161/auto.6.8.13367.
Yang, H., Rivera, Z., Jube, S., Nasu, M., Bertino, P., Goparaju, C., Franzoso, G., Lotze, M.T., Krausz, T., Pass, H.I., Bianchi, M.E., & Carbone, M. (2010). Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A, 107(28), 12611-12616.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.1006542107.
Anunobi, R., Lotze, M.T., & Zeh, H.J. (2009). QS358. Toll Like Receptor-9 Signaling in Tumor Cells Promotes Survival Following Cytotoxic Insult. Journal of Surgical Research, 151(2), 298.Elsevier. doi: 10.1016/j.jss.2008.11.667.
Cardinal, J., Pan, P., Dhupar, R., Ross, M., Nakao, A., Lotze, M., Billiar, T., Geller, D., & Tsung, A. (2009). Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology, 50(2), 565-574.Wolters Kluwer. doi: 10.1002/hep.23021.
Chavez, A.R.D.V., Buchser, W., Basse, P.H., Liang, X., Appleman, L.J., Maranchie, J.K., Zeh, H., de Vera, M.E., & Lotze, M.T. (2009). Pharmacologic administration of interleukin-2. Ann N Y Acad Sci, 1182(1), 14-27.Wiley. doi: 10.1111/j.1749-6632.2009.05160.x.
Davé, S.H., Tilstra, J.S., Matsuoka, K., Li, F., DeMarco, R.A., Beer-Stolz, D., Sepulveda, A.R., Fink, M.P., Lotze, M.T., & Plevy, S.E. (2009). Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol, 86(3), 633-643.Oxford University Press (OUP). doi: 10.1189/jlb.1008662.
Englert, J.M., Sparvero, L.J., Amoscato, A.A., Lotze, M.T., & Oury, T.D. (2009). RAGE and the Lung Extracellular Matrix: A Novel Protective Function. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 179.American Thoracic Society. doi: 10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4990.
Ito, N., Zeh, H.J., & Lotze, M.T. (2009). Activated Natural Killer Cells. In Encyclopedia of Cancer. (pp. 20-23).Springer Nature. doi: 10.1007/978-3-540-47648-1_48.
Lee, J.J., & Lotze, M.T. (2009). Molecular basis of metastasis. N Engl J Med, 360(16), 1679.
Liang, X., Chavez, A.R.D.V., Schapiro, N.E., Loughran, P., Thorne, S.H., Amoscato, A.A., Zeh, H.J., Beer-Stolz, D., Lotze, M.T., & de Vera, M.E. (2009). Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol, 86(3), 599-607.Oxford University Press (OUP). doi: 10.1189/jlb.0908578.
Liang, X., Farkas, A., de Vivar, A.R., Lotze, M.T., & de Vera, M.E. (2009). QS144. The Damage Associated Molecular Pattern Molecule HMGB1 Stimulates Hepatic Stellate Cell (HSC) Activation. Journal of Surgical Research, 151(2), 288.Elsevier. doi: 10.1016/j.jss.2008.11.442.
Liang, X., Titler, A., Schapiro, N., de Vivar, A.R., Zeh, H., Lotze, M.T., & de Vera, M.E. (2009). 67. Ethyl Pyruvate Inhibits the Growth of Metastatic Tumors in the Liver by Inducing Apoptosis. Journal of Surgical Research, 151(2), 201-202.Elsevier. doi: 10.1016/j.jss.2008.11.080.
Livesey, K.M., Tang, D., Zeh, H.J., & Lotze, M.T. (2009). Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs, 10(12), 1269-1279.
Lotfi, R., Herzog, G.I., DeMarco, R.A., Beer-Stolz, D., Lee, J.J., Rubartelli, A., Schrezenmeier, H., & Lotze, M.T. (2009). Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol, 183(8), 5023-5031.Oxford University Press (OUP). doi: 10.4049/jimmunol.0900504.
Lotfi, R., Schrezenmeier, H., & Lotze, M.T. (2009). Immunotherapy for cancer: promoting innate immunity. Front Biosci (Landmark Ed), 14(3), 818-832.IMR Press. doi: 10.2741/3280.
Loux, T.J., Bailey, L., Kang, R., Basse, P., Lotze, M.T., & Zeh, H.J. (2009). 186. The Receptor for Advanced Glycation End-Products (RAGE) Limits NK Activity. Journal of Surgical Research, 151(2), 257.Elsevier. doi: 10.1016/j.jss.2008.11.225.
Mailliard, R.B., Moschios, S., Edington, H., Lotze, M.T., Kirkwood, J., & Kalinski, P. (2009). Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Lymphocyte Responses. JOURNAL OF IMMUNOTHERAPY, 32(9), 972.
Pan, P., Cardinal, J., Dhupar, R., Rosengart, M.R., Lotze, M.T., Geller, D.A., Billiar, T.R., & Tsung, A. (2009). Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J Leukoc Biol, 86(3), 625-632.Oxford University Press (OUP). doi: 10.1189/JLB.1108713.
Romo de Vivar Chavez, A., de Vera, M.E., Liang, X., & Lotze, M.T. (2009). The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Med Oncol, 26 Suppl 1(Suppl 1), 3-12.Springer Nature. doi: 10.1007/s12032-008-9162-z.
Shurin, M.R., & Lotze, M.T. (2009). Dendritic Cells in Cancer: Emergenceof the Discipline. In Dendritic Cells in Cancer. (pp. 11-30).Springer Nature. doi: 10.1007/978-0-387-88611-4_2.
Sparvero, L.J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A.A., Zeh, H.J., & Lotze, M.T. (2009). RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med, 7(1), 17.Springer Nature. doi: 10.1186/1479-5876-7-17.
Tahara, H., Sato, M., Thurin, M., Wang, E., Butterfield, L.H., Disis, M.L., Fox, B.A., Lee, P.P., Khleif, S.N., Wigginton, J.M., Ambs, S., Akutsu, Y., Chaussabel, D., Doki, Y., Eremin, O., Fridman, W.H., Hirohashi, Y., Imai, K., Jacobson, J., Jinushi, M., Kanamoto, A., Kashani-Sabet, M., Kato, K., Kawakami, Y., Kirkwood, J.M., Kleen, T.O., Lehmann, P.V., Liotta, L., Lotze, M.T., Maio, M., Malyguine, A., Masucci, G., Matsubara, H., Mayrand-Chung, S., Nakamura, K., Nishikawa, H., Palucka, A.K., Petricoin, E.F., Pos, Z., Ribas, A., Rivoltini, L., Sato, N., Shiku, H., Slingluff, C.L., Streicher, H., Stroncek, D.F., Takeuchi, H., Toyota, M., Wada, H., Wu, X., Wulfkuhle, J., Yaguchi, T., Zeskind, B., Zhao, Y., Zocca, M.B., & Marincola, F.M. (2009). Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med, 7(1), 45.Springer Nature. doi: 10.1186/1479-5876-7-45.
Tang, D., Kang, R., Xiao, W., Zhang, H., Lotze, M.T., Wang, H., & Xiao, X. (2009). Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol, 41(6), 651-660.American Thoracic Society. doi: 10.1165/rcmb.2008-0119OC.
Tör, M., Lotze, M.T., & Holton, N. (2009). Receptor-mediated signalling in plants: molecular patterns and programmes. J Exp Bot, 60(13), 3645-3654.Oxford University Press (OUP). doi: 10.1093/jxb/erp233.
Ueda, R., Kohanbash, G., Sasaki, K., Fujita, M., Zhu, X., Kastenhuber, E.R., McDonald, H.A., Potter, D.M., Hamilton, R.L., Lotze, M.T., Khan, S.A., Sobol, R.W., & Okada, H. (2009). Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A, 106(26), 10746-10751.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.0811817106.
Liang, X., Farkas, A.M., Lotze, M.T., & DeVera, M.E. (2008). THE DAMAGE ASSOCIATED MOLECULAR PATTERN MOLECULE [DAMP] HMGB1 ENHANCE TLR AND RAGE EXPRESSION ON HEPATIC STELLATE CELL (HSC), STIMULATES ACTIVATION AND PROLIFERATION. Transplantation, 86(2S), 550.Wolters Kluwer. doi: 10.1097/01.tp.0000331164.09755.6c.
Livesey, K.M., Tang, D., Zeh, H.J., & Lotze, M.T. (2008). Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1. Curr Opin Investig Drugs, 9(12), 1259-1263.
Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Kramer, B.S., Lencioni, R., Zhu, A.X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., Gores, G.J., & Panel of Experts in HCC-Design Clinical Trials. (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100(10), 698-711.Oxford University Press (OUP). doi: 10.1093/jnci/djn134.
Lotfi, R., & Lotze, M.T. (2008). Eosinophils induce DC maturation, regulating immunity. J Leukoc Biol, 83(3), 456-460.Oxford University Press (OUP). doi: 10.1189/jlb.0607366.
Lotze, M.T., & Nepom, G.T. (2008). A nexus of science and clinical immunology: the Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence. Clin Immunol, 127(2), 119-120.Elsevier. doi: 10.1016/j.clim.2008.02.010.
Lotze, M.T., Mapara, M.Y., & June, C.H. (2008). Tumor immunology and immunotherapy. In Clinical Immunology. (pp. 1181-1195).Elsevier. doi: 10.1016/b978-0-323-04404-2.10079-x.
Lotze, M.T., Mapara, M.Y., & June, C.H. (2008). 79 Tumor immunology and immunotherapy. In Clinical Immunology. (pp. 1181-1195).Elsevier. doi: 10.1016/b978-0-323-04404-2.10079-x.
Moschos, S.J., Mandic, M., Kirkwood, J.M., Storkus, W.J., & Lotze, M.T. (2008). Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol, 127(2), 123-129.Elsevier. doi: 10.1016/j.clim.2008.02.011.
Moschos, S.J., Mandic, M., Kirkwood, J.M., Storkus, W.J., & Lotze, M.T. (2008). Focus on FOCIS: Interleukin 2 treatment associated autoimmunity. CLINICAL IMMUNOLOGY, 127(2), 123-129. doi: 10.1016/j.clim.2008.02.011.
Ostberg, T., Wähämaa, H., Palmblad, K., Ito, N., Stridh, P., Shoshan, M., Lotze, M.T., Harris, H.E., & Andersson, U. (2008). Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther, 10(1), R1.Springer Nature. doi: 10.1186/ar2347.
Sparvero, L.J., Englert, J., Oury, T., Amoscato, A.A., & Lotze, M.T. (2008). BioLayer Interferometry (BLI) for label-free measurement of ligand binding of RAGE and HMGB1. JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), A28.
Sparvero, L.J., Kucherer, S., Zeh, H., Lotze, M., & Amoscato, A. (2008). MALDI-TOF Mass Spectrometry assessment of sRAGE and high mobility group box protein-1 [HMGB1] in cancer and healthy tissues. JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), A34.
Torti, F.M., Altieri, D., Broach, J., Fan, H., Lotze, M., Manfredi, J., Matrisian, L., Yu, D., Giaccia, A., & Cancer Biology Training Consortium. (2008). Ph.D. Training in cancer biology. Cancer Res, 68(22), 9122-9124.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-08-2626.
Turner, J.L.H., Kilgore, T.M., Farkas, A.M., Sparvero, L.J., Amoscato, A.A., & Lotze, M.T. (2008). Biolayer interferometry to assess the presence and activity of HMGB1 in serum. JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), A34-A35.
Vakkila, J., Demarco, R.A., & Lotze, M.T. (2008). Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scand J Immunol, 67(3), 260-269.Wiley. doi: 10.1111/j.1365-3083.2007.02068.x.
Zetterström, C.K., Jiang, W., Wähämaa, H., Ostberg, T., Aveberger, A.C., Schierbeck, H., Lotze, M.T., Andersson, U., Pisetsky, D.S., & Erlandsson Harris, H. (2008). Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol, 83(1), 31-38.Oxford University Press (OUP). doi: 10.1189/jlb.0507323.
Atkins, M.B., Carbone, D., Coukos, G., Dhodapkar, M., Ernstoff, M.S., Finke, J., Gajewski, T.F., Gollob, J., Lotze, M.T., Storkus, W., & Weiner, L.M. (2007). Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother, 30(6), 577-590.Wolters Kluwer. doi: 10.1097/CJI.0b013e318064e7b2.
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M.T., Wesa, A., Parmiani, G., & Anichini, A. (2007). Interleukin-12: biological properties and clinical application. Clin Cancer Res, 13(16), 4677-4685.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-07-0776.
Dong, X.D.E., Ito, N., Lotze, M.T., Demarco, R.A., Popovic, P., Shand, S.H., Watkins, S., Winikoff, S., Brown, C.K., Bartlett, D.L., & Zeh, H.J. (2007). High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother, 30(6), 596-606.Wolters Kluwer. doi: 10.1097/CJI.0b013e31804efc76.
Ellerman, J.E., Brown, C.K., de Vera, M., Zeh, H.J., Billiar, T., Rubartelli, A., & Lotze, M.T. (2007). Masquerader: high mobility group box-1 and cancer. Clin Cancer Res, 13(10), 2836-2848.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-06-1953.
Farkas, A.M., Kilgore, T.M., & Lotze, M.T. (2007). Detecting DNA: getting and begetting cancer. Curr Opin Investig Drugs, 8(12), 981-986.
Farkas, A.M., Kilgore, T.M., & Lotze, M.T. (2007). Editorial overview detecting DNA: Getting and begetting cancer. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 8(12), 981-986.
Fujii, S.I., & Lotze, M.T. (2007). Interleukin-10 (IL-10). In Cytokines in the Genesis and Treatment of Cancer. (pp. 165-179).Springer Nature. doi: 10.1007/978-1-59745-455-1_9.
Hikawa, H., Lotze, M.T., & Rosenblum, W.D. (2007). Induction of peripheral tolerance by local delivery of dendritic cell progenitors to cardiac allografts in a murine heterotopic heart transplantation model. Gen Thorac Cardiovasc Surg, 55(8), 307-314.Springer Nature. doi: 10.1007/s11748-007-0133-7.
Ito, N., DeMarco, R.A., Mailliard, R.B., Han, J., Rabinowich, H., Kalinski, P., Stolz, D.B., Zeh, H.J., & Lotze, M.T. (2007). Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol, 81(1), 75-83.Oxford University Press (OUP). doi: 10.1189/jlb.0306169.
Kavanagh, B., Ko, A., Venook, A., Margolin, K., Zeh, H., Lotze, M., Schillinger, B., Liu, W., Lu, Y., Mitsky, P., Schilling, M., Bercovici, N., Loudovaris, M., Guillermo, R., Lee, S.M., Bender, J., Mills, B., & Fong, L. (2007). Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother, 30(7), 762-772.Wolters Kluwer. doi: 10.1097/CJI.0b013e318133451c.
Levy, R.M., Mollen, K.P., Prince, J.M., Kaczorowski, D.J., Vallabhaneni, R., Liu, S., Tracey, K.J., Lotze, M.T., Hackam, D.J., Fink, M.P., Vodovotz, Y., & Billiar, T.R. (2007). Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol, 293(4), R1538-R1544.American Physiological Society. doi: 10.1152/ajpregu.00272.2007.
Lotfi, R., Lee, J.J., & Lotze, M.T. (2007). Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother, 30(1), 16-28.Wolters Kluwer. doi: 10.1097/01.cji.0000211324.53396.f6.
Lotze, M.T. (2007). Interleukin-1 Family of Cytokines and Cancer. In Cytokines in the Genesis and Treatment of Cancer. (pp. 113-133).Springer Nature. doi: 10.1007/978-1-59745-455-1_6.
Lotze, M.T., & Gray, J. (2007). A life in passing: Jonathan Gray. J Transl Med, 5(1), 54.Springer Nature. doi: 10.1186/1479-5876-5-54.
Lotze, M.T., Deisseroth, A., & Rubartelli, A. (2007). Damage associated molecular pattern molecules. Clin Immunol, 124(1), 1-4.Elsevier. doi: 10.1016/j.clim.2007.02.006.
Lotze, M.T., Zeh, H.J., Rubartelli, A., Sparvero, L.J., Amoscato, A.A., Washburn, N.R., Devera, M.E., Liang, X., Tör, M., & Billiar, T. (2007). The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev, 220(1), 60-81.Wiley. doi: 10.1111/j.1600-065X.2007.00579.x.
Matsuoka, K., Davé, S., Tilstra, J., Li, F., DeMarco, R., Fink, M., Lotze, M., & Plevy, S. (2007). O-0003: PAMPs and DAMPs in IBD. Inflammatory Bowel Diseases, 13(Supplement 5), 643.Oxford University Press (OUP). doi: 10.1097/00054725-200705005-00003.
Okada, H., & Lotze, M.T. (2007). Cytokines and Cancer Vaccines. In Cytokines in the Genesis and Treatment of Cancer. (pp. 423-436).Springer Nature. doi: 10.1007/978-1-59745-455-1_22.
Rubartelli, A., & Lotze, M.T. (2007). Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol, 28(10), 429-436.Elsevier. doi: 10.1016/j.it.2007.08.004.
Tsung, A., Zheng, N., Jeyabalan, G., Izuishi, K., Klune, J.R., Geller, D.A., Lotze, M.T., Lu, L., & Billiar, T.R. (2007). Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol, 81(1), 119-128.Oxford University Press (OUP). doi: 10.1189/jlb.0706468.
Whiteside, T.L., Boyiadzis, M., & Herberman, R.B. (2007). Natural Killer (NK) Cells*. 815-821.Elsevier. doi: 10.1016/b978-012373947-6.00269-5.
Chen, Y., Fung, J.J., Lotze, M.T., Qian, S., & Lu, L. (2006). TOLEROGENIC ACTIVITY OF LIVER DENDRITIC CELLS IS REGULATED BY TLR4/B7-H1 PATHWAY. Transplantation, 82(1), 428.Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/00007890-200607152-01087.
D'Aiuto, L., De Marco, R., Edward, N., Rizzo, A., Chaillet, J.R., Montecalvo, A., Lotze, M.T., & Gambotto, A. (2006). Evidence of the capability of the CMV enhancer to activate in trans gene expression in mammalian cells. DNA Cell Biol, 25(3), 171-180.Mary Ann Liebert. doi: 10.1089/dna.2006.25.171.
de Vera, M.E., Langer, C., Wang, L., Nakao, A., Qian, S., Geller, D.A., Lotze, M.T., & Lu, L. (2006). PHENOTYPIC AND FUNCTIONAL ANALYSIS OF CD11c+ HUMAN LIVER AND SPLENIC DENDRITIC CELLS. Transplantation, 82(1), 1023-1024.Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/00007890-200607152-02924.
Eto, M., Bennouna, J., Hunter, O.C., Lotze, M.T., & Amoscato, A.A. (2006). Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol, 13(2), 148-156.Wiley. doi: 10.1111/j.1442-2042.2006.01249.x.
Ito, N., Demarco, R.A., Mailliard, R.B., Han, J., Rabinowich, H., Kalinski, P., Stolz, D.B., Zeh, H.J., & Lotze, M.T. (2006). Immune cytolysis induces HMGB1 release through a partially caspase dependent apoptotic pathway. JOURNAL OF IMMUNOTHERAPY, 29(6), 681.
Izuishi, K., Tsung, A., Jeyabalan, G., Critchlow, N.D., Li, J., Tracey, K.J., Demarco, R.A., Lotze, M.T., Fink, M.P., Geller, D.A., & Billiar, T.R. (2006). Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol, 176(12), 7154-7158.Oxford University Press (OUP). doi: 10.4049/jimmunol.176.12.7154.
Lotze, M.T. (2006). Cancer gene therapy: the power of negative thinking. Gene Ther, 13(3), 191-193.Springer Nature. doi: 10.1038/sj.gt.3302633.
Lotze, M.T., & Yu, Y. (2006). Cancer genomics: the unknown unknowns. Curr Opin Investig Drugs, 7(6), 497-500.
Montag, D.T., & Lotze, M.T. (2006). Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes. Clin Immunol, 121(2), 215-226.Elsevier. doi: 10.1016/j.clim.2006.06.013.
Montag, D.T., & Lotze, M.T. (2006). Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells. J Immunol Methods, 313(1-2), 48-60.Elsevier. doi: 10.1016/j.jim.2006.03.014.
Popovic, P.J., DeMarco, R., Lotze, M.T., Winikoff, S.E., Bartlett, D.L., Krieg, A.M., Guo, Z.S., Brown, C.K., Tracey, K.J., & Zeh, H.J. (2006). High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol, 177(12), 8701-8707.Oxford University Press (OUP). doi: 10.4049/jimmunol.177.12.8701.
Tao, R., Wang, L., Chen, C.H., Wang, S.H., Demarco, R.A., Lotze, M.T., Thai, N.L., Fung, J.J., Lu, L., & Qian, S. (2006). Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus. J Heart Lung Transplant, 25(3), 310-319.Elsevier. doi: 10.1016/j.healun.2005.10.005.
Tsung, A., Zheng, N., Jeyabalan, G., Liang, X., Lotze, M.T., Geller, D.A., Lu, L., & Billiar, T.R. (2006). DENDRITIC CELLS MEDIATE INJURY AFTER HEPATIC ISCHEMIA REPERFUSION THROUGH HIGH-MOBILITY GROUP BOX1 (HMGB1) ENHANCEMENT OF TLR4. Transplantation, 82(1), 364-365.Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/00007890-200607152-00897.
Vakkila, J., Jaffe, R., Michelow, M., & Lotze, M.T. (2006). Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clin Cancer Res, 12(7 Pt 1), 2049-2054.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-05-1824.
Wang, Y., Zheng, N., Lu, Z., Wu, W., Wang, L., Nakao, A., Lotze, M.T., Langer, C.E., Fung, J.J., Qian, S., & Lu, L. (2006). In vivo expansion of two distinct dendritic cells in mouse livers and its impact on liver immune regulation. Liver Transpl, 12(12), 1850-1861.Wolters Kluwer. doi: 10.1002/lt.20919.
DeMarco, R.A., Fink, M.P., & Lotze, M.T. (2005). Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol, 42(4), 433-444.Elsevier. doi: 10.1016/j.molimm.2004.07.023.
Fujii, S.I., Nishimura, M.I., & Lotze, M.T. (2005). Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells. Cancer Sci, 96(12), 897-902.Wiley. doi: 10.1111/j.1349-7006.2005.00124.x.
Guo, Z.S., Naik, A., O'Malley, M.E., Popovic, P., Demarco, R., Hu, Y., Yin, X., Yang, S., Zeh, H.J., Moss, B., Lotze, M.T., & Bartlett, D.L. (2005). The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res, 65(21), 9991-9998.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-05-1630.
Hauskrecht, M., Pelikan, R., Malehorn, D.E., Bigbee, W.L., Lotze, M.T., Zeh, H.J., Whitcomb, D.C., & Lyons-Weiler, J. (2005). Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics, 4(4), 227-246.Springer Nature. doi: 10.2165/00822942-200504040-00003.
Kalinski, P., Mailliard, R.B., Geskin, L., Giermasz, A., Nakamura, Y., Storkus, W.J., Lotze, M.T., Bartlett, D.L., Kirkwood, J.M., & Falo, L.D. (2005). Polarized DC1-based therapeutic cancer vaccines. JOURNAL OF IMMUNOTHERAPY, 28(6), 656.Wolters Kluwer. doi: 10.1097/01.cji.0000191090.97275.78.
Kalinski, P., Mailliard, R.B., Giermasz, A., Zeh, H.J., Basse, P., Bartlett, D.L., Kirkwood, J.M., Lotze, M.T., & Herberman, R.B. (2005). Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther, 5(10), 1303-1315.Taylor & Francis. doi: 10.1517/14712598.5.10.1303.
Lotze, M., & Thomson, A. (2005). Measuring Immunity: Basic Biology and Clinical ssessment.
Lotze, M., & Thomson, A. (2005). Measuring Immunity. Elsevier. doi: 10.1016/b978-0-12-455900-4.x5260-x.
Lotze, M.T., & Tracey, K.J. (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol, 5(4), 331-342.Springer Nature. doi: 10.1038/nri1594.
Lotze, M.T., Day, R., DeVera, M.E., Demetris, A.J., DeMarco, R.A., & Shakil, O. (2005). Serum high mobility group B1[HMGB1] is a damage associated molecular pattern [DAMP] cytokine elevated in chronic hepatitis C patients and diminishing following orthotopic liver transplantation. CLINICAL IMMUNOLOGY, 115, (pp. S198-S199).Boston MA.
Lotze, M.T., Lu, L., & Taylor, D.L. (2005). Imaging Cytometry: High Content Screening for Large-Scale Cell Research. In Measuring Immunity. (pp. 660-665).Elsevier. doi: 10.1016/b978-012455900-4/50320-2.
Lotze, M.T., Lu, L., & Taylor, D.L. (2005). Chapter 58 Imaging Cytometry High Content Screening for Large-Scale Cell Research. In Measuring Immunity. (pp. 660-665).Elsevier. doi: 10.1016/b978-012455900-4/50320-2.
Lotze, M.T., Wang, E., Marincola, F.M., Hanna, N., Bugelski, P.J., Burns, C.A., Coukos, G., Damle, N., Godfrey, T.E., Howell, W.M., Panelli, M.C., Perricone, M.A., Petricoin, E.F., Sauter, G., Scheibenbogen, C., Shivers, S.C., Taylor, D.L., Weinstein, J.N., & Whiteside, T.L. (2005). Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother, 28(2), 79-119.Wolters Kluwer. doi: 10.1097/01.cji.0000154251.20125.2e.
Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., Hishinuma, T., Goto, J., Lotze, M.T., Kolls, J.K., & Sasaki, H. (2005). IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol, 175(9), 6177-6189.Oxford University Press (OUP). doi: 10.4049/jimmunol.175.9.6177.
Pelikan, R., Lotze, M.T., Lyons-Weiler, J., Malehorn, D., & Hauskrecht, M. (2005). Serum Proteomic Profiling and Analysis. In Measuring Immunity. (pp. 649-659).Elsevier. doi: 10.1016/b978-012455900-4/50319-6.
Pelikan, R., Lotze, M.T., Lyons-Weiler, J., Malehorn, D., & Hauskrecht, M. (2005). Chapter 57 Serum Proteomic Profiling and Analysis. In Measuring Immunity. (pp. 649-659).Elsevier. doi: 10.1016/b978-012455900-4/50319-6.
Takahashi, H., Numasaki, M., Lotze, M.T., & Sasaki, H. (2005). Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett, 98(2), 189-193.Elsevier. doi: 10.1016/j.imlet.2004.11.012.
Tsung, A., Hoffman, R.A., Izuishi, K., Critchlow, N.D., Nakao, A., Chan, M.H., Lotze, M.T., Geller, D.A., & Billiar, T.R. (2005). Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol, 175(11), 7661-7668.Oxford University Press (OUP). doi: 10.4049/jimmunol.175.11.7661.
Tsung, A., Sahai, R., Tanaka, H., Nakao, A., Fink, M.P., Lotze, M.T., Yang, H., Li, J., Tracey, K.J., Geller, D.A., & Billiar, T.R. (2005). The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med, 201(7), 1135-1143.Rockefeller University Press. doi: 10.1084/jem.20042614.
Vakkila, J., DeMarco, R.A., & Lotze, M.T. (2005). Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level. Drug Discov Today, Suppl, 19-30.
Vakkila, J., Lotze, M.T., Riga, C., & Jaffe, R. (2005). A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol, 8(1), 43-51.SAGE Publications. doi: 10.1007/s10024-004-5045-2.
Winikoff, S.E., Zeh, H.J., DeMarco, R., & Lotze, M.T. (2005). Handling and Storage of Cells and Sera: Practical Considerations. In Measuring Immunity. (pp. 233-236).Elsevier. doi: 10.1016/b978-012455900-4/50281-6.
Winikoff, S.E., Zeh, H.J., DeMarco, R., & Lotze, M.T. (2005). Cytolytic Assays. In Measuring Immunity. (pp. 343-349).Elsevier. doi: 10.1016/b978-012455900-4/50291-9.
Winikoff, S.E., Zeh, H.J., DeMarco, R., & Lotze, M.T. (2005). Chapter 29 Cytolytic Assays. In Measuring Immunity. (pp. 343-349).Elsevier. doi: 10.1016/b978-012455900-4/50291-9.
Winikoff, S.E., Zeh, H.J., Richard, D., & Lotze, M.T. (2005). Chapter 19 Handling and Storage of Cells and Sera Practical Considerations. In Measuring Immunity. (pp. 233-236).Elsevier. doi: 10.1016/b978-012455900-4/50281-6.
Zeh, H.J., & Lotze, M.T. (2005). Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother, 28(1), 1-9.Wolters Kluwer. doi: 10.1097/00002371-200501000-00001.
Zeh, H.J., Winikoff, S., Landsittel, D.P., Gorelik, E., Marrangoni, A.M., Velikokhatnaya, L., Winans, M.T., Lee, K., Moser, A., Bartlett, D., Lotze, M.T., Siegfried, J.M., Whitcomb, D., Papacristou, G., Slivka, A., Bigbee, W.L., & Lokshin, A.E. (2005). Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark, 1(6), 259-269.SAGE Publications. doi: 10.3233/cbm-2005-1601.
Agha-Mohammadi, S., O'Malley, M., Etemad, A., Wang, Z., Xiao, X., & Lotze, M.T. (2004). Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med, 6(7), 817-828.Wiley. doi: 10.1002/jgm.566.
Lotze, M.T., & Demarco, R.A. (2004). Dying dangerously: Necrotic cell death and chronic inflammation promote tumor growth. Discov Med, 4(24), 448-456.
Lotze, M.T., & Herberman, R.B. (2004). Cancer as a chronic inflammatory disease: role of immunotherapy. In Cancer and Inflammation. (pp. 21-51).Springer Nature. doi: 10.1007/978-3-0348-7861-6_2.
Lotze, M.T., & Papamichail, M. (2004). A primer on cancer immunology and immunotherapy. Cancer Immunol Immunother, 53(3), 135-138.Springer Nature. doi: 10.1007/s00262-003-0467-7.
Lotze, M.T., & Rees, R.C. (2004). Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells. Cancer Immunol Immunother, 53(3), 256-261.Springer Nature. doi: 10.1007/s00262-003-0487-3.
Numasaki, M., Lotze, M.T., & Sasaki, H. (2004). Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett, 93(1), 39-43.Elsevier. doi: 10.1016/j.imlet.2004.01.014.
Tao, R., Lu, L., Wang, S.H., Demarco, R., Lotze, M.T., Fung, J.J., & Qian, S. (2004). MECHANISTIC INSIGHTS: LONG-TERM ALLOGRAFT SURVIVAL BY ADMINISTRATION OF IMMATURE DENDRITIC CELLS AND SUBDOSING SIROLIMUS. Transplantation, 78(2), 600.Wolters Kluwer. doi: 10.1097/00007890-200407271-01616.
Vakkila, J., & Lotze, M.T. (2004). Inflammation and necrosis promote tumour growth. Nat Rev Immunol, 4(8), 641-648.Springer Nature. doi: 10.1038/nri1415.
Vakkila, J., & Lotze, M.T. (2004). Opinion - Inflammation and necrosis promote tumour growth. NATURE REVIEWS IMMUNOLOGY, 4(8), 641-648. doi: 10.1038/nri1415.
Vakkila, J., DeMarco, R.A., & Lotze, M.T. (2004). Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level. J Immunol Methods, 294(1-2), 123-134.Elsevier. doi: 10.1016/j.jim.2004.09.007.
Yu, J., Lu, Y., Zhu, W., Wang, Y., Chen, X., Yi, C., Luo, D., Lotze, M.T., & Zhou, Q. (2004). [Anti-tumor activities of lung cancer dendritic cell vaccine modified by mutant Ki-ras gene in vitro]. Zhongguo Fei Ai Za Zhi, 7(2), 104-107. doi: 10.3779/j.issn.1009-3419.2004.02.06.
Eto, M., Bennouna, J., Hunter, O.C., Hershberger, P.A., Kanto, T., Johnson, C.S., Lotze, M.T., & Amoscato, A.A. (2003). C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate, 57(1), 66-79.Wiley. doi: 10.1002/pros.10275.
Gao, W., Kumar, S., Lotze, M.T., Hanning, C., Robbins, P.D., & Gambotto, A. (2003). Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol, 170(1), 107-113.Oxford University Press (OUP). doi: 10.4049/jimmunol.170.1.107.
Hashimoto, W., Tanaka, F., Robbins, P.D., Taniguchi, M., Okamura, H., Lotze, M.T., & Tahara, H. (2003). Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18. Int J Cancer, 103(4), 508-513.Wiley. doi: 10.1002/ijc.10844.
KALINSKI, P., STORKUS, W., THOMSON, A., & LOTZE, M. (2003). Interleukin-12 Family [IL-12, 23, 12RA and 27]. In The Cytokine Handbook. (pp. 383-408).Elsevier. doi: 10.1016/b978-012689663-3/50020-x.
Kalinski, P., Storkus, W.J., Thomson, A.W., & Lotze, M.T. (2003). Chapter 16 Interleukin-12 Family [IL-12, 23, 12RA and 27]. In The Cytokine Handbook. I, (pp. 383-408).Elsevier. doi: 10.1016/b978-012689663-3/50020-x.
Kitagawa, T., Iwazawa, T., Robbins, P.D., Lotze, M.T., & Tahara, H. (2003). Advantages and limitations of particle-mediated transfection (gene gun) in cancer immuno-gene therapy using IL-10, IL-12 or B7-1 in murine tumor models. J Gene Med, 5(11), 958-965.Wiley. doi: 10.1002/jgm.441.
LOTZE, M., & HAMILTON, J. (2003). Macrophage Colony Stimulating Factor [CSF-1]. In The Cytokine Handbook. (pp. 927-958).Elsevier. doi: 10.1016/b978-012689663-3/50044-2.
LOTZE, M., & THOMSON, A. (2003). Preface to the Fourth Edition. xix-xxi.Elsevier. doi: 10.1016/b978-012689663-3/50003-x.
Lotze, M.T. (2003). The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy. Curr Opin Investig Drugs, 4(6), 649-651.
Lotze, M.T. (2003). Editorial overview: Dealing with death: HMGB1 as a novel target for cancer therapy. Current Opinion in Investigational Drugs, 4(12), 1405-1409.
Lotze, M.T., & DeMarco, R.A. (2003). Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs, 4(12), 1405-1409.
Lotze, M.T., & Kalinski, P. (2003). Interleukin-12 Family Members. In Encyclopedia of Hormones. (pp. 462-470).Elsevier. doi: 10.1016/b0-12-341103-3/00158-3.
Nishioka, Y., Wen, H., Mitani, K., Robbins, P.D., Lotze, M.T., Sone, S., & Tahara, H. (2003). Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide. J Leukoc Biol, 73(5), 621-629.Oxford University Press (OUP). doi: 10.1189/jlb.0402205.
Numasaki, M., Fukushi, J.I., Ono, M., Narula, S.K., Zavodny, P.J., Kudo, T., Robbins, P.D., Tahara, H., & Lotze, M.T. (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101(7), 2620-2627.American Society of Hematology. doi: 10.1182/blood-2002-05-1461.
OKADA, H., BANCHEREAU, J., & LOTZE, M. (2003). Interleukin-4. In The Cytokine Handbook. (pp. 227-262).Elsevier. doi: 10.1016/b978-012689663-3/50014-4.
Okada, H., Banchereau, J., & Lotze, M.T. (2003). Chapter 10 Interleukin-4. In The Cytokine Handbook. I, (pp. 227-262).Elsevier. doi: 10.1016/b978-012689663-3/50014-4.
OKAMURA, H., LOTZE, M., TSUTSUI, H., KASHIWAMURA, S., UEDA, H., YOSHIMOTO, T., & NAKANISHI, K. (2003). Interleukin-18 [IL-1F4]. In The Cytokine Handbook. (pp. 709-733).Elsevier. doi: 10.1016/b978-012689663-3/50033-8.
Okamura, H., Lotze, M.T., Tsutsui, H., Kashiwamura, S.I., Ueda, H., Yoshimoto, T., & Nakanishi, K. (2003). Chapter 29 Interleukin-18 [IL-1F4]. In The Cytokine Handbook. II, (pp. 709-733).Elsevier. doi: 10.1016/b978-012689663-3/50033-8.
Redlinger, R.E., Mailliard, R.B., Lotze, M.T., & Barksdale, E.M. (2003). Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg, 38(3), 301-307.Elsevier. doi: 10.1053/jpsu.2003.50098.
Son, Y.I., Dallal, R.M., & Lotze, M.T. (2003). Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. J Immunother, 26(3), 234-240.Wolters Kluwer. doi: 10.1097/00002371-200305000-00007.
Son, Y.I., Dallal, R.M., & Lotze, M.T. (2003). Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. Journal of Immunotherapy, 26(3), 4738.
Thomson, A.W., & Lotze, M.T. (2003). The Cytokine Handbook. 1-1396.
Agha-MoKamrnodi, S., & Lotze, M.T. (2002). Cytokine Gene Therapy. In Encyclopedia of Cancer. (pp. 33-40).Elsevier. doi: 10.1016/b0-12-227555-1/00061-7.
Dallal, R.M., Christakos, P., Lee, K., Egawa, S., Son, Y.I., & Lotze, M.T. (2002). Paucity of dendritic cells in pancreatic cancer. Surgery, 131(2), 135-138.Elsevier. doi: 10.1067/msy.2002.119937.
Dutcher, J., Logan, T., Gordon, M., Sosman, J., Weiss, G., Margolin, K., Plasse, T., Mier, J., Lotze, M., Clark, J., & Atkins, M. (2002). Phase II trial of interleukin 2, interferon α, and 5-fluorouracil in metastatic renal cell cancer a cytokine working group study. Urologic Oncology Seminars and Original Investigations, 7(2), 83-84.Elsevier. doi: 10.1016/s1078-1439(01)00163-6.
Jonak, Z.L., Trulli, S., Maier, C., McCabe, F.L., Kirkpatrick, R., Johanson, K., Ho, Y.S., Elefante, L., Chen, Y.J., Herzyk, D., Lotze, M.T., & Johnson, R.K. (2002). High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. J Immunother, 25 Suppl 1(SUPPL. 1), S20-S27.Wolters Kluwer. doi: 10.1097/00002371-200203001-00004.
Kumar, S., Hanning, C.R., Brigham-Burke, M.R., Rieman, D.J., Lehr, R., Khandekar, S., Kirkpatrick, R.B., Scott, G.F., Lee, J.C., Lynch, F.J., Gao, W., Gambotto, A., & Lotze, M.T. (2002). Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine, 18(2), 61-71.Elsevier. doi: 10.1006/cyto.2002.0873.
Lotze, M.T., & Kost, T.A. (2002). Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther, 9(8), 692-699.Springer Nature. doi: 10.1038/sj.cgt.7700493.
Lotze, M.T., Mailliard, R.B., Tanaka, F., Tahara, H., Storkus, W.J., & Kalinksi, P. (2002). DC-activating function of cytokines [IL-12, IL-18], T cells and NK cells in the development of antitumor responses. CLINICAL IMMUNOLOGY, 103(3), S103-S104.
Lotze, M.T., Tahara, H., & Okamura, H. (2002). Interleukin-18 as a novel, distinct, and distant member of the interleukin-1 family promoting development of the adaptive immune response: the interleukin-18 issue of the Journal of Immunotherapy. J Immunother, 25 Suppl 1(SUPPL. 1), S1-S3.Wolters Kluwer. doi: 10.1097/00002371-200203001-00001.
Mailliard, R.B., Egawa, S., Cai, Q., Kalinska, A., Bykovskaya, S.N., Lotze, M.T., Kapsenberg, M.L., Storkus, W.J., & Kalinski, P. (2002). Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med, 195(4), 473-483.Rockefeller University Press. doi: 10.1084/jem.20011662.
Odoux, C., Albers, A., Amoscato, A.A., Lotze, M.T., & Wong, M.K.K. (2002). TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer, 97(4), 458-465.Wiley. doi: 10.1002/ijc.1640.
Satoh, Y., Esche, C., Gambotto, A., Shurin, G.V., Yurkovetsky, Z.R., Robbins, P.D., Watkins, S.C., Todo, S., Herberman, R.B., Lotze, M.T., & Shurin, M.R. (2002). Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol, 2(6), 337-349.Wiley. doi: 10.1046/j.1359-4117.2002.01050.x.
Shimamura, H., Cumberland, R., Hiroishi, K., Watkins, S.C., Lotze, M.T., & Baar, J. (2002). Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J Immunother, 25(3), 226-234.Wolters Kluwer. doi: 10.1097/00002371-200205000-00005.
Tanaka, F., Hashimoto, W., Robbins, P.D., Lotze, M.T., & Tahara, H. (2002). Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther, 9(21), 1480-1486.Springer Nature. doi: 10.1038/sj.gt.3301827.
Chi, K.H., Myers, J.N., Chow, K.C., Chan, W.K., Tsang, Y.W., Chao, Y., Yen, S.H., & Lotze, M.T. (2001). Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology, 60(2), 110-115.Karger Publishers. doi: 10.1159/000055306.
Dallal, R.M., & Lotze, M.T. (2001). Immunotherapy of metastasis. Surg Oncol Clin N Am, 10(2), 433-xi.Elsevier. doi: 10.1016/s1055-3207(18)30074-7.
Dworacki, G., Meidenbauer, N., Kuss, I., Hoffmann, T.K., Gooding, W., Lotze, M., & Whiteside, T.L. (2001). Decreased ζ chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. CLINICAL CANCER RESEARCH, 7(3), 947S-957S.
Dworacki, G., Meidenbauer, N., Kuss, I., Hoffmann, T.K., Gooding, W., Lotze, M., & Whiteside, T.L. (2001). Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clinical Cancer Research, 7(3 Suppl), 947s-957s.
Dworacki, G., Meidenbauer, N., Kuss, I., Hoffmann, T.K., Gooding, W., Lotze, M., & Whiteside, T.L. (2001). Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res, 7(3 Suppl), 947s-957s.
Finn, O.J., & Lotze, M.T. (2001). A decade in the life of tumor immunology. Clin Cancer Res, 7(3 Suppl), 759s-760s.
Finn, O.J., & Lotze, M.T. (2001). A Decade in the Life of Tumor Immunology. Clinical Cancer Research, 7(3).
Finn, O.J., & Lotze, M.T. (2001). A decade in the life of tumor immunology. Clinical Cancer Research, 7(11 SUPPL.).
Flaherty, L.E., Atkins, M., Sosman, J., Weiss, G., Clark, J.I., Margolin, K., Dutcher, J., Gordon, M.S., Lotze, M., Mier, J., Sorokin, P., Fisher, R.I., Appel, C., & Du, W. (2001). Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol, 19(13), 3194-3202.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2001.19.13.3194.
Fujii, S., Shimizu, K., Shimizu, T., & Lotze, M.T. (2001). Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood, 98(7), 2143-2151.American Society of Hematology. doi: 10.1182/blood.v98.7.2143.
Iwazawa, T., Chau, G.Y., Mori, T., Dookeran, K.A., Rubin, J.T., Watkins, S., Robbins, P.D., Lotze, M.T., & Tahara, H. (2001). Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cell. Cancer Gene Ther, 8(1), 17-22.Springer Nature. doi: 10.1038/sj.cgt.7700272.
Kalinski, P., Lotze, M.T., & Kapsenberg, M.L. (2001). Chapter 6 Dendritic cell-related immunoregulation Signals and mediators. In Dendritic Cells. (pp. 51-v).Elsevier. doi: 10.1016/b978-012455851-9/50045-6.
Kang, W.K., Park, C., Yoon, H.L., Kim, W.S., Yoon, S.S., Lee, M.H., Park, K., Kim, K., Jeong, H.S., Kim, J.A., Nam, S.J., Yang, J.H., Son, Y.I., Baek, C.H., Han, J., Ree, H.J., Lee, E.S., Kim, S.H., Kim, D.W., Ahn, Y.C., Huh, S.J., Choe, Y.H., Lee, J.H., Park, M.H., Kong, G.S., Park, E.Y., Kang, Y.K., Bang, Y.J., Paik, N.S., Lee, S.N., Kim, S.H., Kim, S., Robbins, P.D., Tahara, H., Lotze, M.T., & Park, C.H. (2001). Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther, 12(6), 671-684.Mary Ann Liebert. doi: 10.1089/104303401300057388.
Kanto, T., Kalinski, P., Hunter, O.C., Lotze, M.T., & Amoscato, A.A. (2001). Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol, 167(7), 3773-3784.Oxford University Press (OUP). doi: 10.4049/jimmunol.167.7.3773.
Keilholz, U., & Lotze, M.T. (2001). Biologic Agents. In Current Cancer Therapeutics. (pp. 55-75).Springer Nature. doi: 10.1007/978-1-4613-1099-0_3.
Kikly, K., & Lotze, M.T. (2001). Chapter 38 DCs in wound healing. In Dendritic Cells. (pp. 539-xxiii).Elsevier. doi: 10.1016/b978-012455851-9/50077-8.
Lotze, M.T., & Jaffe, R. (2001). Chapter 31 The identification of dendritic cells in cancer. In Dendritic Cells. (pp. 425-437).Elsevier. doi: 10.1016/b978-012455851-9/50070-5.
Lotze, M.T., & Kirkwood, J.M. (2001). Melanoma and Other Tumors of the Skin. In Current Cancer Therapeutics. (pp. 205-216).Springer Nature. doi: 10.1007/978-1-4613-1099-0_11.
Lotze, M.T., & Thomson, A.W. (2001). Preface to the Second Edition. In Dendritic Cells. (pp. xviii-xx).Elsevier. doi: 10.1016/b978-012455851-9/50038-9.
Lotze, M.T., & Thomson, A.W. (2001). Preface to the First Edition. In Dendritic Cells. (pp. xxi-xxii).Elsevier. doi: 10.1016/b978-012455851-9/50039-0.
Mailliard, R.B., & Lotze, M.T. (2001). Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets. Clinical Cancer Research, 7(11 SUPPL.).
Mailliard, R.B., & Lotze, M.T. (2001). Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets. CLINICAL CANCER RESEARCH, 7(3), 980S-988S.
Mailliard, R.B., & Lotze, M.T. (2001). Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets. Clin Cancer Res, 7(3 Suppl), 980s-988s.
Mailliard, R.B., Egawa, S., Cai, Q., Kalinska, A., Lotze, M.T., Kapsenberg, M.L., Storkus, W.J., & Kalinski, P. (2001). Polarized dendritic cells mediate CDS help for CD4+ T cells:: Helper function of CD8+ T cells in the development of Th1 responses. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(4), 1022.
Matsko, C.M., Hunter, O.C., Rabinowich, H., Lotze, M.T., & Amoscato, A.A. (2001). Mitochondrial lipid alterations during Fas- and radiation-induced apoptosis. Biochem Biophys Res Commun, 287(5), 1112-1120.Elsevier. doi: 10.1006/bbrc.2001.5696.
Okada, H., Attanucci, J., Giezeman-Smits, K.M., Brissette-Storkus, C., Fellows, W.K., Gambotto, A., Pollack, L.F., Pogue-Geile, K., Lotze, M.T., Bozik, M.E., & Chambers, W.H. (2001). Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res, 61(6), 2625-2631.
Okada, H., Villa, L., Attanucci, J., Erff, M., Fellows, W.K., Lotze, M.T., Pollack, I.F., & Chambers, W.H. (2001). Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther, 8(15), 1157-1166.Springer Nature. doi: 10.1038/sj.gt.3301496.
Pollack, I.F., Okada, H., Lotze, M.T., Lieberman, F., Schiff, D., Attanucci, J., Edington, H., Chambers, W.H., Robbins, P., Baar, J., Kinzler, D., Whiteside, T., Elder, E., & Potter, D. (2001). 765 A Phase I Study of an IL-4-HSV-tk Gene-modified Autologous Glioma Vaccine: Technical Challenges and Promising Initial Results. Neurosurgery, 49(2), 526.Wolters Kluwer. doi: 10.1227/00006123-200108000-00129.
Pollack, I.F., Okada, H., Lotze, M.T., Lieberman, F., Schiff, D., Attanucci, J., Edington, H., Chambers, W.H., Robbins, P., Baar, J., Kinzler, D., Whiteside, T., Elder, E., & Potter, D. (2001). 765 A Phase I Study of an IL-4-HSV-tk Gene-modified Autologous Glioma Vaccine: Technical Challenges and Promising Initial Results. Neurosurgery, 49(2), 526.Wolters Kluwer. doi: 10.1097/00006123-200108000-00129.
Shimizu, T., Berhanu, A., Redlinger, R.E., Watkins, S., Lotze, M.T., & Barksdale, E.M. (2001). Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg, 36(8), 1285-1292.Elsevier. doi: 10.1053/jpsu.2001.25796.
Shimizu, T., Relinger, R., Lotze, M.T., & Barksdale, E.M. (2001). Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. Journal of Surgical Education, 58(5), 503.Elsevier. doi: 10.1016/s0149-7944(01)00522-0.
Shurin, G.V., Shurin, M.R., Bykovskaia, S., Shogan, J., Lotze, M.T., & Barksdale, E.M. (2001). Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res, 61(1), 363-369.
Son, Y.I., Dallal, R.M., Mailliard, R.B., Egawa, S., Jonak, Z.L., & Lotze, M.T. (2001). Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res, 61(3), 884-888.
Son, Y.I., Mailliard, R.B., Watkins, S.C., & Lotze, M.T. (2001). Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2. Laryngoscope, 111(8), 1472-1478.Wiley. doi: 10.1097/00005537-200108000-00026.
Agha-Mohammadi, S., & Lotze, M.T. (2000). Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest, 105(9), 1177-1183.American Society for Clinical Investigation. doi: 10.1172/JCI10027.
Agha-Mohammadi, S., & Lotze, M.T. (2000). Immunomodulation of cancer: potential use of selectively replicating agents. J Clin Invest, 105(9), 1173-1176.American Society for Clinical Investigation. doi: 10.1172/JCI10026.
Dallal, R.M., & Lotze, M.T. (2000). The dendritic cell and human cancer vaccines. Curr Opin Immunol, 12(5), 583-588.Elsevier. doi: 10.1016/s0952-7915(00)00146-1.
Dallal, R.M., Son, Y.I., Mailliard, R., & Lotze, M.T. (2000). Interleukin-18 markedly augments NK cell proliferation and cytotoxicity when combined with low-dose interleukin-2. Journal of the American College of Surgeons, 191(4), s16.Wolters Kluwer. doi: 10.1016/s1072-7515(00)00417-8.
Dutcher, J.P., Logan, T., Gordon, M., Sosman, J., Weiss, G., Margolin, K., Plasse, T., Mier, J., Lotze, M., Clark, J., & Atkins, M. (2000). Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res, 6(9), 3442-3450.
Egawa, S., & Lotze, M.T. (2000). The Laheru/Jaffee article reviewed. ONCOLOGY-NEW YORK, 14(2), 259-260.
Esche, C., Cai, Q., Peron, J.M., Hunter, O., Subbotin, V.M., Lotze, M.T., & Shurin, M.R. (2000). Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivo. European Journal of Immunology, 30(9), 2565-2575. doi: 10.1002/1521-4141(200009)30:9<2565::AID-IMMU2565>3.0.CO;2-V.
Esche, C., Cai, Q., Peron, J.M., Hunter, O., Subbotin, V.M., Lotze, M.T., & Shurin, M.R. (2000). Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivo. Eur J Immunol, 30(9), 2565-2575.Wiley. doi: 10.1002/1521-4141(200009)30:9<2565::AID-IMMU2565>3.0.CO;2-V.
Giezeman-Smits, K.M., Okada, H., Brissette-Storkus, C.S., Villa, L.A., Attanucci, J., Lotze, M.T., Pollack, I.F., Bozik, M.E., & Chambers, W.H. (2000). Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res, 60(9), 2449-2457.
Hirao, M., Onai, N., Hiroishi, K., Watkins, S.C., Matsushima, K., Robbins, P.D., Lotze, M.T., & Tahara, H. (2000). CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res, 60(8), 2209-2217.
Hiroishi, K., Tüting, T., & Lotze, M.T. (2000). IFN-α-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. Journal of Immunology, 164(2), 567-572. doi: 10.4049/jimmunol.164.2.567.
Hiroishi, K., Tüting, T., & Lotze, M.T. (2000). IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol, 164(2), 567-572.Oxford University Press (OUP). doi: 10.4049/jimmunol.164.2.567.
Lotze, M.T. (2000). The future role of interleukin-2 in cancer therapy. Cancer J Sci Am, 6 Suppl 1(SUPPL. 1), S58-S60.
Lotze, M.T., Shurin, M., Esche, C., Tahara, H., Storkus, W., Kirkwood, J.M., Whiteside, T.L., Elder, E.M., Okada, H., & Robbins, P. (2000). Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am, 6 Suppl 1(SUPPL. 1), S61-S66.
Mailliard, R.B., Dallal, R.M., Son, Y.I., & Lotze, M.T. (2000). Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunol Invest, 29(2), 177-185.Taylor & Francis. doi: 10.3109/08820130009062302.
Okada, H., Attanucci, J., Tahara, H., Pollack, I.F., Bozik, M.E., Chambers, W.H., & Lotze, M.T. (2000). Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther, 7(3), 486-494.Springer Nature. doi: 10.1038/sj.cgt.7700140.
Okada, H., Pollack, I.F., Lotze, M.T., Lunsford, L.D., Kondziolka, D., Lieberman, F., Schiff, D., Attanucci, J., Edington, H., Chambers, W., Robbins, P., Baar, J., Kinzler, D., Whiteside, T., & Elder, E. (2000). Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther, 11(4), 637-653.Mary Ann Liebert. doi: 10.1089/10430340050015824.
Pirtskhalaishvili, G., Shurin, G.V., Esche, C., Cai, Q., Salup, R.R., Bykovskaia, S.N., Lotze, M.T., & Shurin, M.R. (2000). Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer, 83(4), 506-513.Springer Nature. doi: 10.1054/bjoc.2000.1289.
Pirtskhalaishvili, G., Shurin, G.V., Esche, C., Cai, Q., Salup, R.R., Bykovskaia, S.N., Lotze, M.T., & Shurin, M.R. (2000). Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. BRITISH JOURNAL OF CANCER, 83(4), 506-513. doi: 10.1054/bjoc.2000.1289.
Ranieri, E., Kierstead, L.S., Zarour, H., Kirkwood, J.M., Lotze, M.T., Whiteside, T., & Storkus, W.J. (2000). Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest, 29(2), 121-125.Taylor & Francis. doi: 10.3109/08820130009062294.
Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Brenner, M., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schuening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., Boucher, R.C., Siegler, H.F., Barranger, J.A., Karlsson, S., Kohn, D., Galpin, J.E., Raffel, C., Hesdorffer, C., Ilan, J., Cassileth, P., O'Shaughnessy, J., Kun, L.E., Das, T.K., Wong-Staal, F., Sobol, R.E., Haubrich, R., Sznol, M., Rubin, J., Sorcher, E.J., Rosenblatt, J., Walker, R., Brigham, K., Vogelzang, N., Hersh, E., & Eck, S.L. (2000). Human gene marker/therapy clinical protocols. Hum Gene Ther, 11(6), 919-979.Mary Ann Liebert. doi: 10.1089/10430340050015536.
Saito, T., Dworacki, G., Gooding, W., Lotze, M.T., & Whiteside, T.L. (2000). Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res, 6(4), 1351-1364.
Shurin, G.V., Lotze, M.T., & Barksdale, E.M. (2000). Neuroblastoma inhibits dendritic cell differentiation and function. Curr Surg, 57(6), 637.Elsevier. doi: 10.1016/s0149-7944(00)00356-1.
Tanaka, F., Hashimoto, W., Okamura, H., Robbins, P.D., Lotze, M.T., & Tahara, H. (2000). Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res, 60(17), 4838-4844.
Watkins, C. (2000). Preface. 21, IV.Elsevier. doi: 10.1016/b978-012455900-4/50261-0.
Weigel, T.L., Lotze, M.T., Kim, P.K., Amoscato, A.A., Luketich, J.D., & Odoux, C. (2000). Paclitaxel-induced apoptosis in non–small cell lung cancer cell lines is associated with increased caspase-3 activity. The Journal of Thoracic and Cardiovascular Surgery, 119(4), 795-803.Elsevier BV. doi: 10.1016/s0022-5223(00)70016-x.
Weigel, T.L., Lotze, M.T., Kim, P.K., Amoscato, A.A., Luketich, J.D., & Odoux, C. (2000). Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J Thorac Cardiovasc Surg, 119(4 Pt 1), 795-803.Elsevier. doi: 10.1016/S0022-5223(00)70016-X.
Atkins, M.B., Lotze, M.T., Dutcher, J.P., Fisher, R.I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Kunkel, L., & Rosenberg, S.A. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 17(7), 2105-2116.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1999.17.7.2105.
Barksdale, E.M., Shurin, G.V., & Lotze, M.T. (1999). Inhibition of ganglioside synthesis abrogrates neuroblastoma mediated lymphocyte apoptosis11The Society of Black Academic Surgeons expresses its appreciation to Dr. Walter Pories and the editorial staff of Current Surgery for their interest in the Society and the publication of these abstracts. Journal of Surgical Education, 56(7-8), 383.Elsevier. doi: 10.1016/s0149-7944(99)00137-3.
Chikamatsu, K., Nakano, K., Storkus, W.J., Appella, E., Lotze, M.T., Whiteside, T.L., & DeLeo, A.B. (1999). Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res, 5(6), 1281-1288.
Egawa, S., Mailliard, R., & Lotze, M.T. (1999). CHARACTERIZATION OF PERIPHERAL BLOOD MONOCY DERIVED DENDRITIC CELLS GENERATED WITH INTERFERON AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATIN FACTOR. Journal of Immunotherapy, 22(5), 457.Wolters Kluwer. doi: 10.1097/00002371-199909000-00023.
Esche, C., Gambotto, A., Satoh, Y., Gerein, V., Robbins, P.D., Watkins, S.C., Lotze, M.T., & Shurin, M.R. (1999). CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol, 29(7), 2148-2155.Wiley. doi: 10.1002/(SICI)1521-4141(199907)29:07<2148::AID-IMMU2148>3.0.CO;2-F.
Esche, C., Lokshin, A., Shurin, G.V., Gastman, B.R., Rabinowich, H., Watkins, S.C., Lotze, M.T., & Shurin, M.R. (1999). Tumor's other immune targets: dendritic cells. J Leukoc Biol, 66(2), 336-344.Oxford University Press (OUP). doi: 10.1002/jlb.66.2.336.
Esche, C., Makarenkova, V.P., Kost, N.V., Lotze, M.T., Zozulya, A.A., & Shurin, M.R. (1999). Murine dendritic cells express functional delta-type opioid receptors. Ann N Y Acad Sci, 885(1), 387-390.Wiley. doi: 10.1111/j.1749-6632.1999.tb08695.x.
Esche, C., Shurin, M.R., & Lotze, M.T. (1999). The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther, 1(1), 72-81.
Esche, C., Shurin, M.R., & Lotze, M.T. (1999). Gene therapy for melanoma. Dermatologic Therapy, 10, 74-82.
Esche, C., Subbotin, V.M., Hunter, O., Peron, J.M., Maliszewski, C., Lotze, M.T., & Shurin, M.R. (1999). Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand. J Invest Dermatol, 113(6), 1028-1032.Elsevier. doi: 10.1046/j.1523-1747.1999.00779.x.
Gambotto, A., Tüting, T., McVey, D.L., Kovesdi, I., Tahara, H., Lotze, M.T., & Robbins, P.D. (1999). Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther, 6(1), 45-53.Springer Nature. doi: 10.1038/sj.cgt.7700013.
Hashimoto, W., Osaki, T., Okamura, H., Robbins, P.D., Kurimoto, M., Nagata, S., Lotze, M.T., & Tahara, H. (1999). Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol, 163(2), 583-589.Oxford University Press (OUP). doi: 10.4049/jimmunol.163.2.583.
Hiroishi, K., Tüting, T., Tahara, H., & Lotze, M.T. (1999). Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther, 6(12), 1988-1994.Springer Nature. doi: 10.1038/sj.gt.3301034.
Lotze, M.T. (1999). In vivo veritas. Clin Immunol, 93(1), 1-4.Elsevier. doi: 10.1006/clim.1999.4786.
Lotze, M.T. (1999). Not just an antigen-presenting cell: 5th international symposium on dendritic cells in fundamental and clinical immunology. J Leukoc Biol, 66(2), 195-200.Oxford University Press (OUP). doi: 10.1002/jlb.66.2.195.
McMasters, K.M., Sondak, V.K., Lotze, M.T., & Ross, M.I. (1999). Recent advances in melanoma staging and therapy. Ann Surg Oncol, 6(5), 467-475.Springer Nature. doi: 10.1007/s10434-999-0467-8.
Muller, A., Buhn, K., Baraki, H., Lotze, M., & Becker, H. (1999). Significance of collection and clinical consequences in HNPCC-patients. Viszeralchirurgie, 34(3), 129-133.
Nishioka, Y., Hirao, M., Robbins, P.D., Lotze, M.T., & Tahara, H. (1999). Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res, 59(16), 4035-4041.
Ohm, J.E., Shurin, M.R., Esche, C., Lotze, M.T., Carbone, D.P., & Gabrilovich, D.I. (1999). Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol, 163(6), 3260-3268.Oxford University Press (OUP). doi: 10.4049/jimmunol.163.6.3260.
Okada, H., Giezeman-Smits, K.M., Tahara, H., Attanucci, J., Fellows, W.K., Lotze, M.T., Chambers, W.H., & Bozik, M.E. (1999). Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther, 6(2), 219-226.Springer Nature. doi: 10.1038/sj.gt.3300798.
Osaki, T., Hashimoto, W., Gambotto, A., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., & Tahara, H. (1999). Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther, 6(5), 808-815.Springer Nature. doi: 10.1038/sj.gt.3300908.
Pirtskhalaishvili, G., Salup, R.R., Esche, C., Lotze, M.T., & Shurin, M.R. (1999). PROTECTION OF HUMAN DENDRITIC CELLS FROM PROSTATE CANCER-INDUCED APOPTOSIS BY IL-12 AND IL-15. Journal of Urology, 161(4S), 126..Wolters Kluwer. doi: 10.1097/00005392-199904010-00506.
Robertson, M.J., Cameron, C., Atkins, M.B., Gordon, M.S., Lotze, M.T., Sherman, M.L., & Ritz, J. (1999). Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res, 5(1), 9-16.
Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schuening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., & Habib, N.A. (1999). Human gene marker/therapy clinical protocols. Hum Gene Ther, 10(18), 3067-3123.Mary Ann Liebert. doi: 10.1089/10430349950016465.
Shurin, M.R., Lu, L., Kalinski, P., Stewart-Akers, A.M., & Lotze, M.T. (1999). Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Seminars in Immunopathology, 21(3), 339-359. doi: 10.1007/BF00812261.
Shurin, M.R., Lu, L., Kalinski, P., Stewart-Akers, A.M., & Lotze, M.T. (1999). Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol, 21(3), 339-359.Springer Nature. doi: 10.1007/BF00812261.
Tahara, H., Kitagawa, T., Iwazawa, T., & Lotze, M.T. (1999). Gene Transfection Using Particle Bombardment. In Gene Therapy. (pp. 93-102).Springer Nature. doi: 10.1007/978-3-0348-7011-5_7.
Tanaka, F., Hirao, M., & Lotze, M.T. (1999). Delivery of dendritic cells to sites of immune reactivity. Clinical and Applied Immunology Reviews, 19(10-11), 128-131.Elsevier. doi: 10.1016/s0197-1859(00)87086-7.
Thomas, R.L., Matsko, C.M., Lotze, M.T., & Amoscato, A.A. (1999). Mass spectrometric identification of increased C16 ceramide levels during apoptosis. J Biol Chem, 274(43), 30580-30588.Elsevier. doi: 10.1074/jbc.274.43.30580.
Tüting, T., Gambotto, A., DeLeo, A., Lotze, M.T., Robbins, P.D., & Storkus, W.J. (1999). Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther, 6(1), 73-80.Springer Nature. doi: 10.1038/sj.cgt.7700020.
Wilson, C.C., Olson, W.C., Tuting, T., Rinaldo, C.R., Lotze, M.T., & Storkus, W.J. (1999). HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol, 162(5), 3070-3078.Oxford University Press (OUP). doi: 10.4049/jimmunol.162.5.3070.
x, O., s, A., & Lotze, M.T. (1999). ACTIVATED-HUMAN DENDRITIC CELLS (DCs) DECREASE PRODUCTION OF PROANGIOGENIC FACTORS WITH PROGRESSIVE MATURATION. Journal of Immunotherapy, 22(5), 463.Wolters Kluwer. doi: 10.1097/00002371-199909000-00044.
Amoscato, A.A., Prenovitz, D.A., & Lotze, M.T. (1998). Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol, 161(8), 4023-4032.Oxford University Press (OUP). doi: 10.4049/jimmunol.161.8.4023.
Couderc, B., Zitvogel, L., Douin-Echinard, V., Djennane, L., Tahara, H., Favre, G., Lotze, M.T., & Robbins, P.D. (1998). Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther, 5(3), 163-175.
Douin-Echinard, V., Robbins, P.D., Lotze, M.T., Favre, G., & Couderc, B. (1998). Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70. Adv Exp Med Biol, 451, 353-357.Springer Nature. doi: 10.1007/978-1-4615-5357-1_55.
Esche, C., Lokshin, A., Lotze, M.T., & Shurin, M.R. (1998). Murine and human melanoma induces apoptosis of dendritic cells: A potential mechanism of tumor-induced immunosuppression. Journal of Dermatological Science, 16, s159.Elsevier. doi: 10.1016/s0923-1811(98)83948-0.
Esche, C., Subbotin, V.M., Maliszewski, C., Lotze, M.T., & Shurin, M.R. (1998). FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res, 58(3), 380-383.
Fernandez, N., Duffour, M.T., Perricaudet, M., Lotze, M.T., Tursz, T., & Zitvogel, L. (1998). Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell Mol Ther, 4(1), 53-65.
Finn, O.J., & Lotze, M.T. (1998). Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer. Introduction. J Immunother, 21(2), 114-118.Wolters Kluwer. doi: 10.1097/00002371-199803000-00004.
Goldman, S.A., Baker, E., Weyant, R.J., Clarke, M.R., Myers, J.N., & Lotze, M.T. (1998). Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg, 124(6), 641-646.American Medical Association (AMA). doi: 10.1001/archotol.124.6.641.
Goydos, J.S., Brumfield, A.M., Frezza, E., Booth, A., Lotze, M.T., & Carty, S.E. (1998). Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg, 227(3), 398-404.Wolters Kluwer. doi: 10.1097/00000658-199803000-00012.
Iwazawa, T., Chau, G.Y., Mori, T., Robbins, P.D., Lotze, M.T., & Tahara, H. (1998). Effective gene therapy for liver tumors with intra-arterial injection of IL-12 gene-engineered fibroblasts (Preliminary study). Biotherapy, 12(12), 1543-1547.
Maeurer, M.J., & Lotze, M.T. (1998). Interleukin-7 (IL-7) knockout mice. Implications for lymphopoiesis and organ-specific immunity. Int Rev Immunol, 16(3-4), 309-322.Taylor & Francis. doi: 10.3109/08830189809042999.
Mailliard, R.B., Ducruet, A.P., & Lotze, M.T. (1998). Human dendritic cells induce apoptosis in activated lymphocytes: Importance of antigen presentation for T-cell survival. JOURNAL OF LEUKOCYTE BIOLOGY, 50.
Martincic, K., Campbell, R., Edwalds-Gilbert, G., Souan, L., Lotze, M.T., & Milcarek, C. (1998). Increase in the 64-kDa subunit of the polyadenylation/cleavage stimulatory factor during the G0 to S phase transition. Proc Natl Acad Sci U S A, 95(19), 11095-11100.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.95.19.11095.
Myers, J.N., Mank-Seymour, A., Zitvogel, L., Storkus, W., Clarke, M., Johnson, C.S., Tahara, H., & Lotze, M.T. (1998). Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope, 108(2), 261-268.Wiley. doi: 10.1097/00005537-199802000-00019.
Okada, H., Tahara, H., Shurin, M.R., Attanucci, J., Giezeman-Smits, K.M., Fellows, W.K., Lotze, M.T., Chambers, W.H., & Bozik, M.E. (1998). Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. International Journal of Cancer, 78(2), 196-201. doi: 10.1002/(SICI)1097-0215(19981005)78:2<196::AID-IJC13>3.0.CO;2-9.
Okada, H., Tahara, H., Shurin, M.R., Attanucci, J., Giezeman-Smits, K.M., Fellows, W.K., Lotze, M.T., Chambers, W.H., & Bozik, M.E. (1998). Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer, 78(2), 196-201.Wiley. doi: 10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9.
Osaki, T., Péron, J.M., Cai, Q., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., & Tahara, H. (1998). IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12- independent antitumor effects. Journal of Immunology, 160(4), 1742-1749.
Osaki, T., Péron, J.M., Cai, Q., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., & Tahara, H. (1998). IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol, 160(4), 1742-1749.Oxford University Press (OUP). doi: 10.4049/jimmunol.160.4.1742.
Péron, J.M., Esche, C., Subbotin, V.M., Maliszewski, C., Lotze, M.T., & Shurin, M.R. (1998). FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol, 161(11), 6164-6170.Oxford University Press (OUP). doi: 10.4049/jimmunol.161.11.6164.
Rao, U.N., Hanan, S.H., Lotze, M.T., & Karakousis, C.P. (1998). Distant skin and soft tissue metastases from sarcomas. J Surg Oncol, 69(2), 94-98.Wiley. doi: 10.1002/(sici)1096-9098(199810)69:2<94::aid-jso9>3.0.co;2-4.
Shurin, G.V., Gerein, V., Lotze, M.T., & Barksdale, E.M. (1998). Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand. Nat Immun, 16(5-6), 263-274.Karger Publishers. doi: 10.1159/000069452.
Shurin, M.R., Esche, C., & Lotze, M.T. (1998). FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev, 9(1), 37-48.Elsevier. doi: 10.1016/s1359-6101(97)00035-x.
Takayama, T., Nishioka, Y., Lu, L., Lotze, M.T., Tahara, H., & Thomson, A.W. (1998). Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation, 66(12), 1567-1574.Wolters Kluwer. doi: 10.1097/00007890-199812270-00001.
Takayama, T., Nishioka, Y., Lu, L., Storkus, W.J., Lotze, M.T., Tahara, H., & Thomson, A.W. (1998). VIRAL IL-10 GENE TRANSDUCTION MARKEDLY INHIBITS THE ALLOSTIMULATORY ACTIVITY OF DENDRITIC CELLS. Transplantation, 65(12), s182.Wolters Kluwer. doi: 10.1097/00007890-199806270-00737.
Takayama, T., Nishioka, Y., Lu, L., Storkus, W.J., Lotze, M.T., Tahara, H., & Thomson, A.W. (1998). VIRAL IL-10 GENE TRANSDUCTION MARKEDLY INHIBITS THE ALLOSTIMULATORY ACTIVITY OF DENDRITIC CELLS. Transplantation, 65(Supplement), 258.Wolters Kluwer. doi: 10.1097/00007890-199805131-00714.
Tjandrawan, T., Martin, D.M., Maeurer, M.J., Castelli, C., Lotze, M.T., & Storkus, W.J. (1998). Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother, 21(2), 149-157.Wolters Kluwer. doi: 10.1097/00002371-199803000-00009.
Tjandrawan, T., Martin, D.M., Maeurer, M.J., Castelli, C., Lotze, M.T., & Storkus, W.J. (1998). Third keystone symposium on cellular immunology and the immunotherapy of cancer antigen processing and presentation autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. Journal of Immunotherapy, 21(2), 157-149. doi: 10.1097/00002371-199803000-00009.
Tüting, T., Wilson, C.C., Martin, D.M., Baar, J., DeLeo, A., Lotze, M.T., & Storkus, W.J. (1998). DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Adv Exp Med Biol, 451, 295-304.Springer Nature. doi: 10.1007/978-1-4615-5357-1_46.
Tüting, T., Wilson, C.C., Martin, D.M., Kasamon, Y.L., Rowles, J., Ma, D.I., Slingluff, C.L., Wagner, S.N., van der Bruggen, P., Baar, J., Lotze, M.T., & Storkus, W.J. (1998). Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol, 160(3), 1139-1147.Oxford University Press (OUP). doi: 10.4049/jimmunol.160.3.1139.
Vokes, E.E., Figlin, R., Hochster, H., Lotze, M., & Rybak, M.E. (1998). A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. Cancer J Sci Am, 4(1), 46-51.
Vu, H.N., Jenkins, F.W., Swerdlow, S.H., Locker, J., & Lotze, M.T. (1998). Pleural effusion as the presentation for primary effusion lymphoma. Surgery, 123(5), 589-591.Elsevier. doi: 10.1067/msy.1998.88087.
Zitvoge, L., Fernandez, N., & Lotze, M.T. (1998). Immunothérapie du cancer par thérapie cellulaire dendritique : Des bases précliniques à la préparation d'essais thérapeutiques. Hematologie, 4(6), 490-491.
Atkins, M.B., Robertson, M.J., Gordon, M., Lotze, M.T., DeCoste, M., DuBois, J.S., Ritz, J., Sandler, A.B., Edington, H.D., Garzone, P.D., Mier, J.W., Canning, C.M., Battiato, L., Tahara, H., & Sherman, M.L. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res, 3(3), 409-417.
Baar, J., & Lotze, M.T. (1997). INTERFERON GAMMA-INDUCIBLE CYTOKINE GENE EXPRESSION IN PLASMID-TRANSFECTED DENDRITIC CELLS. Journal of Immunotherapy, 20(5), 403.Wolters Kluwer. doi: 10.1097/00002371-199709000-00024.
Cameron, J.L., Brennan, M.F., Traverso, L.W., Kelly, K.A., Lotze, M.T., & ZGraggen, K. (1997). Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas - Discussion. ANNALS OF SURGERY, 226(4), 498-500.
Campbell, R.L., Repasky, E.A., & Lotze, M.T. (1997). T-CELL SPECTRIN (FODRIN) AGGREGATION AND UROPOD FORMATION FOLLOWING DENDRITIC CELL ENCOUNTER. Journal of Immunotherapy, 20(5), 405.Wolters Kluwer. doi: 10.1097/00002371-199709000-00035.
Dookeran, K.A., Lotze, M.T., Sikora, S.S., & Rao, U.N. (1997). Pancreatic and ampullary carcinomas with intrascrotal metastases. Br J Surg, 84(2), 198-199.Oxford University Press (OUP). doi: 10.1046/j.1365-2168.1997.02469.x.
Dutcher, J.P., Atkins, M., Fisher, R., Weiss, G., Margolin, K., Aronson, F., Sosman, J., Lotze, M., Gordon, M., Logan, T., & Mier, J. (1997). Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am, 3 Suppl 1(SUPPL. 1), S73-S78.
Elder, E.M., Lotze, M.T., & Whiteside, T.L. (1997). Methods for generation of genetically modified fibroblasts for immunotherapy of cancer. Methods Mol Med, 7, 349-356.Springer Nature. doi: 10.1385/0-89603-484-4:349.
Elder, E.M., Lotze, M.T., & Whiteside, T.L. (1997). CULTURE ON HUMAN DENDRITIC CELLS (DC) FOR THERAPY OF PATIENTS WITH CANCER. Journal of Immunotherapy, 20(5), 407.Wolters Kluwer. doi: 10.1097/00002371-199709000-00042.
Elder, E.M., Stolinski, L.A., Whiteside, T.L., & Lotze, M.T. (1997). CHANGES IN DC AND DC PRECURSOR NUMBERS DURING IN VIVO IL-2 ADMINISTRATION. Journal of Immunotherapy, 20(5), 407.Wolters Kluwer. doi: 10.1097/00002371-199709000-00041.
Esche, C., Shurin, M.R., Haluszczak, C., Peron, J.M., & Lotze, M.T. (1997). GENERATION OF HUMAN DENDRITIC CELLS FROM CD34+ PRECURSORS FOR HUMAN CLINICAL TRIALS. Journal of Immunotherapy, 20(5), 403.Wolters Kluwer. doi: 10.1097/00002371-199709000-00026.
Esway, J., Shurin, G.V., Lotze, M.T., & Barksdale, E. (1997). CREATING IMMUNE PRIVILEGE. Journal of Immunotherapy, 20(5), 402.Wolters Kluwer. doi: 10.1097/00002371-199709000-00023.
Hall, T.D., Kinzler, D.M., Elder, E.M., Whiteside, T.L., Storkus, W.J., & Lotze, M.T. (1997). EVALUATION AND RESPONSE OF PATIENTS IMMUNIZED TO HLA-A2 POLYPEPITOPE PEPTIDE MIXTURE IN PATIENTS WITH METASTATIC MELANOMA USING AUTOLOGOUS DENDRITIC CELLS CULTURED WITH IL-4 AND GM-CSF. Journal of Immunotherapy, 20(5), 405.Wolters Kluwer. doi: 10.1097/00002371-199709000-00033.
Haluszczak, C., Lotze, M.T., & Shurin, M.R. (1997). IL-12 AND FLT3 LIGAND DIFFERENTIALLY STIMULATE LYMPHOID AND MYELOID DENDROPOIESIS IN VIVO. Journal of Immunotherapy, 20(5), 406.Wolters Kluwer. doi: 10.1097/00002371-199709000-00036.
Hunter, O., Haluszczak, C., Subbotin, V.M., Lotze, M.T., & Shurin, M.R. (1997). ADMINISTRATION OF IL-12 AND FL T3 LIGAND ENHANCES MURINE DENDRITIC CELL GENERATION. Journal of Immunotherapy, 20(5), 401.Wolters Kluwer. doi: 10.1097/00002371-199709000-00016.
Kadakia, M.P., Birkenbach, M., Baar, J., Farhood, H., & Lotze, M.T. (1997). MODULATION OF INTERLEUKIN 12 BY EPSTEIN BARR VIRUS INDUCED GENE PRODUCT 3 (EBI3). Journal of Immunotherapy, 20(5), 411.Wolters Kluwer. doi: 10.1097/00002371-199709000-00058.
Kim, S.H., An, C.S., Tahara, H., Park, C., Lotze, M.T., Robbins, P.D., & Kim, S. (1997). Retroviral-mediated IL-12 gene therapy for advanced murine tumors. EXPERIMENTAL AND MOLECULAR MEDICINE, 29(1), 53-58.Springer Nature. doi: 10.1038/emm.1997.8.
Kinzler, D., Tahara, H., Elder, E., Johnson, C., Nguyen, N., Hanan, S., Thomas, R., Vu, H., Duran, P., Kirkwood, J., & Lotze, M. (1997). PATIENT RECRUITMENT ONTO A PHASE I CLINICAL TRIAL OF INTERLEUKIN 12 (IL-12) GENE THERAPY FOR CANCER. Journal of Immunotherapy, 20(5), 400.Wolters Kluwer. doi: 10.1097/00002371-199709000-00012.
Lotze, M., Atkins, M., Dutcher, J., Fisher, R., Margolin, K., Weiss, G., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., & Rosenberg, S.A. (1997). Melanoma patients with durable responses to IL-2 treatment. Melanoma Research, 7(Supplement 1), s30.Wolters Kluwer. doi: 10.1097/00008390-199706001-00104.
Lotze, M.T. (1997). Future directions for recombinant interleukin-2 in cancer: a chronic inflammatory disorder. Cancer J Sci Am, 3 Suppl 1, S106-S108.
Lotze, M.T. (1997). Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg, 226(1), 1-5.Wolters Kluwer. doi: 10.1097/00000658-199707000-00001.
Lotze, M.T. (1997). Interleukin-2. 2, 1-47.Elsevier. doi: 10.1016/s1874-5687(97)80022-5.
Lotze, M.T., Hellerstedt, B., Stolinski, L., Tueting, T., Wilson, C., Kinzler, D., Vu, H., Rubin, J.T., Storkus, W., Tahara, H., Elder, E., & Whiteside, T. (1997). The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am, 3 Suppl 1(SUPPL. 1), S109-S114.
Lotze, M.T., Shurin, M., Davis, I., Amoscato, A., & Storkus, W.J. (1997). Dendritic cell based therapy of cancer. Adv Exp Med Biol, 417, 551-569.Springer Nature. doi: 10.1007/978-1-4757-9966-8_91.
Lotze, M.T., Storkus, W.J., Falo, L., Baar, J., Davis, I., Tueting, T., Esche, C., Whiteside, T.L., Elder, E.M., Kinzler, D.M., Paradise, C., & Kirkwood, J.M. (1997). Dendritic cells (DCs) and the immunotherapy of melanoma. Melanoma Research, 7(Supplement 1), s4.Wolters Kluwer. doi: 10.1097/00008390-199706001-00012.
Maeurer, M.J., & Lotze, M.T. (1997). Tumor Recognition by the Cellular Immune System: New Aspects of Tumor Immunology. International Reviews of Immunology, 14(42038), 97-132. doi: 10.3109/08830189709116848.
Maeurer, M.J., & Lotze, M.T. (1997). Tumor recognition by the cellular immune system: new aspects of tumor immunology. Int Rev Immunol, 14(2-3), 97-132.Taylor & Francis. doi: 10.3109/08830189709116848.
Maeurer, M.J., Walter, W., Martin, D., Zitvogel, L., Elder, E., Storkus, W., & Lotze, M.T. (1997). Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol, 45(2), 182-192.Wiley. doi: 10.1046/j.1365-3083.1997.d01-384.x.
Margolin, K., Atkins, M., Sparano, J., Sosman, J., Weiss, G., Lotze, M., Doroshow, J., Mier, J., O'Boyle, K., Fisher, R., Campbell, E., Rubin, J., Federighi, D., & Bursten, S. (1997). Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res, 3(4), 565-572.
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Garcia-Prats, M.D., DeLeo, A.B., & Lotze, M.T. (1997). Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells, 15(2), 94-103.Oxford University Press (OUP). doi: 10.1002/stem.150094.
Nishioka, Y., Shurin, M., Robbins, P.D., Storkus, W.J., Lotze, M.T., & Tahara, H. (1997). EFFECTIVE TUMOR IMMUNOTHERAPY USING BONE MARROW (BM)-DERIVED DENDRITIC CELLS (DCS) GENETICALLY ENGINEERED TO EXPRESS INTERLEUKIN 12. Journal of Immunotherapy, 20(5), 419.Wolters Kluwer. doi: 10.1097/00002371-199709000-00090.
Numasaki, M., Lotze, M.T., & Tahara, H. (1997). INTERLEUKIN 17 GENE TRANSFECTION INTO MURINE FIBROSARCOMA CELL LINE MCA 205 INCREASES TUMORIGENICITY CORRELATED WITH ENHANCED TUMOR MICROVASCULARITY. Journal of Immunotherapy, 20(5), 399.Wolters Kluwer. doi: 10.1097/00002371-199709000-00011.
Osaki, T., Péron, J.M., Cai, Q., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., & Tahara, H. (1997). ANALYSES ON ANTI-TUMOR EFFECTS OF INTERFERON-γ-INDUCING FACTOR/INTERLEUKIN-18 AGAINST MURINE TUMORS. Journal of Immunotherapy, 20(5), 417.Wolters Kluwer. doi: 10.1097/00002371-199709000-00082.
Park, C., Kang, W.K., Oh, M., Kim, W.S., Yang, J.H., Lotze, M.T., Kim, S., Park, K., & Park, C.H. (1997). Production of IL-12 from gene modified human dermal fibroblasts: A preclinical study for IL-12 cancer gene therapy. EXPERIMENTAL AND MOLECULAR MEDICINE, 29(1), 65-69.Springer Nature. doi: 10.1038/emm.1997.10.
Peron, J.M., Esche, C., Hunter, O., Subbotin, V.M., Lotze, M.T., & n, S. (1997). EFFECTIVE TREATMENT OF MURINE LIVER METASTASES USING FLT3 LIGAND (FL) AND/OR IL-12. Journal of Immunotherapy, 20(5), 400.Wolters Kluwer. doi: 10.1097/00002371-199709000-00015.
Pruitt, B.A., Daly, J.M., Moore, T.C., Lotze, M.T., & Mannick, J.A. (1997). Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection - Discussion. ANNALS OF SURGERY, 226(4), 458-460.
Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schuening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., & Boucher, R.C. (1997). Human gene marker/therapy clinical protocols. Hum Gene Ther, 8(18), 2301-2338.Mary Ann Liebert. doi: 10.1089/hum.1997.8.18-2301.
Shurin, G.V., Esway, J., Subbotin, V.M., Lotze, M.T., & Barksdale, E.M. (1997). FUNCTIONAL FAS LIGAND IS EXPRESSED ON NEUROBLASTOMA AND HEPATOBLASTOMA CELLS. Journal of Immunotherapy, 20(5), 403.Wolters Kluwer. doi: 10.1097/00002371-199709000-00027.
Shurin, M.R., Esche, C., Lokshin, A., & Lotze, M.T. (1997). TUMORS INDUCE APOPTOSIS OF DENDRITIC CELLS IN VITRO. Journal of Immunotherapy, 20(5), 403.Wolters Kluwer. doi: 10.1097/00002371-199709000-00025.
Shurin, M.R., Esche, C., Péron, J.M., & Lotze, M.T. (1997). Antitumor activities of IL-12 and mechanisms of action. Chem Immunol, 68, 153-174.Karger Publishers. doi: 10.1159/000058690.
Shurin, M.R., Pandharipande, P.P., Zorina, T.D., Haluszczak, C., Subbotin, V.M., Hunter, O., Brumfield, A., Storkus, W.J., Maraskovsky, E., & Lotze, M.T. (1997). FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol, 179(2), 174-184.Elsevier. doi: 10.1006/cimm.1997.1152.
Tahara, H., Elder, E.M., Cai, O., Kinzler, D.M., Storkus, W.J., Zitvogel, L., Kirkwood, J.M., Whiteside, T.L., Robbins, P.D., & Lotze, M.T. (1997). PHASE I CLINICAL TRIAL OF INTERLEUKIN-12 (IL-12) CYTOKINE GENE THERAPY WITH OBJECTIVE RESPONSES IN CANCER PATIENTS WITH VARIOUS HISTOLOGIES. Journal of Immunotherapy, 20(5), 416.Wolters Kluwer. doi: 10.1097/00002371-199709000-00078.
Tüting, T., Baar, J., Schurin, M., Mayordomo, J.I., Zitvogel, L., Tahara, H., Storkus, W.J., DeLeo, A., & Lotze, M.T. (1997). Dendritic cell-based therapy for cancer. European Journal of Cancer, 33, s21.Elsevier. doi: 10.1016/s0959-8049(97)89384-7.
Tüting, T., DeLeo, A.B., Lotze, M.T., & Storkus, W.J. (1997). Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol, 27(10), 2702-2707.Wiley. doi: 10.1002/eji.1830271033.
Tüting, T., Gambotto, A., Baar, J., Davis, I.D., Storkus, W.J., Zavodny, P.J., Narula, S., Tahara, H., Robbins, P.D., & Lotze, M.T. (1997). Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther, 4(10), 1053-1060.Springer Nature. doi: 10.1038/sj.gt.3300509.
Tüting, T., Storkus, W.J., & Lotze, M.T. (1997). Gene-based strategies for the immunotherapy of cancer. J Mol Med (Berl), 75(7), 478-491.Springer Nature. doi: 10.1007/s001090050133.
Amoscato, A.A., Storkus, W.J., & Lotze, M.T. (1996). Secretion of a 93 kda gelatinase by human peripheral blood dendritic cells. FASEB JOURNAL, 10(6), 2787.
Berman, R.M., Rilo, H.L., Hoehnke, C., Shurin, M.R., Narula, S.K., Maraskovsky, E., & Lotze, M.T. (1996). INTERLEUKIN-10 EFFECTS ON IN VIVO GENERATION AND IN VITRO FUNCTION OF DENDRITIC CELLS. Journal of Immunotherapy, 19(6), 464.Wolters Kluwer. doi: 10.1097/00002371-199611000-00042.
Berman, R.M., Suzuki, T., Tahara, H., Robbins, P.D., Narula, S.K., & Lotze, M.T. (1996). Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol, 157(1), 231-238.Oxford University Press (OUP). doi: 10.4049/jimmunol.157.1.231.
Bernhard, H., Maeurer, M.J., Jäger, E., Wölfel, T., Schneider, J., Karbach, J., Seliger, B., Huber, C., Storkus, W.S., Lotze, M.T., Meyer zum Büschenfelde, K.H., & Knuth, A. (1996). Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scand J Immunol, 44(3), 285-292.Wiley. doi: 10.1046/j.1365-3083.1996.d01-304.x.
Bozik, M.E., Chambers, W.H., Gilbert, M., & Lotze, M.T. (1996). Treatment of 9L gliosarcoma with IL-4 producing 9L vaccine. FASEB JOURNAL, 10(6), 2385.
Cai, O., Preskey, D., Robbins, P.D., Lotze, M.T., & Tahara, H. (1996). INTERLUKIN-12 (IL-12) EXPRESSION AT THE TUMOR SITE IS CRITICAL IN NATURAL TUMOR REJECTION BUT NOT IN MOUSE IL-10 MEDIATED ANTI-TUMOR EFFECTS. Journal of Immunotherapy, 19(6), 464.Wolters Kluwer. doi: 10.1097/00002371-199611000-00041.
Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., & Falo, L.D. (1996). Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 183(1), 283-287.Rockefeller University Press. doi: 10.1084/jem.183.1.283.
Dumanian, G.A., Llull, R., Ramasastry, S.S., Greco, R.J., Lotze, M.T., & Edington, H. (1996). Postoperative abdominal wall defects with enterocutaneous fistulae. Am J Surg, 172(4), 332-334.Elsevier. doi: 10.1016/S0002-9610(96)00201-2.
Elder, E.M., Lotze, M.T., & Whiteside, T.L. (1996). Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther, 7(4), 479-487.Mary Ann Liebert. doi: 10.1089/hum.1996.7.4-479.
Evans, C.H., Robbins, P.D., Ghivizzani, S.C., Herndon, J.H., Kang, R., Bahnson, A.B., Barranger, J.A., Elders, E.M., Gay, S., Tomaino, M.M., Wasko, M.C., Watkins, S.C., Whiteside, T.L., Glorioso, J.C., Lotze, M.T., & Wright, T.M. (1996). Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther, 7(10), 1261-1280.Mary Ann Liebert. doi: 10.1089/hum.1996.7.10-1261.
Farhood, H., Linsley, P.S., Storkus, W.J., & Lotze, M.T. (1996). IMMUNOPOTENTIATION BY CD28 AND INTERLEUKIN-12. Journal of Immunotherapy, 19(6), 464.Wolters Kluwer. doi: 10.1097/00002371-199611000-00043.
Galon, J., Gauchat, J.F., Mazières, N., Spagnoli, R., Storkus, W., Lötze, M., Bonnefoy, J.Y., Fridman, W.H., & Sautès, C. (1996). Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol, 157(3), 1184-1192.Oxford University Press (OUP). doi: 10.4049/jimmunol.157.3.1184.
Goydos, J.S., Elder, E., Whiteside, T.L., Finn, O.J., & Lotze, M.T. (1996). A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res, 63(1), 298-304.Elsevier. doi: 10.1006/jsre.1996.0264.
Leder, G.H., Oppenheim, M., Rosenstein, M., Hoffman, R., Lotze, M.T., & Beger, H.G. (1996). NO supports tumor growth by suppression of lymphocytes - Experiments in vivo. LANGENBECKS ARCHIV FUR CHIRURGIE, 181-184.
Leder, G.H., Oppenheim, M., Rosenstein, M., Hoffman, R., Lotze, M.T., & Beger, H.G. (1996). NO fördert Tumorwachstum durch Lymphozytensuppression — Versuche in vivo. In Chirurgisches Forum ’96 fur experimentelle und klinische Forschung. (pp. 181-184).Springer Nature. doi: 10.1007/978-3-642-80138-9_37.
Leder, G.H., Oppenheim, M., Rosenstein, M., Shah, N., Hoffman, R., Lotze, M.T., & Beger, H.G. (1996). Inhibition of nitric oxide synthesis does not improve interleukin-2-mediated antitumor effects in vivo. Eur Surg Res, 28(3), 167-178.Karger Publishers. doi: 10.1159/000129455.
Lotze, M.T. (1996). Interleukin 12: cellular and molecular immunology of an important regulatory cytokine. Introduction. Ann N Y Acad Sci, 795(1), xiii-xix.Wiley. doi: 10.1111/j.1749-6632.1996.tb52649.x.
Lotze, M.T. (1996). Cytokine gene therapy of cancer. Cancer J Sci Am, 2(2), 63-72.
Lotze, M.T., Zitvogel, L., Campbell, R., Robbins, P.D., Elder, E., Haluszczak, C., Martin, D., Whiteside, T.L., Storkus, W.J., & Tahara, H. (1996). Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci, 795(1), 440-454.Wiley. doi: 10.1111/j.1749-6632.1996.tb52715.x.
Maeurer, M.J., Chan, H.W., Karbach, J., Salter, R.D., Knuth, A., Lotze, M.T., & Storkus, W.J. (1996). Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. Eur J Immunol, 26(11), 2613-2623.Wiley. doi: 10.1002/eji.1830261112.
Maeurer, M.J., Gollin, S.M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W.J., & Lotze, M.T. (1996). Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest, 98(7), 1633-1641.American Society for Clinical Investigation. doi: 10.1172/JCI118958.
Maeurer, M.J., Gollin, S.M., Storkus, W.J., Swaney, W., Karbach, J., Martin, D., Castelli, C., Salter, R., Knuth, A., & Lotze, M.T. (1996). Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res, 2(4), 641-652.
Maeurer, M.J., Martin, D., Elder, E., Storkus, W.J., & Lotze, M.T. (1996). Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin Cancer Res, 2(1), 87-95.
Maeurer, M.J., Martin, D., Walter, W., Liu, K., Zitvogel, L., Halusczcak, K., Rabinowich, H., Duquesnoy, R., Storkus, W., & Lotze, M.T. (1996). Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med, 183(4), 1681-1696.Rockefeller University Press. doi: 10.1084/jem.183.4.1681.
Maeurer, M.J., Storkus, W.J., Kirkwood, J.M., & Lotze, M.T. (1996). New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res, 6(1), 11-24.Wolters Kluwer. doi: 10.1097/00008390-199602000-00003.
Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Cesare, C.M., Appasamy, P.M., Lotze, M.T., Storkus, W.J., Appella, E., & DeLeo, A.B. (1996). Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med, 183(4), 1357-1365.Rockefeller University Press. doi: 10.1084/jem.183.4.1357.
Mertz, P.M., Corcoran, M.L., McCluskey, K.M., Zhang, Y., Wong, H.L., Lotze, M.T., DeWitt, D.L., Wahl, S.M., & Wahl, L.M. (1996). Suppression of prostaglandin H synthase-2 induction in human monocytes by in vitro or in vivo administration of interleukin 4. Cell Immunol, 173(2), 252-260.Elsevier. doi: 10.1006/cimm.1996.0275.
Myers, J.N., Yasumura, S., Suminami, Y., Hirabayashi, H., Lin, W.C., Johnson, J.T., Lotze, M.T., & Whiteside, T.L. (1996). Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res, 2(1), 127-135.
Qin, L., Chavin, K.D., Ding, Y., Tahara, H., Favaro, J.P., Woodward, J.E., Suzuki, T., Robbins, P.D., Lotze, M.T., & Bromberg, J.S. (1996). Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol, 156(6), 2316-2323.Oxford University Press (OUP). doi: 10.4049/jimmunol.156.6.2316.
Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schuening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., & Aebischer, P. (1996). Human gene marker/therapy clinical protocols. Hum Gene Ther, 7(13), 1621-1647.Mary Ann Liebert. doi: 10.1089/hum.1996.7.13-1621.
Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schuening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., & Tiberghien, P. (1996). Human gene marker/therapy clinical protocols. Hum Gene Ther, 7(18), 2287-2313.Mary Ann Liebert. doi: 10.1089/hum.1996.7.18-2287.
Sikora, S.S., Samsonov, M.E., Dookeran, K.A., Edington, H., & Lotze, M.T. (1996). Peripheral nerve entrapment: an unusual adverse event with high-dose interleukin-2 therapy. Ann Oncol, 7(5), 535-536.Elsevier. doi: 10.1093/oxfordjournals.annonc.a010647.
Storkus, W.J., Zitvogel, L., Tueting, T., Couderc, B.C., Baar, J., Rowles, J., Tjandrawan, T., Robbins, P.D., Wilson, C.C., Ma, D.I., Edington, H.D., & Lotze, M.T. (1996). Genetically-modified dendritic cells serve as effective adjuvants in promoting anti-tumor immunity in vitro and in vivo. FASEB JOURNAL, 10(6), 2551.
Tahara, H., Zitvogel, L., Storkus, W.J., Robbins, P.D., & Lotze, M.T. (1996). Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci, 795(1), 275-283.Wiley. doi: 10.1111/j.1749-6632.1996.tb52677.x.
Tzeng, E., Shears, L.L., Lotze, M.T., & Billiar, T.R. (1996). Gene therapy. CURRENT PROBLEMS IN SURGERY, 33(12), 965-1041.
Tzeng, E., Shears, L.L., Lotze, M.T., & Billiar, T.R. (1996). Gene therapy. Curr Probl Surg, 33(12), 961-1041.Elsevier. doi: 10.1016/s0011-3840(05)80020-6.
Zitvogel, L., Couderc, B., Mayordomo, J.I., Robbins, P.D., Lotze, M.T., & Storkus, W.J. (1996). IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci, 795(1), 284-293.Wiley. doi: 10.1111/j.1749-6632.1996.tb52678.x.
Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., & Storkus, W.J. (1996). Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med, 183(1), 87-97.Rockefeller University Press. doi: 10.1084/jem.183.1.87.
Zitvogel, L., Robbins, P.D., Storkus, W.J., Clarke, M.R., Maeurer, M.J., Campbell, R.L., Davis, C.G., Tahara, H., Schreiber, R.D., & Lotze, M.T. (1996). Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol, 26(6), 1335-1341.Wiley. doi: 10.1002/eji.1830260624.
Abbas, A.K., Cosman, D., Lotze, M.T., Mitchison, N.A., Cantrell, D.A., Liew, F.Y., Sher, A., Lamb, J.R., Romagnani, S., Swain, S.L., Flavell, R., & Mosmann, T.R. (1995). Interleukin 15 and its receptor - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 229-233.
Cai, Q., Rubin, J.T., & Lotze, M.T. (1995). Genetically marking human cells--results of the first clinical gene transfer studies. Cancer Gene Ther, 2(2), 125-136.
Castelli, C., Storkus, W.J., Maeurer, M.J., Martin, D.M., Huang, E.C., Pramanik, B.N., Nagabhushan, T.L., Parmiani, G., & Lotze, M.T. (1995). Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med, 181(1), 363-368.Rockefeller University Press. doi: 10.1084/jem.181.1.363.
Couderc, B., Zitvogel, L., Tahara, H., Storkus, W., Lotze, M., & Robbins, P. (1995). CANCER GENE THERAPY USING IL-4, IL-12 OR IL-15 WITH THE COSTIMULATORY MOLECULES CD27, CD30, CD40 OR B7.1. Journal of Immunotherapy, 18(2), 131.Wolters Kluwer. doi: 10.1097/00002371-199508000-00022.
Dookeran, K.A., Brumfield, A., Lotze, M.T., & Rubin, J.T. (1995). EFFECTIVE THERAPY OF HEPATIC METASTASES WITH INTRA-HEPATIC ARTERIAL INFUSION OF SUSTAINED RELEASE INTERLEUKIN-2. Journal of Immunotherapy, 18(2), 132.Wolters Kluwer. doi: 10.1097/00002371-199508000-00028.
Fitch, F.W., Allen, P.M., Mitchison, N.A., Dutton, R.W., Cantrell, D.A., Lotze, M.T., & Abbas, A.K. (1995). Signalling events in the anergy induction of T helper 1 cells - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 196-202.
Frassanito, M.A., Mayordomo, J.I., DeLeo, R.M., Storkus, W.J., Lotze, M.T., & DeLeo, A.B. (1995). Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. Cancer Res, 55(1), 124-128.
Kaufmann, S.H.E., Liew, F.Y., Ramshaw, I.A., Mitchison, N.A., Lotze, M.T., Allen, P.M., Flavell, R., Sher, A., Mason, D.W., Romagnani, S., Lachmann, P.J., Navikas, V., Abbas, A.K., Cosman, D., & Swain, S.L. (1995). Nitric oxide in infectious and autoimmune diseases - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 239-244.
Kaufmann, S.H.E., Liew, F.Y., Sher, A., Mitchison, N.A., Ramshaw, I.A., Flavell, R., Coffman, R.L., Lotze, M.T., Romagnani, S., Abbas, A.K., Locksley, R.M., & Allen, P.M. (1995). T cells and cytokines in intracellular bacterial infections: Experiences with Mycobacterium bovis BCG - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 132-136.
Leder, G.H., Oppenheim, M., Rosenstein, M., Lotze, M.T., & Beger, H.G. (1995). Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo. Z Gastroenterol, 33(9), 499-502.
Liew, F.Y., Fitch, F.W., Abbas, A.K., Cantrell, D.A., Flavell, R., Locksley, R.M., Lotze, M.T., Allen, P.M., & McMichael, A.J. (1995). General discussion II - Signal transduction in T helper 1 and T helper 2 cells. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 90-94.
Lotze, M.T., Romagnani, S., Liew, F.Y., Trinchieri, G., Cosman, D., Abbas, A.K., Ramshaw, I.A., Mosmann, T.R., Dutton, R.W., & Mitchison, N.A. (1995). Role for CD30 antigen in human T helper 2-type responses - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 62-67.
Maeurer, M., Zitvogel, L., Elder, E., Storkus, W.J., & Lotze, M.T. (1995). Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun, 14(4), 188-197.
Maeurer, M.J., Hurd, S., Martin, D.M., Storkus, W.J., & Lotze, M.T. (1995). Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. Cancer J Sci Am, 1(2), 162-170.
Maeurer, M.J., Martin, D.M., Castelli, C., Elder, E., Leder, G., Storkus, W.J., & Lotze, M.T. (1995). Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother, 41(2), 111-121.Springer Nature. doi: 10.1007/BF01527407.
Maeurer, M.J., Martin, D.M., Storkus, W.J., & Lotze, M.T. (1995). TCR usage in CTLs recognizing melanoma/melanocyte antigens. Immunol Today, 16(12), 603-604.Elsevier. doi: 10.1016/0167-5699(95)80084-0.
Maeurer, M.J., Storkus, W.J., & Lotze, M.T. (1995). New Avenues of Cancer Treatment: Modulation of Host Antitumor Directed Immune Responses by IL-4 and IL-12 in Renal Cell Cancer. In Biology of Renal Cell Carcinoma. (pp. 161-173).Springer Nature. doi: 10.1007/978-1-4612-2536-2_15.
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., & Deleo, A.B. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med, 1(12), 1297-1302.Springer Nature. doi: 10.1038/nm1295-1297.
Mitchison, N.A., Flavell, R., Locksley, R.M., Trinchieri, G., Mosmann, T.R., Swain, S.L., Abbas, A.K., Lotze, M.T., Cantrell, D.A., & Allen, P.M. (1995). Regulation of CD4(+) T cell differentiation - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 168-172.
Mitchison, N.A., Locksley, R.M., Flavell, R., Lachmann, P.J., Coffman, R.L., Shearer, G.M., Allen, P.M., Mosmann, T.R., Liew, F.Y., Lamb, J.R., & Lotze, M.T. (1995). The development of effector T cell subsets in murine Leishmania major infection - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 117-122.
Mitchison, N.A., Sher, A., Trinchieri, G., Lotze, M.T., Coffman, R.L., Lachmann, P.J., Ramshaw, I.A., Liew, F.Y., Rollinghoff, M., Kaufmann, S.H.E., Shearer, G.M., & Navikas, V. (1995). General discussion I - Vaccine development. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 35-38.
Mitchison, N.A., Trinchieri, G., Cantrell, D.A., Ramshaw, I.A., Lachmann, P.J., Mosmann, T.R., Romagnani, S., Sher, A., Liew, F.Y., Lotze, M.T., Shearer, G.M., Mason, D.W., & Swain, S.L. (1995). Final discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 245-250.
Mosmann, T.R., Abbas, A.K., Coffman, R.L., Mitchison, N.A., Allen, P.M., Lamb, J.R., Flavell, R., Swain, S., Locksley, R.M., Dutton, R.W., Lotze, M.T., & Liew, F.Y. (1995). Differentiation and tolerance of CD4(+) T lymphocytes - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 13-19.
Nishihara, K., Barth, R.F., Wilkie, N., Lang, J.C., Oda, Y., Kikuchi, H., Everson, M.P., & Lotze, M.T. (1995). Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha. Cancer Gene Ther, 2(2), 113-124.
Pappo, I., Tahara, H., Robbins, P.D., Gately, M.K., Wolf, S.F., Barnea, A., & Lotze, M.T. (1995). Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res, 58(2), 218-226.Elsevier. doi: 10.1006/jsre.1995.1034.
Qin, L., Chavin, K.D., Ding, Y., Favaro, J.P., Woodward, J.E., Lin, J., Tahara, H., Robbins, P., Shaked, A., & Ho, D.Y. (1995). Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10. Transplantation, 59(6), 809-816.Wolters Kluwer. doi: 10.1097/00007890-199503270-00002.
Romagnani, S., Trinchieri, G., Mitchison, N.A., Dutton, R.W., Coffman, R.L., Locksley, R.M., Lotze, M.T., Ramshaw, I.A., Lachmann, P.J., Rollinghoff, M., Abbas, A.K., & Sher, A. (1995). The two faces of interleukin 12: A pro-inflammatory cytokine and a key immunoregulatory molecule produced by antigen-presenting - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 214-220.
Rubin, J.T., Day, R., Duquesnoy, R., Simonis, B., Adams, S., Lee, J., & Lotze, M.T. (1995). HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol, 2(1), 1-6.
Rubin, J.T., Lotze, M.T., Rosenfelder, D., Brumfield, A., Howells, R., Schwartz, R., Sylvestri, S., Sammon, J., Bron, K., & Orens, P. (1995). Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial. Ann Surg Oncol, 2(4), 351-359.Springer Nature. doi: 10.1007/BF02307069.
Shearer, G.M., Mason, D.W., Ramshaw, I.A., Mitchison, N.A., Lachmann, P.J., Flavell, R., Lotze, M.T., Romagnani, S., Abbas, A.K., Allen, P.M., Locksley, R.M., & Coffman, R.L. (1995). The role of subsets of CD4(+) T cell autoimmunity - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 182-188.
Sher, A., Coffman, R.L., Abbas, A.K., Liew, F.Y., Trinchieri, G., Flavell, R., Swain, S.L., Ramshaw, I.A., Lotze, M.T., Mitchison, N.A., Locksley, R.M., Mosmann, T.R., Fitch, F.W., & Allen, P.M. (1995). Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 25-33.
Suminami, Y., Elder, E.M., Lotze, M.T., & Whiteside, T.L. (1995). In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol, 17(4), 238-248.Wolters Kluwer. doi: 10.1097/00002371-199505000-00006.
Suzuki, T., Tahara, H., Narula, S., Moore, K.W., Robbins, P.D., & Lotze, M.T. (1995). Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med, 182(2), 477-486.Rockefeller University Press. doi: 10.1084/jem.182.2.477.
Swain, S.L., Sher, A., Kaufmann, S.H.E., Mitchison, N.A., Locksley, R.M., Flavell, R., Mosmann, T.R., Abbas, A.K., Trinchieri, G., Lotze, M.T., Coffman, R.L., & Liew, F.Y. (1995). Induction and regulation of host cell-mediated immunity by Toxoplasma gondii - Discussion. T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, 104-109.
Tahara, H., & Lotze, M.T. (1995). Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther, 2(2), 96-106.
Tahara, H., Lotze, M.T., Robbins, P.D., Storkus, W.J., & Zitvogel, L. (1995). IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther, 6(12), 1607-1624.Mary Ann Liebert. doi: 10.1089/hum.1995.6.12-1607.
Tahara, H., Zitvogel, L., Storkus, W.J., Zeh, H.J., McKinney, T.G., Schreiber, R.D., Gubler, U., Robbins, P.D., & Lotze, M.T. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol, 154(12), 6466-6474.Oxford University Press (OUP). doi: 10.4049/jimmunol.154.12.6466.
Tueting, T., Suzuki, T., Tahara, H., Robbins, P.D., & Lotze, M.T. (1995). CYTOKINE GENE THERAPY OF TUMORS TARGETING MEMBERS OF THE TYPE II (INTERFERON) RECEPTOR FAMILY. Journal of Immunotherapy, 18(2), 136.Wolters Kluwer. doi: 10.1097/00002371-199508000-00045.
Zavoral, T.W., Tjandrawan, T., Mayordomo, J.I., Storkus, W.J., & Lotze, M.T. (1995). ENHANCED GENERATION OF HUMAN DENDRITIC CELLS FROM PERIPHERAL BLOOD MONONUCLEAR CELLS BY MONOCYTE DEPLETION WITH L-LEUCYL-L-LEUCINE METHYL ESTER. Journal of Immunotherapy, 18(2), 136.Wolters Kluwer. doi: 10.1097/00002371-199508000-00043.
Zitvogel, L., & Lotze, M.T. (1995). Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Res Immunol, 146(7-8), 628-638.Elsevier. doi: 10.1016/0923-2494(96)83041-0.
Zitvogel, L., Tahara, H., Robbins, P.D., Storkus, W.J., Clarke, M.R., Nalesnik, M.A., & Lotze, M.T. (1995). Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol, 155(3), 1393-1403.Oxford University Press (OUP). doi: 10.4049/jimmunol.155.3.1393.
Berman, R., Suzuki, T., Tahara, H., Robbins, P., & Lotze, M. (1994). Human and viral interleukin-10 (hIL-10 and vIL-10) mediate opposing effects in tumor immunity. Cytokine, 6(5), 571.Elsevier. doi: 10.1016/1043-4666(94)90276-3.
Di Bisceglie, A.M., Simpson, L.H., Lotze, M.T., & Hoofnagle, J.H. (1994). Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol, 19(3), 222-226.Wolters Kluwer. doi: 10.1097/00004836-199410000-00011.
Irshaid, Y., Adedoyin, A., Lotze, M., & Branch, R.A. (1994). Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes. Drug Metab Dispos, 22(1), 161-164.Elsevier. doi: 10.1016/s0090-9556(25)08292-3.
Itoh, T., Storkus, W.J., Gorelik, E., & Lotze, M.T. (1994). Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J Immunol, 153(3), 1202-1215.Oxford University Press (OUP). doi: 10.4049/jimmunol.153.3.1202.
Leder, G.H., Storkus, W.J., Stuber, G., Modrow, S., & Lotze, M.T. (1994). Erratum: (Langenbecks Archiv fur Chirurgie, Forumband 1994). Langenbecks Archiv fur Chirurgie, 379(4), 254.
Lotze, M.T. (1994). Molecular biology and clinical applications to cancer. Curr Opin Gen Surg, 245-254.
Lotze, M.T., Agarwala, S.S., & Kirkwood, J.M. (1994). Clinical applications of IL-2: Commentary I. ONCOLOGY, 8(6).
Lotze, M.T., Rubin, J.T., Carty, S., Edington, H., Ferson, P., Landreneau, R., Pippin, B., Posner, M., Rosenfelder, D., & Watson, C. (1994). Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther, 5(1), 41-55.Mary Ann Liebert. doi: 10.1089/hum.1994.5.1-41.
Mayordomo, I.I., Storkus, W.I., DeLeo, R., Lotze, M.T., & DeLeo, A.B. (1994). A CTL CLONE SPECIFIC FOR THE METH A MURINE SARCOMA SUCCESSFULLY TREATS ESTABLISHED METASTATIC DISEASE. Journal of Immunotherapy, 16(3), 240.Wolters Kluwer. doi: 10.1097/00002371-199410000-00034.
Nastala, C.L., Edington, H.D., McKinney, T.G., Tahara, H., Nalesnik, M.A., Brunda, M.J., Gately, M.K., Wolf, S.F., Schreiber, R.D., & Storkus, W.J. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol, 153(4), 1697-1706.Oxford University Press (OUP). doi: 10.4049/jimmunol.153.4.1697.
Oppenheim, M.H., & Lotze, M.T. (1994). lnterleukin-2: Solid-Tumor Therapy. Oncology, 51(2), 154-169.S. Karger AG. doi: 10.1159/000227330.
Oppenheim, M.H., & Lotze, M.T. (1994). Interleukin-2: solid-tumor therapy. Oncology, 51(2), 154-169.Karger Publishers. doi: 10.1159/000227330.
Pippin, B.A., Rosenstein, M., Jacob, W.F., Chiang, Y., & Lotze, M.T. (1994). Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Ther, 1(1), 35-42.
Pockaj, B.A., Yang, J.C., Lotze, M.T., Lange, J.R., Spencer, W.F., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., White, D.E., & Rosenberg, S.A. (1994). A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol, 15(1), 22-28.Wolters Kluwer. doi: 10.1097/00002371-199401000-00003.
Robbins, P.D., Tahara, H., Mueller, G., Hung, G., Bahnson, A., Zitvogel, L., Galea-Lauri, J., Ohashi, T., Patrene, K., & Boggs, S.S. (1994). Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis. Ann N Y Acad Sci, 716(1), 72-88.Wiley. doi: 10.1111/j.1749-6632.1994.tb21704.x.
Schwarz, R.E., Reynolds, J.C., & Lotze, M.T. (1994). "Pseudo-pseudotumor" of the liver. Adenocarcinoma presenting as an inflammatory pseudotumor. Dig Dis Sci, 39(12), 2679-2684.Springer Nature. doi: 10.1007/BF02087709.
Strumph, P.S., Carty, S.E., Rilo, H.L., Carroll, P.B., Ricordi, C., & Lotze, M.T. (1994). Interleukin-1 receptor antagonist is not detrimental to human islet cell insulin secretion but decreases insulin content. Transplant Proc, 26(2), 694.
Stuber, G., Leder, G.H., Storkus, W.T., Lotze, M.T., Modrow, S., Székely, L., Wolf, H., Klein, E., Kärre, K., & Klein, G. (1994). Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol, 24(3), 765-768.Wiley. doi: 10.1002/eji.1830240341.
Suminami, Y., Elder, E.M., Lotze, M.T., & Whiteside, T.L. (1994). QUANTITATIVE PCR FOR EXPRESSION OF THE IL4 GENE IN BIOPSIES OF PATIENTS RECEIVING GENETICALLY-MODIFIED TUMOR VACCINE. Journal of Immunotherapy, 16(3), 244.Wolters Kluwer. doi: 10.1097/00002371-199410000-00050.
Suzuki, T., Tahara, H., Robbins, P.D., & Lotze, M.T. (1994). DISCORDANT BIOLOGIC EFFECTS OF VIRAL IL-10 AND AUTHENTIC IL-10 IN MURINE TUMOR MODELS. Journal of Immunotherapy, 16(3), 245.Wolters Kluwer. doi: 10.1097/00002371-199410000-00051.
Tahara, H., Zeh, H.J., Storkus, W.J., Pappo, I., Watkins, S.C., Gubler, U., Wolf, S.F., Robbins, P.D., & Lotze, M.T. (1994). Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res, 54(1), 182-189.
Tahara, H., Zitvogel, L., Storkus, W.J., McKinney, T.G., Robbins, P.D., & Lotze, M.T. (1994). CANCER GENE THERAPY USING INTERLEUKIN-12 (IL-12). Journal of Immunotherapy, 16(3), 245.Wolters Kluwer. doi: 10.1097/00002371-199410000-00053.
Zeh, H.J., Leder, G.H., Lotze, M.T., Salter, R.D., Tector, M., Stuber, G., Modrow, S., & Storkus, W.J. (1994). Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol, 39(2), 79-86.Elsevier. doi: 10.1016/0198-8859(94)90105-8.
Zitvogel, L., Tahara, H., Cai, Q., Storkus, W.J., Muller, G., Wolf, S.F., Gately, M., Robbins, P.D., & Lotze, M.T. (1994). Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther, 5(12), 1493-1506.Mary Ann Liebert. doi: 10.1089/hum.1994.5.12-1493.
Zitvogel, L., Tahara, H., Robbins, P., Clark, M., & Lotze, M.T. (1994). B7.1 EXPRESSION ENHANCES EFFECTIVE IL-12 MEDIATED ANTITUMOR IMMUNITY. Journal of Immunotherapy, 16(3), 247.Wolters Kluwer. doi: 10.1097/00002371-199410000-00059.
Zorina, T., Mayordomo, I.I., Watkins, S., Lotze, M.T., DeLeo, A.B., & Ildstad, S.T. (1994). CULTURE OF DENDRITIC CELLS FROM MURINE BONE MARROW SUPPLEMENTED WITH GM-CSF AND TNF-ALPHA. Journal of Immunotherapy, 16(3), 247.Wolters Kluwer. doi: 10.1097/00002371-199410000-00061.
Berman, R.M., Zeh, H.J., Storkus, W.J., & Lotze, M.T. (1993). INTERLEUKIN-10 INDUCES LYMPHOKINE-ACTIVATED KILLER (LAK) CELL ACTIVITY. Journal of Immunotherapy, 13(1), 56.Wolters Kluwer. doi: 10.1097/00002371-199301000-00011.
Cai, O., Elder, E., Whiteside, T., Rubin, J., Moen, R., & Lotze, M.T. (1993). TRACKING GENETICALLY MARKED TUMOR INFILTRATING LYMPHOCYTES IN VIVO IN IL-2 AND IL-4 TREATED MELANOMA PATIENTS USING PCR. Journal of Immunotherapy, 14(4), 368.Wolters Kluwer. doi: 10.1097/00002371-199311000-00061.
Frassanito, A., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., DeLeo, R., & DeLeo, A.B. (1993). IDENTIFICATION OF A CLASS I MHC-ASSOCIATED PEPTIDE DERIVED FROM THE METH A SARCOMA AND RECOGNIZED BY CD8+ T CELLS. Journal of Immunotherapy, 14(4), 369.Wolters Kluwer. doi: 10.1097/00002371-199311000-00062.
Hunt, J.D., Pippin, B.A., Landreneau, R.J., Jacob, W.F., Lotze, M.T., & Siegfried, J.M. (1993). Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. J Immunother Emphasis Tumor Immunol, 14(4), 314-321.Wolters Kluwer. doi: 10.1097/00002371-199311000-00011.
Kawakami, Y., Haas, G.P., & Lotze, M.T. (1993). Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J Immunother Emphasis Tumor Immunol, 14(4), 336-347.Wolters Kluwer. doi: 10.1097/00002371-199311000-00014.
Leder, G.H., Storkus, W.J., Zeh, H.J., & Lotze, M.T. (1993). Can p53 peptides serve as tumor-specific antigens?. In Peptides 1992. (pp. 136-138).Springer Nature. doi: 10.1007/978-94-011-1470-7_50.
LOTZE, M.T. (1993). TRANSPLANTATION AND ADOPTIVE CELLULAR THERAPY OF CANCER - THE ROLE OF T-CELL GROWTH-FACTORS. CELL TRANSPLANTATION, 2(1), 33-47.SAGE Publications. doi: 10.1177/096368979300200106.
Lotze, M.T., & Finn, O.J. (1993). Introduction: Report on the keystone symposium: Cellular immunity and the immunotherapy of cancer II. Journal of Immunotherapy, 14(2), 79-87. doi: 10.1097/00002371-199308000-00001.
Lotze, M.T., & Finn, O.J. (1993). Report on the Keystone symposium: cellular immunity and the immunotherapy of cancer II. J Immunother Emphasis Tumor Immunol, 14(2), 79-87.Wolters Kluwer. doi: 10.1097/00002371-199308000-00001.
Lotze, M.T., Storkus, W.J., Hurd, S.D., Maeurer, M.J., & Kirkwood, J.M. (1993). Immunotherapy of melanoma. Melanoma Research, 3(1), 5-6.Wolters Kluwer. doi: 10.1097/00008390-199303000-00009.
Miller, D.L., & Lotze, M.T. (1993). A plea for a standard standard. Radiology, 188(1), 19-20.Radiological Society of North America (RSNA). doi: 10.1148/radiology.188.1.8390068.
Oppenheim, M.H., Leder, G., Rosenstein, M., Shah, N., Hoffman, R.A., Simmons, R.L., & Lotze, M.T. (1993). AMINOGUANIDINE ADMINISTRATION DECREASES SERUM NITRIC OXIDE LEVELS IN ANIMALS TREATED WITH INTERLEUKIN-2. Journal of Immunotherapy, 14(4), 368.Wolters Kluwer. doi: 10.1097/00002371-199311000-00059.
Pippin, B.A., Kuebbing, D., Nishihara, K., Hurd, S.D., & Lotze, M.T. (1993). TRANSFECTION OF INTERLEUKIN-4 INTO FIBRO-BLASTS FOR CYTOKINE GENE THERAPY OF CANCER. Journal of Immunotherapy, 13(1), 69.Wolters Kluwer. doi: 10.1097/00002371-199301000-00048.
Rosenberg, S.A., Lotze, M.T., & Yang, J.C. (1993). Erratum: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer (J Natl Cancer Inst (1993) 85 (622-632)). Journal of the National Cancer Institute, 85(13), 1091.
Rosenberg, S.A., Lotze, M.T., Yang, J.C., Topalian, S.L., Chang, A.E., Schwartzentruber, D.J., Aebersold, P., Leitman, S., Linehan, W.M., & Seipp, C.A. (1993). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst, 85(8), 622-632.Oxford University Press (OUP). doi: 10.1093/jnci/85.8.622.
Storkus, W.J., Zeh, H.J., Maeurer, M.J., Salter, R.D., & Lotze, M.T. (1993). Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol, 151(7), 3719-3727.Oxford University Press (OUP). doi: 10.4049/jimmunol.151.7.3719.
Storkus, W.J., Zeh, H.J., Salter, R.D., & Lotze, M.T. (1993). Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol, 14(2), 94-103.Wolters Kluwer. doi: 10.1097/00002371-199308000-00003.
Weidmann, E., Elder, E.M., Trucco, M., Lotze, M.T., & Whiteside, T.L. (1993). Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer, 54(3), 383-390.Wiley. doi: 10.1002/ijc.2910540306.
Wong, H.L., Costa, G.L., Lotze, M.T., & Wahl, S.M. (1993). Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med, 177(3), 775-781.Rockefeller University Press. doi: 10.1084/jem.177.3.775.
Zeh, H.J., Hurd, S., Storkus, W.J., & Lotze, M.T. (1993). Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphasis Tumor Immunol, 14(2), 155-161.Wolters Kluwer. doi: 10.1097/00002371-199308000-00012.
Zitvogel, L., Tahara, H., Robbins, P.D., & Lotze, M.T. (1993). EFFICIENT EXPRESSION OF IL12 AFTER TRANSDUCTION OF TUMOR CELLS WITH A RETROVIRAL VECTOR ENCODING BOTH SUBUNITS OF HUMAN IL12. Journal of Immunotherapy, 14(4), 364.Wolters Kluwer. doi: 10.1097/00002371-199311000-00046.
Choyke, P.L., Miller, D.L., Lotze, M.T., Whiteis, J.M., Ebbitt, B., & Rosenberg, S.A. (1992). Delayed reactions to contrast media after interleukin-2 immunotherapy. Radiology, 183(1), 111-114.Radiological Society of North America (RSNA). doi: 10.1148/radiology.183.1.1549655.
Elder, E.M., Kuebbing, D., Lotze, M., & Whiteside, T.L. (1992). SELECTION OF NEOMYCIN-RESISTANT TIL OBTAINED FROM HUMAN MELANOMA AND CULTURED IN THE PRESENCE OF IL-2 AND IL-4. Journal of Immunotherapy, 11(2), 125.Wolters Kluwer. doi: 10.1097/00002371-199202000-00019.
Emery, B.E., White, M.V., Igarashi, Y., Mullol, J., Berkebile, C., Peden, D., Lotze, M.T., & Kaliner, M.A. (1992). The effect of IL-4 on human nasal mucosal responses. J Allergy Clin Immunol, 90(5), 772-781.Elsevier. doi: 10.1016/0091-6749(92)90101-7.
Lange, J.R., Raubitschek, A.A., Pockaj, B.A., Spencer, W.F., Lotze, M.T., Topalian, S.L., Yang, J.C., & Rosenberg, S.A. (1992). A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunother (1991), 12(4), 265-271.Wolters Kluwer. doi: 10.1097/00002371-199211000-00007.
Lotze, M.T. (1992). T-cell growth factors and the treatment of patients with cancer. Clin Immunol Immunopathol, 62(1 Pt 2), S47-S54.Elsevier. doi: 10.1016/0090-1229(92)90040-u.
Lotze, M.T. (1992). Keystone symposium. Melanoma and biology of the neural crest. Taos City Hall, Taos, New Mexico, USA, 1-8 February 1992. Melanoma Res, 2(2), 131-138.Wolters Kluwer. doi: 10.1097/00008390-199207000-00009.
LOTZE, M.T. (1992). PAPERS FROM THE 1992 KEYSTONE SYMPOSIUM ON MELANOMA AND BIOLOGY OF THE NEURAL CREST - INTRODUCTION. JOURNAL OF IMMUNOTHERAPY, 12(3), 153.Wolters Kluwer. doi: 10.1097/00002371-199210000-00001.
LOTZE, M.T. (1992). The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. Hum Gene Ther, 3(2), 167-177.Mary Ann Liebert. doi: 10.1089/hum.1992.3.2-167.
LOTZE, M.T. (1992). NATIONAL INSTITUTES OF HEALTH CONSENSUS DEVELOPMENT CONFERENCE - DIAGNOSIS AND TREATMENT OF EARLY MELANOMA - NATIONAL-INSTITUTES-OF-HEALTH, BETHESDA, MARYLAND, USA, 27-29 JANUARY 1992 - KEYSTONE SYMPOSIUM - MELANOMA AND BIOLOGY OF THE NEURAL CREST - TAOS CITY HALL, TAOS, NEW-MEXICO, USA, 1-8 FEBRUARY 1992. MELANOMA RESEARCH, 2(2), 131-138. doi: 10.1097/00008390-199207000-00009.
Lotze, M.T., Rubin, J.T., & Zeh, H.J. (1992). New biologic agents come to bat for cancer therapy. Curr Opin Oncol, 4(6), 1116-1123.Wolters Kluwer. doi: 10.1097/00001622-199212000-00017.
Lotze, M.T., Zeh, H.J., Elder, E.M., Cai, Q., Pippin, B.A., Rosenstein, M.M., Whiteside, T.L., & Herberman, R. (1992). Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. J Immunother (1991), 12(3), 212-217.Wolters Kluwer. doi: 10.1097/00002371-199210000-00015.
Marincola, F.M., Venzon, D., White, D., Rubin, J.T., Lotze, M.T., Simonis, T.B., Balkissoon, J., Rosenberg, S.A., & Parkinson, D.R. (1992). HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res, 52(23), 6561-6566.
Pippin, B., Cai, Q., & Lotze, M.T. (1992). EVALUATION OF IMMUNE REACTIVITY TO IL-2 TRANSFECTED TUMORS. Journal of Immunotherapy, 11(2), 137.Wolters Kluwer. doi: 10.1097/00002371-199202000-00045.
Pockaj, B.A., Lotze, M.T., Yang, J., Steinberg, S., & Rosenberg, S.A. (1992). A PROSPECTIVE RANDOMIZED TRIAL EVALUATING CRYSTALLOID VERSUS COLLOID FLUID RESUSCITATION FOR INTERLEUKIN-2 BASED THERAPY. Journal of Immunotherapy, 11(2), 138.Wolters Kluwer. doi: 10.1097/00002371-199202000-00047.
Rubin, J.T., & Lotze, M.T. (1992). Immune function and dysfunction. A primer for the radiologist. Radiol Clin North Am, 30(3), 507-523.Elsevier. doi: 10.1016/s0033-8389(22)02507-6.
Rubin, J.T., & Lotze, M.T. (1992). Acute gastric mucosal injury associated with the systemic administration of interleukin-4. Surgery, 111(3), 274-280.
Rubin, J.T., Adams, S., Simonis, T., & Lotze, M.T. (1992). HLA-POLYMORPHISM AND RESPONSE TO IL-2− BASED THERAPY IN PATIENTS WITH MELANOMA. Journal of Immunotherapy, 11(2), 141.Wolters Kluwer. doi: 10.1097/00002371-199202000-00053.
Sanda, M.G., Yang, J.C., Topalian, S.L., Groves, E.S., Childs, A., Belfort, R., de Smet, M.D., Schwartzentruber, D.J., White, D.E., & Lotze, M.T. (1992). Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J Clin Oncol, 10(10), 1643-1649.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1992.10.10.1643.
Spencer, W.F., Linehan, W.M., Walther, M.M., Haas, G.P., Lotze, M.T., Topalian, S.L., Yang, J.C., Merino, M.J., Lange, J.R., & Pockaj, B.A. (1992). Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol, 147(1), 24-30.Wolters Kluwer. doi: 10.1016/s0022-5347(17)37124-0.
Storkus, W.J., & Lotze, M.T. (1992). MELANOMA IMMUNOGENICITY. Journal of Immunotherapy, 11(2), 147.Wolters Kluwer. doi: 10.1097/00002371-199202000-00065.
Tahara, H., Mueller, G.M., Ricordi, C., Robbins, P.D., & Lotze, M.T. (1992). Islet cell transplantation facilitated by gene transfer. Transplant Proc, 24(6), 2975-2976.
White, M.V., Igarashi, Y., Emery, B.E., Lotze, M.T., & Kaliner, M.A. (1992). Effects of in vivo administration of interleukin-2 (IL-2) and IL-4, alone and in combination, on ex vivo human basophil histamine release. Blood, 79(6), 1491-1495.American Society of Hematology. doi: 10.1182/blood.V79.6.1491.bloodjournal7961491.
Wong, H.L., Lotze, M.T., Wahl, L.M., & Wahl, S.M. (1992). Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J Immunol, 148(7), 2118-2125.Oxford University Press (OUP). doi: 10.4049/jimmunol.148.7.2118.
Aebersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J., & Rosenberg, S.A. (1991). Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst, 83(13), 932-937.Oxford University Press (OUP). doi: 10.1093/jnci/83.13.932.
Culver, K., Cornetta, K., Morgan, R., Morecki, S., Aebersold, P., Kasid, A., Lotze, M., Rosenberg, S.A., Anderson, W.F., & Blaese, R.M. (1991). Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci U S A, 88(8), 3155-3159.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.88.8.3155.
Lotze, M.T. (1991). Trials and tribulations: the cost of developing gene therapies. FASEB J, 5(15), 3013-3014.Wiley. doi: 10.1096/fasebj.5.15.1743433.
Lotze, M.T. (1991). Concerning repeat hepatic resections for colorectal metastases [4]. Surgery, 109(3 I), 347-348.
Lotze, M.T. (1991). Concerning repeat hepatic resections for colorectal metastases. Surgery, 109(3 Pt 1), 347-348.
LOTZE, M.T. (1991). CONCERNING REPEAT HEPATIC RESECTIONS FOR COLORECTAL METASTASES. SURGERY, 109(3), 347-348.
Stötter, H., & Lotze, M.T. (1991). Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. Arch Surg, 126(12), 1525-1530.American Medical Association (AMA). doi: 10.1001/archsurg.1991.01410360099017.
Stötter, H., Custer, M.C., Bolton, E.S., Guedez, L., & Lotze, M.T. (1991). IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J Immunol, 146(1), 150-155.Oxford University Press (OUP). doi: 10.4049/jimmunol.146.1.150.
Bock, S.N., Lee, R.E., Fisher, B., Rubin, J.T., Schwartzentruber, D.J., Wei, J.P., Callender, D.P., Yang, J.C., Lotze, M.T., & Pizzo, P.A. (1990). A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol, 8(1), 161-169.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1990.8.1.161.
Custer, M.C., & Lotze, M.T. (1990). A biologic assay for IL-4. Rapid fluorescence assay for IL-4 detection in supernatants and serum. J Immunol Methods, 128(1), 109-117.Elsevier. doi: 10.1016/0022-1759(90)90469-c.
Huang, C.M., Elin, R.J., Ruddel, M., Sliva, C., Lotze, M.T., & Rosenberg, S.A. (1990). Changes in laboratory results for cancer patients treated with interleukin-2. Clin Chem, 36(3), 431-434.Oxford University Press (OUP). doi: 10.1093/clinchem/36.3.431.
Jablons, D., Bolton, E., Mertins, S., Rubin, M., Pizzo, P., Rosenberg, S.A., & Lotze, M.T. (1990). IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. J Immunol, 144(9), 3630-3636.Oxford University Press (OUP). doi: 10.4049/jimmunol.144.9.3630.
Jablons, D.M., Donohue, R., Kawakami, Y., Young, J.D., & Lotze, M.T. (1990). Interleukin-3 induces proliferation but not lymphokine activated killer activity from human and murine mononuclear cells. Eur Cytokine Netw, 1(2), 91-98.
Kasid, A., Director, E.P., Stovroff, M.C., Lotze, M.T., & Rosenberg, S.A. (1990). Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells. Cancer Res, 50(16), 5072-5076.
Kasid, A., Morecki, S., Aebersold, P., Cornetta, K., Culver, K., Freeman, S., Director, E., Lotze, M.T., Blaese, R.M., & Anderson, W.F. (1990). Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci U S A, 87(1), 473-477.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.87.1.473.
Kragel, A.H., Travis, W.D., Feinberg, L., Pittaluga, S., Striker, L.M., Roberts, W.C., Lotze, M.T., Yang, J.J., & Rosenberg, S.A. (1990). Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Hum Pathol, 21(5), 493-502.Elsevier. doi: 10.1016/0046-8177(90)90005-p.
Laue, L., Lotze, M.T., Chrousos, G.P., Barnes, K., Loriaux, D.L., & Fleisher, T.A. (1990). Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab, 71(6), 1474-1480.The Endocrine Society. doi: 10.1210/jcem-71-6-1474.
Lotze, M.T., & Finn, O.J. (1990). Recent advances in cellular immunology: implications for immunity to cancer. Immunol Today, 11(6), 190-193.Elsevier. doi: 10.1016/0167-5699(90)90079-o.
Lotze, M.T., & Finn, O.J. (1990). Recent advances in cellular immunology: implications for immunity to cancer. Immunology Today, 11(C), 190-193. doi: 10.1016/0167-5699(90)90079-o.
Lotze, M.T., Custer, M.C., Bolton, E.S., Wiebke, E.A., Kawakami, Y., & Rosenberg, S.A. (1990). Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Hum Immunol, 28(2), 198-207.Elsevier. doi: 10.1016/0198-8859(90)90020-p.
Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., & Topalian, S.L. (1990). Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med, 323(9), 570-578.Massachusetts Medical Society. doi: 10.1056/NEJM199008303230904.
Stötter, H., & Lotze, M.T. (1990). Cytolytic effector cells against human tumors: distinguishing phenotype and function. Cancer Cells, 2(2), 44-55.
Ward, B., McGarvey, C., & Lotze, M.T. (1990). Excellent shoulder function is attainable after partial or total scapulectomy. Analysis at prolonged follow-up. Arch Surg, 125(4), 537-542.American Medical Association (AMA). doi: 10.1001/archsurg.1990.01410160125024.
Wiebke, E.A., Custer, M.C., Rosenberg, S.A., & Lotze, M.T. (1990). Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. J Biol Response Mod, 9(2), 113-126.
Del Vecchio, S., Reynolds, J.C., Carrasquillo, J.A., Blasberg, R.G., Neumann, R.D., Lotze, M.T., Bryant, G.J., Farkas, R.J., & Larson, S.M. (1989). Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res, 49(10), 2783-2789.
Denicoff, K.D., Durkin, T.M., Lotze, M.T., Quinlan, P.E., Davis, C.L., Listwak, S.J., Rosenberg, S.A., & Rubinow, D.R. (1989). The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab, 69(2), 402-410.The Endocrine Society. doi: 10.1210/jcem-69-2-402.
Fisher, B., Keenan, A.M., Garra, B.S., Steinberg, S.M., White, D.E., DiBisceglie, A.M., Hoofnagle, J.H., Yolles, P., Rosenberg, S.A., & Lotze, M.T. (1989). Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol, 7(12), 1852-1862.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1989.7.12.1852.
Jablons, D.M., McIntosh, J.K., Mulé, J.J., Nordan, R.P., Rudikoff, S., & Lotze, M.T. (1989). Induction of interferon-beta 2/interleukin-6 (IL-6) by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state. Ann N Y Acad Sci, 557(1), 157-160.Wiley. doi: 10.1111/j.1749-6632.1989.tb24008.x.
Jablons, D.M., Mule, J.J., McIntosh, J.K., Sehgal, P.B., May, L.T., Huang, C.M., Rosenberg, S.A., & Lotze, M.T. (1989). IF-6/IFN-β2 as a circulating hormone: Induction by cytokine administration in humans. Journal of Immunology, 142(5), 1542-1547.
Jablons, D.M., Mulé, J.J., McIntosh, J.K., Sehgal, P.B., May, L.T., Huang, C.M., Rosenberg, S.A., & Lotze, M.T. (1989). IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol, 142(5), 1542-1547.Oxford University Press (OUP). doi: 10.4049/jimmunol.142.5.1542.
Kawakami, Y., Custer, M.C., Rosenberg, S.A., & Lotze, M.T. (1989). IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol, 142(10), 3452-3461.Oxford University Press (OUP). doi: 10.4049/jimmunol.142.10.3452.
Lee, R.E., Lotze, M.T., Skibber, J.M., Tucker, E., Bonow, R.O., Ognibene, F.P., Carrasquillo, J.A., Shelhamer, J.H., Parrillo, J.E., & Rosenberg, S.A. (1989). Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol, 7(1), 7-20.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1989.7.1.7.
Lotze, M. (1989). Disturbing homeostasis: recent results of ongoing immunotherapy trials at the NCI. Biotechnol Ther, 1(2), 125-162.
LOTZE, M.T. (1989). High-output cardiac failure in multiple myeloma. N Engl J Med, 320(21), 1419-1420.Massachusetts Medical Society. doi: 10.1056/NEJM198905253202116.
Lotze, M.T., Jablons, D.M., Rubin, J.T., Chang, A.E., & Rosenberg, S.A. (1989). Cytokine Therapy of Patients with Cancer. In Progress in Immunology. (pp. 1213-1220).Springer Nature. doi: 10.1007/978-3-642-83755-5_161.
MCINTOSH, J.K., JABLONS, D.M., MULE, J.J., NORDAN, R.P., RUDIKOFF, S., LOTZE, M.T., & ROSENBERG, S.A. (1989). INVIVO INDUCTION OF IL-6 BY ADMINISTRATION OF EXOGENOUS CYTOKINES AND DETECTION OF DENOVO SERUM LEVELS OF IL-6 IN TUMOR-BEARING MICE. JOURNAL OF IMMUNOLOGY, 143(1), 162-167.
McIntosh, J.K., Jablons, D.M., Mulé, J.J., Nordan, R.P., Rudikoff, S., Lotze, M.T., & Rosenberg, S.A. (1989). In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol, 143(1), 162-167.Oxford University Press (OUP). doi: 10.4049/jimmunol.143.1.162.
MCINTOSH, J.K., MULE, J.J., JABLONS, D.M., NORDAN, R.P., RUDIKOFF, S., LOTZE, M.T., & ROSENBERG, S.A. (1989). THE KINETICS OF INTERLEUKIN-6 INDUCTION BY THE SYSTEMIC ADMINISTRATION OF RHTNF-ALPHA IN MICE. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 557(1), 572-575.Wiley. doi: 10.1111/j.1749-6632.1989.tb24070.x.
Rosenberg, S.A., Lotze, M.T., Yang, J.C., Aebersold, P.M., Linehan, W.M., Seipp, C.A., & White, D.E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg, 210(4), 474-484.Wolters Kluwer. doi: 10.1097/00000658-198910000-00008.
Rosenberg, S.A., Lotze, M.T., Yang, J.C., Linehan, W.M., Seipp, C., Calabro, S., Karp, S.E., Sherry, R.M., Steinberg, S., & White, D.E. (1989). Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol, 7(12), 1863-1874.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1989.7.12.1863.
Rubin, J.T., Elwood, L.J., Rosenberg, S.A., & Lotze, M.T. (1989). Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res, 49(24 Pt 1), 7086-7092.
RUBIN, J.T., ELWOOD, L.J., ROSENBERG, S.A., & LOTZE, M.T. (1989). IMMUNOHISTOCHEMICAL CORRELATES OF RESPONSE TO RECOMBINANT INTERLEUKIN-2-BASED IMMUNOTHERAPY IN HUMANS. CANCER RESEARCH, 49(24), 7086-7092.
Sakahara, H., Reynolds, J.C., Carrasquillo, J.A., Lora, M.E., Maloney, P.J., Lotze, M.T., Larson, S.M., & Neumann, R.D. (1989). In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med, 30(8), 1311-1317.
SAKAHARA, H., REYNOLDS, J.C., CARRASQUILLO, J.A., LORA, M.E., MALONEY, P.J., LOTZE, M.T., LARSON, S.M., & NEUMANN, R.D. (1989). INVITRO COMPLEX-FORMATION AND BIODISTRIBUTION OF MOUSE ANTITUMOR MONOCLONAL-ANTIBODY IN CANCER-PATIENTS. JOURNAL OF NUCLEAR MEDICINE, 30(8), 1311-1317.
Stötter, H., Wiebke, E.A., Tomita, S., Belldegrun, A., Topalian, S., Rosenberg, S.A., & Lotze, M.T. (1989). Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol, 142(5), 1767-1773.Oxford University Press (OUP). doi: 10.4049/jimmunol.142.5.1767.
Begley, M.G., Shawker, T.H., Robertson, C.N., Bock, S.N., Wei, J.P., & Lotze, M.T. (1988). Fournier gangrene: diagnosis with scrotal US. Radiology, 169(2), 387-389.Radiological Society of North America (RSNA). doi: 10.1148/radiology.169.2.3051115.
Chang, A.E., Kinsella, T., Glatstein, E., Baker, A.R., Sindelar, W.F., Lotze, M.T., Danforth, D.N., Sugarbaker, P.H., Lack, E.E., & Steinberg, S.M. (1988). Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol, 6(9), 1491-1500.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1988.6.9.1491.
Cotran, R.S., Pober, J.S., Gimbrone, M.A., Springer, T.A., Wiebke, E.A., Gaspari, A.A., Rosenberg, S.A., & Lotze, M.T. (1988). Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol, 140(6), 1883-1888.Oxford University Press (OUP). doi: 10.4049/jimmunol.140.6.1883.
Di Bisceglie, A.M., Rustgi, V.K., Hoofnagle, J.H., Dusheiko, G.M., & Lotze, M.T. (1988). NIH conference. Hepatocellular carcinoma. Ann Intern Med, 108(3), 390-401.American College of Physicians. doi: 10.7326/0003-4819-108-3-390.
DIBISCEGLIE, A.M., RUSTGI, V.K., HOOFNAGLE, J.H., DUSHEIKO, G.M., & LOTZE, M.T. (1988). HEPATOCELLULAR-CARCINOMA. ANNALS OF INTERNAL MEDICINE, 108(3), 390-401.American College of Physicians. doi: 10.7326/0003-4819-108-3-390.
Jablons, D.M., & Lotze, M.T. (1988). Derivation of cells with lytic activity against fresh and cultured tumors from human bone marrow. J Surg Res, 44(4), 404-416.Elsevier. doi: 10.1016/0022-4804(88)90183-7.
Kawakami, Y., Rosenberg, S.A., & Lotze, M.T. (1988). Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med, 168(6), 2183-2191.Rockefeller University Press. doi: 10.1084/jem.168.6.2183.
Lee, R.E. (1988). Interleukin 2 and Psoriasis. Archives of Dermatology, 124(12), 1811.American Medical Association (AMA). doi: 10.1001/archderm.1988.01670120027005.
Lee, R.E., Gaspari, A.A., Lotze, M.T., Chang, A.E., & Rosenberg, S.A. (1988). Interleukin 2 and psoriasis. Arch Dermatol, 124(12), 1811-1815.American Medical Association (AMA). doi: 10.1001/archderm.124.12.1811.
Lotze, M.T., & Rosenberg, S.A. (1988). The immunologic treatment of cancer. CA Cancer J Clin, 38(2), 68-94.Wiley. doi: 10.3322/canjclin.38.2.68.
Lotze, M.T., & Rosenberg, S.A. (1988). CHAPTER 12 INTERLEUKIN 2 AS A PHARMACOLOGIC REAGENT. In Interleukin. (pp. 237-294).Elsevier. doi: 10.1016/b978-0-12-651420-9.50017-8.
Lotze, M.T., Ross, W.G., Tomita, S., & Custer, M.C. (1988). Cells invading tumors: strategies for the identification and expansion of tumor reactive lymphocytes. Transplant Proc, 20(2), 326-331.
Ognibene, F.P., Rosenberg, S.A., Lotze, M., Skibber, J., Parker, M.M., Shelhamer, J.H., & Parrillo, J.E. (1988). Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest, 94(4), 750-754.Elsevier. doi: 10.1378/chest.94.4.750.
Rizzoni, W.E., Miller, K., Rick, M., & Lotze, M.T. (1988). Heparin-induced thrombocytopenia and thromboembolism in the postoperative period. Surgery, 103(4), 470-476.
Roberts, K., & Lotze, M.T. (1988). Interleukin 2 promotes conjugate formation by purified LAK precursors and T lymphocytes: evaluation of conjugates using flow cytometric techniques. J Biol Response Mod, 7(3), 249-266.
ROSENBERG, S.A., LOTZE, M.T., & MULE, J.J. (1988). NEW APPROACHES TO THE IMMUNOTHERAPY OF CANCER USING INTERLEUKIN-2. ANNALS OF INTERNAL MEDICINE, 108(6), 853-864.American College of Physicians. doi: 10.7326/0003-4819-108-6-853.
Rosenberg, S.A., Lotze, M.T., & Mulé, J.J. (1988). NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med, 108(6), 853-864.American College of Physicians. doi: 10.7326/0003-4819-108-6-853.
Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., & Seipp, C.A. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med, 319(25), 1676-1680.Massachusetts Medical Society. doi: 10.1056/NEJM198812223192527.
Schwartzentruber, D., Lotze, M.T., & Rosenberg, S.A. (1988). Colonic perforation: An unusual complication of therapy with high‐dose lnterleukin‐2. Cancer, 62(11), 2350-2353. doi: 10.1002/1097-0142(19881201)62:11<2350::AID-CNCR2820621116>3.0.CO;2-S.
Schwartzentruber, D., Lotze, M.T., & Rosenberg, S.A. (1988). Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. Cancer, 62(11), 2350-2353.Wiley. doi: 10.1002/1097-0142(19881201)62:11<2350::aid-cncr2820621116>3.0.co;2-s.
Topalian, S.L., Solomon, D., Avis, F.P., Chang, A.E., Freerksen, D.L., Linehan, W.M., Lotze, M.T., Robertson, C.N., Seipp, C.A., & Simon, P. (1988). Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol, 6(5), 839-853.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1988.6.5.839.
Wiebke, E.A., Rosenberg, S.A., & Lotze, M.T. (1988). Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol, 6(9), 1440-1449.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1988.6.9.1440.
Cohen, P.J., Lotze, M.T., Roberts, J.R., Rosenberg, S.A., & Jaffe, E.S. (1987). The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol, 129(2), 208-216.
Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D., & Rosenberg, S.A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med, 107(3), 293-300.American College of Physicians. doi: 10.7326/0003-4819-107-2-293.
Edington, H.D., & Lotze, M.T. (1987). V-Y closure for abdominal wall stomal reduction. Surg Gynecol Obstet, 164(4), 381-382.
Gaspari, A.A. (1987). Dermatologic Changes Associated With Interleukin 2 Administration. JAMA: The Journal of the American Medical Association, 258(12), 1624.American Medical Association (AMA). doi: 10.1001/jama.1987.03400120074028.
Gaspari, A.A., Lotze, M.T., Rosenberg, S.A., Stern, J.B., & Katz, S.I. (1987). Dermatologic changes associated with interleukin 2 administration. JAMA, 258(12), 1624-1629.American Medical Association (AMA). doi: 10.1001/jama.258.12.1624.
Lotze, M.T. (1987). Surgical management of hepatocellular carcinoma. Gastroenterol Clin North Am, 16(4), 613-626.Elsevier. doi: 10.1016/s0889-8553(21)00334-4.
Lotze, M.T., & Rosenberg, S.A. (1987). In Reply. JAMA: The Journal of the American Medical Association, 257(13), 1730-1731. doi: 10.1001/jama.1987.03390130047019.
LOTZE, M.T., & ROSENBERG, S.A. (1987). INTERLEUKIN-2 THERAPY FOR DISSEMINATED CANCER - REPLY. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 257(13), 1730-1731.American Medical Association (AMA). doi: 10.1001/jama.1987.03390130047019.
Lotze, M.T., Custer, M.C., Sharrow, S.O., Rubin, L.A., Nelson, D.L., & Rosenberg, S.A. (1987). In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res, 47(8), 2188-2195.
LOTZE, M.T., CUSTER, M.C., SHARROW, S.O., RUBIN, L.A., NELSON, D.L., & ROSENBERG, S.A. (1987). INVIVO ADMINISTRATION OF PURIFIED HUMAN INTERLEUKIN-2 TO PATIENTS WITH CANCER - DEVELOPMENT OF INTERLEUKIN-2 RECEPTOR POSITIVE CELLS AND CIRCULATING SOLUBLE INTERLEUKIN-2 RECEPTORS FOLLOWING INTERLEUKIN-2 ADMINISTRATION. CANCER RESEARCH, 47(8), 2188-2195.
Lotze, M.T., Roberts, K., Custer, M.C., Segal, D.A., & Rosenberg, S.A. (1987). Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors. J Surg Res, 42(5), 580-589.Elsevier. doi: 10.1016/0022-4804(87)90036-9.
Roberts, K., Lotze, M.T., & Rosenberg, S.A. (1987). Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res, 47(16), 4366-4371.
Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., & Rubin, J.T. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med, 316(15), 889-897.Massachusetts Medical Society. doi: 10.1056/NEJM198704093161501.
Skibber, J.M., Lotze, M.T., Muul, L.M., Uppenkamp, I.K., Ross, W., & Rosenberg, S.A. (1987). Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell. Nat Immun Cell Growth Regul, 6(6), 291-305.
Skibber, J.M., Lotze, M.T., Seipp, C.A., Salcedo, R., & Rosenberg, S.A. (1987). Limb-sparing surgery for soft tissue sarcomas: wound related morbidity in patients undergoing wide local excision. Surgery, 102(3), 447-452.
Skibber, J.M., Lotze, M.T., Uppenkamp, I., Ross, W., & Rosenberg, S.A. (1987). Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. J Surg Res, 42(6), 613-621.Elsevier. doi: 10.1016/0022-4804(87)90004-7.
Skibber, J.M., Matter, G.J., Pizzo, P.A., & Lotze, M.T. (1987). Right lower quadrant pain in young patients with leukemia. Annals of Surgery, 206(6), 711-716. doi: 10.1097/00000658-198712000-00005.
Skibber, J.M., Matter, G.J., Pizzo, P.A., & Lotze, M.T. (1987). Right lower quadrant pain in young patients with leukemia. A surgical perspective. Ann Surg, 206(6), 711-716.Wolters Kluwer. doi: 10.1097/00000658-198712000-00005.
Vetto, J.T., Papa, M.Z., Lotze, M.T., Chang, A.E., & Rosenberg, S.A. (1987). Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol, 5(3), 496-503.American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.1987.5.3.496.
Wiebke, E.A., Lotze, M.T., & Rosenberg, S.A. (1987). Tumor cell susceptibility to lysis: Marked increase in lysis by tumor-infiltrating lymphocytes following target stimulation with interferon-γ and tumor necrosis factor-α - Implications for immunotherapy. Surgical Forum, 38, 436-438.
Lotze, M.T. (1986). Surgical considerations in the diagnosis and management of AIDS. AIDS Res, 2(2), 141-148.Mary Ann Liebert. doi: 10.1089/aid.1.1986.2.141.
Lotze, M.T. (1986). High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer. JAMA, 256(22), 3117.American Medical Association (AMA). doi: 10.1001/jama.1986.03380220083027.
Lotze, M.T., & Rosenberg, S.A. (1986). Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology, 172(3-5), 420-437.Elsevier. doi: 10.1016/S0171-2985(86)80122-X.
Lotze, M.T., & Rosenberg, S.A. (1986). Protocol design for lymphokine testing in clinical studies of human cancer. Lymphokine Res, 5 Suppl 1(SUPPL. 1), S177-S181.
Lotze, M.T., Carrasquillo, J.A., Weinstein, J.N., Bryant, G.J., Perentesis, P., Reynolds, J.C., Matis, L.A., Eger, R.R., Keenan, A.M., & Hellström, I. (1986). Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection. Ann Surg, 204(3), 223-235.Wolters Kluwer. doi: 10.1097/00000658-198609000-00002.
Lotze, M.T., Chang, A.E., Seipp, C.A., Simpson, C., Vetto, J.T., & Rosenberg, S.A. (1986). High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA, 256(22), 3117-3124.American Medical Association (AMA). doi: 10.1001/jama.256.22.3117.
Lotze, M.T., Custer, M.C., & Rosenberg, S.A. (1986). Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg, 121(12), 1373-1379.American Medical Association (AMA). doi: 10.1001/archsurg.1986.01400120019002.
Lotze, M.T., Matory, Y.L., Rayner, A.A., Ettinghausen, S.E., Vetto, J.T., Seipp, C.A., & Rosenberg, S.A. (1986). Clinical effects and toxicity of interleukin‐2 in patients with cancer. Cancer, 58(12), 2764-2772. doi: 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z.
Lotze, M.T., Matory, Y.L., Rayner, A.A., Ettinghausen, S.E., Vetto, J.T., Seipp, C.A., & Rosenberg, S.A. (1986). Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer, 58(12), 2764-2772.Wiley. doi: 10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z.
Perez, P., Titus, J.A., Lotze, M.T., Cuttitta, F., Longo, D.L., Groves, E.S., Rabin, H., Durda, P.J., & Segal, D.M. (1986). Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol, 137(7), 2069-2072.Oxford University Press (OUP). doi: 10.4049/jimmunol.137.7.2069.
Rosenberg, S.A., & Lotze, M.T. (1986). Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol, 4(1), 681-709.Annual Reviews. doi: 10.1146/annurev.iy.04.040186.003341.
ROSENBERG, S.A., & LOTZE, M.T. (1986). CANCER-IMMUNOTHERAPY USING INTERLEUKIN-2 AND INTERLEUKIN-2-ACTIVATED LYMPHOCYTES. ANNUAL REVIEW OF IMMUNOLOGY, 4(1), 681-709.Annual Reviews. doi: 10.1146/annurev.iy.04.040186.003341.
Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Vetto, J.T., Seipp, C.A., & Simpson, C. (1986). A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery, 100(2), 262-272.
Skibber, J.M., Lotze, M.T., Garra, B., & Fauci, A. (1986). Successful management of hepatic abscesses by percutaneous catheter drainage in chronic granulomatous disease. Surgery, 99(5), 626-630.
Chang, A.E., Lotze, M.T., Ames, R.S., Roth, J.A., & Rosenberg, S.A. (1985). A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma. J Immunopharmacol, 7(1), 17-31.Taylor & Francis. doi: 10.3109/08923978509026466.
Chang, A.E., Lotze, M.T., Ames, R.S., Roth, J.A., & Rosenberg, S.A. (1985). A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma. Journal of Immunopharmacology, 7(1), 17-31.
Lotze, M.T. (1985). AIDS: a surgeon's responsibility. Bull Am Coll Surg, 70(9), 6-12.
Lotze, M.T., & Sugarbaker, P.H. (1985). Femoral artery based myocutaneous flap for hemipelvectomy closure: amputation after failed limb-sparing surgery and radiotherapy. Am J Surg, 150(5), 625-630.Elsevier. doi: 10.1016/0002-9610(85)90451-9.
Lotze, M.T., Frana, L.W., Sharrow, S.O., Robb, R.J., & Rosenberg, S.A. (1985). In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol, 134(1), 157-166.Oxford University Press (OUP). doi: 10.4049/jimmunol.134.1.157.
LOTZE, M.T., FRANA, L.W., SHARROW, S.O., ROBB, R.J., & ROSENBERG, S.A. (1985). INVIVO ADMINISTRATION OF PURIFIED HUMAN INTERLEUKIN-2 .1. HALF-LIFE AND IMMUNOLOGICAL EFFECTS OF THE JURKAT CELL LINE DERIVED INTERLEUKIN-2. JOURNAL OF IMMUNOLOGY, 134(1), 157-166.
Lotze, M.T., Matory, Y.L., Ettinghausen, S.E., Rayner, A.A., Sharrow, S.O., Seipp, C.A., Custer, M.C., & Rosenberg, S.A. (1985). In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol, 135(4), 2865-2875.Oxford University Press (OUP). doi: 10.4049/jimmunol.135.4.2865.
LOTZE, M.T., MATORY, Y.L., ETTINGHAUSEN, S.E., RAYNER, A.A., SHARROW, S.O., SEIPP, C.A.Y., CUSTER, M.C., & ROSENBERG, S.A. (1985). INVIVO ADMINISTRATION OF PURIFIED HUMAN INTERLEUKIN-2 .2. HALF-LIFE, IMMUNOLOGICAL EFFECTS, AND EXPANSION OF PERIPHERAL LYMPHOID-CELLS INVIVO WITH RECOMBINANT IL-2. JOURNAL OF IMMUNOLOGY, 135(4), 2865-2875.
Lotze, M.T., Rayner, A.A., & Grimm, E.A. (1985). Problems with the isolation of lymphoid clones with reactivity to human tumors. Behring Inst Mitt, (77), 105-114.
Rayner, A.A., Grimm, E.A., Lotze, M.T., Chu, E.W., & Rosenberg, S.A. (1985). Lymphokine‐activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer, 55(6), 1327-1333. doi: 10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O.
Rayner, A.A., Grimm, E.A., Lotze, M.T., Chu, E.W., & Rosenberg, S.A. (1985). Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer, 55(6), 1327-1333.Wiley. doi: 10.1002/1097-0142(19850315)55:6<1327::aid-cncr2820550628>3.0.co;2-o.
Rayner, A.A., Grimm, E.A., Lotze, M.T., Wilson, D.J., & Rosenberg, S.A. (1985). Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst, 75(1), 67-75.Oxford University Press (OUP). doi: 10.1093/jnci/75.1.67.
Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., & Vetto, J.T. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med, 313(23), 1485-1492.Massachusetts Medical Society. doi: 10.1056/NEJM198512053132327.
Donohue, J.H., Lotze, M.T., Robb, R.J., Rosenstein, M., Braziel, R.M., Jaffe, E.S., & Rosenberg, S.A. (1984). In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res, 44(4), 1380-1386.
DONOHUE, J.H., LOTZE, M.T., ROBB, R.J., ROSENSTEIN, M., BRAZIEL, R.M., JAFFE, E.S., & ROSENBERG, S.A. (1984). INVIVO ADMINISTRATION OF PURIFIED JURKAT-DERIVED INTERLEUKIN-2 IN MICE. CANCER RESEARCH, 44(4), 1380-1386.
Donohue, J.H., Rosenstein, M., Chang, A.E., Lotze, M.T., Robb, R.J., & Rosenberg, S.A. (1984). The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol, 132(4), 2123-2128.Oxford University Press (OUP). doi: 10.4049/jimmunol.132.4.2123.
Grimm, E.A., Vose, B.M., Chu, E.W., Wilson, D.J., Lotze, M.T., Rayner, A.A., & Rosenberg, S.A. (1984). The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues. Cancer Immunol Immunother, 17(2), 83-89.Springer Nature. doi: 10.1007/BF00200041.
Longo, D.L., Steis, R.G., Lane, H.C., Lotze, M.T., Rosenberg, S.A., Preble, O., Masur, H., Rook, A.H., Fauci, A.S., & Jacob, J. (1984). Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results. Ann N Y Acad Sci, 437(DEC), 421-430.Wiley. doi: 10.1111/j.1749-6632.1984.tb37163.x.
Lotze, M.T., & Rosenberg, S.A. (1984). In vivo use of cytokines. Clinical and Applied Immunology Reviews, 5(8), 116-120.Elsevier. doi: 10.1016/s0197-1859(84)80031-x.
LOTZE, M.T., FRANA, L.W., SEIPP, C.A., SHARROW, S.O., & ROSENBERG, S.A. (1984). IMMUNOLOGICAL CHANGES IN PATIENTS WITH CANCER GIVEN INTERLEUKIN-2 (IL-2) IN A PHASE-I TRIAL. SURGICAL FORUM, 35, 407-408.
Lotze, M.T., Robb, R.J., Sharrow, S.O., Frana, L.W., & Rosenberg, S.A. (1984). Systemic administration of interleukin-2 in humans. J Biol Response Mod, 3(5), 475-482.
Ouriel, K., Lotze, M.T., & Hinshaw, J.R. (1984). Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet, 159(4), 373-376.
RAYNER, A.A., GRIMM, E.A., LOTZE, M.T., & ROSENBERG, S.A. (1984). DEMONSTRATION OF SHARED RECOGNITION AND LYSIS OF AUTOLOGOUS AND ALLOGENEIC FRESH HUMAN-TUMORS BY CLONED LYMPHOKINE-ACTIVATED KILLER CELLS. SURGICAL FORUM, 35, 415-417.
Rosenberg, S.A., Rosenstein, M., Grimm, E., Lotze, M., & Mazumder, A. (1984). The Use of Lymphoid Cells Expanded in IL-2 for the Adoptive Immunotherapy of Murine and Human Tumors. In Thymic Hormones and Lymphokines. (pp. 191-207).Springer Nature. doi: 10.1007/978-1-4684-4745-3_19.
Duncan, M.A., Lotze, M.T., Gerber, L.H., & Rosenberg, S.A. (1983). Incidence, recovery, and management of serratus anterior muscle palsy after axillary node dissection. Phys Ther, 63(8), 1243-1247.Oxford University Press (OUP). doi: 10.1093/ptj/63.8.1243.
Harvey, J., Lotze, M., Arnett, F.C., Bias, W.B., Billingsley, L.M., Harvey, E., Hsu, S.H., Sutton, J.D., Zizic, T.M., & Stevens, M.B. (1983). Rheumatoid arthritis in a Chippewa band. II. Field study with clinical serologic and HLA-D correlations. J Rheumatol, 10(1), 28-32.
Lotze, M.T., Marquis, D.M., & Carey, A.S. (1983). Two new assays for the early detection of transplant rejection: IL-2 response and PHA-augmented NK activity. Transplantation Proceedings, 15(3), 1796-1799.
LOTZE, M.T., MARQUIS, D.M., CAREY, A.S., BYER, B.J., HOY, W.E., & MAY, A.G. (1983). 2 NEW ASSAYS FOR THE EARLY DETECTION OF TRANSPLANT REJECTION - IL-2 RESPONSE AND PHA-AUGMENTED NK ACTIVITY. TRANSPLANTATION PROCEEDINGS, 15(3), 1796-1799.
Rosenberg, S.A., Eberlein, T.J., Grimm, E.A., Lotze, M.T., Mazumder, A., & Rosenstein, M. (1982). Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery, 92(2), 328-336.
Bias, W.B., Hsu, S.H., Pollard, M.K., Harvey, J., Lotze, M.T., Arnett, F.C., & Stevens, M.B. (1981). HLA-DR characterization of a Chippewa Indian subpopulation with high prevalence of rheumatoid arthritis. Hum Immunol, 2(2), 155-163.Elsevier. doi: 10.1016/0198-8859(81)90062-8.
Harvey, J., Lotze, M., Stevens, M.B., Lambert, G., & Jacobson, D. (1981). Rheumatoid arthritis in a Chippewa Band. I. Pilot screening study of disease prevalence. Arthritis Rheum, 24(5), 717-721.Wiley. doi: 10.1002/art.1780240515.
Lotze, M.T., & Rosenberg, S.A. (1981). In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. J Immunol, 126(6), 2215-2220.Oxford University Press (OUP). doi: 10.4049/jimmunol.126.6.2215.
LOTZE, M.T., & ROSENBERG, S.A. (1981). INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .3. THE PREPARATION OF LECTIN-FREE T-CELL GROWTH-FACTOR (TCGF) AND AN ANALYSIS OF ITS ACTIVITY. JOURNAL OF IMMUNOLOGY, 126(6), 2215-2220.
Lotze, M.T., Duncan, M.A., Gerber, L.H., Woltering, E.A., & Rosenberg, S.A. (1981). Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg, 193(3), 288-295.Wolters Kluwer. doi: 10.1097/00000658-198103000-00007.
Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L., & Rosenberg, S.A. (1981). Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res, 41(11 Pt 1), 4420-4425.
LOTZE, M.T., GRIMM, E.A., MAZUMDER, A., STRAUSSER, J.L., & ROSENBERG, S.A. (1981). INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .4. LYSIS OF FRESH AND CULTURED AUTOLOGOUS TUMOR BY HUMAN-LYMPHOCYTES CULTURED IN T-CELL GROWTH-FACTOR. CANCER RESEARCH, 41(11), 4420-4425.
Strausser, J.L., Mazumder, A., Grimm, E.A., Lotze, M.T., & Rosenberg, S.A. (1981). Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol, 127(1), 266-271.Oxford University Press (OUP). doi: 10.4049/jimmunol.127.1.266.
Dubois, M., Lotze, M.T., Diamond, W.J., Kim, Y.D., Flye, M.W., & Macnamara, T.E. (1980). Pulmonary shunting during leukoagglutinin-induced noncardiac pulmonary edema. JAMA, 244(19), 2186-2189.American Medical Association (AMA). doi: 10.1001/jama.244.19.2186.
Lotze, M.T., Line, B.R., Mathisen, D.J., & Rosenberg, S.A. (1980). The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol, 125(4), 1487-1493.Oxford University Press (OUP). doi: 10.4049/jimmunol.125.4.1487.
LOTZE, M.T., LINE, B.R., MATHISEN, D.J., & ROSENBERG, S.A. (1980). THE INVIVO DISTRIBUTION OF AUTOLOGOUS HUMAN AND MURINE LYMPHOID-CELLS GROWN IN T-CELL GROWTH-FACTOR (TCGF) - IMPLICATIONS FOR THE ADOPTIVE IMMUNOTHERAPY OF TUMORS. JOURNAL OF IMMUNOLOGY, 125(4), 1487-1493.
Lotze, M.T., Strausser, J.L., & Rosenberg, S.A. (1980). In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J Immunol, 124(6), 2972-2978.Oxford University Press (OUP). doi: 10.4049/jimmunol.124.6.2972.
LOTZE, M.T., STRAUSSER, J.L., & ROSENBERG, S.A. (1980). INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .2. USE OF T-CELL GROWTH-FACTOR (TCGF) TO CLONE HUMAN T-CELLS. JOURNAL OF IMMUNOLOGY, 124(6), 2972-2978.
LOTZE, M.T., STRAUSSER, J.L., LINE, B.R., & ROSENBERG, S.A. (1980). TUMOR LYSIS BY HUMAN LYMPHOCYTES-T IN LONG-TERM CULTURE AND THEIR DISTRIBUTION INVIVO - IMPLICATIONS FOR IMMUNOTHERAPY. SURGICAL FORUM, 31, 404-406.
Dhupar, R., & Lotze, M.T. PD-1 antagonist antibody treatment for patients with oesophageal squamous-cell carcinoma. AME Medical Journal, 2(8), 106.AME Publishing Company. doi: 10.21037/amj.2017.08.03.
Unlu, S., Tang, S., Wang, E.N., Martinez, I., Tang, D., Bianchi, M.E., Zeh, H.J., & Lotze, M.T. Correction: Damage Associated Molecular Pattern Molecule-Induced microRNAs (DAMPmiRs) in Human Peripheral Blood Mononuclear Cells. In Wachsmann, D. (Ed.). PLOS ONE, 7(8), 10.1371/annotation/18ec64ae-e086-446c-b63c-a71fa2bba046.Public Library of Science (PLoS). doi: 10.1371/annotation/18ec64ae-e086-446c-b63c-a71fa2bba046.
Anderko, R.R., Walgren, A., Murthy, P., Bradley, S., Kunning, S., Bahary, N., Singhi, A., Lotze, M., Zeh, H.J.I.I.I., Zureikat, A., & Bruno, T. (2024). Autophagy Inhibition Enhances the Maturation and Activity of Tertiary Lymphoid Structures in Patients with Pancreatic Cancer. In ANNALS OF SURGICAL ONCOLOGY, 31(1), (pp. S28-S29).
Carleton, N., Zou, J., Lee, S., Mary, D.J.S.J., Li, R., Atkinson, J., Huang, Z., Osmanbeyoglu, H., Lucas, P., Diego, E., Lotze, M., Tseng, G., Hooda, J., Zervantonakis, I., McAuliffe, P., Oesterreich, S., & Lee, A. (2024). Age-related remodeling of the systemic and breast microenvironment promotes a tumor-permissive locale for ER plus breast cancer in older women. In CANCER RESEARCH, 84(9).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.SABCS23-PO1-14-09.
Mohammed, M.A., Zureikat, A.H., Lotze, M., Paniccia, A., Lee, K.K., Shogan, J., Vera, A.A., Elgohari, B., Abdelhakiem, M.K., Zhang, J.Y., Burton, S.A., & Ellsworth, S.G. (2024). Stereotactic Body Radiation Following Prior Radiotherapy for Pancreatic Cancer: A Single Institution Experience. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 120(2), (p. E473).Elsevier. doi: 10.1016/j.ijrobp.2024.07.1052.
Vera, A.A., Zureikat, A.H., Lotze, M., Paniccia, A., Lee, K.K., Shogan, J., Elgohari, B., Abdelhakiem, M.K., Mohammed, M.A., Zhang, J.Y., Burton, S.A., & Ellsworth, S.G. (2024). Long-Term Outcomes after Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 120(2), (p. E490).Elsevier. doi: 10.1016/j.ijrobp.2024.07.1086.
Anderko, R.R., Murthy, P., Singhi, A., Paniccia, A., Mailliard, R., Lotze, M., & Zureikat, A. (2023). 341 γδ T cells support pancreatic cancer immunity by enhancing αβ T cell activation. In Regular and Young Investigator Award Abstracts, (p. a390).BMJ. doi: 10.1136/jitc-2023-sitc2023.0341.
Ellsworth, S.G., Ross, A., Shiue, K., Murthy, P., Patel, R.B., Zellars, R.C., Miller, A.C., Russ, K.A., & Lotze, M. (2023). Influence of Radiation Fractionation on Immune Repertoire Diversity in Solid Tumor Patients. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 117(2), (p. S157).Elsevier. doi: 10.1016/j.ijrobp.2023.06.582.
Girda, E., Zsiros, E., Nakayama, J., Whelan, S., Nandakumar, S., Rogers, S., Benson, B., Basile, F.G., Lotze, M.T., Brown, R.J., & Wenham, R.M. (2022). A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies. In JOURNAL OF CLINICAL ONCOLOGY, 40(16).
Girda, E., Zsiros, E., Nakayama, J., Whelan, S., Nandakumar, S., Rogers, S., Benson, B., Lotze, M., Brown, R., & Wenham, R. (2022). A PHASE 1 ADOPTIVE CELL THERAPY USING DRUGENHANCED, TUMOR-INFILTRATING LYMPHOCYTES, DETIL-0255, IN ADULTS WITH ADVANCED MALIGNANCIES. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 10, (p. A701).BMJ. doi: 10.1136/jitc-2022-SITC2022.0671.
Murthy, P., Li, K., Anderko, R.R., Singhi, A.D., DeSilva, A., Chopra, A., Hammad, A.Y., Paniccia, A., Morris, A., Lee, K.K., Mailliard, R.B., Lotze, M.T., Methe, B., & Zureikat, A.H. (2022). Gut microbiota composition and outcomes following neoadjuvant therapy in patients with localized pancreatic cancer: A prospective biomarker study. In JOURNAL OF CLINICAL ONCOLOGY, 40(16).
Murthy, P., Narasappa, N.N., Liang, X., Wu, X., Luu, I., Jeevan, J., Sharma, S., Ross, A., Lampenfeld, C., Zahn, S., Musial, T., Bone, J., Nakayama, J., Bartlett, D., Chapman, J., Garrido, G., Shinners, N., Sands, A., Blackton, M., Wang, E., & Lotze, M. (2022). UNIVERSAL EXPANSION OF CBL-B-INHIBITED TUMOR INFILTRATING LYMPHOCYTES, DETIL-0255, FROM WOMEN WITH OVARIAN CANCER: PROCESS VALIDATION. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 10, (p. A380).BMJ. doi: 10.1136/jitc-2022-SITC2022.0361.
Bone, J., Washburn, N., Han, J., Steele, M., Murthy, P., & Lotze, M. (2021). INTERLEUKIN 2(IL-2) SYSTEMS IMMUNOLOGY MODELING: MACHINE LEARNING FOR CANCER IMMUNOTHERAPY. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(Suppl 2), (p. A375).BMJ. doi: 10.1136/jitc-2021-SITC2021.348.
Dhupar, R., Jones, K., Powers, A., Eisenberg, S., Ding, K., Chen, F., Nasarre, C., Larue, A., Yeh, E., Luketich, J., Lee, A., Oesterreich, S., Lotze, M., Gemmill, R., & Soloff, A. (2021). ISOFORMS OF NEUROPILIN-2 REGULATE DISTINCT MACROPHAGE FUNCTIONS AND ARE ASSOCIATED WITH UNIQUE TUMOR-ASSOCIATED MACROPHAGES IN MURINE AND HUMAN BREAST CANCER. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(Suppl 2), (p. A708).BMJ. doi: 10.1136/jitc-2021-SITC2021.680.
Fei, N., Wen, S., Ramanathan, R., Hogg, M.E., Zureikat, A.H., Lotze, M.T., Bahary, N., Singhi, A.D., Zeh, H.J., & Boone, B.A. (2021). SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. In Clin Transl Sci, 14(5), (pp. 1822-1829).Wiley.United States. doi: 10.1111/cts.13029.
Murthy, P., Weber, D., Sharma, S.N., Saini, P., Pan, W., Byrne-Steele, M., Han, J., Pai, R.K., Zureikat, A.H., Choudry, H.A., & Lotze, M.T. (2021). Shared B cell but not T cell intratumoral immune repertoire among patients with low grade appendiceal mucinous neoplasms. In JOURNAL OF IMMUNOLOGY, 206(1_Supplement).Oxford University Press (OUP). doi: 10.4049/jimmunol.206.supp.109.05.
Murthy, P., Weber, D., Sharma, S.N., Singhi, A.D., Bahary, N., Pan, W., Byrne-Steele, M.L., Han, J., Zeh, H., Bruno, T.C., Zureikat, A.H., & Lotze, M.T. (2021). Intratumoral T cell clonality and survival in a randomized phase II study of preoperative autophagy inhibition in combination with gemcitabine and nab-paclitaxel treatment in patients with resectable pancreatic cancer. In JOURNAL OF CLINICAL ONCOLOGY, 39(15).American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2021.39.15_suppl.e16001.
Murthy, P., Zenati, M.S., AlMasri, S.S., Singhi, A.D., DeSilva, A., Paniccia, A., Lee, K.K., Simmons, R.L., Bahary, N., Lotze, M.T., & Zureikat, A.H. (2021). Impact of G-CSF during neoadjuvant therapy on outcomes of operable pancreatic cancer. In JOURNAL OF CLINICAL ONCOLOGY, 39(15).American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2021.39.15_suppl.4126.
Powers, A.A., Jones, K.E., Eisenberg, S.H., Rigatti, L.H., Luketich, J.D., Lotze, M.T., LaRue, A.C., Dhupar, R., & Soloff, A.C. (2021). Respiratory exposure to putative Gulf War toxins induces phenotypic and transcriptional alterations with effector dysfunction in alveolar macrophages. In JOURNAL OF IMMUNOLOGY, 206(1_Supplement).Oxford University Press (OUP). doi: 10.4049/jimmunol.206.supp.12.20.
Biradar, S., Lotze, M., & Mailliard, R.B. (2020). Immunologic outcomes of bidirectional cross talk between gamma delta T cells and dendritic cells is context dependent. In JOURNAL OF IMMUNOLOGY, 204(1).
Chopra, A., Hodges, J.C., Olson, A., Burton, S., Lee, K.K., Bahary, N., Singhi, A.D., Boone, B., Lotze, M.T., Hogg, M., Bartlett, D., Zeh, H., & Zureikat, A. (2020). Outcomes and Efficacy of Neoadjuvant Chemoradiation Versus Chemotherapy in Localized Pancreatic Cancer: A Case-Control Matched Analysis. In ANNALS OF SURGICAL ONCOLOGY, 27(SUPPL 1), (p. S30).
Chopra, A., Hodges, J.C., Olson, A., Burton, S.A., Lee, K.K., Bahary, N., Singhi, A.D., Boone, B.A., Lotze, M.T., Hogg, M.E., Zeh, H., & Zureikat, A.H. (2020). Outcomes and efficacy of neoadjuvant chemoradiation versus chemotherapy in localized pancreatic cancer. In JOURNAL OF CLINICAL ONCOLOGY, 38(4).
Fei, N., Wen, S., Rao, P., Ramanathan, R., Hogg, M.E., Zureikat, A.H., Lotze, M.T., Bahary, N., Singhi, A.D., Zeh, H., & Boone, B.A. (2020). Association of SMAD4 loss with response to neoadjuvant chemotherapy with the autophagy inhibitor hydroxychloroquine in patients with pancreatic adenocarcinoma. In JOURNAL OF CLINICAL ONCOLOGY, 38(4).
Murthy, P., Russell, P.S.K., Pan, W., Weber, D., Byrne-Steele, M., Han, J., Espina, V., Liotta, L., Zeh, H.I.I.I., Bahary, N., Singhi, A., Bruno, T., Zureikat, A., & Lotze, M. (2020). T CELL INFILTRATING REPERTOIRE DIVERSITY IS ASSOCIATED WITH ENHANCED SURVIVAL FOLLOWING NEOADJUVANT THERAPY IN PATIENTS WITH RESECTABLE PANCREATIC CANCER. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(Suppl 3), (pp. A158-A159).BMJ. doi: 10.1136/jitc-2020-SITC2020.0260.
Yuan, J.M., Yue, W., Wang, R., Admas-Haduch, J., Koh, W.P., Gao, Y.T., & Lotze, M.T. (2020). Serum interleukin-27 serves as an early biomarker predicting development of hepatocellular carcinoma (HCC) in two large prospective cohorts. In CANCER RESEARCH, 80(16).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2020-1050.
Depinet, M., Pan, W., Wu, S.G., Hou, X., Brown, B., Eisenhower, M., Weber, D., Byrne-Steele, M., Lotze, M., & Han, J. (2019). All-in-One, quantitative immune repertoire profiling of PBMC and FFPE for renal cancer treatment evaluation. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7.
Lotze, M.T., Appleman, L.J., Zhai, S., Wang, Y.Y., Forte, A., Pan, W., Byrne-Steele, M.L., & Han, J. (2019). Full adaptome repertoire analysis of immunotherapy to predict responsiveness and correlation with CD8-LAG3, sLAG3, and hepatocyte growth factor levels in patients with renal cancer. In JOURNAL OF CLINICAL ONCOLOGY, 37(15).American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2019.37.15_suppl.e16116.
Soloff, A.C., Stanton, R.A., Radio, N.M., Freilino-Glunt, M., Nasarre, C., Dimou, A., Nasarre, P., Denlinger, C.E., Oesterreich, S., Lee, A.V., Lotze, M.T., Dhupar, R., & Gemmill, R. (2019). Neuropilin-2 Isoforms Regulate Distinct Functions of Tumor-associated Macrophages in Breast Cancer. In JOURNAL OF IMMUNOLOGY, 202(1).
Wang, Y., & Lotze, M.T. (2019). Deep serial analysis of the TCR/BCR CDR3 adaptome repertoire in peripheral blood of pancreatic cancer patients in a randomized study of neoadjuvant chemotherapy with or without autophagy inhibition. In CANCER RESEARCH, 79(13).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.SABCS18-3963.
Wu, R., Chuckran, C., Somasundaram, A., Dhupar, R., Nason, K., Soloff, A., Lotze, M., Lampenfeld, C., Kunning, S., Bruno, T., & Vignali, D. (2019). PD1+T regulatory cells in metastatic cancer patients co-express CD39 and exhibit attenuated suppressive function due to decreased survival. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7.
Appleman, L.J., Logan, T.F., Normolle, D.P., Ernstoff, M.S., Parikh, R.A., McDermott, D.F., Monk, P., Olencki, T., Friedland, D., Maranchie, J.K., Butterfield, L.H., Liang, X., & Lotze, M.T. (2018). Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study. In JOURNAL OF CLINICAL ONCOLOGY, 36(5).American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2018.36.5_suppl.106.
Appleman, L.J., Normolle, D.P., Logan, T.F., Monk, P., Olencki, T., McDermott, D.F., Ernstoff, M.S., Maranchie, J.K., Parikh, R.A., Friedland, D., Zeh, H., Liang, X., Butterfield, L.H., & Lotze, M.T. (2018). Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study. In JOURNAL OF CLINICAL ONCOLOGY, 36(15).American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2018.36.15_suppl.4573.
Murthy, P., Lotze, M.T., Neal, M.D., Whitcomb, D.C., Papachristou, G.I., Zureikat, A.H., Zeh, H.J., & Boone, B.A. (2018). PAD4 Mediated Neutrophil Extracellular Traps (NETs) Promote Platelet Aggregation and Worsen Severity of Acute Pancreatitis. In PANCREAS, 47(10), (p. 1412).
Boone, B.A., Miller-Ocuin, J.L., Doerfler, W., Ellis, J.T., Lotze, M.T., Neal, M.D., & Zeh, H.J. (2017). Neutrophil Extracellular Traps Promote Hypercoagulability in Cancer Through Release of Tissue Factor and Platelet Aggregation. In ANNALS OF SURGICAL ONCOLOGY, 24, (pp. S110-S111).
Karyampudi, L., Gokuldass, A., Blaskovich, M., Fardis, M., & Lotze, M.T. (2017). Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma. In ANNALS OF ONCOLOGY, 28.
Miller-Ocuin, J.L., Bahary, N.S., Singhi, A.D., Normolle, D.P., Lembersky, B., Stoller, R., Sun, W., Ahrendt, S., Hogg, M., Lee, K., Bartlett, D., Marsh, J., Tsung, A., Zureikat, A.H., Boone, B.A., Lotze, M.T., & Zeh, H.J. (2017). Inhibition of Autophagy Improves Pathologic and Biomarker Response to Preoperative Gemcitabine/Nab-Paclitaxel in Potentially Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial. In ANNALS OF SURGICAL ONCOLOGY, 24, (p. S6).
Sarnaik, A., Kluger, H.M., Chesney, J.A., Sethuraman, J., Veerapathran, A., Simpson-Abelson, M., Lotze, M.T., Larsen, B., Fischkoff, S.A., Suzuki, S., Wang, L., Mirgoli, M., Fardis, M., & Curti, B.D. (2017). Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy. In JOURNAL OF CLINICAL ONCOLOGY, 35(15_suppl).American Society of Clinical Oncology (ASCO). doi: 10.1200/JCO.2017.35.15_suppl.3045.
Simpson-Abelson, M.R., Mosychuk, C., Fardis, M., & Lotze, M.T. (2017). Emigrant pre-REP tumor infiltrating lymphocytes profoundly differ from remnant T-cells. In CANCER RESEARCH, 77(13_Supplement).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2017-649.
Wardell, S., Fardis, M., Lotze, M.T., Frank, I., Stramer, A., Sethuraman, J., Bender, J., Abelson, M., & Karyumpudi, L. (2017). A cryopreserved TIL product, LN-144, generated with an abbreviated method suitable for high throughput commercial manufacturing exhibits favorable quality attributes for adoptive cell transfer. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5.
Grant, K., Ahmed, R., Lotze, M., Anderson, C., & Mountz, J. (2016). 18F-ML10 PET/CT demonstrates therapy-induced apoptosis in murine pancreatic adenocarcinoma. In JOURNAL OF NUCLEAR MEDICINE, 57.
Grant, K., Ahmed, R., Lotze, M., Anderson, C., & Mountz, J. (2016). 18F-ML10 PET/CT demonstrates therapy-induced apoptosis in murine pancreatic adenocarcinoma. In JOURNAL OF NUCLEAR MEDICINE, 57.
Grant, K., Miller, J., Lotze, M., Bahary, N., Singhi, A., Kurland, B., Zeh, H., & Mountz, J. (2016). Value of FDG PET/CT in early response assessment of neoadjuvant chemotherapy for patients with pancreatic adenocarcinoma. In JOURNAL OF NUCLEAR MEDICINE, 57.
Wang, Q., Miskov-Zivanov, N., Liu, B., Faeder, J.R., Lotze, M., & Clarke, E.M. (2016). Formal Modeling and Analysis of Pancreatic Cancer Microenvironment. In Lecture Notes in Computer Science, 9859, (pp. 289-305).Springer Nature. doi: 10.1007/978-3-319-45177-0_18.
Ahmed, R., Beaino, W., Lotze, M., Anderson, C., & Mountz, J. (2015). Monitoring response to Hydroxychloroquine (HCQ) in xenograft mouse model with [18F] ML-10 apoptosis molecular imaging probe. In JOURNAL OF NUCLEAR MEDICINE, 56(3).
Grant, K., Zeh, H., Miller, J., Laymon, C., Lotze, M., & Mountz, J. (2015). FDG PET analysis of treatment response in patients with pancreatic adenocarcinoma randomized to preoperative therapy with or without hydroxychloroquine. In JOURNAL OF NUCLEAR MEDICINE, 56(3).
Li, G., Vernon, P.J., van Houten, B., Liang, X., & Lotze, M.T. (2015). HMGB1 regulates natural killer (NK) cell metabolism and cross-talk with dendritic cells (DCs). In CANCER RESEARCH, 75(1).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.CHTME14-B08.
Basse, P., Fan, R., Bailey, L., Wynn, J., & Lotze, M. (2014). Nk cells induce tumor cell resistance to Nk cell cytolysis. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.71.42.
Boone, B.A., Lotze, M.T., Zureikat, A.H., Bahary, N., Singhi, A.D., Bartlett, D.L., Espina, V., Liotta, L.A., & Zeh, H.J. (2014). Phase I/II Trial of Autophagy Inhibition in Combination with Neoadjuvant Gemcitabine in High-risk Pancreatic Adenocarcinoma: Safety, Clinical Response, and Correlative Studies. In ANNALS OF SURGICAL ONCOLOGY, 21, (p. S7).
Brancho, M., Chang, Y., Zhang, X., Okada, H., Li, A., Grandi, P., Lotze, M., & Amankulor, N. (2014). IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS. In NEURO-ONCOLOGY, 16(suppl_5).Oxford University Press (OUP). doi: 10.1093/neuonc/nou257.3.
Kang, R., Zhang, Q., Hou, W., Chen, R., Lotze, M., Zeh, H., & Tang, D. (2014). HMGB1 regulates pancreatic cancer initiation and pogression. In CANCER RESEARCH, 74(19).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2014-2031.
Kron, F., Glossmann, J.P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., von Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K.A., Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Hallek, M., & Wolf, J. (2014). A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany. In ONCOLOGY RESEARCH AND TREATMENT, 37, (p. 95).
Li, G., Liang, X., Kaus, J., Basse, P., Zeh, H., & Lotze, M. (2014). Natural killer (NK) cell high-mobility group box 1 (HMGB1) is required for anti-tumor function. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.71.19.
Liang, X., Li, G., Vernon, P., Buchser, W., Loughran, P., Basse, P., Zeh, H., & Lotze, M. (2014). Endogenous NK cell HMGB1 is central to HDIL-2 induced systemic autophagy. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.73.8.
Lotze, M.T., Boone, B.A., Zureikat, A.H., Bahary, N., Lehman, D., Liotta, L.A., & Zeh, H.J. (2014). Phase I/II trial of autophagy inhibition in combination with neoadjuvant gemcitabine in patients with high-risk pancreatic adenocarcinoma: Safety, clinical response, and correlative studies. In JOURNAL OF CLINICAL ONCOLOGY, 32(3).American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2014.32.3_suppl.218.
Tang, D., Kang, R., Lotze, M., & Zeh, H. (2014). Endogenous HMGB1 prevents nuclear catastrophe and proinflammatory nucleosomal release. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.128.2.
Vernon, P., Liang, X., Wang, W., Schapiro, N., Lowe, D., Billiar, T., Zeh, H., & Lotze, M. (2014). Genomic ablation of HMGB1 in dendritic cells mitigates their capacity to both promote carcinogenesis and effectively confer anti-tumor immunity as vaccines. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.138.20.
Wang, W., Vernon, P., Li, G., Billiar, T., Sampath, P., Stephen, T., Morelli, A., Liang, X., & Lotze, M. (2014). DC-specific HMGB1 KO mice clear vaccinia viral infection more effectively. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.144.1.
Zhang, X., Chang, Y., Brancho, M., Kohanbash, G., Leo, M., Okada, H., Lotze, M., & Amankulor, N. (2014). Isocitrate dehydrogenase mutant glial cell resist natural killer cell cytotoxicity. In JOURNAL OF IMMUNOLOGY, 192(Supplement_1).Oxford University Press (OUP). doi: 10.4049/jimmunol.192.supp.71.30.
Zhu, X., Messer, J.S., Wang, Y., Lin, F., Cham, C.M., Chang, J., Billiar, T., Lotze, M.T., Boone, D.L., & Chang, E.B. (2014). HMGB1 Controls the Intestinal Epithelial Autophagy/Apoptosis Checkpoint During Mucosal Inflammation and IBD. In GASTROENTEROLOGY, 146(5), (p. S283).
Bauer, E., Zheng, H., Bauer, P., & Lotze, M. (2013). Successful immunotherapy with interleukin 2 for hypoxia-induced pulmonary hypertension. In JOURNAL OF IMMUNOLOGY, 190.
Bauer, E., Zheng, H., Lotze, M.T., & Bauer, P.M. (2013). Chloroquine, A Pharmacological Inhibitor Of Autophagy, Attenuates Hypoxia-Induced Pulmonary Hypertension. In AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 187.
Lotze, M., Vernon, P., Li, G., & Liang, X. (2013). High-mobility group box 1 promotes NK and DC function as well as crosstalk: studies of selective knockout in immune cells. In JOURNAL OF IMMUNOLOGY, 190.
Kang, R., Tang, D., Schapiro, N.E., Lotze, M.T., & Zeh, H.J. (2012). Abstract B96: The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. In Tumor Biology, (p. b96).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.panca2012-b96.
Keyel, P., Vernon, P., Chu, J., Lotze, M., & Salter, R. (2012). HMGB1 facilitates inflammasome-dependent IL-1β release. In JOURNAL OF IMMUNOLOGY, 188.
Lotfi, R., Lotze, M.T., Eisenbacher, J., Herzog, G., Wiegmann, D.S., & Schrezenmeier, H. (2012). Necrosis and oxidation as counterparts within the tumor microenvironment. In INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 30, (p. S18).
Lotze, M.T., Appleman, L.J., Ramanathan, R.K., Tolcher, A.W., Beeram, M., Papadopoulos, K.P., Rasco, D.W., Weiss, G.J., Mountz, J.M., Toledo, F.G.S., Alvarez, R.J., Oborski, M.J., Rajagopalan, P., Jeffers, M., Roth, D., Dubowy, R.L., & Patnaik, A. (2012). Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. In JOURNAL OF CLINICAL ONCOLOGY, 30(15).
Patnaik, A., Ramanathan, R.K., Appleman, L.J., Tolcher, A.W., Mountz, J.M., Beerham, M., Weiss, G.J., Rasco, D.W., Lotze, M.T., Toledo, F.G.S., Oborski, M.J., Rajagopalan, P., Jeffers, M., Kelly, A., & Genvresse, I. (2012). Phase I Study of Intravenous PI3K Inhibitor Bay 80-6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort. In BLOOD, 120(21).American Society of Hematology. doi: 10.1182/blood.V120.21.3704.3704.
Patnaik, A., Ramanathan, R.K., Dubowy, R., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Mountz, J.M., Rasco, D., Lotze, M.T., Laymon, C., Rajagopalan, P., Carrizales, G., Rankin, N., Hull, L., Jeffers, M., Roth, D., & Appleman, L.J. (2012). THE EVOLUTION OF PI3 KINASE INHIBITORS: RESULTS OF A FIRST-IN-HUMAN PHASE I STUDY OF BAY80-6946 IN ADVANCED SOLID TUMORS. In ANNALS OF ONCOLOGY, 23, (p. 16).
Gong, H., Wang, Q., Zuliani, P., Faeder, J., Lotze, M., & Clarke, E. (2011). Symbolic model checking of signaling pathways in pancreatic cancer. In 3rd International Conference on Bioinformatics and Computational Biology 2011, BICoB 2011, (pp. 245-250).
Kim, S.D., Pribis, J., Barclay, D., Shapiro, R., Lotze, M., Scott, M., & Billiar, T.R. (2011). HMGB1, TLR4 DEPENDENT AND INDEPENDENT INFLAMMATORY SIGNALING AND CYTOKINE RESPONSES. In SHOCK, 35, (p. 81).
Patnaik, A., Appleman, L.J., Mountz, J.M., Ramanathan, R.K., Beeram, M., Tolcher, A.W., Papadopoulos, K.P., Lotze, M.T., Petro, D.P., Laymon, C., Paige, L., Rajagopalan, P., Jeffers, M., Roth, D., & Dubowy, R.L. (2011). A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. In JOURNAL OF CLINICAL ONCOLOGY, 29(15).
Buchser, W., Laskow, T., Loux, T., Kalinski, P., Basse, P., Zeh, H., & Lotze, M. (2010). Peripheral Blood Lymphocytes Induce Survival and Autophagy in Human Renal and Bladder Carcinoma Cell Lines. In JOURNAL OF IMMUNOTHERAPY, 33(8), (p. 885).
Buchser, W., Loux, T., Kalinski, P., Basse, P., Zeh, H., & Lotze, M. (2010). Peripheral Blood Lymphocytes Induce Autophagy in Human Renal and Hepatocellular Carcinoma Cell Lines. In CLINICAL IMMUNOLOGY, 135, (p. S104).Elsevier. doi: 10.1016/j.clim.2010.03.311.
Kang, R., Tang, D., Lotze, M.T., & Zeh, H.J. (2010). Receptor for advanced glycation endproducts (RAGE) regulates β-catenin function and chemosensitivity in pancreatic cancer cells. In CANCER RESEARCH, 70(8_Supplement).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM10-4674.
Liang, X., de Vivar Chavaz, A.R., Schapiro, N.E., Thorne, S.H., Wang, T., van Houten, B., Lotze, M.T., & de Vera, M. (2010). Altering tumor cell metabolism may contribute to the antitumor activity of ethyl pyruvate. In CANCER RESEARCH, 70(8_Supplement).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM10-60.
Tang, D., Kang, R., Zeh, H.J., & Lotze, M.T. (2010). Inhibition of high-mobility group box 1 protein (HMGB1) release sensitizes cancer cells to chemotherapy. In CANCER RESEARCH, 70(8_Supplement).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM10-4854.
Brown, B.N., Daly, K.A., Lotze, M.T., & Badylak, S.F. (2009). The role of DAMPs in the host immune and remodeling response to xenogeneic biologic scaffold materials. In JOURNAL OF IMMUNOLOGY, 182(1_Supplement).Oxford University Press (OUP). doi: 10.4049/jimmunol.182.supp.141.27.
John, E., Buchser, W., Pitt, B., & Lotze, M. (2009). Damage and Pathogen-associated Molecular Pattern Molecules Decrease Cytoplasmic Zinc in Human Dendritic Cells and Promote High Mobility Group B1 Cytosolic Translocation. In JOURNAL OF IMMUNOTHERAPY, 32(9), (p. 982).
Kang, R., Tang, D., Loux, T., Schapiro, N., Lotze, M., & Zeh, H. (2009). The Receptor for Advanced Glycation End Products (RAGE) Promotes Activation of the Inflammasome in Murine Macrophages. In CLINICAL IMMUNOLOGY, 131, (pp. S107-S108).Elsevier. doi: 10.1016/j.clim.2009.03.314.
Liang, X., Romo-de Vivar, A., Wang, T., Schapiro, N.E., Van Houten, B., Amoscato, A.A., Zeh, H.J., Lotze, M.T., & de Vera, M.E. (2009). Ethyl Pyruvate Administration Inhibits Hepatic Metastases and Alters Tumor Cell Metabolism. In JOURNAL OF IMMUNOTHERAPY, 32(9), (pp. 989-990).
Liang, X., Schapiro, N., de Vivar, A.R., Fink, M., Zeh, H., Lotze, M., & de Vera, M. (2009). Ethyl pyruvate administration decreases autophagy in hepatic metastatic tumors. In CANCER RESEARCH, 69.
Livesey, K.M., Tang, D., Loughtan, P., Buchsler, W., & Lotze, M.T. (2009). Cyclic Pifithrin-α Decrease High-mobility Group Box-1 Expression and Increases Cell Viability, ATP Conservation, IIMGB1 Translocation, and Autophagy. In JOURNAL OF IMMUNOTHERAPY, 32(9), (p. 990).
Lotfi, R., Herzog, G.I., DeMarco, R.A., Beer-Stolz, D., Lee, J.I., Rubartelli, A., Schrezenmerer, H., & Lotze, M.T. (2009). Eosinophilic Granulocytes Modulate Tumor Microenvironment by Oxidizing Damage-associated Molecular Pattern Molecules Derived From Necrotic Tumor Cells. In JOURNAL OF IMMUNOTHERAPY, 32(9), (p. 990).
Okada, H., Ueda, R., Kohanbash, G., Sasaki, K., Fujita, M., Zhu, X., Lotze, M.T., Sobol, R.W., & Khan, S.A. (2009). DICER-REGULATED MICRORNAS 222 AND 339 PROMOTE IMMUNE ESCAPE OF CANCER CELLS THROUGH DOWNREGULATION OF ICAM-1. In NEURO-ONCOLOGY, 11(2), (p. 225).
Tang, D., Kang, R., Loux, T., Cheh, C.W., Zeh, H., & Lotze, M. (2009). The Receptor for Advanced Glycation End Products (RAGE)Regulates Nuclear Transcription Factor κB (NF-κB) Activation. In CLINICAL IMMUNOLOGY, 131, (p. S108).Elsevier. doi: 10.1016/j.clim.2009.03.316.
Turner, J., Sparvero, L., Amoscato, A., & Lotze, M. (2009). Novel Dual-luminescence Biolayer Interferometry Assay to Measure the Damage Associated Molecular Pattern Molecule HMGB1 in Serum. In CLINICAL IMMUNOLOGY, 131, (p. S48).Elsevier. doi: 10.1016/j.clim.2009.03.135.
Ueda, R., Kohanbash, G., Sasaki, K., Fujita, M., Zhu, X., Kastenhuber, E.R., McDonald, H.A., Potter, D.M., Lotze, M.T., Khan, S.A., Sobol, R.W., & Okada, H. (2009). DICER-REGULATED MICRORNAS 222 AND 339 PROMOTE RESISTANCE OF CANCER CELLS TO CYTOTOXIC T-LYMPHOCYTES BY DOWNREGULATING ICAM-1 EXPRESSION. In NEURO-ONCOLOGY, 11(6), (p. 962).
Wong, J.I., Giermasz, A., Mailliard, R.B., Muthuswamy, R., Wieckowski, E., Lotze, M.T., & Kalinski, P. (2009). Powerful Induction of Natural Killer Cell Tumoricidal Functions by Type-1 Polarized Dendritic Cell: Positive Feedback Between DC and NK Cells. Poster session presented at the meeting of Annual Meeting, International Society for Biological Therapy of Cancer.National Harbor, MD.
Yu, S., Wynn, J., Fischer, A., Rich, J., Lotze, M.T., & Basse, P.H. (2009). Synergistic Killing of Tumor Cells by IL-2 activated NK Cells and Tumor-specific CTLs. In JOURNAL OF IMMUNOTHERAPY, 32(9), (pp. 950-951).
Farkas, A.M., & Lotze, M.T. (2008). Autophagic stress in cocultured cells induces translocation of HMGB1 from the nucleus to the cytosol of macrophages in vitro. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A21).
Goding, S., Yang, Q., Kublo, L., Bailey, L., Kalinski, P., Lotze, M.T., & Basse, P. (2008). Supernatants from IL-12 gene-transduced, IL-2-activated NK cells suppress expression of TLR4 and RAGE by tumor cells. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A13).
Hanse, C., Lotze, M.T., DeMarco, R., Horvath, K., Gouttefangeas, C., Demetris, A., Day, R., Pereira, P., Shakil, O., Amoscato, A.A., & DeVera, M.E. (2008). High mobility group B1 matures dendritic cells and is a DAMP elevated in the serum of hepatoma patients with chronic hepatitis C diminishing following resection and orthotopic liver transplantation or radiofrequency ablation [RFA]. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (pp. A24-A25).
Kang, R., Tang, D., Schapiro, N., Lotze, M., & Zeh, H. (2008). The receptor for advanced glycation end products (RAGE) is associated with the tumor cell response to stress. In CLINICAL IMMUNOLOGY, 127, (p. S147).Elsevier. doi: 10.1016/j.clim.2008.03.421.
Kang, R., Tang, D., Schapiro, N., Loughran, P., Farkas, A.M., Lotze, M.T., & Zeh, H.J. (2008). The inflammatory receptor RAGE shRNA increases sensitivity of a pancreatic tumor cell line to chemotherapy in vitro. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (pp. A10-A11).
Liang, X., Farkas, A., Schapiro, N., Zeh, H., Lotze, M.T., & de Vera, M.E. (2008). The damage associated molecular pattern molecule (DAMP) HMGB1 stimulates hepatic stellate cell (HSC) activation. In AMERICAN JOURNAL OF TRANSPLANTATION, 8, (p. 578).
Livesey, K., Tang, D., Loughran, P., Hoppe, G., Bianchi, M., & Lotze, M.T. (2008). Imaging intracellular HMGB1 during autophagic flux. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A25).
Lotze, M., Farkas, A., Tang, D., Hughes, J., Kilgore, T., Tang, S., Unlu, S., Popovich, P., Lotfi, R., & Zeh, H. (2008). Immune cells and response to DAMPs in cancer. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A9).
Sadik, A.O., Turner, J.L.H., Kilgore, T.M., Farkas, A.M., & Lotze, M.T. (2008). Comparative analysis of biolayer interferometry, small-volume spectrophotometry, and intercalating fluorometric assays for the detection of DNA in serum. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A34).
Schapiro, N., Liang, X., Kang, R., Lotze, M.T., DeVera, M.E., & Zeh, H.J. (2008). Ethyl pyruvate enhances the antitumor effects of chemotherapy. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (pp. A27-A28).
Sun, S., Bencherif, S.A., Farkas, A.M., Lotze, M.T., & Washburn, N.R. (2008). Development of cytokine-regulating matrices. In WOUND REPAIR AND REGENERATION, 16(2), (p. A16).
Tang, D., Kang, R., Farkas, A., & Lotze, M. (2008). The damage associated molecular pattern molecule [DAMP] high mobility group box protein-1 [HMGB1] is an activator of autophagy driving immunity. In CLINICAL IMMUNOLOGY, 127, (p. S37).Elsevier. doi: 10.1016/j.clim.2008.03.099.
Tang, D., Kang, R., Loughran, P., Farkas, A.M., Zeh, H.J., & Lotze, M.T. (2008). The damage associated molecular pattern molecule [DAMP] High Mobility Group Box protein-1 [HMGB1] is an activator of autophagy. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (pp. A19-A20).
Tang, S., Farkas, A.M., Unlu, S., & Lotze, M.T. (2008). Identification of sentinel cell phenotypic changes [CD4] in response to DAMPs. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A30).
Ueda, R., Kohanbash, G., Sasaki, K., Fujita, M., Zhu, X., Lotze, M., Sobol, R., Khan, S., & Okada, H. (2008). DICER-REGULATED MICRORNAS 222 AND 339 PROMOTE IMMUNE-ESCAPE OF GLIOMA CELLS THROUGH DOWN REGULATION OF ICAM-1. In NEURO-ONCOLOGY, 10(5), (p. 807).
Ueda, R., Kohanbash, G., Sasaki, K., Fujita, M., Zhu, X., Lotze, M., Sobol, R., Khan, S., & Okada, H. (2008). ADDRESSING THE ANGIOGENIC SWITCH BY STUDYING TUMOR-HOST INTERACTIONS IN AN ANIMAL MODEL OF GLIOBLASTOMA MULTIFORME. In NEURO-ONCOLOGY, 10(5), (p. 807).
Unlu, S., Zeh, H., & Lotze, M. (2008). MiR-155 is upregulated by HMGB1 in MEF-derived damage associated molecular pattern molecules [DAMPs]. In CLINICAL IMMUNOLOGY, 127, (p. S154).Elsevier. doi: 10.1016/j.clim.2008.03.442.
Unlu, S., Zeh, H.J., & Lotze, M.T. (2008). Overexpression of miR-155 in human peripheral blood mononuclear cells down-regulates RAGE and TLR4 expression. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (pp. A16-A17).
Washburn, N.R., Sun, S., Bencherif, S.A., Farkas, A., & Lotze, M.T. (2008). Local regulation of inflammation in wound healing responses. In 8th World Biomaterials Congress 2008, 4, (p. 2162).
Yang, H., Nasu, M., Bocchetta, M., Pass, H., Franzoso, G., Lotze, M.T., & Carbone, M. (2008). Asbestos-induced human mesothelial cell death causes the release of HMGB1 and resultant inflammation. In JOURNAL OF LEUKOCYTE BIOLOGY, 84(2), (p. A30).
Yang, H., Nasu, M., Bocchetta, M., Pass, H.I., Franzoso, G., Lotze, M., & Carbone, M. (2008). Asbestos-induced Human Mesothelial Cell Death Causes the Release of HMGB1 and Resultant Inflammation. In JOURNAL OF IMMUNOTHERAPY, 31(9), (p. 932).
Yang, Q., Herberman, R.B., Lotze, M.T., Kalinski, P., & Basse, P.H. (2008). Anti-tumor effect by dendritic cells stimulated with IL-2 in OT-1 model. In FASEB JOURNAL, 22(S1).Wiley. doi: 10.1096/fasebj.22.1_supplement.1076.1.
Lotfi, R., Demarco, R.A., Steitz, J., & Lotze, M.T. (2007). Eosinophils induce dendritic cell maturation: Implications for regulation of immunity. In INFLAMMATION RESEARCH, 56, (pp. S98-S99).
Lotze, M.T. (2007). Interleukin 1 family members regulate tumor immunity in response to damage associated molecular pattern molecules [DAMPS]. In JOURNAL OF IMMUNOTHERAPY, 30(8), (p. 876).
Lotze, M.T., Zeh, H.J., Billiar, T.R., Kalinski, P., Vakkila, J., Hoffman, R., DeMarco, R., Tsung, A., Lotfi, R., Ito, N., & Rubartelli, A. (2007). Cancer immunotherapy: TLRs, NLRs, and RLRs. In ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 57(1), (pp. 68-69).
Matsuoka, K., Dave, S., Tilstra, J., Li, F., DeMarco, R., Fink, M., Lotze, M., & Plevy, S. (2007). PAMPs and DAMPs in IBD. In INFLAMMATORY BOWEL DISEASES, 13(5), (p. 643).Oxford University Press (OUP). doi: 10.1097/00054725-200705001-00003.
Mollen, K.Mollen, K., Kaczorowski, D., Yoneyama, T., Vallabhaneni, R., Kilgore, T., Bo, M., Lotze, M., & Billiar, T. (2007). MD2 and CD14 mediate toll-like receptor 4 (TLR4) activation by high mobility group box 1 (HMGB1). In JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 205(3), (p. S28).Wolters Kluwer. doi: 10.1016/j.jamcollsurg.2007.06.063.
DeMarco, R., Yang, S., Ito, N., Guo, Z., Zeh, H.J., & Lotze, M.T. (2006). Imaging cytometric assessment of apoptosis, autophagy, and necrosis. In JOURNAL OF IMMUNOTHERAPY, 29(6), (p. 660).
Ito, N., DeMarco, R., & Lotze, M. (2006). Successful identification of necrotic cell death at the single cell level: Flow cytometric analysis of high mobility group B1 and histone H1. In CLINICAL IMMUNOLOGY, 119, (p. S127).Elsevier. doi: 10.1016/j.clim.2006.04.295.
Ostberg, T., Palmblad, K., Wahamaa, H., Shoshan, M., Lotze, M., Andersson, U., & Harris, H.E. (2006). Anti-rheumatic and HMGB1 blocking effects of oxaliplatin. In CLINICAL IMMUNOLOGY, 119, (pp. S48-S49).Elsevier. doi: 10.1016/j.clim.2006.04.423.
Chen, Y., Wang, L.F., Wu, W.H., Lotze, M.T., Fung, J.J., Lu, L.N., & Qian, S. (2005). TLR9 agonist differentially stimulates liver myeloid dendritic cells resulting in T cell hyporesponsiveness. In AMERICAN JOURNAL OF TRANSPLANTATION, 5, (pp. 293-294).
Dave, S.H., DeMarco, R.A., Yang, H., Tracey, K.J., Fink, M.P., Lotze, M.T., & Plevy, S.E. (2005). Hmgb1 is an endogenous danger signal in inflammatory bowel disease. In GASTROENTEROLOGY, 128(4), (p. A651).
Eto, M., Hunter, O.C., Lotze, M.T., Naito, S., & Amoscato, A.A. (2005). A protective role of phosphatidylglycerol against apoptosis induced by androgen ablation in prostate cancer cells. In JOURNAL OF UROLOGY, 173(4), (p. 112).Wolters Kluwer. doi: 10.1016/S0022-5347(18)34664-0.
Ito, N., DeMarco, R.A., & Lotze, M.T. (2005). Flow cytometric assessment of HMGB1 and histone H1 release during tumor cell death following in vitro treatment. In JOURNAL OF IMMUNOTHERAPY, 28(6), (p. 621).Wolters Kluwer. doi: 10.1097/01.cji.0000190976.77975.48.
Langer, C., Chen, Y., Liang, X.Y., Zheng, N., Lotze, M., Geller, D., Qian, S., Lu, L., & de Vera, M. (2005). Human CD11c+ intrahepatic dendritic cells (IHDC) are immunogenic by nature. In JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 201(3), (p. S92).Wolters Kluwer. doi: 10.1016/j.jamcollsurg.2005.06.218.
Lotfi, R., DeMarco, R.A., & Lotze, M.T. (2005). Eosinophil survival and chemotaxis are enhanced by HMGB1: Implications for the immunotherapy of cancer. In JOURNAL OF IMMUNOTHERAPY, 28(6), (p. 624).Wolters Kluwer. doi: 10.1097/01.cji.0000190983.54212.70.
Lotze, M.T., DeMarco, R.A., Horvath, K., Gouttefangeas, C., Demetris, A.J., DeVera, M.E., Day, R., Pereira, P.L., & Shakil, O. (2005). High mobility group B1 matures dendritic cells and is a DAMP elevated in the serum of hepatoma patients with chronic hepatitis C diminishing following resection and orthotopic liver transplantation or Radiofrequency ablation [RFA]. In JOURNAL OF IMMUNOTHERAPY, 28(6), (pp. 627-628).Wolters Kluwer. doi: 10.1097/01.cji.0000190995.55998.ad.
Montag, D.T., & Lotze, M.T. (2005). Don't judge a cell by its surface only: Combination with functional assays. In CLINICAL IMMUNOLOGY, 115, (pp. S71-S72).
Vakkila, J., Jaffe, R., Michelow, M., & Lotze, M.T. (2005). Pediatric cancers are infiltrated predominantly by macrophages and dendritic cells are lacking. In JOURNAL OF IMMUNOTHERAPY, 28(6), (p. 637).Wolters Kluwer. doi: 10.1097/01.cji.0000191027.28663.51.
Winikoff, S.E., Popovic, P., DeMarco, R.A., Dong, E., Lotze, M.T., Bartlett, D.L., & Zeh, H.J. (2005). rHMGB-1 inhibits IFNα release from plasmacytoid dendritic cells and blocks Th-1 responses. In ANNALS OF SURGICAL ONCOLOGY, 12(2), (p. S50).
Zheng, N., Wang, Y., Lu, Z., Wang, L.F., Lotze, M.T., Fung, J.J., Qian, S., & Lu, L.N. (2005). TLR ligation-mediated diviation of cytokine profile in liver dendritic cells: An insight into immune regulation in the liver. In AMERICAN JOURNAL OF TRANSPLANTATION, 5, (p. 436).
DeMarco, R., Christ, L., Wright, E., Montag, D., & Lotze, M. (2004). ATP and HMGB1 act as endogenous danger signals in cancer. In JOURNAL OF IMMUNOTHERAPY, 27(6), (p. S14).Wolters Kluwer. doi: 10.1097/00002371-200411000-00054.
Guo, Z.S., Naik, A., Hu, Y., DeMarco, R., O'Malley, M., Alexander, R., Moss, B., Lotze, M., & Bartlett, D.L. (2004). Systemic cancer therapy with an enhanced tumor-selective vaccinia virus lacking anti-apoptosis viral genes Spi-2 and Spi-1. In MOLECULAR THERAPY, 9, (p. S27).
Lotze, M.T. (2004). HMGB1 and tumor immunology. In SHOCK, 21(Supplement), (p. 36).Wolters Kluwer. doi: 10.1097/00024382-200403001-00143.
Lotze, M.T., Tahara, H., Storkus, W.J., Whiteside, T.L., Hall, T., Kinzler, D., & Zeh, H.J. (2004). Ten year experience and followup of effective gene therapy in patients with cancer. In ANNALS OF SURGICAL ONCOLOGY, 11(2), (pp. S78-S79).Springer Nature. doi: 10.1007/BF02524058.
Tao, R., Lu, L.N., Wang, S.H., Demarco, R., Lotze, M.T., Fung, J.J., & Qian, S.G. (2004). Immature dendritic cells plus subdosing sirolimus achieve long-term allograft survive. A mechanistic insight. In AMERICAN JOURNAL OF TRANSPLANTATION, 4, (p. 406).
Winikoff, S., Lokshin, A., Landsittel, D., Lee, K.L., Moser, A.J., Schraut, W.H., Lotze, M.T., Bartlett, D.L., & Zeh, H.J. (2004). A novel method of pancreatic cancer detection by simultaneous analysis of multiple serum markers. In ANNALS OF SURGICAL ONCOLOGY, 11(2), (p. S114).Springer Nature. doi: 10.1007/BF02524171.
DeMarco, R., Fink, M., & Lotze, M. (2003). HMGB1 promotes macrophage dependent production of interferon gamma by human NK cells: Cellular synergy. In JOURNAL OF IMMUNOTHERAPY, 26(6), (p. S2).
Lotze, M., DeMarco, R., & Vakkila, J. (2003). Inhibition of the growth promoting death signals in tumor biology: A hypothesis. In JOURNAL OF IMMUNOTHERAPY, 26(6), (p. S27).
Lotze, M., Winikoff, S., DeMarco, R., Lu, L.N., Zeh, H., & Vakkila, J. (2003). YOYO-1 as a measure of tumor cytolysis by activated NK: Strategies for evaluation of the adoptive immunotherapy of cancer patients. In JOURNAL OF IMMUNOTHERAPY, 26(6), (p. S21).
Lotze, M.T., Gambotto, A., Kumar, S., Jonak, Z.L., Vakkila, J., & Kalinski, P. (2003). The IL-1 family members regulate the acute inflammatory response to melanoma. In CANCER GENE THERAPY, 10, (pp. S33-S34).
Amoscato, A.A., Matsko, C., Rabinowich, H., & Lotze, M. (2001). Mitochondrial lipid alterations during apoptosis of Jurkat cells. In FASEB JOURNAL, 15(4), (p. A511).
Egawa, S., Mailliard, R., & Lotze, M.T. (2000). Peripheral blood monocytes derived dendritic cells generated with interferon-α and granulocyte-macrophage colony-stimulating factor are potent IL-12 producers. Poster session presented at the meeting of AACR 91st Annual Meeting.San Francisco, CA.
Kim, S.H., Gambotto, A., Tahara, H., Lotze, M.T., & Robbins, P.D. (2000). Cancer immunotherapy of interleukin-10 gene delivery with direct injection of AdV-IL-10 or genetically-modified dendritic cells. In CANCER GENE THERAPY, 7(12), (p. S26).
Lotze, M.T., Tahara, H., Robbins, P., Jonak, Z., Johnson, R., Tanaka, F., Hashimoto, W., Ho, Y.S., Mailliard, B., Dallal, R., & Son, Y.I. (2000). Interleukin 18 protein or gene therapy promotes development of an adaptive immune response to cancer. Poster session presented at the meeting of 11th NCI � EORTC � AACR Symposium on New Drugs in Cancer Therapy.San Francisco, CA.
Lotze, M.T., Tahara, H., Storkus, W., Okada, H., Robbins, P., Chambers, W., Hiroishi, K., Egawa, S., & Mohammadi, S. (2000). Cytokine gene therapy of cancer using fibroblasts or DCs. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 114(1), (p. 208).
Zdenka, L.J., Yen, S.H., Trulli, S., McCabe, F.L., Maier, C., Kirkpatrick, R., Elefante, L., Chen, Y.J., Herzyk, D., Johanson, K., Whitacre, M., Lotze, M.T., & Johnson, R.K. (2000). Interleukin-18 protein mediates T-cell dependent antitumor effects. In CLINICAL CANCER RESEARCH, 6, (p. 4559S).
Barksdale, E.M., Shurin, G.V., & Lotze, M.T. (1999). Neuroblastoma-derived factors inhibit dendritic cell (DC) generation from CD34+hematopoietic precursors. In PEDIATRICS, 104(3), (p. 784).
Esche, C., Shurin, G.V., Yurkovetsky, Z.R., Barksdale, E., Lotze, M.T., & Shurin, M.R. (1999). The maturation level of dendritic cells (DC) modifies their sensitivity to melanoma-induced apoptosis. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 113(3), (p. 475).
Lotze, M.T., Sproul, L., Pratt, V., & Rubinstein, W.S. (1999). APC mutation in woman with multiple desmoids: A new syndrome or FAP variation?. In AMERICAN JOURNAL OF HUMAN GENETICS, 65(4), (p. A315).
Lotze, M.T., Tahara, H., Storkus, W., Okada, H., Robbins, P., Chambers, W., Hiroishi, K., Egawa, S., & Mohammadi, S. (1999). Cytokine gene therapy using fibroblasts or dendritic cells (DCs) in the therapy of cancer. In CANCER GENE THERAPY, 6(6), (p. S24).
Mailliard, R.B., & Lotze, M.T. (1999). MAJOR PHENOTYPIC, MORPHOLOGIC AND FUNCTIONAL DIFFERENCES BETWEEN DCs STIMULATED WITH MONOCYTE-CONDITION MEDIUM OR CYTOKINE COCKTAIL. Poster session presented at the meeting of SBT 14th Annual Scientific Meeting.Cambridge MA.
Shurin, G., Johnson, K., Lotze, M., & Barksdale, E.M. (1999). Neuroblastoma inhibits dendritic cell differentiation and function in a murine model. In PEDIATRICS, 104(3), (p. 783).
Amoscato, A.A., Prenovitz, D.A., & Lotze, M.T. (1998). Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 75).
Baar, J., Cumberland, R., Shimamura, H., & Lotze, M.T. (1998). A CpG oligodeoxynucleotide enhances IL-12 production by murine dendritic cells. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 40).
Campbell, R.L., Wright, S.E., Repasky, E.A., Watkins, S.C., & Lotze, M.T. (1998). Early polar spectrin aggregation during CD45RA+ T-cell activation. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 55).
Cumberland, R., Shimamura, H., Lotze, M.T., & Baar, J. (1998). A CpG oligodeoxynucleotide synergizes with CD11c receptor-binding to enhance IL-12 production by dendritic cells. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 42).
Esche, C., Lokshin, A., Lotze, M.T., & Shurin, M.R. (1998). Murine and human melanoma induces apoptosis of dendritic cells: A potential mechanism of tumor-induced immunosuppression. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 110(4), (p. 630).
Esche, C., Subbotin, V.M., Hunter, O.C., Peron, J.M., Lotze, M.T., & Shurin, M.R. (1998). Accumulation and maturation of murine skin dendritic cells (DC) are regulated by FLT3 ligand (FL) and interleukin-12 (IL-12). In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 75).
Giezeman-Smits, K.M., Okada, H., Brissette-Storkus, C.S., Villa, L.A., Attanucci, J., Tahara, J., Lotze, M.T., Chambers, W.H., & Bozik, M.E. (1998). Immunity against interleukin 4-producing 9L rat glioma is mediated by tumor-specific, interferon-γ producing CD8+ T cells. In FASEB JOURNAL, 12(4), (p. A278).
Kaplan, J.A., Mailliard, R.B., Birkenbach, M., & Lotze, M.T. (1998). Terminal differentiation of monocyte derived dendritic cells: Marked phenotypic differences and EBI-3 expression. Poster session presented at the meeting of 5th International Symposium of Dendritic Cells.Pittsburgh PA.
Lokshin, A., Peng, X., Esche, C., Lotze, M.T., & Shurin, M.R. (1998). Involvement of transglutaminase in dendritic cell function and apoptosis. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 30).
Okada, H., Tahara, H., Shurin, R., Attanucci, J., Giezeman-Smits, K.M., Fellows, W.K., Bozik, M.E., Chambers, W.H., & Lotze, M.T. (1998). Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 98).
Péron, J.M., Subbotin, V., Haluszczak, C., Lotze, M.T., & Shurin, M.R. (1998). The anti-tumor effect of FLT3-ligand administration on murine liver metastases is mediated in part by NK cells. In GASTROENTEROLOGY, 114(4), (p. A1322).Elsevier. doi: 10.1016/S0016-5085(98)85364-X.
Sato, Y., Gambatto, A., Esche, C., Yamabe, K., Lotze, M.T., & Shurin, M.R. (1998). Treatment of liver tumors transfected dendritic cell. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 86).
Shimamura, H., Cumberland, R., Lotze, M.T., & Baar, J. (1998). Anti-tumor effector function of dendritic cells. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 47).
Shimamura, H., Cumberland, R., Lotze, M.T., & Baar, J. (1998). Anti-tumor effector function of dendritic cells. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 96).
Shurin, M.R., Esche, C., Peron, J.M., Hunter, O.C., & Lotze, M.T. (1998). FLT3 ligand (FL) and interleukin-12 (IL-12) regulate generation, migration, and survival of dendritic cells (DC). In EUROPEAN CYTOKINE NETWORK, 9(3), (p. 509).
Takayama, T., Nishioka, Y., Lu, L., Lotze, M.T., Tahara, H., & Thomson, A.W. (1998). Retroviral delivery of viral IL-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T cell hyporesponsiveness. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 42).
Thomas, R.L., Lotze, M.T., & Amoscato, A.A. (1998). Mass spectrometric analysis of cellular lipids from tumor cells undergoing apoptosis. In FASEB JOURNAL, 12(4), (p. A596).
Yamabe, K., Peron, J.M., Esche, C., Lotze, M.T., & Shurin, M.R. (1998). New method for the isolation of murine lymphoid dendritic cells: Kinetics of short-time survival in culture. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 17).
DouinEchinard, V., Robbins, P.D., Lotze, M.T., Favre, G., & Couderc, B. (1997). Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express two co-stimulatory molecules CD70 and CD80. In CANCER GENE THERAPY, 4(5), (p. 320).
Esche, C., Shurin, M.R., & Lotze, M.T. (1997). FLT3-ligand administration induces tumour growth inhibition in the murine B16 melanoma. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 109(3), (p. 452).
Esche, C., Shurin, M.R., Carlos, T., & Lotze, M.T. (1997). B16 melanoma induces downregulation of beta 2 integrin and ICAM-1 expression on murine dendritic cells. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 617).
Gambotto, A., Tuting, T., Numasaki, M., Hierholzen, C., McVey, D.L., Kovesdi, I., Tahara, H., Lotze, M.T., & Robbins, P.D. (1997). Induction of antitumor immunity by a recombinant adenovirus vector expressing interleukin-12. In CANCER GENE THERAPY, 4(6), (p. P142).
Lotze, M.T., Osaki, T., Peron, J.M., Shurin, M., Baar, J., & Tahara, H. (1997). Cytokines which induce interferon-gamma (IFN-gamma)-IL-2, IL-12, and IL-18: Regulation of tumor immunity. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 112).
Lotze, M.T., Tahara, H., Storkus, W.J., Suzuki, T., Cai, Q., Couderc, B., & Zitvogel, L. (1997). Cytokine gene therapy of cancer. In CANCER GENE THERAPY, 4(1), (p. 68).
Peron, J.M., Subbotin, V., Shurin, M., & Lotze, M.T. (1997). Effective treatment of murine liver tumors with FLT-3 ligand involves dentritic cell infiltration. In HEPATOLOGY, 26(4), (p. 407).
Robertson, M.J., Cameron, C., Atkins, M.B., Gordon, M.S., Lotze, M.T., Sherman, M.L., & Ritz, J. (1997). Immunologic effects of interleukin-12 administered by bolus intravenous injection to patients with advanced cancer. In BLOOD, 90(10), (p. 1227).
Tuting, T., Baar, J., Schurin, M., Mayordomo, J.I., Zitvogel, L., Tahara, H., Storkus, W.J., DeLeo, A., & Lotze, M.T. (1997). Dendritic cell-based therapy for cancer. In EUROPEAN JOURNAL OF CANCER, 33, (p. 37).
Tuting, T., Kasamon, Y., Martin, D., Wilson, C.C., Baar, J., Lotze, M.T., & Storkus, W.J. (1997). Human blood-derived dendritic cells genetically modified to express melanoma antigens induce primary cytotoxic T cell responses in vitro. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 164).
Tuting, T., Wilson, C.C., Martin, D.I., Baar, J., DeLeo, A., Storkus, W.J., & Lotze, M.T. (1997). DNA vaccines targeting dendritic cells for the immunotherapy of cancer. In CANCER GENE THERAPY, 4(5), (p. 316).
Tüting, T., Zorina, T., Ma, D.I., Wilson, C.C., De Cesare, C.M., De Leo, A.B., Lotze, M.T., & Storkus, W.J. (1997). Development of dendritic cell-based genetic vaccines for cancer. In Adv Exp Med Biol, 417, (pp. 511-518).Springer Nature.United States. doi: 10.1007/978-1-4757-9966-8_84.
Wilson, C.C., Tueting, T., Ma, D., Haluszczak, C., Lotze, M., & Storkus, W. (1997). Activation of dendritic cells by surrogate T cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inductive capacity. In Adv Exp Med Biol, 417, (pp. 335-343).Springer Nature.United States. doi: 10.1007/978-1-4757-9966-8_55.
Zitvogel, L., Triebel, F., Lotze, M.T., & Escudier, B. (1997). Dendritic cell-based immunotherapy of cancer from preclinical studies to clinical applications. In EUROPEAN JOURNAL OF CANCER, 33, (p. 38).
DOUGHTY, L.A., PATRENE, K., BOGGS, S.S., TAHARA, H., LOTZE, M.T., EVANS, C.H., & ROBBINS, P.D. (1995). THE EFFECT OF CONSTITUTIVE EXPRESSION OF VIRAL IL-10 OR SOLUBLE TNF RECEPTOR (P75) IN MICE RECONSTITUTED WITH GENETICALLY-MODIFIED BONE-MARROW STEM-CELLS ON ENDOTOXIN-INDUCED IL-6 PRODUCTION. In PEDIATRIC RESEARCH, 37(4), (p. A44).
Lotze, M.T. (1995). T-cell growth factors - Cytokine and cytokine gene therapy of cancer and transplantation. In Biotherapy, 9(3), (pp. 263-265).
MAYORDOMO, J.I., STORKUS, W.J., KAST, W.M., ZORINA, T., DELEO, A.B., & LOTZE, M.T. (1995). BONE-MARROW-DERIVED DENDRITIC CELLS SERVE AS POTENT ADJUVANTS FOR PEPTIDE-BASED ANTITUMOR VACCINES. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 21).
QIN, L., CHAVIN, K.D., TAHARA, H., DING, Y., LIN, J., ROBBINS, P.D., LOTZE, M.T., & BROMBERG, J.S. (1995). VIRAL IL-10 GENE-TRANSFER PROLONGS CARDIAC ALLOGRAFT SURVIVAL BY INHIBITING CELL-MEDIATED-IMMUNITY. In FASEB JOURNAL, 9(4), (p. A784).
Rollinghoff, M., Lotze, M.T., Coffman, R.L., Mitchison, N.A., & Mosmann, T.R. (1995). General discussion I - Receptor constructs and cytokine antibody complexes. In T CELL SUBSETS IN INFECTIOUS AND AUTOIMMUNE DISEASES, 195, (pp. 38-41).
MAEURE, M., CASTELLI, C., HURD, S., MARTIN, D., STORKUS, W., & LOTZE, M. (1994). IN-VIVO SELECTION OF MELANOMA VARIANTS LACKING CTL-DEFINED EPITOPES. In FASEB JOURNAL, 8(4), (p. A209).
QIN, L., CHAVIN, K.D., TAHARA, H., ROBBINS, P.D., LOTZE, M.T., & BROMBERG, J.S. (1994). IL-10 GENE-TRANSFER PROLONGS CARDIAC ALLOGRAFT SURVIVAL. In FASEB JOURNAL, 8(5), (p. A738).
ITOH, T., STORKUS, W.J., GORELIK, E., & LOTZE, M.T. (1993). IDENTIFICATION OF MURINE MELANOMA T-CELL EPITOPES RECOGNIZED BY CD8+ TUMOR INFILTRATING LYMPHOCYTES IN THE CONTEXT OF H-2K(B). In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 138).
LEDER, G.H., STORKUS, W.J., STUBER, G., MODROW, S., & LOTZE, M.T. (1993). P53 PEPTIDES RECONSTITUTE HLA-A2 EXPRESSION AND CONFER SUSCEPTIBILITY TO TIL-LYSIS. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 109).
LOTZE, M.T., & LEVY, R. (1993). NEW APPROACHES TO IMMUNOTHERAPY AND VACCINES AGAINST CANCER. In JOURNAL OF IMMUNOLOGY, 150(8), (p. A1).
LOTZE, M.T., CAI, Q., ELDER, E., RUBIN, J., PIPPIN, B., JACOB, W., CHEN, Y.W., NISHIHARA, K., SIEGFRIED, J., STORKUS, W., EDINGTON, H., ROSENSTEIN, M., NASTALA, C., PAPPO, I., ZITVOGEL, L., ROBBINS, P., & TAHARA, H. (1993). GENE-THERAPY OF CANCER - IMMUNOLOGICAL APPROACHES. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 184).
LOTZE, M.T., RUBIN, J.T., STORKUS, W.J., HURD, S., NASTALA, C.L., EDINGTON, H.E., MCKINNEY, T.G., PIPPIN, B., NISHIHARA, K., TAHARA, H., ELDER, E., WHITESIDE, T., ZIMMERMAN, R., & LOUIE, A. (1993). NEW T-CELL GROWTH-FACTORS IN THE TREATMENT OF CANCER. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 59).
LOTZE, M.T., TAHARA, H., PIPPIN, B., CAI, Q., ELDER, E., JACOB, W., CHEN, Y.W., SIEGFRIED, J., STRUMPF, P., CARTY, S., ROBBINS, P., & STORKUS, W. (1993). MODULATION OF MURINE REACTIVITY TO TUMOR AND TRANSPLANTATION ANTIGENS BY CYTOKINE GENE-THERAPY. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 100).
MAEURER, M.J., STORKUS, W.J., SALTER, R.D., & LOTZE, M.T. (1993). MICROPOCKET USAGE IN HLA-A2 PRESENTATION OF MELANOMA PEPTIDES TO CD8+ TUMOR INFILTRATING LYMPHOCYTES (TIL). In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 105).
NASTALA, C.L., EDINGTON, H., MCKINNEY, T.G., TAHARA, H., BRUNDA, M., GATELY, M., & LOTZE, M.T. (1993). LOCAL-ADMINISTRATION OF INTERLEUKIN-12 BLOCKS INVIVO PROGRESSION OF MURINE ADENOCARCINOMA AND SARCOMA. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 134).
RAGNI, M.V., & LOTZE, M.T. (1993). HEMOPHILIA - AN IMPORTANT TARGET FOR GENE-THERAPY. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 216).
SIEGFRIED, J.M., HUNT, J.D., PIPPIN, B.A., LANDERNEAU, R.J., JACOBS, W.F., & LOTZE, M.T. (1993). TRANSFER AND EXPRESSION OF THE HUMAN INTERLEUKIN-4 GENE INTO PRIMARY STROMAL AND CARCINOMA-CELLS FROM LUNG-CANCER PATIENTS. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 121).
STORKUS, W.J., MAEURER, M.J., ZEH, H.J., & LOTZE, M.T. (1993). IDENTIFICATION OF HUMAN-MELANOMA DERIVED EPITOPES RECOGNIZED BY HLA-A2 RESTRICTED, CD8+ TUMOR INFILTRATING LYMPHOCYTES. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 100).
TAHARA, H., ZEH, H., PAPPO, I., NASTALA, C., ROBBINS, P.D., & LOTZE, M.T. (1993). TUMOR-GROWTH ALTERATION WITH LOCAL INTERLEUKIN-12 SECRETION ACHIEVED BY GENE-TRANSFER. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 247).
ZEH, H.J., STORKUS, W.J., BRUNDA, M., GATELY, M., TAHARA, H., & LOTZE, M.T. (1993). IL-12 - A NOVEL-T AND NK STIMULATORY FACTOR - IMPLICATIONS FOR CANCER-IMMUNOTHERAPY. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 113).
DIBISCEGLIE, A.M., SIMPSON, L.H., LOTZE, M.T., & HOOFNAGLE, J.H. (1992). DEVELOPMENT OF HEPATOCELLULAR-CARCINOMA AFTER PROLONGED HEPATITIS-C VIRAL-INFECTION. In HEPATOLOGY, 16(2), (p. 530).
Lotze, M.T. (1992). National Institutes of Health Consensus Development Conference. Diagnosis and Treatment of Early Melanoma. In Melanoma Research, 2(2), (pp. 131-139).Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/00008390-199207000-00009.
LOTZE, M.T. (1992). T-CELL GROWTH-FACTORS AND THE TREATMENT OF PATIENTS WITH CANCER. In CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 62(1), (pp. S47-S54).Elsevier BV. doi: 10.1016/0090-1229(92)90040-U.
LOTZE, M.T., ZEH, H.J., ELDER, E.M., CAI, Q., PIPPIN, B.A., ROSENSTEIN, M.M., WHITESIDE, T.L., & HERBERMAN, R. (1992). USE OF T-CELL GROWTH-FACTORS (INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-7, INTERLEUKIN-10, AND INTERLEUKIN-12 IN THE EVALUATION OF T-CELL REACTIVITY TO MELANOMA. In JOURNAL OF IMMUNOTHERAPY, 12(3), (pp. 212-217). doi: 10.1097/00002371-199210000-00015.
WONG, H.L., COSTA, G.L., LOTZE, M.T., & WAHL, S.M. (1992). IL-4 UP-REGULATES EXPRESSION OF IL-1 RECEPTOR ANTAGONIST BY HUMAN PERIPHERAL-BLOOD MONOCYTES INVITRO AND INVIVO. In FASEB JOURNAL, 6(5), (p. A2055).
GARRA, B.S., INSANA, M., FISHER, B., LOTZE, M.T., SHAWKER, T.H., WAGNER, R.F., & RUSSELL, M.A. (1988). QUANTITATIVE ULTRASONIC-DETECTION OF LIVER CHANGES IN PATIENTS UNDERGOING INTERLEUKIN-2 THERAPY. In ULTRASONIC IMAGING, 10(1), (p. 73).Elsevier. doi: 10.1016/0161-7346(88)90100-9.
HUANG, C.M., RUDDEL, M., SLIVA, C., ELIN, R.J., LOTZE, M.T., & ROSENBERG, S.A. (1988). THE EFFECT OF INTERLEUKIN 2 (IL-2) ON TESTS OF LIVER-FUNCTION. In CLINICAL CHEMISTRY, 34(6), (p. 1199).
KAWAKAMI, Y., CUSTER, M., ROSENBERG, S.A., & LOTZE, M.T. (1988). HUMAN INTERLEUKIN 4(IL4) INHIBITS INTERLEUKIN 2(IL2) INDUCTION OF HUMAN LYMPHOKINE ACTIVATED KILLER(LAK) ACTIVITY FROM PERIPHERAL-BLOOD AND SPLEEN-CELLS. In FASEB JOURNAL, 2(4), (p. A660).
KAWAKAMI, Y., ROSENBERG, S.A., & LOTZE, M.T. (1988). INTERLEUKIN-4 (IL4) PROMOTES THE GROWTH OF TUMOR INFILTRATING LYMPHOCYTES (TIL) SPECIFIC FOR HUMAN AUTOLOGOUS MELANOMA. In LYMPHOKINE RESEARCH, 7(3), (p. 336).
LOTZE, M.T. (1988). DISTURBING HOMEOSTASIS - CURRENT STATUS OF LYMPHOKINE TRIALS AT THE NCI. In LYMPHOKINE RESEARCH, 7(3), (p. 258).
REYNOLDS, J.C., SAKAHARA, H., CARRASQUILLO, J.A., LORA, M.E., MALONEY, P.J., LOTZE, M.T., NEUMANN, R.D., & LARSON, S.M. (1988). MURINE ANTIBODY PHARMACOKINETICS AND INVITRO MEASUREMENT OF ANTIBODY-ANTIBODY COMPLEX. In EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 14(5-6), (p. 246).
COHEN, P., LOTZE, M., ROSENBERG, S., & JAFFE, E. (1987). THE IMMUNOPATHOLOGY OF SEQUENTIAL TUMOR-BIOPSIES IN PATIENTS TREATED WITH INTERLEUKIN-2. In LABORATORY INVESTIGATION, 56(1), (p. A14).
TOMITA, S., LOTZE, M.T., & ROSENBERG, S.A. (1987). CLONAL ANALYSIS OF TUMOR INFILTRATING LYMPHOCYTES (TIL) AGAINST HUMAN-MALIGNANT MELANOMA. In FEDERATION PROCEEDINGS, 46(4), (p. 1195).
WIEBKE, E.A., LOTZE, M.T., & ROSENBERG, S.A. (1987). HUMAN-TUMOR SUSCEPTIBILITY TO LYMPHOKINE ACTIVATED KILLER (LAK) LYSIS - INTERFERON AND TUMOR-NECROSIS-FACTOR DECREASE NK BUT NOT LAK LYSIS. In FEDERATION PROCEEDINGS, 46(4), (p. 1510).
OGNIBENE, F.P., ROSENBERG, S.A., SKIBBER, J., SHELHAMER, J.H., LOTZE, M., & PARRILLO, J.E. (1986). INTERLEUKIN-2 HEMODYNAMICS MIMIC SEPTIC SHOCK. In CLINICAL RESEARCH, 34(2), (p. A413).
OGNIBENE, F.P., ROSENBERG, S.A., SKIBBER, J., SHELHAMER, J.H., LOTZE, M.T., & PARRILLO, J.E. (1986). INTERLEUKIN-2 PRODUCES HEMODYNAMIC-CHANGES SIMILAR TO SEPTIC SHOCK IN HUMANS. In CRITICAL CARE MEDICINE, 14(4), (p. 352).Wolters Kluwer. doi: 10.1097/00003246-198604000-00085.
ROBERTS, K., LOTZE, M.T., & ROSENBERG, S.A. (1986). LYMPHOKINE ACTIVATED KILLER (LAK)-TUMOR CELL CONJUGATES ENUMERATED BY FLOW-CYTOMETRY. In FEDERATION PROCEEDINGS, 45(3), (p. 719).
DUBOIS, M., LOTZE, M.T., DIAMOND, W.J., KIM, Y.D., FLYE, M.W., & MACNAMARA, T.E. (1981). INTRA-OPERATIVE ACUTE RESPIRATORY-FAILURE INDUCED BY LEUKOCYTE ANTIBODIES. In CRITICAL CARE MEDICINE, 9(3), (p. 195).Wolters Kluwer. doi: 10.1097/00003246-198103000-00207.
BIAS, W.B., HSU, S.H., POLLARD, M.K., HARVEY, J., LOTZE, M., ARNETT, F., & STEVENS, M.B. (1980). HLA-DR CHARACTERIZATION OF A CHIPPEWA INDIAN SUB-POPULATION WITH HIGH PREVALENCE OF RHEUMATOID-ARTHRITIS. In HUMAN IMMUNOLOGY, 1(3), (pp. 247-248).Elsevier. doi: 10.1016/0198-8859(80)90022-1.
DUNCAN, M.A., LOTZE, M.T., GERBER, L.H., & ROSENBERG, S.A. (1980). SERRATUS ANTERIOR PALSY FOLLOWING AXILLARY DISSECTION - A PROSPECTIVE-STUDY. In ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 61(10), (p. 497).